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Introduction and Overview
Interventional cardiology has witnessed tremendous change since 1977 when Andreas Gruentzig 
successfully performed the first balloon angioplasty. Whereas initial concerns revolved around 
maintaining vessel patency with issues of recoil and restenosis, the introduction of stents 
changed the landscape forever. Inherent with their use, stents, and, more specifically, drug-
eluting stents (DES), have become central to improved patient outcomes but, at some cost. 
Catastrophic, yet fortunately still rare complications such as stent thrombosis have re-ignited an 
intense need for greater scrutiny when developing and, subsequently implanting DES into our 
patients.   
The demand for detailed information regarding coronary artery disease has seen intravascular 
imaging become pivotal at delineating atherosclerosis and tissue responses following stent 
implantation. In fact, the strategy that relied on angiography alone is evolving to include better 
confirmation of disease severity and stenting technique. With this, optical coherence tomography 
(OCT) has grown exponentially with a broad diffusion amongst catheterisation laboratories 
worldwide.  
Optical coherence tomography is a procedurally demanding technique. Individual experience is 
often frustrated initially with disappointing images as a result of inadequate blood clearance. 
With perseverance and adequate proctorship however, one cannot help but be impressed by the 
clarity and resolution afforded by this imaging modality. It is these images that have attracted 
considerable attention at cardiology conferences internationally and have helped instil OCT as 
the most sensitive intravascular imaging technique available today. 
The aim of this thesis was to evaluate the role of OCT in contemporary coronary intervention. 
Part 1 embraces the principles of the technique and the physical properties of OCT (chapter 2) 
and gives an insight into where OCT is placed compared to other intravascular imaging 
modalities (chapter 3). Despite the adoption of OCT in more and more catheterisation 
laboratories, little has been documented as to its safety, so, in chapter 4, we review the 
procedural safety of intracoronary OCT in a large group of patients across six leading European 
centres.  
In part 2, we focus on the means of achieving adequate visualisation of the vessel and we 
provide evidence for the validity of quantitative OCT data. Chapter 5 is a landmark piece of 
work and draws upon our initial experience at the Royal Brompton Hospital, London, UK while 
introducing OCT to our lab. For the first time, we also reported on a classification system to 
assess stent strut apposition, namely by incorporating the precise strut width (inclusive of metal 
and polymer) when categorising a strut as apposed or not. The validity of data is robustly 
depicted in chapters 6 & 7 with a comparison to a novel quantitative analysis system and the 
proprietary system, respectively.  
In an attempt to do away with the cumbersome occlusion balloon whilst imaging with OCT, a 
simplified technique of using contrast flush through the guiding catheter has been developed. 
Chapter 8 focuses on the significant advantages of this method, namely the ability to visualise 
ostial and proximal coronary segments and improved patient tolerability. This technique has now 
become established and is also incorporated in the next generation OCT consoles using Fourier 
domain imaging. 
Part 3 of the thesis explores the exciting area of coronary stent imaging. This is emerging as a key 
indication for OCT given the increased scrutiny placed on DES as a result of the risk of 
thrombosis. Tissue coverage or the lack thereof has been linked to stent thrombosis in post-
mortem studies, hence, a technique that can detect microscopic amounts of tissue in-vivo is 
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appealing. The LEADERS trial OCT sub-study (chapter 11) looked at tissue coverage of 
biolimus and sirolimus-eluting stents 9 months following implantation in an ‘all-comer’ patient 
population. The novel biolimus stent incorporates a biodegradable polymer and may offer 
several advantages over and above permanent polymer-based platforms. Chapter 12 goes further 
and uses OCT to explore the advantages of a bare metal stent sprayed with rapamycin compared 
to the first generation sirolimus stent. 
Apart from its unique ability to detect tissue coverage, its high resolution makes OCT applicable 
in assessing strut apposition. Chapters 13 explores the use of OCT in overlapping DES. We 
identified that this region was associated with a significantly higher rate of malapposed struts 
despite high pressure dilatation. Chapter 15 gives insights into the role of different stent 
platforms and the influence of cell design and strut thickness on the incidence of incomplete 
stent apposition. Other applications afforded to be the high resolution of OCT are in examining 
suspected cases of stent fracture (chapter 16) and stent thrombosis (chapter 20) where we 
identify incomplete strut apposition on OCT and the presence of eosinophils histologically, 
raising the possibility of a hypersensitivity reaction to polymer in this multi-faceted disease entity. 
Part 4 of the thesis focuses on the application of OCT in assessing atherosclerotic plaque. The 
modality can accurately differentiate between different plaque types, namely fibrous, lipid-rich 
and calcific. Chapter 22 describes a unique pilot study using the first generation OCT system to 
examine culprit and non-culprit coronary lesions in patients presenting with acute coronary 
syndromes or stable angina pectoris. Chapter 23 also incorporates intravascular ultrasound, 
virtual histology and intravascular magnetic resonance imaging to compare a multi-modality 
strategy and detecting and characterising atherosclerotic plaque in-vivo. 
The final section of the main body of the thesis (Part 5) deals with new developments in OCT 
technology. Fourier-domain OCT (FD-OCT) systems employ a novel wavelength-swept laser as 
a light source and acquire images at line rates at least 10 times faster than time-domain systems 
without loss of image quality (pullback speed of 20mm/sec compared to 3.0mm/sec).  This 
speed advantage results from the elimination of mechanical scanning of the reference mirror and 
the signal-to-noise advantages of Fourier-domain signal processing. Such advances with faster 
pullback speeds will see OCT become simpler and will help minimise the need for large volumes 
of contrast during image acquisition. 
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Principles of OCT 
Intravascular imaging techniques remain complimentary to assessing vascular structures or 
results following stent implantation. The recent introduction of optical coherence tomography 
(OCT) to the coronary circulation has given unique insights into vessel microstructures and 
responses following stenting. Compared to intravascular ultrasound (IVUS), OCT has a ten-fold 
higher resolution with fewer artefacts, primarily as a result of the near infra-red light used as 
opposed to sound to generate the image. This advantage has seen OCT successfully applied to 
the assessment of atherosclerotic plaque (including thin cap fibroatheroma and macrophage 
distribution within a culprit lesion), stent apposition and tissue coverage, introducing a new era 
in intravascular coronary imaging. (1-11) This chapter will introduce the principles of OCT and 
how this novel technology has been implemented into both the clinical and research arenas. 
Technical considerations 
Whereas ultrasound produces images from backscattered sound "echoes," OCT uses infrared 
light waves that reflect off the internal microstructure within the biological tissues. Table 1 
illustrates the characteristics of OCT compared to other imaging modalities.  
 OCT IVUS Fluoroscopy Angioscopy MRI 
Resolution 
(Ƭm) 
10-15 80-120 100-200 <200 80-300 
Probe size 
(Ƭm) 
140 700 NA 800 NA 
Ionizing 
radiation 
No (near 
infra-red 
light) 
No 
(ultrasound) 
Yes No No 
Table 1: Overview of image resolution of different coronary imaging modalities 
Since the speed of light is much faster than that of sound, an interferometer is required to 
measure the backscattered light. The interferometer splits the light source into two “arms” – a 
reference arm and a sample arm, which is directed into the tissue. The frequencies and 
bandwidths of infrared light (1310nm broadband super luminescent) are orders of magnitude 
higher than medical ultrasound. The imaging depth of current OCT systems is approximately 
1.5-2.0mm with an axial and lateral resolution of 15μm and 25μm, respectively. The mobile 
OCT System cart (LightLab Imaging Inc., Westford, MA, USA) contains the optical imaging 
engine and the computer. The mouse, keyboard, two monitors, two storage drawers, and the 
patient interface unit (PIU) are all mounted on top of the cart (Figure 1). 
The ImageWire 
The imaging probe (ImageWire™ LightLab Imaging Inc., Westford, MA, USA) has a maximum 
outer diameter of 0.019″ (with a standard 0.014" radiolucent coiled tip) and contains a single-
mode fiber optic core within a translucent sheath (Figure 2).  
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Figure 1: the mobile OCT cart incorporating the system console, monitor, and patient interface unit 
 
Figure 2: The OCT catheter and dedicated optical imaging wire (LightLab Imaging Inc., Westford, MA, USA) in 
current commercial use. The occlusion balloon is positioned proximal to the region of interest and the imaging wire 
is then inserted with real-time image acquisition performed at a rate up to 3 mm/sec 
 
The image wire is connected at its proximal end to the imaging console that permitted real-time 
data processing and two-dimensional representation of the backscattered light in a cross-
sectional plane. Since the imaging wire is not torquable, it can be advanced distal to the region of 
interest using the over-the-wire occlusion balloon (for the occlusive technique, see below) or a 
see colour section
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simple micro-catheter for the non-occlusive technique (see below, e.g. Transit, Cordis Johnson 
&Johnson, USA or ProGreat, Terumo Japan, with inner lumens >0.020″). Unlike an IVUS 
transducer, the optical sensor of the image wire is invisible under fluoroscopy and therefore one 
must estimate the correct position, using the distal 15mm radiopaque tip of the ImageWire. As 
there are no direct radiopaque markers for the infrared sensor, it is possible to inadvertently miss 
imaging an area of interest resulting in incomplete distal lesion edge assessment. Imaging after 
stent implantation facilitates positioning because it is sufficient to advance the proximal end of 
the radiopaque wire tip at least 1cm distal to the stent struts to image the entire stented segment. 
For imaging prior to treatment, it is important to note that the occlusion balloon is too bulky to 
cross severe stenoses before pre-dilatation and that the imaging wire should be advanced distal 
to the lesion to ensure that the segment of interest is fully visualised. In such circumstances, the 
non-occlusive technique is advantageous.  
Techniques for blood removal 
As the light used is unable to penetrate red blood cells, OCT requires temporary blood 
evacuation prior to image acquisition. This remains one of the major limitations precluding the 
routine use of OCT and warrants further consideration.  
Proximal balloon occlusion and flush 
The proximal occlusion balloon catheter (Helios, Goodman Co, Japan) is an over-the-wire 4.4Fr 
catheter (inner diameter 0.025”), compatible with 6Fr guiding catheters (inner lumen diameter 
≥0.071”), which is advanced distal to region of interest using a conventional angioplasty guide 
wire (0.014’’). The guide wire is then replaced by the OCT ImageWire™ (0.019’’ maximum 
diameter), and the occlusion balloon catheter is withdrawn proximal to the segment to be 
assessed leaving the imaging wire in distal position.  
During imaging acquisition, coronary blood flow is removed by continuous flush of Ringer’s 
lactate solution via the end-hole of the occlusion balloon catheter at a flow rate of 0.5-0.7ml/sec 
during simultaneous balloon inflation (0.5-0.7atm). The vessel occlusion time is limited to a 
maximum of 30sec to avoid haemodynamic instability or arrhythmias. A 1.0 mm/sec pullback 
permits the assessment of an up to 30mm long coronary segment with a frame rate of 15.6 
frames/sec. 
This technique permits OCT image acquisition without the use of additional contrast for 
flushing however, as the balloon needs to be positioned in the proximal segment of the vessel, 
visualisation of such regions of the artery is limited. Further, occlusion balloon use is frequently 
associated with chest discomfort for the patient with associated electrocardiographic ischemia 
changes. 
Non-occlusive technique 
With improvements in the acquisition speeds of OCT data (currently peaking at 3.0mm/sec 
however, up to 20mm/sec will be available with optical frequency domain OCT), blood can be 
evacuated by continuous flush through the guiding catheter, thus doing away with the 
cumbersome proximal balloon occlusion and thereby simplifying the acquisition process. Here, 
Peter BW 13-5.indd   23 13-05-09   16:17
Chapter 2
24
 
the OCT imaging wre is advanced carefully distal to the region of interest. As the fragile wire 
does not have the properties of a guidewire, it needs to be directed distally using an over the wire 
catheter (e.g.Transit, Cordis, Johnson & Johnson or ProGreat, Terumo, Japan). With the wire in 
position, viscous iso-osmolar contrast (Iodixanol, Visipaque™, GE Health Care, Cork, Ireland) 
at 37° Celsius is used to clear the artery from blood and connected to the standard Y-piece of the 
guiding catheter. The contrast is either injected manually through the Y-piece or automatically 
using a pump injector. During continuous contrast injection, the automated OCT pullback is 
performed at 3.0mm/sec. The pullback is stopped after visualisation of the region of interest or 
in case of significant signs of ischaemia, arrhythmia or patient intolerance. Cross sectional images 
are acquired at 20 frames/sec.  
After completion of the OCT study, the image wire is removed, and intra-coronary nitrates are 
usually administered according to local standards and an angiogram should be taken. The 
procedure should be terminated if there is any haemodynamic compromise during the infusion 
and OCT acquisition. 
OCT Applications 
Although OCT has a number of varied clinical and research uses, the main applications at this 
present time are the assessment of: 
1. Stent apposition 
2. Stent strut neointimal coverage at follow-up 
3. Atherosclerotic plaques (including the characterisation of vulnerable plaques) 
1. Stent Apposition 
OCT is more accurate in assessing strut apposition compared with IVUS because of higher 
resolution but its poor penetration (approximately 1.5mm) makes it inferior to IVUS in assessing 
stent expansion. Stent struts appear as highly reflective surfaces and cast shadows on the vessel 
wall behind. Even if the stent struts are well apposed to the vessel wall with OCT, the stent may 
not be optimally expanded given that it is more difficult to identify the external elastic membrane 
compared with IVUS. Since OCT can show only the endo-luminal surface of the strut due to 
limited penetration through the metal with resulting shadowing (Figure 3, arrows), strut and 
polymer thickness should be considered in assessing apposition for each type of DES design. 
Table 2 lists the thickness of commercially available.  
In an evaluation of OCT findings following stent implantation to complex coronary lesions, 
Tanigawa et al (12) examined a total of 6,402 struts from 23 patients (25 lesions) and found 
9.1±7.4% of all struts in each lesion treated were malapposed. Univariate predictors of 
malapposition on multilevel logistic regression analysis where: implantation of a sirolimus-eluting 
stent (SES), presence of overlapping stents, longer stent length and type C lesions. Likely 
mechanical explanations for malapposition of stent struts include increased strut thickness, 
closed cell design or acute stent recoil. The latter has been demonstrated in SES to be in the 
range of 15%, despite the use of high pressure balloon dilatation. (13) 
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Manufacturer Name Drug Metal Strut Polymer 
Total 
Thickness 
Cordis, J&J Cypher Select Sirolimus 0.0055" 
(140μm) 
0.0003" (7μm) 0.0061" 
(154μm) 
Boston 
Scientific 
Taxus Liberte Paclitaxel 0.0038" (97μm) 0.0006" (15μm) 0.0050" 
(127μm) 
Medtronic Endeavor Zotarolimus 0.0036" (91μm) 0.0003" (8μm) 0.0042" 
(107μm) 
Abbott Xience V Everolimus 0.0032" (81μm) 0.0003" (8μm) 0.0035" 
(89μm) 
Translumina Yukon Rapamycin 0.0034" (87 μm) NA 0.0034" (87 
μm) 
Orbus Neich Genous EPC capture 0.0040” 
(100μm) 
NA 0.0040” 
(100μm) 
Medtronic Driver NA 0.0036" (91Ƭm) NA 0.0036" 
(91Ƭm) 
Table 2: Thickness of stent struts (NA - not applicable) 
2. Stent strut tissue coverage 
One of the ‘hotly’ debated topics currently in the interventional cardiology literature remains 
stent thrombosis. It appears that this condition is multi-factorial with premature discontinuation 
of dual anti-platelet therapy, stent under-expansion, hypersensitivity and lack of endothelial tissue 
coverage all being implicated.(14-18) Unlike conventional stents which developed circumferential 
coverage with an average thickness of 500μm or more, well visualised with IVUS and 
angiography (corresponding to 1mm late loss),(6) DES delay and prevent the hyperplastic 
response so that the average late lumen loss for sirolimus- or paclitaxel- eluting stents can be as 
Figure 3 – This OCT cross-section shows a thin layer 
of tissue covering the stent struts. As infrared light is 
unable to penetrate the metal struts, shadowing results 
(arrows) 
 
see colour section
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low as 0.1 or 0.2mm,(19,20) which means the amount of intimal thickening will not be detectable 
with IVUS. OCT offers a potential alternative to detect and measure these tiny layers of intimal 
coverage and to assess late strut malapposition that can be distinguished, if images immediately 
after implantation are also available, into persistent (present already at the time of stent 
implantation) and acquired (negative remodeling or disappearance of superficial components 
behind struts such as thrombus).(6) 
Small-scale studies have successfully used OCT to evaluate neointimal stent strut coverage at 
follow-up. Matsumoto et al studied 34 patients following sirolimus-eluting stent (SES) 
implantation. The mean neointima thickness was 52.5 microns, and the prevalence of struts 
covered by thin neointima undetectable by IVUS was 64%. The average rate of neointima-
covered struts in an individual SES was 89%. Nine SES (16%) showed full coverage by 
neointima, whereas the remaining stents had  no visible  strut coverage.(5) Similarly, Takano et al 
(10) studied 21 patients (4,516 struts) 3 months following SES implantation. Rates of exposed 
struts and exposed struts with malapposition were 15% and 6%, respectively. These were more 
frequent in patients with acute coronary syndrome (ACS) than in those with non-ACS (18% vs 
13%, p <0.0001; 8% vs 5%, p <0.005, respectively). The same group have recently reported 2 
year follow-up OCT findings with the thickness of neointimal tissue at 2-years being greater than 
that at 3-months (71 ±93 μm vs. 29 ± 41 μm, respectively; p<0.001). Frequency of uncovered 
struts was found to be lower in the 2-year group compared to the 3-month group (5% vs. 15%, 
respectively; p<0.001) and, in contrast, prevalence of patients with uncovered struts did not 
differ between the 3-month and the 2-year group (95% vs. 81%, respectively) highlighting that 
exposed struts continued to persist at long-term follow-up. (21) 
3. Atherosclerotic plaque assessment 
Several imaging modalities have been used to assess and identify VP including coronary 
angioscopy, intravascular ultrasound (IVUS) and magnetic resonance imaging. Recently, there 
has been significant interest in the field of VP detection using OCT,(1-4,22-26) with the 
technique able to detect and quantify thin cap fibroatheroma (TCFA) and macrophage 
distribution.(2-4,25) Several morphologic features described in autopsy series are of particular 
interest in such vulnerable plaques. These include the presence of a thin fibrous cap, a necrotic 
lipid core and the accumulation of macrophages.(2,3,25) Nevertheless, the assessment of plaque 
by OCT remains largely qualitative with the notable exception of the measurement of the 
thickness of the fibrous cap covering necrotic areas. The other limitation of OCT for plaque 
quantification is the inability to provide a full thickness analysis of large plaques because of its 
limited penetration. OCT however, offers obvious advantages when dealing with superficial 
structures such as the fibrous cap.(6)  
Optical coherence tomography is highly sensitive and specific for the characterization of plaques 
when compared to histological examination. Yabushita et al (27) performed an in-vitro study of 
more than 300 human atherosclerotic artery segments. When compared to histological 
examination, OCT had a sensitivity and specificity of 71-79% and 97-98% for fibrous plaques, 
95-96% and 97% for fibrocalcific plaques, and 90-94.5% and 90-92% for lipid-rich plaques, 
respectively. Further, the inter-observer and intra-observer variability of OCT measurements 
were high (κ values of 0.88 and 0.91 respectively). Table 3 highlights the OCT features of 
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fibrous, lipid and calcific plaques. Figure 4 demonstrates the OCT appearance of lipid-rich 
plaque with TCFA. 
Recently, Kubo et al (22) used OCT, together with IVUS and angioscopy to assess plaque 
characteristics in 30 patients presenting with AMI. The imaging devices were consecutively used 
following initial mechanical thrombectomy and found the incidence of plaque rupture by OCT 
to be 73%, significantly higher than that detected by both angioscopy (47%, p= 0.035) and IVUS 
(40%, p =0.009). The incidence of TCFA was 83% in this patient population and only OCT was 
able to estimate the fibrous cap thickness (mean 49±21μm). Further, intracoronary thrombus 
was observed in all cases by OCT and angioscopy but was identified only in 33% of patients by 
IVUS (p< 0.001). The potential for OCT in such circumstances is clearly evident with intense 
research currently ongoing to detect vulnerable lesions early on in their natural history, thereby 
limiting morbidity and mortality. 
Fibrous Lipid-rich Calcified
High reflectivity 
Homogenous 
Finely textured 
Low reflectivity
Homogenous 
Diffuse margins 
Low reflectivity
Inhomogeneous 
Sharp margins 
or 
Isolated, strong 
reflections in dark 
background 
Table 3: OCT appearance of different atherosclerotic plaques 
OCT Precautions and Limitations 
OCT remains a specialised technique that should not be performed unless a thorough 
proctorship has been undertaken. As the procedure demands temporary blood removal and flush 
(either lactated ringers or contrast), it should not be performed in patients with poor left 
ventricular function or those presenting with haemodynamic compromise. Further, it is contra-
indicated in patients with single remaining vessel or those with impaired renal function. Lesions 
that are ostial or proximally located cannot be adequately imaged using proximal balloon 
occlusion and thus a non-occlusive technique may be preferred in these circumstances. Large 
calibre vessels often preclude complete circumferential imaging and this remains a technological 
limitation that is currently being refined. 
 The next generation image wires will offer improved durability and trackability. Future systems 
will offer smoother L-mode acquisition and edge-detection software with faster acquisition 
speeds such as optical frequency-domain imaging (OFDI). Eventually, automated plaque 
morphology detection will also be included.(6) All these advances will build on an already unique 
imaging technology that will play a pivotal role in better understanding coronary artery disease 
well into the future.  
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The ability to detect vulnerable plaques in vivo is essential to study their natural history and to 
evaluate potential therapeutic interventions that may ultimately favorably impact on acute 
coronary syndrome (ACS) and death. Coronary angiography offers valuable information on the 
long-term behavior of complex coronary lesions but does have several limitations. Goldstein et 
al (1) reported that patients with ST-segment elevation myocardial infarction (STEMI) and 
multiple complex lesions had an increased incidence of recurrent ACS during the year following 
STEMI compared to patients with a single complex lesion (19.0% vs 2.6%, p <0.001, 
respectively). Taking this into consideration however, angiography only permits a 2-dimensional 
view of the arteries and is unable to give precise detail about the vessel wall. As a result, a 
number of invasive imaging modalities are being tested or used, specifically geared toward the 
evaluation of vulnerable plaque (2). These techniques are capable of giving unique detail on the 
vessel wall, lumen, plaque tissue composition and the status of inflammation and therefore 
circumvent many of the limitations of coronary angiography. This chapter will provide a 
contemporary review of these technologies with particular reference to their use in the 
assessment of vulnerable plaque and coronary stents. 
  
 
1. Histopathological vulnerable plaque definitions 
 
 
The “classical”, most described phenotype of vulnerable plaque is a thin capped fibroatheroma 
(TCFA) (3), characterized by a large necrotic core with an overlying thin cap infiltrated by 
macrophages. Smooth muscle cells within the cap are absent or few. The thickness of the fibrous 
cap near the rupture site measures 23 ± 19 Ƭm, with 95% of caps measuring <65 Ƭm(4,5). 
Rupture of a TCFA with exposure of the thrombogenic necrotic core to circulating platelets is 
thought to be responsible for 60% of all acute coronary syndromes (ACS) (5). Macrophage 
infiltration of the thin cap with release of matrix metalloproteinases and local inflammation can 
cause extracellular matrix degradation and subsequent plaque rupture (6,7). Excessive mechanical 
strain, particularly at the junction of the TCFA and the normal vessel wall is another factor 
predisposing to rupture (8,9). 
Chevuru et al. (10) reported new pathological evidence on TCFA characterization. The 
prevalence of TCFA and rupture is low (0.46±0.95 and 0.38±0.70 per heart, respectively), focal in 
nature and located in the proximal segments of coronary arteries. In earlier studies, up to 3 TCFA 
were found per heart(11). Necrotic core size was relatively small for both, TCFA (1.6±1.8mm2; 
length 2.7±2.0mm) and ruptured plaques (2.2±1.9mm2; length 1.9±3.6mm). In previous studies, 
the size of necrotic core in TCFAs was 1.7±1.1mm2 with a length of 8mm (range 2-17mm), and 
in ruptured plaques 3.8±5.5mm2, with a length of 9mm (range 2.5-22mm)(12).  
The second recognized phenotype of vulnerable plaque, accounting for approximately 40% of 
coronary thromboses in pathology series is plaque erosion in lesions consisting of either 
pathological intimal thickening or thick-capped fibroatheroma (13). These lesions typically have a 
high smooth muscle cell content and are rich in proteoglycans and are more common in young 
women and smokers, but are not associated with other conventional risk factors such as 
hypercholesterolemia (14,15).  
Thirdly, there are calcified nodules, which may protrude into the vessel lumen and comprise up 
to 5% of lesions in pathological series. These lesions are characterized by an absence of 
endothelial and inflammatory cells (15). In addition, intra-plaque hemorrhage secondary to 
leakage from the vasa vasorum may also play a pathological role (16). 
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2. Imaging of vulnerable plaques 
 
Angioscopy 
 
Coronary angioscopy (CAS) is a well-established technique that allows direct visualization of the 
plaque surface and intra-luminal structures. It enables assessment of the plaque color (white, red, 
yellow), and can illuminate plaque complications such as rupture, intimal tears and thrombosis 
with a higher sensitivity compared to angiography (17-20). On angioscopy, normal artery 
segments appear as glistening white, whereas atherosclerotic plaques can be categorized based on 
their angioscopic color as yellow. Platelet-rich thrombus at the site of plaque rupture is 
characterized as white granular material, and fibrin/erythrocyte-rich thrombus as an irregular, red 
structure protruding into the lumen. Yellow plaques are associated with ACS (21) and 
thrombosis (22). They have also been correlated with other features of vulnerability such as 
positive remodeling and increased distensibility (23). 
The major limitation of angioscopy is that it is a rather specialized technique that requires a 
blood-free field during image acquisition, which can be obtained either by complete vessel 
occlusion or by continuous saline flushing distal to the angioscope. Presently, coronary 
angioscopy (Vecmova®, Clinical Supply Co., Gifu, Japan) can be performed while blood is 
cleared from the field of view by injection of 5-10 ml normal saline. Nevertheless, angioscopy 
only allows limited assessment of the coronary tree (i.e. vessels > 2 mm diameter) and 
assessment of stenotic lesions may prove technically difficult. Furthermore, imaging is only of 
the luminal surface and, although changes in the vessel wall are reflected on the surface, this 
might not be sufficiently sensitive to detect subtle alterations in plaque composition or plaque 
burden in the presence of positive remodeling (24). 
Kubo et al (20) recently used CAS, optical coherence tomography (OCT) and IVUS to assess 
culprit lesion morphology in acute myocardial infarction (AMI). The incidence of plaque rupture 
observed by OCT was 73%, 47% by CAS (p=0.035) and by IVUS 40%, (p=0.009). Furthermore, 
OCT (23%) was superior to CAS (3%, p=0.022) and IVUS (0%, p=0.005) in the detection of 
fibrous cap erosion. The intra-coronary thrombus was observed in all cases by OCT and CAS, 
but was identified in 33% by IVUS (vs. OCT, p<0.001).  
 
 
Intravascular ultrasound radiofrequency analysis: Virtual histology 
 
Description of the technique 
 
Grey-scale IVUS imaging is formed by the envelope (amplitude) of the radiofrequency signal, 
discarding a considerable amount of information lying beneath and between the peaks of the 
signal. The frequency and power of the signal commonly differ between tissues, regardless of 
similarities in the amplitude. IVUS-Virtual Histology (IVUS-VH, Volcano Corp., Rancho 
Cordoba, USA) involves spectral analysis of the data and evaluates different spectral parameters 
(Y-intercept, minimum power, maximum power, mid-band power, frequency at minimum 
power, frequency at maximum power, slope, etc.) to construct tissue maps that classify plaque 
into four major components (fibrous, fibrolipidic, necrotic core and calcium). Different plaque 
components are assigned different color codes: calcified (white), fibrous (green), fibrolipidic 
(greenish-yellow) and necrotic core (red) (25). Although this classification was initially evaluated 
in vitro, more recently IVUS-VH pre- and post-procedure have also been correlated with 
pathological atherectomy specimens showing good correlation for all 4 tissue types (26). As 
assessed by IVUS-VH, the sensitivity and specificity for fibrous tissue was 86% and 90.5%, 
fibrofatty 79.3% and 100%, necrotic core 67.3% and 92.9% and dense calcium 50% and 98.9% 
respectively. 
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IVUS-VH data is currently acquired using a commercially available 64-element phased-array 
catheter (Eagle EyeTM 20 MHz catheter, Volcano Corporation, Rancho Cordova, USA). Using an 
automated pullback device, the transducer is withdrawn at a continuous speed of 0.5 mm/s up to 
the ostium. IVUS-VH acquisition is ECG-gated at the R-wave peaks using a dedicated console. 
IVUS B-mode images are reconstructed by customized software and contour detection is 
performed using cross-sectional views with semi-automatic contour detection software to 
provide quantitative geometrical and compositional measurements. Due to the limitations of 
manual calibration (27), the radiofrequency data is normalized using a technique known as “Blind 
Deconvolution”, an iterative algorithm that deconvolves the catheter transfer function from the 
backscatter, thus accounting for catheter-to-catheter variability (28,29). 
It has been our observation that in the near field, an excessive amount of necrotic core is 
present. The developers have accounted for this with a corrected version introduced in the latest 
release of the classification tree. 
 
 
Virtual histology and plaque characterization 
 
Lesion classification is based on static images obtained from autopsy specimens. In brief, some 
believe that atherosclerotic lesion progression starts with pathologic intimal thickening in which 
lipid accumulates in areas rich in proteoglycans (lipid pools), but no trace of necrotic core. 
Others believe that the earliest change of atherosclerosis is the fatty streak, also called as intimal 
xanthoma. The earliest lesion with a necrotic core is the fibroatheroma (FA), and this is the 
precursor lesion that may give rise to symptomatic heart disease. Thin-capped fibroatheroma 
(TCFA) is a lesion characterized by a large necrotic core containing numerous cholesterol clefts. 
The overlying cap is thin and rich in inflammatory cells, macrophages and T lymphocytes with 
few smooth muscle cells. Plaques prone to rupture are those with decrease cap thickness, large 
lipid-necrotic core and severe inflammatory infiltrate A study done by Burke et al(4). identified a 
cut-off value for cap thickness of <65 microns for vulnerable coronary plaque definition.  
Virtual Histology can potentially identify detect thin-cap fibroatheromas (TCFAs). In addition, 
the progression of the disease can also be followed-up. Table 1 outlines the virtual histology 
plaque and lesion types that are proposed based on the above pathologic data. (figure 1).  
 
 
Lesion Type Brief Description
Adaptive Intimal Thickening (AIT) <600 μm of intima thickness
Pathological Intimal Thickening (PIT) 600 μm thickness for >20% of the circumference 
with FF >15%, and no confluent NC or DC 
Fibrotic Plaque (FT) Dominant FT and no confluent NC or DC 
Fibrocalcific Plaque (FC) Confluent DC with no confluent NC 
Fibroatheroma (FA) Confluent NC not at the lumen on three consecutive 
frames 
Thin Cap Fibroatheroma (TCFA) Confluent NC at the lumen on three consecutive 
frames  
FT – fibrous tissue; FF – fibro-fatty tissue; NC – necrotic core; and DC – dense calcium. 
 
Table 1: VH-IVUS Proposed Lesion Types 
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Figure 1. IVUS-Virtual histology proposed lesion types. AIT, adaptative intimal thickening; PIT, pathological 
intimal thickening; FT, fibrotic plaque; FC, fibrocalcific; FA, fibroatheroma;CaFA, calcified fibroatheroma; TCFA, 
thin-capped fibroatheroma. 
 
 
Our group recently evaluated the incidence of IVUS-derived thin-cap fibroatheroma (IDTCFA) 
using IVUS-VH (30). Two independent IVUS analysts defined IDTCFA as a lesion fulfilling the 
following criteria in at least 3 consecutive cross-sectional areas: 1) necrotic core 10% without 
evident overlying fibrous tissue, 2) lumen obstruction  40%. In this study, 62% of patients had 
at least one IDTCFA in the interrogated vessels.  ACS patients had a significantly higher 
incidence of IDTCFA than stable patients [3.0 (interquartile range 0.0, 5.0) IDTCFA/coronary 
vs. 1.0 (interquartile range 0.0, 2.8) IDTCFA/coronary, p= 0.018]. Finally, a clear clustering 
pattern was seen along the coronaries, with 66.7 % of all IDTCFAs located in the first 20 mm 
whereas further along the vessels the incidence was significantly lower (33.3%, p=0.008). This 
distribution of IDTCFAs is consistent with previous ex vivo and clinical studies, with a clear 
clustering pattern from the ostium demonstrating a non-uniform distribution of vulnerable 
plaques along the coronary tree (31). Patients presenting with ACS had a significantly higher 
prevalence of IDTCFA even in non-culprit vessels, supporting the concept of a multi-focal 
process (32). Of note, the lesion percent area stenosis and the mean necrotic core areas of the 
IDTCFAs detected by IVUS-VH were also similar to previously reported histopathological data 
(55.9 % vs. 59.6 % and 19 % vs. 23 % respectively) (12). 
It is worth mentioning that, although the most accepted threshold to define a cap as “thin” has 
previously been set at <65 Ƭm, this was based on post mortem studies that studied ruptured 
plaques (33). Extrapolation of such criteria to in vivo studies therefore requires caution. It is well 
established that tissue shrinkage occurs during tissue fixation (34). Shrinkage (particularly of 
collagen, the main component of fibrous caps) of up to 60 %, 15 % and 80% can occur during 
critical-point-drying, free-drying, and air-drying respectively (35). Furthermore, post-mortem 
contraction of arteries is an additional confounding factor (36,37). Since the axial resolution of 
IVUS-VH is 246 Ƭm, we assumed that the absence of visible fibrous tissue overlying a necrotic 
core suggested a cap thickness of below 246 Ƭm and used the absence of such tissue to define a 
thin fibrous cap (38). 
We have recently developed software to quantify the amount of necrotic core in contact with the 
lumen, enabling refinement of our analysis. Our current definition of an IVUS-derived TCFA 
see colour section
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(IDTCFA) is a lesion fulfilling the following criteria in at least 3 consecutive cross-sectional areas 
(CSAs): 1) plaque burden  40%; 2) confluent necrotic core  10% in direct contact with the 
lumen (i.e. no visible overlying tissue) in the investigated CSA; all consecutive CSAs having the 
same morphologic characteristics are considered as part of the same IDTCFA lesion (39). In a 
recent study, using this refined definition of TCFA as assessed by IVUS-VH, in patients with 
ACS underwent IVUS of all three epicardial coronaries, on average, there were 2 IVUS-derived 
thin cap fibroatheroma (IDTCFA) per patient with half of them showing outward 
remodeling(39). 
The potential value of IVUS-VH in the prediction of adverse coronary events is currently under 
evaluation in two international multicentre prospective studies (PROSPECT and IBIS 2 trials). 
 
Virtual histology and coronary embolization 
 
Recently, two studies evaluated the usefulness of IVUS-VH plaque composition to predict the 
risk of embolization during stenting (40,41). In one of them, 71 patients with STEMI that 
underwent primary PCI within 12 hours of the beginning of the symptoms were included. After 
crossing the lesion with a guidewire and performing thrombectomy with an aspiration catheter, 
VH-IVUS of the infarct-related vessel was performed. The stent was then deployed without 
embolic protection.  ST segment re-elevation was used as a marker of distal embolization during 
stenting. Eleven patients presented with ST segment re-elevation after stenting. Total plaque 
volume was similar in both groups, but the NC volume was significantly higher in the group of 
patients with ST segment re-elevation (32.9 ± 14.1 mm3 vs. 20.4 ± 19.1 mm3, p < 0.05). On 
receiver-operating characteristic curves, NC volume was the best predictor of ST re-elevation 
after stent deployment as compared with fibrous, fibro-lipid, dense calcium, and total plaque 
volumes. The cut-off point for NC volume that was best predictive for ST re-elevation was 33.4 
mm3, with a sensitivity of 81.7% and a specificity of 63.6%. The second study included 44 
patients who underwent elective coronary stenting. Plaque composition was assessed with VH-
IVUS, and small embolic particles liberated during stenting were detected as high-intensity 
transient signals (HITS) with a Doppler guidewire. Patients were divided into the tertiles 
according to the HITS counts. Dense calcium and NC area were significantly larger in the 
highest tertile. In the multivariate logistic regression analysis, only necrotic core area was an 
independent predictor of high HITS counts (odds ratio 4.41, p = 0.045).  
 
 
Intravascular Ultrasound Radiofrequency analysis: Palpography 
 
This technique allows the assessment of local mechanical tissue properties. For a defined 
pressure difference, soft tissue (e.g. lipid-rich) components will deform more than hard tissue 
components (e.g. fibrous, calcified) (42,43). Radiofrequency data obtained at different pressure 
levels are compared to determine the local tissue deformation. 
Each palpogram represents the strain information for a certain cross section over the full cardiac 
cycle. The longitudinal resolution of the acquisitions depend on heart rate and pullback speed. 
With a heart rate of 60 bpm and a pullback speed of 1.0 mm/s, the longitudinal resolution is 1.0 
mm. Palpograms are acquired using a 20-MHz phased array IVUS catheter (Eagle EyeTM 20 MHz 
catheter, Volcano Therapeutics, Rancho Cordova, USA). Digital radiofrequency data are 
acquired using a custom-designed workstation.  
The local strain is calculated from the gated radiofrequency traces using cross-correlation analysis 
and displayed, color-coded, from blue (for 0% strain) to red to yellow (for 2% strain) (44). Plaque 
strain values are assigned a Rotterdam Classification (ROC) score ranging from 1 to 4 (ROC I= 
0-<0.6 %; ROC II= 0.6- <0.9 %; ROC III= 0.9-<1.2 %; ROC IV= >1.2 %) (45) (figure 2).  
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Figure 2. IVUS-palpography. In the upper left side the palpography strain map is opened up. The local strain is 
calculated from the gated radiofrequency traces using cross-correlation analysis and displayed, color-coded, from 
blue (for 0% strain) to red to yellow (for 2% strain). Plaque strain values are assigned a Rotterdam Classification 
(ROC) score ranging from 1 to 4 (ROC I= 0-<0.6 %; ROC II= 0.6- <0.9 %; ROC III= 0.9-<1.2 %; ROC IV= 
>1.2 %). At the bottom, in the same cross-sectional area a high-strain spot (ROC III) is shown (left); in the virtual 
histology (VH) image (right) a confluent necrotic core area in contact with the lumen is seen, suggesting an IVUS-
derived thin capped fibroatheroma.  The IVUS-VH color-code is fibrous tissue (green), fibro-fatty tissue (light 
green), necrotic core (red) and dense calcium (white).  
 
 
Our group has demonstrated that palpography has a high sensitivity (88%) and specificity (89%) 
to detect vulnerable plaques in vitro (42). Postmortem coronary arteries were investigated with 
intravascular elastography and subsequently processed for histology. There was a positive 
correlation between the presence of high strain and the degree of macrophage infiltration 
(P<0.006) and an inverse relation between the amount of smooth muscle cells and strain 
(P<0.0001). Vulnerable plaques identified by palpography had a thinner cap than non-vulnerable 
plaques (P<0.0001). In a subsequent study, 55 patients with either stable or unstable angina, or 
acute MI were analyzed. Among patients with stable angina, the prevalence of deformable 
plaques was significantly lower per vessel (0.6+/-0.6) than in patients presenting with unstable 
angina (1.6+/-0.7, p=0.0019) or with acute MI (2.0+/-0.7, p<0.0001). In the IBIS I study, on 
palpography, both the absolute number of high-strain spots (grade 3/4) in the ROI (p=0.009) 
and their density per cm (p=0.012) decreased significantly between baseline and follow-up. This 
decrease in the overall population was largely driven by changes in the subgroup of patients with 
STEMI; this group had both the highest number of high-strain spots at baseline and the most 
marked relative decrease during follow-up compared to patients with other clinical presentations. 
At 6-month follow-up, the density of high-strain spots (1.2±1.4/cm) was comparable among 
clinical subgroups (46).  
The potential value of IVUS-palpography is currently under evaluation in two international 
multicentre prospective studies, PROSPECT and IBIS 2 trials. These two studies have also 
see colour section
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obtained IVUS-virtual histology during the same IVUS pullback, allowing for the assessment of 
both morphological and biomechanical properties of a particular plaque. Assessing several 
characteristics of a given plaque could potentially enhance invasive risk stratification by 
identifying very high-risk plaques, thereby lowering the number of vulnerable plaques that 
deserve to be serially followed and, ultimately treated (figure 2). 
 
 
Optical coherence tomography 
 
Optical coherence tomography OCT) is an optical analogue of ultrasound, however it uses light 
instead of sound to create an image (47,48). For OCT imaging, low coherence, near infrared light 
with a wavelength around 1300 nm is used since it minimizes the energy absorption in the light 
beam caused by protein, water, hemoglobin, and lipid. The light waves are reflected by the 
internal microstructures within biological tissues as a result of their differing optical indices. 
This technique provides a resolution of 10-20μm in vivo (49); this level of detail is well beyond the 
level of resolution of IVUS (100-150μm) (50). OCT has been demonstrated to be highly sensitive 
and specific for characterizing atherosclerotic plaques in vitro when compared with histological 
analysis (51-53) with a sensitivity and specificity of 71-79% and 97-98% for fibrous plaques, 95-
96% and 97% for fibrocalcific plaques, and 90-94% and 90%-92% for lipid-rich plaques, 
respectively. In addition, the inter- and intra-observer reliabilities of OCT assessment were high 
(kappa values of 0.88 and 0.91, respectively) (53). In vitro comparison of OCT with IVUS have 
demonstrated superior delineation by OCT of structural details such as thin caps, lipid pools or 
tissue proliferation (54). An in vitro comparison of OCT, integrated backscatter IVUS (similar 
methodology to IVUS-VH) and conventional IVUS found that OCT had the best potential for 
tissue characterization of coronary plaques, with higher sensitivity and specificity compared to 
the other imaging modalities (55). However, a recent study comparing OCT to histopathology 
reported a lower sensitivity for plaque components.  Misclassification occurred in 41% of 
lesions, predominantly due to a combination of  incomplete penetration depth into the vessel 
wall  and the inability to distinguish calcium deposits from lipid pools (56). 
In a pilot clinical study, our group performed in vivo OCT analysis of the coronary arterial wall in 
patients who were undergoing percutaneous coronary intervention. Imaging was possible in all 
patients and the entire vessel circumference was visualized at all times. A wide spectrum of 
different plaque morphologies was observed. OCT allowed for differentiation of the normal 
artery wall and inhomogeneous, mixed plaques, as well as thin cap fibroatheromas with 
inhomogeneous, low-reflecting necrotic cores, covered by highly-reflecting thin fibrous caps 
(50).  
As a result of its high axial resolution, there is no doubt that OCT is the in vivo gold standard for 
identifying and measuring the thickness of the fibrous cap (figure 3); an in vivo study found a 
significant difference in minimal cap thickness between acute MI and stable angina patients, with 
median (interquartile range) values of 47.0 (25.3-184.3) μm and 102.6 (22.0-291.1) μm 
respectively (p= 0.02) (57). On top of its reliability as a tool to measure the thickness of the cap 
in vivo, recent post-mortem and in vivo studies have shown that OCT is capable of evaluating the 
macrophage content of infiltrated fibrous caps (58,59). 
Kubo et al. (20) evaluated the ability of intracoronary OCT to assess culprit lesions during 
primary PCI in patients with acute MI. The thickness of the remnants of the fibrous cap after 
symptomatic rupture measured was 49±21μm. The main limitation of OCT is the shallow tissue 
penetration depth (1.5-2mm) which hampers imaging of the entire vessel wall in large vessels and 
light absorbance by blood that currently needs to be overcome by saline infusion and balloon 
occlusion, thereby precluding interrogation of long and proximal segments of the coronary tree. 
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Figure 3: thin cap fibroatheroma visualised with OCT as a highly reflective thin band (arrows) 
 
 
This has recently been partly overcome with the use of non-occlusive techniques whereby 
contrast is flushed through the guiding catheter during simultaneous image acquisition at 
3.0mm/seconds (M3, LightLab Imaging Inc., Westford, MA, USA). Furthermore, even more 
encouraging is the use of optical frequency domain imaging (OFDI) that enables even faster 
pullback speeds without compromise of image quality and resolution. 
 
Thermography 
 
Atherosclerosis is accompanied by inflammation, and vulnerable plaques have been associated 
with increased macrophage activity, metabolism and inflammation (60). Activated macrophages 
produce thermal energy, which might be detected on the surface of these atherosclerotic lesions 
using specially-designed catheters equipped with thermistor sensors at the distal tip (61). A rise in 
temperature can be found in atherosclerotic plaques as compared to disease-free coronary 
segments. Temperature differences between an atherosclerotic plaque and normal vessel wall 
increase progressively from patients with stable angina to patients with acute MI with a 
maximum temperature difference to the background temperature of 1.5±0.7°C (62). In a 
prospective study, Stefanadis et al reported an association between temperature heterogeneity 
and the incidence of adverse events at follow-up in patients with coronary artery disease 
undergoing successful PCI (63). In addition, treatment with statins seemed to affect the 
thermographic results: in non-culprit lesions the temperature difference was lower in the group 
treated with statins compared with the untreated group (0.06 ± 0.05°C vs. 0.11 ± 0.10°C; p = 
0.05) (64). 
However, there are several different aspects that deserve further investigation. The prevalence 
and distribution of inflammatory cells in stable and unstable atherosclerotic plaque is unclear, 
and the predictive value of ‘warm’ lesions remains elusive. Furthermore, the impact of different 
coronary flow conditions on plaque temperature (‘cooling effect’) is still not completely 
understood (65,66).  Simulations have revealed that the correct interpretation of intravascular 
thermographic measurements requires data on the flow and on the morphologic characteristics 
of the atherosclerotic plaque (67). 
There are a few limitations to the routine use of thermography in the catheterization laboratory: 
(i) most of the catheters used still comprise over-the-wire systems; (ii) accurate temperature 
see colour section
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assessment requires direct contact of the thermistors with the vessel wall, with the associated 
potential risk of endothelial damage (68) and (iii) as the temperature within the vessel changes 
rapidly with fluid application, any intracoronary injection of contrast, flush or medication has to 
be avoided before and during measurements. 
 
Intravascular Magnetic Resonance  
 
Magnetic resonance (MR) is a non-ionizing diagnostic tool exploiting the spins of the nuclear 
protons in a strong magnetic field. For intravascular diagnosis, two different approaches have 
been introduced.  
The first, conventional approach visualizes the anatomical structure by using a coil placed in a 
catheter or wire in combination with an external magnet (MR imaging). While this approach has 
previously been shown to be able to provide detailed information on structure and composition 
of the arterial wall and plaque, (69) the procedure has to be performed in a MR magnet, not in a 
cardiac catheterization laboratory. The accuracy for MRI differentiation of plaque components 
has been validated in vitro and feasibility demonstrated in vivo (70). The 0.030-inch IVMRI coil 
had a sensitivity and specificity of 73% and 85% respectively for lipid, 83% and 81% respectively 
for fibrous tissue and 100% and 97% respectively for calcification. Subsequently, the same 
system was applied in human iliac arteries in vivo using a 1.5T magnet with a resolution of 312Ƭm. 
Complete vessel wall analysis was possible in all 25 patients and required 20 minutes for an 
arterial segment of 20mm length. Compared to IVUS, mean lumen diameters were similar, but 
the outer wall area was overestimated by IVMRI (mean 116.4±4.7mm2 vs. 86.6±5.8mm2, 
p=0.0001). However, inter-observer agreements for IVMRI were much higher (kappa 0.68-0.79) 
than for IVUS (kappa 0.21).  
 
The other, novel approach analyses the chemical composition by placing both, the coils and 
miniaturized magnets on the tip of a catheter, without the need of external magnets (MR 
spectroscopy) and can be performed in the cardiac catheterization laboratory(71). MR 
spectroscopy can identify fibrous and lipid-rich tissue by measuring differential water diffusion in 
a field of view.  Acquired data is displayed as color-code sectors based on the lipid fraction index 
(LFI) for each zone of the FOV. Blue indicates no lipid, gray correspond to intermediate lipid 
content and yellow indicates high-lipid content (figure 4). Clinical feasibility of  catheter-based, 
self-contained IV MR spectroscopy has been recently demonstrated in patients scheduled for 
coronary catheterization(72).  
 
Preclinical trials employing this technology demonstrated its capacity to differentiate plaque 
components of human aortas, coronary and carotid arteries in vitro: IVMR spectroscopy was 
able to accurately detect different components (fibrous cap, smooth muscle cells, organizing 
thrombus, fresh thrombus, edema, lipid and calcium) with sensitivities and specificities ranging 
from 84-100%.  Agreement with histology for grading the extent of intra-plaque lipid 
accumulation was 74% and 80% for grading intimal thickness. Further analysis revealed high 
correlation to histological analysis of a wide spectrum of plaque types in 15 of 16 (94%) aortic 
lesions and 16 of 18 (89%) coronary lesions (sensitivity 100%, specificity 89%), including one 
plaque rupture, three TFCAs, seven thick-cap fibrous atheroma, four fibrocalcific plaques, two 
intimal xanthomas, and one adaptive intimal thickening (73).  
Current limitations include the limited field of view, the size of the catheter, the need for direct 
vessel wall contact and the time required for acquisition. In the past, the use of an auto-perfusion 
balloon during data acquisition has been proposed to limit ischemia(74). 
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Figure 4. Multi-modality imaging in the coronary arteries. The same coronary segment (represented by one 
frame) has been imaged by 4 different imaging techniques. In the grey-scale IVUS (panel A), IVUS-virtual histology 
(panel B), optical coherence tomography (panel C) and intravascular magnetic resonance spectroscopy (IVMR) the 
results of the same frame across different techniques are shown. Of note, in the upper left quadrant of the plaque a 
calcified area is seen in three imaging modalities, but in IVMR where an artifact is observed. On the right hand side, 
the different plaque and tissues types across the coronary imaging techniques is shown. 
 
 
 
Clearly IVMR diagnostics remain an exciting area still under development. Catheter-based system 
will further increase the user friendliness, their sample volume and allow for scanning of longer 
arterial segments. Upcoming developments include the improvement MR plaque differentiation 
by the use of contrast agents, such as paramagnetic gadolinium-based contrast(75) or supra-
paramagnetic contrast agents (iron oxide nanoparticles), that can accumulate in macrophages 
(76). There are still a few unanswered questions, including the effect of the thermal energy 
generated on small arteries and on coronary artery stents, although conventional MRI appears 
safe in this setting(77).  
 
Recently in our center, a study has been started to explore a multi-modality imaging approach of 
atherosclerotic plaque in-vivo. The same coronary segment is assessed by greyscale IVUS, IVUS-
VH and OCT and IVMR (figure 4). This has been a challenging process, since we are dealing 
with the different imaging resolutions and the lack of common nomenclature and classification 
across these imaging techniques. 
 
 
 
see colour section
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Raman and near infrared spectroscopy 
 
A number of spectroscopic intravascular imaging techniques have been developed recently and 
are still under investigation (78). Spectroscopy can provide qualitative and quantitative 
information about chemical plaque composition. The Raman effect is created when incident 
laser light (typically 750-850nm wavelength) excites molecules in a tissue sample, which scatter 
light at a different wavelength. This change in wavelength, called the "Raman effect" is 
dependent on the chemical components of the tissue sample (79,80) and can therefore provide 
quantitative information about molecular composition (81-83). Raman spectroscopy has shown 
acceptable correlation compared with histology (r = 0.68 for cholesterol and r = 0.71 
calcification) (83) and with IVUS in vitro (82). 
Raman spectroscopy technology collect scattered light with optical fibers and route the collected 
signal to spectrometer systems for analysis.  Previously optical fiber probes utilized a region of 
the Raman spectrum called the “fingerprint” (FP) region (< ~1800 cm-1 shifted light) to conduct 
remote assays, but due to techinical problems with this approach, it has been recently replaced by 
using another region of the Raman spectrum, called high wavenumber (HW) Raman shifted light 
(> ~2500 cm-1 shifted light). This  
allows us to collect Raman spectra via a single optical fiber, simplifying the size and complexity 
of the catheter and making it clinically feasible. Thus, the optical catheter system (OCS) 
(vPredict™) has been introduced as a tool for measuring the chemical composition of coronary 
vessels in-vivo using Raman spectroscopy and the subsequent mapping and quantification of the 
vessel and plaque components for evaluating plaque progression. In a xenograft model, lipid-
laden plaque were identified with the collected Raman spectra by utilizing the overall cholesterol 
content, i.e. the sum of the free cholesterol and cholesterol esters contents, and setting a decision 
threshold at 12 %, as determined in previous studies.  As expected, the lipid laden plaques 
exhibit an increased content of free cholesterol and cholesterol esters, while the non-
atherosclerotic samples are mainly protein and triglycerides. Table 2. 
 
 
Demonstrated:   Collagen,  
Elastin,  
Myosin,  
Triglycerides,  
Beta-carotene,  
Foam cells,  
Cholesterol/esters,  
Hemoglobin,  
Fibrin 
Possible:  Metalloproteinases, 
Low density lipoprotein (LDL), Oxidized LDL,  
Proteoglycans, Glycosaminoglycans,  
Plasmin,  
Nucleic acids,  
Nitrotyrosine 
Table 2. Plaque/vessel components detectable by Raman spectroscopy. 
 
 
The vPredict OCS delivers infrared light to the vessel wall through optical fibers contained 
within a small flexible catheter and captures a portion of the reflected light for spectral analysis. 
This analysis provides information about the composition of the underlying tissue.  
Alternatively, near infrared (NIR) molecular vibrational transitions can be measured in the NIR 
region (750–2500 nm) (84) and laser spectroscopy using wavelengths of 360-510 nm has been 
evaluated in vitro (85).  
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Near-infrared spectroscopy observes how different substances absorb and scatter NIR light to 
different degrees at various wavelengths. A NIR spectrometer emits light into a sample and 
measures the proportion of light that is returned over a wide range of optical wavelengths. The 
return signal is then plotted as a graph of absorbance (y-axis) at different wavelengths (x-axis) 
called a spectrum. 
In aortic and coronary artery autopsy specimens, the ability of the technique to identify lipid-rich 
TCFA through blood has been confirmed (86). A catheter-based system has been developed to 
address the challenges of access to the coronary artery, blood, motion, and the need to scan that 
must be overcome for use in patients. Initial clinical experience in six patients with stable angina 
demonstrates that high-quality NIR spectra can be safely obtained (87). Additional studies are 
planned to validate the ability of the technique to identify lipid-rich coronary artery plaques and 
ultimately link chemical characterization with subsequent occurrence of an ACS (88,89).  
 
3. Imaging of coronary stents 
 
Intravascular Ultrasound radiofrequency analysis: Virtual Histology 
 
Intravascular ultrasound– virtual histology classifies stent struts as “dense calcium” (DC) and 
“necrotic core” (NC). We applied this property to follow-up the degradation of a bioabsorbable 
stent by measuring the temporal changes in IVUS-VH characteristics. 27 consecutive patients 
treated with a single bioabsorbable everolimus-eluting stent (BVS, Abbott Laboratories, IL USA) 
in simple lesions were imaged with IVUS-VH after predilation (pre-stenting cohort of 13 pts), 
post-stenting and again following 6 months. There was an increase in absolute “dense calcium” 
and “necrotic core” by 297% and 256% respectively from pre- to post-stenting. Overall, patients 
(n=27) with post-stenting and follow-up VH showed a significant decrease in “dense calcium” 
(28.3% vs. 20.9, p<0.001). Individually, in 21 out of 27 patients, there was a regression in the 
“calcified” pattern. Although not significantly, “necrotic core” content also decreased (22.4% vs. 
20.3, p=0.227). In turn, both fibrofatty and fibrous tissue increased (5.0% vs. 7.4, p=0.024 and 
44.3% vs. 51.4%, p=0.006 respectively). In conclusion, the quantitative assessment of the IVUS-
VH changes at 6 months suggests a reduction of the DC compatible with early struts alteration 
of the BVS. (figure 5). 
 
Optical coherence tomography 
 
OCT permits the detailed assessment of stents and their relation to the vessel wall, both 
immediately following implantation and, at follow-up. Furthermore, OCT also allows the 
quantification of neointimal tissue surrounding each individual stent strut. Unlike bare metal 
stents (BMS), which develop circumferential coverage with an average thickness of 500μm or 
more, well visualized with IVUS and angiography, (90) drug-eluting stents (DES) delay and 
prevent this hyperplastic response so that the average late lumen loss can be as low as 0.1 or 
0.2mm, (91,92) which means the amount of intimal tissue will not be detectable with IVUS. (90) 
Several small studies have recently been published highlighting the application of OCT in the 
detection of stent tissue coverage at follow-up. Matsumoto et al (93) studied 34 patients 
following sirolimus-eluting stent (SES) implantation. The mean neointima thickness was 52.5 
microns, and the prevalence of struts covered by thin neointima undetectable by IVUS was 64%. 
The average rate of neointima-covered struts in an individual SES was 89%. Nine SES (16%) 
showed full coverage by neointima, whereas the remaining stents had partially uncovered 
struts.(93) Similarly, Takano et al (94) studied 21 patients (4,516 struts) 3 months following SES 
implantation. Rates of exposed struts and exposed struts with malapposition were 15% and 6%, 
respectively. These were more frequent in patients with ACS than in those with non-ACS (18% 
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vs 13%, p <0.0001; 8% vs 5%, p <0.005, respectively). The ability of OCT to image at high 
resolution is the major advantage over IVUS and it also affords the potential to quantify the 
amount of neointimal tissue formed over struts, an application which remains elusive for a 
technique like angioscopy. OCT is now also being incorporated in more and more clinical stent 
trials with the goal of assessing neointimal tissue coverage, an important potential surrogate 
marker for late thrombosis. (95,96) (figure 6) 
 
 
Figure 5. IVUS-virtual histology in stented segments. In the left hand side, a coronary angiogram of the left 
coronary system shows on the distal segment of the left circumflex artery an eccentric lesion. A pre-stenting virtual 
histology (VH) frame showed a fibrotic type of plaque (location of VH frame is indicated by a black line). On the 
right hand side, the post-stenting VH frame is depicted. Of note, at the lumen and surrounding areas an increase in 
the amount of “dense calcium” and “necrotic core” is observed. This is due to the presence of stent struts that are 
misclassified by VH. (percutaneous coronary intervention – PCI).  
 
 
 
Figure 6: A: Demonstrates the optical coherence tomography (OCT) imaging of a bare metal stent 4 months 
following implantation. The circumferential tissue struts are visible with shadowing induced by the metal. The 
neointimal tissue measured between 140 and 220 microns in thickness 
B: OCT imaging of a drug-eluting stent (DES) at 4 months follow-up showing the circumferential struts with a very 
thin neointimal layer (10-40 microns thick). The arrow indicates a strut with no visible tissue coverage  
 
 
see colour section
Peter BW 13-5.indd   45 13-05-09   16:17
Chapter 3
46
    
Conclusions 
Several invasive imaging techniques are currently under development to detect vulnerable 
coronary plaques in human coronary arteries in vivo. To date however, none of the techniques 
described above have been sufficiently validated and, more importantly, they have not 
demonstrated a sound and reproducible ability to predict future adverse cardiac events. 
Intravascular palpography and virtual histology, based on conventional IVUS catheters, appear 
to be very promising and their predictive role is presently under investigation in a large 
international trial. 
Very rigorous and well-designed studies are compelling for defining the role of each imaging 
modality. Non-invasive techniques and the assessment of humoral and genetic factors comprise 
complementary and important tools in this direction. 
At present, the main purpose of all these evolving techniques is to improve our understanding of 
atherosclerotic disease and to define its natural history. Ultimately, the aim is to identify patients 
at high risk for future cardiovascular events and to evaluate the benefits from either local or 
systemic therapeutic interventions.  
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Aims: Optical coherence tomography (OCT) is increasingly being applied to the coronary arteries. However, the 
risks associated with the imaging procedure are not yet well defined. The purpose of the present multi-centre registry 
was, for the first time, to assess the acute complications associated with the clinical use of intra-coronary OCT in a 
large number of patients. 
Methods & Results: Consecutive patients from 6 centres who had OCT examination were retrospectively 
included. All adverse events and complications, even if transient, were noted. Risks were categorised into: 1) self-
limiting 2) major complications including major adverse cardiac events (MACE) and 3) mechanical device failure. 
A total of 468 patients underwent OCT examination for evaluation of: plaque (40.0%), percutaneous coronary 
intervention (28.2%) or follow-up stent tissue coverage (31.8%). OCT was performed using a non-occlusive flush 
technique in 45.3% with a mean contrast volume of 36.6±9.4ml. Transient chest pain and QRS widening/ST-
depression/elevation were observed in 47.6% and 45.5% respectively. Major complications included 5 (1.1%) 
cases of ventricular fibrillation due to balloon occlusion and/or deep guide catheter intubation, 3 (0.6%) cases of 
air embolism and 1 case of vessel dissection (0.2%). There were no cases of coronary spasm or MACE during or 
within the 24 hour period following OCT examination. 
Conclusions: OCT is a specialised technique with a relatively steep learning curve. Major complications are 
uncommon and can be minimised with careful procedural planning and having an awareness of the potential 
contributory risks, especially deep guide catheter intubation during contrast flushing. Upcoming developments will 
make OCT more practical and less procedurally demanding, also potentially conserving contrast volume 
considerably. 
 
 
 
Optical coherence tomography (OCT) is an intracoronary imaging technique using near infrared 
light with a much higher spatial resolution than intravascular ultrasound (IVUS). The 15 micron 
resolution permits detailed characterisation of the vessel wall giving new insights into the in-vivo 
characterisation of atherosclerotic plaque and tissue responses following stent implantation. 
Unlike IVUS however, the technique requires flushing of the coronary artery to allow light 
transmission with the first generation OCT system also mandating proximal vessel balloon 
occlusion. Whilst the imaging resolution benefits of OCT are clear, the need for a flush system 
increases the complexity of the technique, and the risks associated with this have not been 
evaluated. The purpose of the present multi-centre registry was, for the first time, to assess the 
acute complications associated with the clinical use of intracoronary OCT in a large number of 
patients. 
 
Methods 
Study population and OCT procedure 
We conducted a multicentre registry to evaluate the safety of OCT. Data from patients 
undergoing OCT examination in 6 centres were reviewed. Consecutive patients who had OCT 
examination performed before January 31, 2008 were retrospectively included. Weight adjusted 
heparin was administered as standard prior to OCT imaging. All OCT examinations were carried 
out using a dedicated optical wire (ImageWire, LightLab Imaging Inc., Westford, MA, USA) 
connected to either the M2 or M3 OCT console (LightLab Imaging Inc., Westford, MA, USA). 
All participating centres completed the demographic, clinical and procedural case information 
using a uniform datasheet that was centrally analysed. The indications to perform OCT were 
categorised into evaluation of (A) lesion/plaque, (B) percutaneous coronary intervention (PCI) 
or (C) stent tissue coverage at follow-up. The number of vessels imaged, together with the OCT 
flushing strategy (with or without proximal vessel balloon occlusion, see below) were recorded. 
OCT exclusion criteria applied by operators/centres included impaired left ventricular ejection 
fraction (<30%), renal impairment (serum creatinine >1.5mg/dL), single remaining or tortuous 
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vessel. When the non-occlusive technique was used, the additional contrast load required to 
permit imaging in a blood-free environment was documented.  
Flush strategy 
Infrared light is unable to penetrate blood, thus imaging must be accompanied by transient 
clearance of the field of view from blood. In clinical intracoronary OCT, two methods have been 
established: 1) using a proximal occlusion balloon with flushing of crystalloid solution through 
the end hole of the balloon catheter using a power injector or 2) A non-occlusive approach with 
contrast flush injection via the guiding catheter.(1) 
Balloon occlusion method 
A low-pressure, short over-the-wire balloon (Helios, Goodman Inc, Nagoya, Japan) with large 
inner lumen is advanced over a conventional guidewire distal to the region of interest. The 
guidewire is then replaced with the dedicated OCT imaging wire and the balloon catheter is 
positioned in the proximal part of the vessel. Inflation of the balloon is performed using a 
dedicated indeflator to 0.5-0.7atm during which coronary blood flow is replaced by continuous 
infusion of Ringer’s lactate or physiological saline at a rate of 0.5-1.2ml/sec using a power 
injector (e.g. Mark-V ProVis, Medrad, Inc. Indianola, PA, US).(1-3) A motorised pullback of the 
image wire is then commenced at a rate of 1.0mm/sec to acquire images. 
Non-occlusive technique 
As the handling of the OCT image wire is limited by the fact that it contains an optical fibre and 
is not comparable to a standard guidewire with respect to steerability, pushability and 
torqueability, its safe passage distal to the region of interest can be facilitated by use of an over-
the-wire catheter (e.g. single lumen Transit, Cordis, Johnson & Johnson, Miami, FL, US or 
double lumen 0.023” TwinPass, Vascular Solutions Inc, Minneapolis, Minnesota, US). The 
automated pullback (at 3.0mm/sec) is then commenced during simultaneous flushing of viscous 
iso-osmolar contrast (e.g. Iodixanol 320, Visipaque™, GE Health Care, Cork, Ireland) through 
the guiding catheter. This can be achieved either manually or by use of an automated power 
injector (e.g. Mark-V ProVis, Medrad, Inc. Indianola, PA, US).(1-3) 
OCT risks 
Any complication judged by the operators to have occurred during or within the immediate 24-
hour period following OCT examination was included. All events and complications were 
included, even if transient with no clinical sequeale 
Risks were categorised into: 
1) Self-limiting events  
2) Major complications (arrhythmia, embolisation, coronary dissection or spasm) including 
major adverse cardiac events (defined as MI, emergency revascularisation including 
percutaneous or surgical, and death).  
3) Mechanical device failure 
 
Furthermore, all risks were classified based on their eventual outcome as: A) Immediate 
correction with no specific action required B) transient but requiring specific treatment with 
resolution before the patient left the catheterisation laboratory or C) required 
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treatment/surveillance following discharge from the catheterisation laboratory (including 
lengthening patient’s hospitalisation). 
Study centres 
The 6 participating centres were located in the Netherlands (1 centre), United Kingdom (2 
centres), Italy (1 centre), Germany (2 centres). The number of OCT studies contributed by each 
centre was: Thoraxcenter (Rotterdam, the Netherlands n= 162, 34.6%), Royal Brompton 
Hospital (London, UK, n=91 19.4%), St Giovanni Hospital (Italy, n=85, 18.2%), Helios Heart 
Centre (Siegburg, Germany, n=64, 13.7%). Medizinische Poliklinik, University of Munich 
(Munich, Germany, n=36, 7.7%) and Harefield Hospital (Middlesex, UK, n=30, 6.4%).  
Statistical analysis 
Descriptive analyses were used. Results are quoted as percentages for categorical data or as mean 
± standard deviation for continuous variables. Continuous and categorical variables were 
compared with the t-test and the chi-square/Fisher's exact test as appropriate. A p value of 
<0.05 was considered significant. 
 
Results 
Baseline clinical and procedural characteristics 
A total number of 468 OCT examinations were recorded. Table 1 shows the baseline clinical and 
procedural characteristics. OCT was performed for plaque/lesion evaluation in 187 (40.0%), PCI 
evaluation in 132 (28.2%) and for the assessment of stent tissue coverage at follow-up in 149 
(31.8%) of patients. A total of 510 vessels were imaged (1.1±0.3/patient). The LAD and RCA 
were the most frequently imaged vessels. A small proportion of patients had OCT imaging of the 
left main coronary artery (1.2%) and a bypass graft (1.0%). 
Of the 468 patients, 256 (54.7%) had images acquired during proximal balloon occlusion while 
the remaining 212 (45.3%) had OCT using a non-occlusive technique. In these patients, the 
additional mean contrast load used for flushing during OCT imaging was 36.6±9.4ml. 
Risks of OCT  
All observed complications are summarised in Table 2. The eventual outcome of the adverse 
events and complications encountered is depicted in Table 3. 
1) Self-limiting events 
As expected, the most frequent observation was transient chest pain during OCT image 
acquisition (47.6%). In all cases this settled following cessation of imaging and was significantly 
more frequent in patients imaged using the occlusive compared to non-occlusive technique 
(69.9% vs. 20.8%, p<0.001). In association, transient electrocardiographic changes were also 
observed with widening of the QRS complex or ST-segment depression in 41.0% and ST-
elevation in 4.5%, almost exclusively in those imaged using proximal vessel balloon occlusion. 
Sinus brady and tachycardia was infrequently observed and settled promptly following cessation 
of imaging. There were 2 (0.4%) cases of transient atrio-ventricular block that spontaneously 
resolved following deflation of the proximal occlusion balloon and withdrawal of the catheter. 
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 n=468 
Age (yrs) 63.7±9.1
Males 367 (78.4)
Hypertension 264 (56.4)
Diabetes Mellitus 94 (20.1)
Dyslipidaemia 279 (59.6)
Baseline LVEF (%) 61.5±11.2
Prior myocardial infarction 138 (29.5)
Prior coronary artery bypass grafting 23 (4.9)
Prior PCI 247 (52.7)
Clinical Presentation 
   Stable angina 248(53.0)
   Unstable angina 121 (25.9)
   ACS/STEMI 99 (21.1)
Indication for OCT
   Plaque/lesion assessment 187 (40.0)
   PCI assessment 132 (28.2)
   Follow-up stent tissue coverage 149 (31.8)
Target vessel n=510
   Number of vessels imaged/patient 1.1±0.3
   Left Main 6 (1.2)
   Left anterior descending 222 (43.5)
   Diagonal 14 (2.7)
   Right 163 (32.0)
   Left circumflex 83 (16.3)
   Obtuse marginal 17 (3.3)
   Graft 5 (1.0)
OCT System used
   M2 323 (69.0)
   M3 145 (31.0)
OCT flushing technique 
   Proximal balloon occlusion 
technique 
256 (54.7)
   Non-occlusive technique 212 (45.3)
Mean contrast volume (non-occlusive 
technique, ml) 
36.6±9.4
Table 1: Baseline clinical and procedural characteristics 
 
LVEF-left ventricular ejection fraction; PCI-percutaneous coronary intervention; ACS-acute coronary syndrome; STEMI-ST 
elevation myocardial infarction; OCT-optical coherence tomography; 
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 All (n=468) Occlusive 
technique 
(n=256) 
Non-
occlusive 
technique 
(n=212) 
p-value 
Self-limiting events   
Chest pain  223 (47.6) 179 (69.9) 44 (20.8) <0.001 
Widening QRS/ST     
depression 
192 (41.0) 139 (54.3) 53 (25) <0.001 
ST elevation 21 (4.5) 17 (6.6) 4 (1.9) 0.01 
Sinus bradycardia 14 (3.0) 11 (4.3) 3 (1.4) 0.07 
Sinus tachycardia 10 (2.1) 7 (2.7) 3 (1.4) 0.33 
Atrio-ventricular 
block 
2 (0.4) 2 (0.8) 0 0.19 
Major Complications   
Arrhythmias   
Atrial fibrillation 0 0 0 - 
Ventricular 
tachycardia 
0 0 0 - 
Ventricular 
fibrillation 
5 (1.1) 3 (1.2) 2 (0.9) 0.81 
Coronary spasm 0 0 0 - 
Dissection 1 (0.2) 1 (0.4) 0 0.36 
Perforation 0 0 0 - 
Thrombus 0 0 0 - 
Air embolism 3 (0.6) 2 (0.8) 1 (0.5) 0.68 
Mechanical device 
failure 
  
Wire tip fracture 1 (0.2) 0 1 (0.5) 0.45 
Major adverse cardiac 
events during the 
procedure or in the 24 
hour period post. 
0 0 0 - 
 
Table 2: Risks of OCT 
 
 
 
Immediate resolution 96.7%
Required specific treatment but resolved before 
leaving the catheterisation laboratory 
3.1%
Persisting  beyond discharge from catheterisation 
laboratory  (including requiring ongoing clinical 
surveillance) 
0.2%
 
Table 3: Outcome of adverse events/complications 
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2) Major complications 
Ventricular fibrillation 
Ventricular fibrillation (VF) occurred in 5 (1.1%) patients. In all cases, sinus rhythm was 
promptly restored following cessation of OCT imaging and external defibrillation. Three of the 5 
cases occurred during proximal balloon occlusion. The 2 cases seen with the non-occlusive 
technique were in the context of deep guide catheter intubation of the left coronary artery during 
simultaneous contrast injection.  
Air embolism 
There were 3 (0.6%) cases of air embolisation. In 1 case, this occurred early on in the procedure, 
when introducing the guiding catheter specifically with the intention to perform OCT. Two 
other cases occurred during flushing of the crystalloid solution with air inadvertently introduced 
during connection of the flush lines. All cases responded promptly to air aspiration, treatment 
with nitrates and in 1 case, nitroprusside administration.  
Coronary dissection 
A minor type-A coronary dissection was observed in 1 (0.4%) patient as a result of the imaging 
wire. Coronary blood flow was not impaired and further treatment was not indicated.  
Coronary spasm 
There were no cases of coronary spasm observed during OCT imaging.  
MACE 
There were no MACEs observed during or in the 24 hour period following OCT imaging. In 
one patient, stenosis was observed at the site of previous balloon occlusion 4 months following 
OCT evaluation of the LCx. Due to the presence of multi-vessel coronary disease with angina, 
the patient was referred for CABG. 
3) Mechanical device failure 
Although there was no adverse clinical outcome observed, in 1 (0.2%) patient having OCT 9 
months following stent implantation, the imaging wire became entrapped amongst stent struts in 
the LAD with subsequent fracture at the distal tip. Four month follow-up was uneventful with 
control angiography showing patent vessel without flow abnormalities. 
Discussion 
This is the first systematic registry to demonstrate the acute risks related to OCT imaging in a 
large number of patients. The high-resolution, together with advantages over other imaging 
modalities such as IVUS, have made OCT very popular for the detailed assessment of 
atherosclerotic plaque and coronary stents. As a result, this study provides essential safety 
information that will see OCT performed in a more informed manner, both for operators and 
patients alike. 
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Several groups have reported their clinical experience with OCT over the last few years.(2-11) 
Nevertheless, only limited information about acute complications of this procedure is available. 
Recently, Yamaguchi et al (12) examined the feasibility of OCT and IVUS imaging in 76 patients. 
Although transient chest pain and electrocardiographic changes caused by imaging were not 
considered as part of their study, there were no adverse events reported following both IVUS 
and OCT, with the latter being performed exclusively using the occlusive method. In contrast, 
the present study included a large number of consecutive patients undergoing OCT examination, 
and recorded all potential adverse events, even if transient and benign. We believe this permits a 
more informed assessment and is therefore representative of the ‘real world’ application and 
safety of OCT imaging.  
The present study also assessed patients having OCT imaging using the non-occlusive technique 
that will, because of its simpler procedural requirements, become the mainstay method for OCT 
image acquisition, eliminating the cumbersome proximal balloon occlusion requirements. Such 
developments will be realised in the not too distant future with the introduction into clinical 
practice of faster image acquisition speeds thanks to optical frequency-domain technologies. 
Therefore, the expected rise in OCT use is another reason why comprehensively reporting the 
safety profile of the technique remains of paramount clinical importance. 
The spectrum of adverse events observed in relation to OCT imaging in our study was broad. 
The majority of events recorded were minor and transient, with chest pain being the most 
frequent. This is not surprising as, in a significant proportion of patients (54.7%), images were 
obtained during proximal balloon vessel occlusion. In all cases, the chest pain resolved following 
cessation of imaging or deflation of the occlusion balloon. The mechanisms purporting to link 
balloon coronary occlusion and chest pain are complex and include the triggering of several 
neural responses stimulating coronary mechanoceptors and vagal/sympathetic cardiac afferent 
fibres.(13,14)  
Electrocardiographic changes were observed in almost half the patients. Such changes are also 
frequently observed during angioplasty and stent implantation and are likely reflective of 
underlying ischaemia. In addition to ST-segment changes, transient prolongation of the QRS 
interval was seen. Although this study was not designed to measure the QRS interval, 
prolongation was judged visually during OCT imaging. This remains a highly sensitive marker of 
ischaemia during percutaneous coronary intervention (PCI), even more so than ST-segment 
changes and chest pain which is highly subjective.(15) Furthermore, coronary occlusion, 
particularly of proximal or middle artery segments is directly linked to observations of QRS 
prolongation.(15) The knowledge that almost half of all patients are likely to experience some 
level of chest discomfort and/or electrocardiographic changes of ischaemia during OCT imaging 
should serve to inform patients prior to the procedure and, where indicated, encourage the use 
of pre-medication, such as short acting analgesics.  
The frequency of arrhythmias observed, particularly life-threatening VF that occurred in 5 (1.1%) 
of patients, warrants further analysis. Several studies have shown the incidence of VF during 
coronary angioplasty is about 1.5%,(16,17) with the rate dropping down to around 0.6% for 
diagnostic procedures.(18,19) In addition to ischaemia, other mechanisms have also been 
identified including reperfusion, electrolyte imbalances, coronary instrumentation, osmolarity and 
electrolyte composition of contrast agents and intra-coronary thrombus. (20-26)  
Iodixanol (Visipaque™, GE Health Care, Cork, Ireland) is the contrast agent that is 
preferentially used for flushing during the non-occlusive method. The advantage lies in its higher 
viscosity relative to other agents, which permits optimal blood clearance for OCT imaging at the 
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given flush volumes through the guiding catheter. This agent has also been shown to have a 
lower propensity to cause VF given its lower osmolality, higher viscosity and higher 
concentration of sodium and calcium chloride molecules compared to other non-ionic media. 
(27-30) 
In the 2 cases in which VF occurred during contrast flush, the operators reported deeply 
intubating the guide into the left coronary artery in an attempt to optimally deliver the contrast 
flush. Such a move, in hindsight is thought to potentiate the risk of VF with prior reports 
showing that the combination of a wedged catheter and contrast flush is a high-risk situation for 
inducing VF.(24,31,32) Given that VF was more frequent in the patients during the occlusive 
technique with flush of crystalloid solution and, therefore no contrast, it is obvious that other 
mechanisms are at play, with ischemia still a major contributor. Nevertheless, reporting of such 
events encourages further work in developing alternative, non-contrast based flushing solutions 
that are bio-compatible while eliminating the potential unwanted effects of contrast agents. 
Other complications, such as dissection and air embolisation are not specific to OCT and can be 
observed at any stage of an invasive procedure. Recently Kim et al (33) reported a single case of 
thrombus formation during elective OCT interrogation of LAD stents at 7 months follow-up. 
Although this is a potential complication with any arterial instrumentation, we did not observe 
any such cases in our cohort of patients, all treated with weight adjusted heparin prior to OCT 
assessment.  
Compared to IVUS, the present study did not identify cases of vessel spasm with dissection seen 
in 1 patient and device related failure in a further 1 patient. Prior IVUS studies found an 
incidence of 3% of coronary spasm, in some, also resulting in abrupt vessel occlusion.(34) This 
was irrespective of the size of the IVUS catheter used.(34) Technical failure of the IVUS system 
was observed in 0.4% including guide wire winding or breakage of the catheter.(34) Such 
complications are fortunately uncommon but are inherent with invasive procedures requiring 
intra-coronary catheter manipulation and instrumentation.  
The incidence of complications encountered in relation to the OCT procedure is consistent with 
safety data from coronary angioscopy. Similarly, angioscopy requires balloon occlusion during 
image acquisition although balloon-related vessel injury has not been shown to be a problem 6 
months following angioscopic examination.(35) The general trend for OCT image acquisition is 
to eliminate this aspect thereby simplifying the procedure considerably. 
Angioscopic technology has also remained rather stagnant over the years causing it to be used 
only by a select few specialised centres world-wide. In contrast, OCT has rapidly evolved from 
the initial use of angioplasty balloons and catheters to dedicated, low profile materials, all 
contributing to a safer procedure. Further, OCT permits the accurate quantification of both 
plaque and tissue strut coverage and is also compatible with 6 French guiding catheters.  With 
rapid technology progression in the field, we expect OCT to being widely applied in the near 
future  
Limitations 
This study was a retrospective analysis, however included a large number of consecutive patients 
undergoing OCT at different centres. Also, as OCT is a relative ‘new comer’ to the field of 
intravascular imaging, cases from the early phase of OCT technology development were included 
in this study meaning that complication rates were also inclusive of this early experience and 
might reflect to a certain degree the learning curve of the technique. Nevertheless, to allow an 
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informed assessment about the safety profile, all potential adverse events were included, even if 
transient and benign. 
Conclusions 
OCT technology has moved at a rapid pace with greater refinements in materials and technique 
already contributing to increased clinical uptake. Future developments such as optical frequency 
domain imaging will see OCT use simplified and therefore become conducive to more centres 
and operators world-wide. Nevertheless, OCT is a specialized technique with a relatively steep 
learning curve and therefore, requires adequate proctorship. Major complications are uncommon 
and can be minimised with careful procedural planning and being aware of the potential 
contributory risks, especially deep guide catheter intubation during contrast flushing and 
minimising the duration of image acquisition in preference for more frequent but shorter 
imaging runs. Developments will also make OCT more practical and less procedurally 
demanding, also potentially conserving contrast volume considerably. The benefits in relation to 
a greater understanding of coronary artery disease and responses following stent implantation are 
enormous, meaning that light-based imaging will continue to develop well beyond the current, 
predominantly research based applications. Knowledge of the procedural safety profile is 
therefore essential to help inform patients and operators. 
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Optimising image acquisition 
Stent expansion, apposition and symmetry were the three criteria of intravascular ultrasound 
(IVUS) guided optimal stent deployment in the bare metal stent era (1), with at least the criterion 
of stent expansion maintaining its clinical relevance in the drug-eluting stent (DES) era (2). Two 
prospective studies showed that stent malapposition immediately following DES implantation 
was not associated with increased adverse clinical events (3,4). Thus, initial concerns that 
immediate stent malapposition would affect drug delivery to the vessel wall and lead to DES 
failure appeared to be unfounded. Coronary IVUS, however, formerly the gold standard for 
assessing stent strut apposition, is imprecise in the detection of stent malapposition observed in 
around 7% of lesions (3,4), a figure which is probably grossly underestimated. This is due to the 
limited axial and lateral resolution of the ultrasound waves (100-150 Ƭm) and the constant 
presence of artefacts around stent struts (side-lobes, shadowing). Optical coherence tomography 
(OCT) uses infrared light with the advantage of greater resolution (10-15 Ƭm) and less strut 
induced artefacts compared with IVUS (5,6). Unlike the first OCT prototypes used by Jang et al 
(5,6), new commercial systems (LightLab Imaging Inc., Westford, MA, USA) can acquire 
contiguous images with a motorised pullback system as used with IVUS7. Still, OCT has some 
disadvantages including a more complex process of image acquisition that requires transient 
proximal flow occlusion with a balloon. Since there is definite learning curve to achieve optimal 
image quality, this article will focus on methods and techniques to attain optimal assessment of 
stent strut apposition, using the current OCT system. 
 
Proximal balloon occlusion and blood removal 
The new OCT system consists of the Helios™ proximal occlusion balloon catheter and 
ImageWire™. Because of the length and maximal diameter of the currently available occlusion 
balloon, the luminal diameter proximal to the culprit lesion must be between 2.5 mm and 4.0 
mm, and ostial or very proximal lesions (< 15 mm from ostium) are not suitable for imaging. 
Other contraindications are listed in Table 1. 
Table 1. Exclusion criteria for optical coherence tomography. 
Poor left ventricular function
Haemodynamic instability
Single remaining vessel
Lumen proximal to the culprit lesion < 2.5mm or > 4.0mm
Ostial/very proximal (< 15mm from ostium) lesion
Highly tortuous proximal vessel
 
 The Helios™ proximal occlusion balloon catheter is an over-the-wire 4.4 Fr catheter (inner 
diameter 0.025”), compatible with 6Fr guiding catheters (inner lumen diameter > 0.071”), which 
is advanced distal to the stented lesion using a conventional angioplasty guidewire (0.014’’). The 
guide wire is then replaced by the OCT ImageWire™ (0.019’’ maximum diameter), and the 
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occlusion balloon catheter is withdrawn proximal to the segment to be assessed leaving the 
imaging wire in position (Figure 1).  
 
 
Figure 1. Helios™ proximal occlusion balloon catheter and ImageWire™. Intra-coronary flush is continuously 
performed via the end-hole of the (over-the-wire) occlusion balloon catheter and the occlusion balloon dilated 
proximal to the target segment during observation 
During imaging acquisition, coronary blood flow must be removed and we adopted a continuous 
flush of Ringer’s lactate solution via the end hole of the occlusion balloon catheter at a flow rate 
of 0.5- 1.5 ml/sec. Two Y-connectors are needed and attached to both a guiding and an 
occlusion balloon catheter respectively as shown in Figure 2. We use a power injector (Mark V 
ProVis, Medrad, Inc., Indianola, PA, USA) for this slow injection with a setting of rise/fall: 0 
sec, pressure limit: 100 psi, delay: 0 sec under inflation of the highly compliant occlusion balloon 
proximal to the lesion (0.5- 0.7 Atm). The vessel occlusion time is limited to a maximum of 30 
sec to avoid haemodynamic instability or arrhythmias. The stented segments are imaged using an 
automated pull-back (1.0 mm/sec) from distal to proximal. The cross sectional images are 
acquired at 15.4 frames/sec. In case the segment of interest is not completely studied because its 
length is > 30 mm or the continuous pull-back has to be interrupted due to patient instability, 
chest pain or arrhythmias, a second pull-back is performed again to accomplish complete lesion 
assessment. 
 
Figure 2. Proximal end of guiding catheter and proximal occlusion balloon catheter showing the connections for 
the indeflator, power injector and guidewire. 
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How to optimise image quality 
With increasing experience, we are generally able to acquire optimal images in around 90% of 
each lesion or stented segment studied. The main cause of failure remains inadequate blood 
removal. We believe optimal positioning of the balloon and selection of the infusion rate can 
overcome this problem in most cases. In the last 20 cases studied, images inadequate for 
assessment were taken in 1/20 (5%) and the cause of failure was inability to cross a very calcified 
and tortuous vessel with a stiff and bulky delivery balloon. There are however, some limitations 
that may preclude complete lesion and stent assessment and these will be discussed in detail 
below. In brief, the major limitations have to do with incomplete lesion assessment during 
placement of the imaging wire, inadequate blood removal and finally the limited scan range (5 
mm) of the current OCT system. It has also been challenging to remove coronary blood flow 
completely in lesions involving large side branches and immediately following recanalisation of 
chronic total occlusions due to the flow from collaterals. The two crucial points therefore 
required to obtain optimal cross sectional images using the current OCT system are correct 
placement of the imaging optic sensor and optimisation of blood removal using the proximal 
occlusion balloon with continuous intra-coronary flush. We provide some tips and tricks that 
may be useful. 
 
 
Imaging wire placement 
Since the imaging wire is not torquable, we advance the over-the-wire occlusion balloon distal to 
the lesion to be assessed / stented segment to obtain a distal wire placement. Unlike the IVUS 
transducer, the optical sensor is invisible under fluoroscopy (Figure 3C) and therefore one must 
estimate the correct position, using the distal 15 mm radiopaque tip (Figure 3D) of the imaging 
wire and the two markers of the balloon catheter (Figure 3A, 3B). When fully advanced, the 
sensor is located 6-7 mm proximal to the radiopaque part as easily confirmed by direct 
observation of the position of the red light emitted when the imaging wire is handled out of the 
body. As there are no direct radiopaque markers for the infrared sensor, and despite meticulous 
attention, it is still possible to miss imaging an area of interest resulting in incomplete distal 
Figure 3. ImageWireTM  placement. The infrared 
sensor (C), located 6-7 mm proximal to the distal 
15 mm radiopaque wire tip (D) when fully 
advanced is invisible under fluoroscopy. It is 
correctly positioned distal to the stent (indicated by 
dotted lines). The occlusion balloon catheter tip 
marker (B; 5 mm proximal to the distal end) is 
above the proximal end of the stented segment. (A) 
indicates the centre marker of the occlusion balloon 
(10 mm proximal to B). 
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lesion edge assessment. Imaging after stent implantation facilitates positioning because it is 
sufficient to advance the proximal end of the radiopaque wire tip at least 1 cm distal to the stent 
struts to image the entire stented segment. For imaging prior to treatment, it is important to note 
that the occlusion balloon is too bulky to cross severe stenoses before pre-dilatation and that the 
imaging wire should be advanced distal to the lesion to ensure that the segment of interest is 
fully visualised. 
Proximal occlusion balloon 
Although the company’s instruction manual advises the use of diluted contrast (30-50% mix) to 
inflate the occlusion balloon, we use 0.9% normal saline. Saline takes less time for the occlusion 
balloon to be both fully dilated (to occlude blood flow) and deflated (to restore flow), resulting 
in a shorter period of ischaemia. The disadvantage of this method is that the balloon is not 
identifiable under fluoroscopy, however complete occlusion of the target vessel can be 
confirmed with test injection of contrast through the guiding catheter. 
Intra-coronary flush 
We use Ringer’s lactate during infusion because we expect it to be less arrhythmogenic than 
other crystalloid solutions. In most cases, we use a pump with an injection rate of 0.7 or 1.2 
ml/sec of intracoronary flush with good clearance of blood (Figure 4A). Some particularly large 
vessels, those receiving good collateral flow or those with large side branches require higher 
flushing rates, with the potential for endothelial damage. Fortunately, however, thus far we have 
not experienced any complications such as coronary dissection, target vessel failure or clinical 
adverse events at index procedure or at follow- up. For a large coronary the flow rates required 
are still in a physiological range (0.5–1.5 ml/sec) resulting in a physiological pressure rise. The Y-
connector attached to the guiding catheter must be fastened securely enough to prevent leakage 
of the flushing solution but not too tight as to damage the optical fibre during pull-back. 
 
Complementary flush 
The proximal occlusion balloon can be dilated up to 4.0 mm in diameter, but if it fails to 
completely occlude the vessel being assessed, blood will escape. This will, depending on the 
severity, compromise image quality considerably (Figure 4B) or only partially (Figure 4C) where 
you may continue to visualise the vessel wall albeit in a suboptimal fashion. Even for partially 
insufficient imaging like figure 4C, inflating the occlusion balloon to 0.7 atm (max) and 
increasing flush volume do not always resolve the issue. Repositioning of the occlusion balloon 
or complementary manual injection through the guiding catheter are alternative solutions. 
Despite all efforts, chronically occluded segments following recanalisation are difficult to 
evaluate as collateral flow synchronised to cardiac motion complicates blood removal rendering 
strut assessment every sec (mm) almost impossible (Figure 4D-4F).  
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Figure 4. Optimal and various patterns of suboptimal blood removal. Optimal imaging clearly shows all struts with 
shadows cast (A), (B) indicates considerably deteriorated imaging with bright layers of blood lacking circumferential 
visualisation of vessel wall and (C) indicates minimally deteriorated imaging showing some blood speckles inside the 
lumen and circumferential vessel wall but without clear strut identification compared with (A). Double white rings 
(arrow) are shadows of the proximal balloon catheter tip. (D-F) indicate typical patterns of suboptimal blood 
removal immediately following recanalisation of chronically occluded segments. Blood removal was not easy during 
pull-back because of the collateral blood flow synchronised to cardiac motion rendering strut assessment difficult. In 
the image of (F) some struts can be evaluated, but contiguous assessment at every sec (mm) was almost impossible. 
 
Usage of the fragile imaging wire 
In multiple attempts for pre- and post-procedural assessment or multi-vessel observation, it is 
important to be meticulous in handling the imaging wire: leaving it straight on the table rather 
than keeping it back in the hoop helps to avoid damaging the fragile optical fibre. Furthermore, 
the imaging sensor should not be advanced when either the wire is being inserted or pulled out 
of the guiding catheter or when it is within the hoop. 
Quantitative analysis with OCT: focus on strut apposition 
OCT offers the possibility of a detailed analysis of the superficial plaque components, with 
resolution far superior to IVUS (Figure 5) (8,9). However, the assessment remains largely 
qualitative with the notable exception of the measurement of the thickness of the fibrous cap 
covering necrotic areas. Unless spectroscopy is introduced in the analysis package, with major 
changes in the hardware required to allow dual light emission, OCT cannot quantify the various 
plaque components as IVUS does using radiofrequency analysis (10). The other limitation of 
OCT for plaque quantification is the inability to provide a full thickness analysis of large plaques 
because of its limited penetration. OCT however, offers obvious advantages when dealing with 
superficial structures such as the fibrous plaques and stent struts. In the remaining part of this 
review we will focus on the methods we use to assess strut apposition. 
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Figure 5. Qualitative analysis of superficial plaque components. A) Fibrous plaque: Homogeneous signal-rich 
plaque extending circumferentially (arrow: guidewire artefact). B) Fibroatheroma: Heterogeneous plaque includes 
signal poor regions (arrowhead) with diffuse border indicating lipid components. Cap thickness can also be 
measured. C) Calcified plaque: Image acquired following balloon dilatation of chronically occluded segments 
showing calcium characterised by well delineated signal poor regions extending from 3 to 7 o’clock positions 
(arrows) 
Off-line analysis of contiguous cross sections within the stented segment is performed at 1 mm 
intervals. Firstly, the distal end should be detected with images of circumferential struts. From 
the identified distal end of the stent, every 15 frames (almost equivalent to 1 mm with an 
acquisition rate of 15.4 frames/sec) cross sections are checked and the best images with clearly 
identifiable vessel wall and struts within 2 frames distal or proximal are selected for evaluation of 
strut apposition (‘Selected cross sections’). A proximal end with circumferential struts is also 
detected, and the interval from identified distal to proximal stent end is defined as the ‘scanned 
stent length (mm)’. ‘Percent (%) scanned stent length’ is calculated as scanned stent length 
divided by total stent length implanted for the lesion. Detected overlapping length should be 
added to the scanned length for this calculation when two or more stents have been implanted in 
an overlapping fashion. In each selected cross section ‘Complete cross sectional imaging’ is 
defined as entirely circumferential image acquisition of the luminal border (Figure 6). ‘Percent 
(%) complete cross sectional imaging’ is calculated as the rate of complete cross sectional 
imaging divided by the number of selected cross sections. 
Stent struts appear as highly reflective surfaces and cast shadows on the vessel wall behind. 
When the strut is not fully attached to the vessel wall by visual estimate (almost equivalent to > 
50 Ƭm), the position of a stent strut relative to the vessel wall is measured by magnifying the 
individual stent strut to maximise accuracy. Firstly, one pointer is placed on the endo-luminal 
surface of the reflection, followed by another at the surface of the vessel wall within the stent 
strut shadow using the reflections of the wall on either side of the strut shadow. The 
measurement line should be as perpendicular to the strut and vessel wall as possible (Figure 7). 
In case a strut protrudes into a side branch ostium, this should be classified as ‘malapposed’ and 
excluded from quantitative strut analysis. 
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Figure 6. Complete cross sectional imaging of drug-eluting stents with apposed struts. (A) Cypher Select, (B) Taxus 
Liberte, (C) Endeavor, (D) CoStar. Cypher struts appear wider than the other 3, but all of their strut thicknesses are 
underestimated because of limited penetration of OCT. 
 
Figure 7. Measurement of strut apposition. The distance between the endo-luminal surface of the strut reflection 
and the vessel wall is measured prolonging and joining the contours of the wall on either side of the strut shadow 
with a measurement line as perpendicular as possible to the strut and vessel wall. The distance between (a) and (a’) is 
equal to 230 mm. 
Definition of strut apposition in DES 
Since OCT can show only the endo-luminal surface of the strut due to limited penetration 
through the metal (Figure 8), strut and polymer thickness should be considered in assessing 
apposition for each type of DES design. Apart from Yukon® DES stent (Translumina GmbH, 
Hechingen, Germany) with 115 Ƭm (0.0045”) metal strut thickness, no polymer and an uneven 
rapamycin sprayed coating, four types of DES are clinically available in Europe presently: Cypher 
Select™ stent (Cordis, Johnson and Johnson Co., Miami Lake, FL, USA) with 140 Ƭm strut and 
7 Ƭm polymer, Taxus® Liberte™ (Boston Scientific, Natick, MA, USA) with 97 Ƭm and 15 Ƭm, 
Endeavor™ (Medtronic AVE, Santa Rosa, CA, USA) with 91 Ƭm and 8 Ƭm and CoStar™ 
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(Conor Medsystems, Inc., Hamilton Court Menlo Park, CA, USA) with 89 Ƭm strut with no 
polymer around the struts. 
 
 
Figure 8. Visible and real strut thickness and width. A and B: OCT can show only the endo-luminal surface of the 
strut (bright white line) due to limited penetration through the metal; B and C: strut width is overestimated 
compared with the actual profile (black square) due to lateral resolution of 25-40 mm and there is a shadow behind 
struts where the vessel wall is not visible. 
As a composite of metal strut and polymer, the thicknesses of each type of DES differ. 
Consequently, we define ‘malapposed’ stent struts as struts with detachment from the vessel wall 
> 160 Ƭm for Cypher Select, > 130 Ƭm for Taxus Liberte, > 110 Ƭm for Endeavor and > 90 Ƭm 
for CoStar. Struts with distances less than half of the above cut-off values are defined as 
‘embedded’ while all others are defined as ‘protruding’. In combination, both embedded and 
protruding struts are considered apposed to the vessel wall (Figure 9). This classification may 
also be adopted to assess persistent or acquired late malapposition. 
 
Figure 9. Definition of stent strut apposition. Note only endo-luminal surface of the metal can be identified with 
Optical Coherence Tomography. Different cut-offs should be adopted for each stent type. A strut is classified as 
embedded when less than half of a whole strut thickness is protruding into the lumen. 
Peter BW 13-5.indd   74 13-05-09   16:18
75
Optimising image acquisition 
Assessment of tissue coverage following DES implantation 
Unlike conventional stents which developed circumferential coverage with an average thickness 
of 500 Ƭm or more, well visualised with IVUS and angiography (1mm late loss), DES delay and 
prevent the hyperplastic response so that the average late lumen loss for sirolimus- or paclitaxel- 
eluting stents can be as low as 0.1 or 0.2 mm which means the amount of intimal thickening will 
not be detectable with IVUS (11-13). OCT offers a potential alternative to detect and measure 
these tiny layers of intimal coverage (Figure 10) and to assess late strut malapposition that can be 
distinguished, if images immediately after implantation are also available, into persistent (present 
already at the time of stent implantation) and acquired (negative remodelling or disappearance of 
superficial components behind struts such as thrombus). 
 
Figure 10. Definition of late strut coverage. Classified into 3 groups. A: Complete - fully embedded in the tissue or 
circumferentially covered if a strut is protruding. B: Incomplete - partially covered with tissue. C: Absent - no visible 
tissue around a strut. 
 
Limitations 
Current intravascular OCT has some limitations. The imaging wire is extremely difficult to 
manipulate for delivery and the occlusion balloon needs to be advanced over the lesion, with a 
2.3 Fr tip and 4.0 Fr shaft (proximal to the balloon) that may not cross a tight lesion or have 
difficulty being advanced over stented lesions. This last limitation is, however, common to IVUS 
catheters as well. Ostial and very proximal lesions are not suitable for this system using the 
proximal occlusion balloon, because of the length of the tip, approximately 12 mm, and long 
occlusion balloon of 6.5 mm (Figure 1). This is currently under refinement. It should be noted 
however that, an image can still be acquired within the distal catheter end and through the 
balloon. OCT is more accurate in assessing strut apposition compared with IVUS because of 
higher resolution, but its poor penetration (1.5 mm approximately) makes it inferior to IVUS in 
assessing stent expansion. Even if the stent struts are well apposed to the vessel wall (well 
attached to the intimal plaque) the stent may not be optimally expanded because balloon sizing 
with OCT is more difficult as it is often impossible to identify the external elastic membrane and 
the lumen of the distal vessel reference may be collapsed. 
The system requires 30 seconds of complete coronary flow occlusion to observe a lesion of the 
length of 30 mm with the minimal pull-back speed of 1.0 mm/sec. The pull-back speed can be 
increased from 1.0 to 2.0 mm/sec with fixed frame rates of 15.4/sec, but the quality of imaging 
degrades with faster pull-back speeds. We have not experienced any haemodynamic instability or 
arrhythmias, but are compulsive in deflating the balloon and stopping flushing if significant 
ischaemic changes begin to develop. In some cases we have had to perform multiple pull-backs 
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for periods shorter than 30 seconds because of ischaemia. All laborious manipulations with 
multiple pull-backs complicate the procedure and tend to result in incomplete blood removal and 
thereby hamper the quantitative analysis. Uneven images (shifted to one side due to wire bias) 
are often seen in large and tortuous vessels and cause elliptical distortion of the lumen with part 
of the vessel outside the imaging screen. This is at present the most annoying limitation of the 
current software which has a limited scan range of 5 mm. The next generation ImageWire™ will 
offer improved durability and trackability. Similarly, the Helios™ occlusion balloon catheter will 
be modified to have a shorter tip and a more kink resistant shaft. The M2 system (OCT 
hardware) will be improved to offer smoother L-mode (longitudinal) acquisition and edge-
detection software. Eventually, automatic plaque morphology detection will also be included. 
Even after these changes, OCT will still be limited by suboptimal tissue penetration, because 
high resolution and penetration are mutually exclusive. 
Conclusions 
Although the current intravascular OCT system still needs some refinement for better handling 
and image quality, it should be considered the new gold standard in assessing apposition of stent 
struts quantitatively. The techniques and classifications discussed in this review can also be used 
for assessment of late stent malapposition taking into consideration tissue (fibrin or intimal) 
coverage. Clinical relevance between stent strut apposition and late adverse events such as stent 
thrombosis and restenosis in the DES era may also be clarified by OCT. 
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Chapter 6
A Novel approach for quantitative analysis of intracoronary optical 
coherence tomography: High inter-observer agreement with semi-
automated contour detection in native and in stented human coronary 
arteries 
Shuzou Tanimoto, Gaston Rodriguez-Granillo, Peter Barlis, Sebastiaan de 
Winter, Nico Bruining, Ronald Hamers, Michiel Knappen, Stefan Verheye, 
Patrick W. Serruys, Evelyn Regar 
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Objective: This study aims to examine observer related variability of quantitative optical coherence tomography 
(OCT) derived measurements from both in-vitro and in-vivo pullback data 
Background: Intravascular OCT is a new imaging modality using infrared light and offering 10 times higher 
image resolution (15Ƭm) compared to intravascular ultrasound. The quantitative analysis of in-vivo intracoronary 
OCT imaging is complicated by the presence of blood, motion artifacts and the large quantity of information that 
has to be processed.  
Methods: We developed a standardized, automated quantification process for intracoronary OCT pullback 
data with inter-observer variability assessed both in-vitro using post-mortem human coronary arteries and in-vivo 
by studying simple and complex coronary pathology and outcomes following stent implantation. The consensus 
between measurements by two observers was analyzed using the intra- and interclass correlation coefficient and the 
reliability coefficients. Bland-Altman plots were generated to assess the relationship between variability and 
absolute measurements. 
Results: In-vitro OCT assessment was performed in 9 post-mortem coronary arteries. The time needed for semi-
automated contour detection of a 15mm long coronary segment was approximately 40 min. The absolute and 
relative difference between lumen area measurements derived from 2 observers was low (0.02±0.10mm2; 
0.3±0.5% respectively) with excellent correlation confirmed by linear regression analysis (R2 0.99; p<0.001). 
Similarly, in-vivo measurements demonstrated a high correlation with the main source of inter-observer variation 
occurring as a result of coronary dissection and motion artifact. The absolute and relative difference between 
measurements were 0.11±0.33mm2 (1.57±0.05%) for lumen area (R2 0.98; p<0.001), 0.17±0.68mm2 
(1.44±0.08%) for stent area (R2 0.94; p<0.001) and 0.26±0.72mm2 (14.08±0.37%) for neointimal area 
(R2 0.78; p<0.001).  
Conclusions: Highly accurate computer-assisted quantitative analysis of intracoronary OCT pullbacks is 
feasible with low inter-observer variability. The presented approach allows for observer independent analysis of 
detailed vessel structures and may be a valuable tool for future longitudinal studies incorporating OCT. 
 
 
Optical coherence tomography (OCT) is a light-based imaging modality that can be used to 
study biological tissues in vivo (1). Recently, the concept of catheter-based intracoronary OCT has 
been introduced (2-4) allowing in-vivo imaging of the coronary vessel wall with a lateral resolution 
of 15Ƭm and an axial resolution of 25Ƭm (5). The currently accepted gold standard, intravascular 
ultrasound (IVUS), operates at a lateral resolution of approximately 120Ƭm and axial resolution 
of 80Ƭm. The unique high-resolution OCT imaging modality permits the analysis of coronary 
structures in greater detail. The measurement accuracy of intracoronary OCT has been 
established in post-mortem human coronary arteries and showed good correlation to histo-
morphometry (6). However, compared to ex-vivo imaging, quantitative analysis of in-vivo 
intracoronary imaging is more complicated due to the presence of blood and motion artifacts 
during cardiac cycle. Furthermore, the OCT dataset acquired during motorized pullback in-vivo 
is much larger than local imaging of selected cross sections as performed in post mortem studies. 
A pullback through the region of interest (ROI) is necessary in order to visualize the three-
dimensional morphology of the coronary artery. The present research proposes a standardized 
automated quantification process for intracoronary OCT pullback data. To test its accuracy, 
inter-observer variability was assessed in-vitro and in-vivo including, both, simple and complex 
vessel anatomy, represented by native coronary arteries before and after stent implantation.  
 
Methods 
 
OCT imaging system 
 
We used a commercially available system for intravascular OCT imaging (LightLab Imaging Inc., 
Westford, MA, USA). The light source was a 1310nm broadband super luminescent diode with 
an output power in the range of 8.0mW. The imaging depth was approximately 1.5mm with an 
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axial and lateral resolution of 15μm and 25μm, respectively. The imaging probe (ImageWire ™ 
LightLab Imaging Inc., Westford, MA, USA) had a maximum outer diameter of 0.019 inch and 
contained a single-mode fiber optic core within a translucent sheath. The image wire was 
connected at its proximal end to the imaging console that permitted real-time data processing 
and two-dimensional representation of the backscattered light in a cross-sectional plane. Images 
were acquired at 15 frames per second. The fiber optic core was withdrawn within the catheter 
sheath using automated pullback at 1.0 mm/s.   
The accuracy of the OCT system has been recently reported. Diameters of phantoms with 
precision-drilled circular holes were measured in-vitro using proprietary software from LightLab 
with excellent accuracy (-0.03) and precision (0.02)(7). 
 
Human coronary arteries – post mortem study 
In all cases (n=9), the left anterior descending artery was studied after pressure fixation using 
10% buffered formalin. The take off of the first diagonal branch was used as proximal landmark. 
Both, the proximal and the distal end of the coronary specimen were sutured to a 6F introducer 
sheath and positioned in a saline bath at 37° C. The OCT imaging wire was introduced via the 
proximal sheath into the specimen and positioned in such a way that the distal OCT catheter tip 
was fixed in the distal sheath and an automated OCT pullback was performed.  
 
Human coronary arteries – clinical studies 
Patients undergoing a stent-implantation procedure (n=10) or a 6-month follow-up angiogram 
post stent implantation (n=10) were studied. A standard femoral approach with 7F guiding 
catheters was used. All patients received weight-adjusted intravenous heparin in order to 
maintain the activated clotting time > 300 sec and intravenous analgesics before imaging. First, a 
dedicated compliant occlusion catheter (Helios, Goodman Inc, Japan) was introduced into the 
artery and positioned proximally to the region of interest (ROI). The occlusion catheter allows 
(a) for limiting the coronary blood flow by very low-pressure (0.3 atm) inflation of a short 
(6.0mm length) balloon, (b) for simultaneous clearing of the artery by delivering flush distally to 
the balloon into the lumen, (c) for introduction of the OCT imaging wire into the artery. After 
positioning the occlusion catheter in over the wire technique, the standard 0.014” guide wire was 
withdrawn and the OCT imaging wire introduced via the central lumen distal into the target 
vessel. An automated OCT pullback was then performed. During OCT image acquisition, the 
artery was cleared with lactated ringer’s solution (flow rate 0.5ml/s; temperature 37° C). 
Sufficient occlusion of the lumen was documented by contrast injection via the guiding catheter 
and the balloon pressure increased to 0.5 atm if necessary. 
 
Quantitative OCT (QOCT) 
 
The digitized tomographic OCT image dataset was transformed from digital movie file format 
(AVI) into the medical DICOM image standard and stored onto a picture archiving system. 
Quantitative OCT analysis was performed using dedicated software (CURAD vessel analysis, 
CURAD BV, Wijk bij Duurstede, Netherlands)(8) (Figure 1).  
 
Every 3rd frame of the pullback of long segments was entered. This reduced the number of 
frames in the Curad software from n to at most (n/2)+1 per set. Two blinded observers 
experienced in the theory and practice of OCT performed the analysis. In non-stented arteries, 
the lumen area was directly traced and the mean lumen diameter calculated using a circular 
model. In stented arteries, lumen- and stent area were both directly traced, the mean lumen- and 
mean stent diameter were calculated. Neointimal area was calculated as stent area minus lumen 
area. 
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Figure 1: Example of quantitative OCT analysis in an ex-vivo coronary artery. The digitized tomographic OCT 
image dataset was transformed from digital movie file format (AVI) into the medical DICOM image standard and 
stored onto a picture archiving system. The dedicated software (CURAD) allows for simultaneous display of a cross 
sectional view (A) and two longitudinal cut planes (B). After a selection of a region of interest, the lumen contours 
are traced using automated contour detection whereby both, the cross sectional and the longitudinal image 
information is exploited. 
 
OCT cross sections with a major side branch (diameter >2mm; or side branch take off 
occupying more than 60 degrees of the lumen circumference of the parent vessel) were excluded 
from analysis as well as cross sections in which the complete lumen circumference of 360 
degrees could not be visualized due to motion artifacts during the cardiac cycle. 
 
Statistical analysis 
 
Statistical analyses were performed using SPSS 12.0.1 for Windows (SPSS Inc., Chicago, IL). 
Data are expressed as mean ± SD or median and inter-quartile range, if appropriate. Inter-
observer agreement was determined by comparing measurements of each observer (observer 1 
vs. observer 2) using the Bland-Altman method (9). Data are given as plots showing the absolute 
difference between corresponding measurements of both observers (y-axis) against the average 
of both observers (x-axis). The relative difference between measurements (absolute difference 
divided by the average) gives the bias, its standard deviation gives the random variation. The 
limits of agreement were calculated as mean bias ± 2 SD. Confidence intervals (95%) were 
calculated. In addition, absolute data were analyzed for correlation by regression analysis as 
necessary, but not sufficient, condition for agreement. The regression line was forced through 
the origin. A p-value less than 0.05 (two-tailed students T-test) was considered statistically 
significant. 
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Results 
 
In-vitro coronary arteries 
OCT imaging was successfully performed in all specimens (n=9). Computer-assisted contour 
detection was possible in all pullbacks. In each coronary artery, a ROI of 15mm in length was 
selected for analysis. The time needed for computer-assisted contour detection of a 15mm long 
coronary segment was approximately 40 min. Data for lumen dimensions by both observers are 
given in Table 1. The absolute difference in lumen area between the observers was low 
(0.02±0.10mm2). Linear regression analysis confirmed these observations and showed excellent 
correlation between measurements (R2 0.99). Bland Altman plots for lumen area and lumen 
diameter are shown in Figure 2. 
 Lumen area Lumen diameter 
Observer 1 
      Median (IQR) 2.48 (1.81) mm2 1.78 (0.64) mm
      Mean ± 1SD 3.03±1.95mm2 1.88±0.58mm
Observer 2 
      Median (IQR) 2.49  (1.75) mm2 1.78 (0.62) mm
      Mean ± 1SD 3.02±1.93mm2 1.87±0.58mm
Absolute difference 0.02±0.10mm2 0.00±0.04mm
Relative difference 0.3±0.5% 0.1±0.2 %
Linear regression 
      Slope 0.9904x 0.9905x
      Intercept 0.0125 0.0135
      R2 0.9974 0.9957
      p <0.001 <0.001
 
Table 1: Comparison of lumen measurements in ex-vivo coronary arteries, n=772 frames 
In-vivo native coronary arteries 
OCT imaging could be successfully performed without complications in all patients. The 
majority of patients (90%) developed transient ECG changes indicative of ischemia during 
imaging. Ten coronary segments of 28±9mm lengths were studied. A total of 1807 frames were 
included in the analysis and 399 frames were excluded due to the presence of a major side 
branch or due to incomplete visualization of the lumen circumference due to motion artifacts. 
OCT data are summarized in Table 2. The absolute difference between observers was low 
(lumen area 0.04±0.14mm2) and in the same order of magnitude as for in-vitro measurements. 
Linear regression analysis confirmed these observations and showed high correlation between 
measurements (R2 0.99). Bland Altman plots for lumen area and lumen diameter are shown in 
Figure 3. The bias between the observers was again very low. Main sources of disagreement 
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between observers were situations, in which lumen borders were ambiguous due to anatomical 
factors (e.g. dissections) or due to motion artifacts during the cardiac cycle.  
 
Figure 2: Bland Altman plots for measurements in ex-vivo coronary arteries. The x- axis shows the mean cross 
sectional area, and the Y axis shows the difference between the cross sectional measurements by observer 1 and 
observer 2. The dotted lines indicate the limits of agreement (bias ±2 SD). A) Lumen area B) Lumen diameter 
 
 Lumen area Lumen diameter
Observer 1  
     Median (IQR) 4.34 (2.21) mm2 2.35 (0.6) mm
     Mean ± 1SD 4.29±1.37mm2 2.30±0.40mm
Observer 2  
     Median (IQR) 4.36 (2.19) mm2 2.36 (0.59)mm
     Mean ± 1SD 4.25±1.34mm2 2.30±0.39mm
Absolute difference 0.04±0.14mm2 0.01±0.04mm
Relative difference 0.6±0.4% 0.3±0.2 %
Linear regression  
      Slope 0.9755 0.9731
      Intercept 0.0647 0.0523
      R2 0.9904 0.9894
      p <0.001 <0.001
Table 2: Comparison of measurements in in-vivo coronary arteries, n=1807 frames 
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Figure 3:  Bland Altman plots for measurements in in-vivo coronary arteries. The x- axis shows the mean cross 
sectional area, and the Y axis shows the difference between the cross sectional measurements by observer 1 and 
observer 2. The dotted lines indicate the limits of agreement (bias ±2 SD). A) Lumen area B) Lumen diameter 
 
In-vivo stented coronary arteries at follow-up 
 
Ten coronary segments of 25±11mm lengths were studied. Stent struts covered by neotinimal 
tissue were clearly visible in all segments and in all cross sections. Inter-observer agreement on 
the presence of neointimal tissue was 100%. A total of 2331 cross sections were included for 
analysis. In two patients, totally of 80 cross sections were excluded from analysis because of the 
take-off of a major side branch, and another 73 cross sections because of incomplete 
visualization of the lumen circumference due to motion artifacts.   
OCT data for lumen, stent and neointimal area are summarized in Table 3. Bland Altman plots 
for lumen stent and neointimal area, as well as lumen and stent diameter are shown in Figure 4. 
As expected, the bias for the calculated variable of neointimal area was somewhat higher than for 
directly traced stent and lumen area with greater variability observed in assessing stent area. This 
relates to the operator having to manually trace each individual stent strut compared to a sharply 
demarcated lumen/vessel border when assessing lumen area. 
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Table 3: Comparison of measurements in in-vivo stented coronary arteries, n=2331 frames 
 
Discussion 
The main findings of this study are: (1) Inter-observer variability for lumen dimensions as 
measured by computer-assisted QOCT is extremely low and in a similar range for both in-vitro 
as well for in-vivo studies, despite the occurrence of motion induced artifacts during the 
acquisition in-vivo. (2) Similarly, inter-observer variability in complex vessel anatomy as 
represented by chronic coronary stents was very low. 
 
 
Optical coherence tomography 
OCT is a new intravascular imaging technology that permits the visualization of vascular 
microstructures with high precision. Its unique image resolution, in the range of 15μm, is in the 
magnitude of 10 times higher than the current golden standard, IVUS. Further, the visualization 
of plaque morphology in close proximity to the vessel lumen is superior to that obtained with 
IVUS (10). To date, findings based on single frame analysis only in distinct areas within the 
coronary tree have been published. The clinical application of intracoronary OCT has already 
been demonstrated in both in stable and unstable patients (11). Potential future applications are 
manifold. They may include in-vivo visualization of features associated with vulnerable plaque 
(e.g. thin fibrous cap) (12), analysis of early atherosclerotic lesions (e.g. local intimal thickening), 
the assessment of progression mechanisms of coronary artery disease and the analysis of the 
impact of pharmacological or catheter-based interventions on plaque structures and vessel 
architecture. Intracoronary OCT also provides detailed information relating to stent apposition 
while allowing the accurate quantification of neointimal stent coverage at follow-up. Such 
analyses, however, require OCT studies over relatively long epicardial artery segments. We 
therefore used a dedicated OCT system that allows for data acquisition over long coronary 
segments using an automated motorized pullback.  
 
Computer-assisted analysis approach 
During a motorized OCT pullback a large quantity of cross-sectional images of the coronary 
artery are acquired. For example, at a rate of 15 frames/sec and a pullback speed of 1.0mm/sec a 
ROI of 30mm will result in 450 individual cross-sections. Separate analysis of all these individual 
 Lumen area 
 
Lumen 
diameter 
Stent area Stent diameter Neointima area
Observer 
1
   
Median 
(IQR)
6.1 (3.45) mm2 2.79 (0.815) mm 9.28 (4.055) 
2
3.44 (0.77) mm 2.96 (2.105) mm2
Mean ±1 
SD
5.97±2.41mm2 2.69±0.58mm 9.02±2.77mm2 3.34±0.55mm 3.05±1.48mm2
Observer 
2
   
Median 6.2 (3.63) mm2 2.81 (0.85) mm 9.07 (3.915) 
2
3.4 (0.75) mm 2.77 (2.14) mm2
Mean ±1 
SD
6.07±2.46mm2 2.72±0.59mm 8.84±2.63mm2 3.31±0.52mm 2.79±1.53mm2
Absolute 
diff
0.11±0.33mm2 0.023±0.07mm 0.17±0.68mm2 0.03±0.13mm 0.26±0.72mm2
Relative 
diff
1.57±0.05% 0.79±0.03% 1.44±0.08% 0.72±0.04% 14.08±0.37%
Linear 
i
0.9699x+0.077
7
0.9763x+0.0416 0.9191x+0.5561 0.924x+0.2255 0.8556x+0.6645
R2 0.9818 0.9849 0.9407 0.9471 0.7827 
p <0.001 <0.001 <0.001 <0.001 <0.001 
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cross-sections is cumbersome and time-consuming. In this study, a method similar to established 
quantitative IVUS (QCU) was adapted and applied. This resulted in a user-friendly analysis 
system that allows rapid and observer-independent quantitative analysis. This particular QCU 
software has been validated in the past (8) and is in use as the golden standard for the analysis of 
IVUS studies, having been applied in numerous multi-center trials (13-16).  
 
 
Figure 4: Bland Altman plots for measurements in in-vivo stented coronary arteries. The x- axis shows the mean 
cross sectional area, and the Y axis shows the difference between the cross sectional measurements by observer 1 
and observer 2. The dotted lines indicate the limits of agreement (bias ±2 SD). A)   Stent area B)   Lumen area C) 
Neointimal area D) Stent diameter E) Lumen diameter 
 
Comparison to previous studies 
In a study using IVUS, inter-observer agreement for the presence of neointimal tissue was 62% 
with discrepancy between observers exclusively in very thin neointmal layers and a neointimal 
area <2mm2 (17). In the present study, the inter-observer agreement on the presence of 
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neointimal tissue was 100% with neointima visible in all cross sections, whereby 23% of cross 
section had a neointimal area <2mm2. The higher resolution of OCT compared to IVUS makes 
this imaging modality more sensitive at detecting even small quantities of intimal tissue, and this 
remains one of the major advantages, particularly in the era of drug-eluting stents.   
Recent reports using OCT to assess tissue coverage after stent implantation (18,19) have used 
proprietary off-line software provided by LightLab Imaging Inc. Such an approach involves the 
operator individually measuring each stent strut at 1mm intervals (approximately each 15 frames) 
followed by manually tracing both the stent and lumen area, to derive the neointimal area. We 
have found this technique to be quite cumbersome and heavily operator dependent with each 
analysis of a stented segment taking between 120 to 240 minutes to complete, depending on the 
stent length. The method presented in this study achieves a more robust and reproducible 
analysis in a time and cost-effective fashion. 
 
Clinical implications 
OCT is a unique intravascular imaging modality with the sensitivity to delineate mural and 
luminal structures. As a result, the scope of OCT as both a research and clinical tool remains 
vast. Such a technology allows the precise assessment of lumen dimensions, plaques, thrombi 
and dissections (20), while also being able to assess both immediate and late results of stent 
implantation. While OCT provides additional morphologic information than IVUS, a 
considerable quantity of information still needs to be processed. Adopting a semi-automated, 
computer assisted approach with contour detection remains pivotal in making future studies 
incorporating OCT more reliable and reproducible with less potential sources of operator error. 
 
Limitations 
This study is obviously limited by the number of observations and the narrow range of arterial 
dimensions evaluated. However, the target vessel dimensions represent the majority of clinically 
relevant dimensions in patients. Motion artifacts during the cardiac cycle hampered the 
visualization of the complete vessel circumference in 9% of the cross sections using the current 
OCT software. Modifications in software, OCT imaging catheter design and ECG gated data 
acquisition (21) or retrospective image-based gating (22) of acquired IVUS data might alleviate 
such limitations in the future. The high resolution of OCT is at the expense of penetration 
depth, which is typically limited to approx 1-2mm into the vessel wall limiting analysis to 
structures that are relatively close to the inner lumen border. 
 
Conclusions 
Computer-assisted contour analysis of intracoronary OCT pullback is feasible and enables OCT 
morphometry with low inter-observer variability. This approach allows for observer independent 
QOCT analysis and may be a valuable tool for future longitudinal studies incorporating OCT. 
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Quantitative analysis of intracoronary optical coherence tomography 
measurements of stent strut apposition and tissue coverage 
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Quantitative analysis of OCT data
Background:  The introduction of optical coherence tomography (OCT) as an intracoronary imaging modality 
has allowed accurate assessment of strut apposition and neointimal tissue coverage. This study set out to assess the 
inter and intraobserver variability of measurements of acute stent apposition and strut tissue coverage using OCT. 
Methods: Thirty patients were studied (14 immediately after stent implantation and 16 during follow-up 
angiography [mean of 4.7±2.8 months]) using OCT. Data analysis was performed by 2 experienced observers. 
Struts were classified as embedded, protruding or malapposed to the vessel well. Intimal coverage at follow-up was 
measured as the thickness of tissue covering each strut (Ƭm). Intra and interobserver variability was assessed by 
Bland-Altman plots and the intraclass correlation coefficient (ICC). 
Results: An average of 3967 struts was examined by each observer and, overall, 53.7% of struts were 
embedded, 36.4% protruding and 9.9% malapposed. Low intraobserver variability for all measures of strut 
apposition was found, with repeatability coefficients that ranged between 5.1% and 9.3% and ICC exceeding 
95% in all cases. Interobserver variability was also low (repeatability coefficients 6.6-10.8 and ICC>91.3%). 
Mean intimal thickness in the follow-up group was 172.5μm. Bland-Altman plots demonstrated a low 
intraobserver and interobserver variability for intimal thickness, with repeatability coefficients 26.7Ƭm and 
24.1Ƭm, respectively and ICC exceeding 98.6% for both 
Conclusions: Low intra and interobserver variability can be expected when analyzing OCT data for stent 
apposition and tissue coverage. This supports the validity of OCT as a clinical and research tool in the setting of 
intracoronary stent imaging. 
 
 
Optical coherence tomography (OCT) is rapidly achieving widespread diffusion in 
catheterization laboratories worldwide. Its advantage over intravascular ultrasound (IVUS) is its 
superior resolution (15Ƭm) and fewer artifacts. The current technology permits image acquisition 
using a 1310 nm near-infrared light source that detects backscattering of light from superficial 
microstructures within the coronary wall. OCT has been used as an intra-coronary imaging tool 
for the assessment of stent apposition, neointimal tissue coverage and plaque characterization.(1-
10) To date, there is only one commercially available OCT system which uses a proprietary 
software for offline analysis of acquired images. We sought to assess the inter- and intra-observer 
variability of the current OCT system for stent strut apposition immediately following stent 
deployment and for tissue coverage at follow-up. 
 
 
Methods 
A total of 30 patients were prospectively included in this study. OCT was performed 
immediately after stent deployment in 14 patients and on follow-up angiography in a separate 
group of 16 patients, using the LightLab system (Westford, Massachusetts, US). Blood clearance 
was achieved using a proximal occlusion balloon (Helios, Goodman, Japan) with intra-coronary 
flush of lactated Ringer’s solution through the end-hole of the balloon catheter (flow rate 0.6-
0.9ml/sec) during simultaneous image acquisition at 1.0mm/sec using the dedicated ImageWire 
(LightLab Imaging, Westford, Massachusetts, US) at 15.6 frames/second.  
 
OCT data analysis 
 
Offline OCT images were analyzed by 2 experienced observers. For intraobserver variability, 
measurements were repeated 3-months after the initial assessment by the same observer, who 
was blinded to the previous results. For interobserver variability, measurements were carried out 
independently by the two observers, blinded to each other’s analysis. 
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Acute stent strut apposition 
Analysis of contiguous cross-sections within the stented segment was performed at 1mm 
intervals. In each selected cross section, the distance between the endoluminal border of the strut 
and the intima was measured. As OCT can only image the endoluminal strut border, distances 
were adjusted based on the thickness of the strut, including the polymer, for each of the stent 
types used.(9) Struts were classified as “embedded” when buried into the vessel wall, 
“protruding” when in contact with the vessel wall but protruding into the lumen and 
“malapposed” when no contact between the intima and the strut was detected (Figure 1).  
 
Figure 1 Optical coherence tomography classification of stent apposition into embedded, protruding or 
malapposed. 
 
Strut tissue coverage  
Tissue coverage was assessed by OCT at a minimum of 3 months post-implantation of different 
stents types and the thickness of the tissue overlying each stent strut was measured. 
Statistical Analysis 
Statistical analyses and generation of plots was performed using R version 2.6.1 (The R 
Foundation for Statistical Computing, Vienna, Austria). To assess intra and inter-observer 
agreement, Bland-Altman plots were produced and mean difference and 95% limits of 
agreement with 95% confidence intervals were calculated. The repeatability coefficient (within 
which 95% of all differences are included) was calculated as twice the standard deviation of the 
differences between measurements on the same segment, as described by Bland and Altman. (11) 
Intra-class correlation coefficients (ICC) with 95% confidence intervals were also calculated as 
an additional measure of intra and inter-examiner reliability. 
see colour section
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Results 
Acute stent strut apposition 
Clinical and angiographic and procedural characteristics of the 14 patients having OCT 
immediately following stent implantation are shown in Table 1. The target vessel was the left 
anterior descending artery (LAD) in 50%, left circumflex artery (LCx) in 21.4% and the right 
coronary artery (RCA) in 28.6%. OCT was performed uneventfully in all cases. 
 
 Assessment of 
Acute Apposition 
(n=14) 
Assessment of 
intimal 
coverage 
(n=16) 
Age (yrs) 62 + 11 60+7
Men 11 (78.6%) 15 (93.7%) 
Hypertension  6 (42.9%) 8 (50%)
Diabetes Mellitus 1 (7.1%) 5 (31.2%) 
Hypercholesterolemia* 12 (85.7%) 10 (62.5%) 
Current smoker 4 (28.6%) 3 (18.7%) 
Prior myocardial infarction 5 (35.7%) 7 (43.7%) 
Prior coronary artery bypass grafting 0 (0%) 3 (18.7%) 
Prior percutaneous coronary intervention 3 (21.4%) 16 (100%) 
1-vessel disease  8 (57.1%) 6 (37.5%) 
2-vessel disease 4 (28.6%) 6 (37.5%) 
3-vessel disease 2 (14.3%) 4 (25.0%) 
Clinical presentation 
   Stable Angina Pectoris 8 (57.1%) 10 (62.5%) 
   Unstable Angina Pectoris 6 (42.9%) 6 (37.5%) 
Time to optical coherence tomography (months) - 4.7±2.8
Artery treated and imaged 
   Left anterior descending 7 (50%) 8 (50.0%) 
   Left circumflex 3 (21.4%) 3 (18.8%) 
   Right  4 (28.6%) 5 (31.2%) 
Number of stents/patient 1.8+0.9 1.6±0.6
Stent type 
   Cypher stent 8 (57.1%) 6 (37.5%) 
   Taxus stent 4 (28.6%) 3 (18.8%) 
   Endeavour stent 1 (7.1%) 2 (12.5%) 
   Costar stent 2 (14.2%) 1 (6.2%) 
   Yukon 0 (0%) 4 (25.0%) 
Table 1: Baseline clinical, lesion and procedural characteristics 
A mean of 3930 struts were examined by observer 1 and 4042 by observer 2. The average 
percent embedded, protruding and malapposed struts for observer 1 was 52.1%, 38.2% and 
9.7%, respectively, and for observer 2, 55.3%, 34.6%, and 10.1%, respectively.  
The Bland-Altman plots showed low intra-observer variability for all measures of strut 
apposition, with repeatability coefficients that ranged between 5.1% and 9.3% (Figure 2, Table 
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2). The intraclass correlation coefficient, exceeding 95% in all cases, confirmed the high intra-
observer repeatability of the OCT measurements. No consistent bias was observed (mean 
absolute difference between observations ranging between 0.0-1.8%). 
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Figure 2 Bland-Altman plots of intraobserver variability 
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 Reproducibility 
coefficient 
ICC 95%CI
Acute strut apposition 
Intra-observer  
Embedded 9.2% 97.8% 93.5 - 99.2%
Protruding 7.5% 98.4% 95.2 - 99.4%
Malapposed 5.1% 94.9% 85.5 - 98.3%
Inter-observer  
Embedded 10.8% 98.3% 95.1 - 99.4%
Protruding 8.6% 97.3% 92.2 - 99.1%
Malapposed 6.6% 91.3% 75.8 - 97.0%
Neointimal tissue coverage 
Intra-observer 26.7μm 99.4% 98.6 - 99.8%
Inter-observer 24.1μm 99.6% 98.8 - 99.8%
ICC-intraclass coefficient, CI-confidence interval; 
Table 2: Reproducibility coefficient and intraclass correlation coefficient (expressed as %) 
 
Good agreement was also found between observers for measures of strut apposition, with 
narrow limits of agreement on the Bland-Altman plots. Repeatability coefficients ranged between 
6.6-10.8%, with intraclass correlation coefficients exceeding 91%. No consistent bias was 
observed (mean absolute difference between observations ranged between 1.2-3.5%).  
Strut tissue coverage 
Sixteen patients underwent OCT evaluation of late stent strut tissue coverage at a mean follow-
up 4.7±2.8 months from stent implantation. Clinical, angiographic and procedural characteristics 
of this population are also depicted in Table 1. Mean intimal thickness for observers 1 and 2 was 
169.6μm and 175.5μm, respectively. The Bland-Altman plots demonstrated a low intraobserver 
variability for intimal thickness, with no bias (Figure 3). The repeatability coefficient was 26.7μm, 
with a high ICC (98.6%). A high degree of agreement between different observers was also 
found. Limits of agreement were narrow and the repeatability coefficient was 24.1μm. ICC was 
very high (99.6%).  
Discussion 
This is the first systematic study to evaluate inter and intra-observer variability for both acute 
stent apposition and late tissue stent strut coverage using OCT. With its high resolution, OCT 
permits a detailed assessment of coronary structures while giving unique insights into tissue 
responses following stent implantation. Our study shows that OCT analysis gives highly 
reproducible data for both the assessment of acute stent strut apposition and late strut tissue 
coverage.  
Stent strut apposition 
Until recently, IVUS has been the gold standard for the assessment of acute and late stent strut 
apposition. Many studies have examined the implications of incomplete stent apposition with 
some showing no relation to adverse events (12,13) while others finding a link with in-stent 
restenosis and stent thrombosis.(14-16) Such inconsistencies are likely explained by the known 
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limitations of IVUS, namely its low resolution (100 μm) and the presence of artifacts. OCT uses 
near infra-red light with 10 times higher resolution than IVUS. This unique imaging modality 
gives precise quantification of stent struts and their relation to the vessel wall without the 
artifacts associated with echo. 
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Figure 3- Bland-Altman plots of Interobserver variability 
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The infra-red light used by OCT is, however, unable to penetrate metal, thus producing dorsal 
shadowing behind the endoluminal aspect of the stent struts (Figure 2, arrow).  As a result, when 
evaluating strut apposition, the additional thickness of the strut must also be taken into account 
(including the metal and polymer thickness) when assessing the distance between the strut and 
the intima. Moreover, position of the intima behind the strut of interest must be deduced from 
the adjacent intimal border, which is shadow-free. Despite these limitations of OCT, the low 
inter and intra observer variability found in this study reflects the high definition of this 
technology for microstructures such as stent struts.  
The classification of strut apposition used in this study was previously proposed by our group. 
(9) (Figure 1) The rationale of this classification into “embedded”, “protruding” and 
“malapposed” derives from the concept that struts buried into the intima (embedded) have a 
lower % exposed surface to flow and a higher probability of being covered by the intima in a 
timely fashion. Protruding struts, although in contact with the intima, have a higher % of 
exposed surface area to blood, which may affect local flow dynamics and potentially lead to 
delayed tissue coverage. Malapposed struts are not in contact with the intima, with 100% of their 
surface exposed to blood flow, possibly resulting in very delayed or no intimal coverage. This 
may have a bearing both on short and long-term risk of stent thrombosis, given that post-
mortem studies have shown a clear link between malapposed struts, lack of tissue coverage and 
stent thrombosis. (15,17) This study showed a very high degree of inter and intraobserver 
agreement using the above classification. Serial OCT studies with long-term follow-up are 
needed demonstrate the clinical relevance of acute strut apposition classified in this manner.  
Stent strut tissue coverage 
OCT is likely to become the new gold standard for assessing stent tissue coverage in-vivo. 
Several studies have recently been published highlighting the application of OCT in the detection 
of stent tissue coverage at follow-up. Matsumoto et al (18) studied 34 patients following 
sirolimus-eluting stent (SES) implantation. The mean neointima thickness was 52.5 μm.  We 
found comparable intra and interobserver variability to Matsumoto et al, despite a much higher 
mean neontimal thickness (170 in our study versus 52), likely due to the use of different stent 
types.  The low variability is reassuring, given the potential application and importance of tissue 
coverage to the clinical setting, with studies having found a link between delayed or incomplete 
endothelialization and stent thrombosis. (19,20)  
Clinical implications 
When considering the valuable information gained from OCT, in particular its ability to detect 
minute tissue coverage over stent struts in-vivo, the intense interest now shown in this field is 
understandable. OCT is fast becoming an integral component of large clinical stent trials in an 
attempt to assess tissue coverage and possibly address the incidence of incomplete stent 
endothelialization in different stent types. Knowledge of intra and interobserver variability of 
OCT measurements is essential when designing such trials and when considering OCT findings 
as a surrogate marker of possible late thrombosis. 
 
Limitations 
Even though our study included a limited number of patients, a very large number of struts were 
examined using a highly sensitive imaging modality, resulting in very small intra and 
interobserver variability.  Given the relatively recent introduction of OCT for the coronary 
circulation, only one system with its proprietary analysis software is currently available. 
Measurements of apposition and intimal tissue are currently performed manually, and are thus 
extremely time-consuming. In the near future, developments in analysis and data systems will see 
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the extension of IVUS based analysis packages to OCT data. New semi-automated or automated 
software will be developed and will need to be validated against the current proprietary software. 
Furthermore, until a precise threshold for the percentage of struts malapposed within a stent is 
defined by large series of patients undergoing serial OCT, the clinical relevance of the intra and 
interobserver variability found in our study will remain unclear. Regardless, a high degree of intra 
and interobserver agreement was present for all measures of apposition.  
Conclusions 
Low intra and interobserver variability can be expected when analyzing intracoronary derived 
OCT data for stent strut apposition and intimal coverage. This supports the validity of OCT as a 
clinical and research tool in the setting of intracoronary stent imaging. 
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Comparison of an occlusive vs non-occlusive technique
Aims: The established technique for acquiring optical coherence tomography (OCT) images depends on temporary 
balloon occlusion of the proximal vessel with subsequent flush of crystalloid solution distally to clear blood. A new 
technique of flushing viscous contrast through the guiding catheter is increasingly being used although has not been 
compared to the established method. This study sought to compare the non-occlusive with the traditional occlusive 
technique for intracoronary OCT imaging. 
Methods and Results: Eighty-two patients underwent OCT imaging. Fifty (61.0%) had images acquired 
during proximal balloon occlusion with coronary blood flow replaced by infusion of Ringer’s lactate. Thirty-two 
(39.0%) patients underwent OCT imaging using the non-occlusive technique with flushing of iso-osmolar contrast 
through the guiding catheter. The additional procedure time for OCT imaging was shorter with the non-occlusive 
compared to occlusive technique (8.5±5.2 versus 19.9±8.5 min, p<0.001). The non-occlusive technique allowed 
for a shorter pullback time, achieving a longer pullback distance (37.8±9.0mm versus 28.2±6.2mm, p<0.001) 
and thus a greater length of vessel visualized. This was also better tolerated by patients with significantly less chest 
pain (68% versus 15.6%, p<0.001). Contrast use was higher for the non-occlusive technique (30.3±11.0ml 
versus 3.4±3.0ml, p<0.001). 
Conclusions: The non-occlusive technique for OCT imaging is simpler and better tolerated by patients and 
allows for a more comprehensive assessment of the coronary tree. New developments with even faster acquisition 
speeds and the use of alternative, non-contrast based flushing solutions will mean quicker OCT assessments with 
even less contrast load. 
 
Optical coherence tomography (OCT) has been a welcome addition to the armamentarium of 
interventional cardiologists and researchers world-wide. The first generation system (M2, 
LightLab Imaging Inc., Westford, MA, USA) introduced commercially in 2004, demands 
transient vessel occlusion, achieved by dilatation of a balloon in the proximal vessel, with 
simultaneous flush of crystalloids (Ringer’s lactate) through the end hole of the catheter. 
Refinements in OCT technology, with faster acquisition speeds (currently peaking at 3mm/sec 
but with 20mm/sec in the foreseeable future with the new generation Fourier domain OCT) 
have seen a gradual shift from the cumbersome occlusive technique to a simpler non-occlusive 
approach with flushing of viscous contrast through the guiding catheter. Even though initial 
reports have shown this to be feasible, (1) it continues to remain “off-label”. The non-occlusive 
technique offers many potential advantages (Table 1) and reduces the risk of balloon-related 
vessel injury, but its application into clinical practice has not been tested in comparison to the 
conventional occlusive technique. This study is a single-center comparison of the non-occlusive 
and occlusive techniques for the acquisition of intra-coronary OCT images in 2 consecutive 
groups of patients examined between February 2006-March 2007 and March 2007–January 2008, 
respectively.  
Methods 
Eighty-two patients underwent OCT imaging at the time of percutaneous coronary intervention 
(PCI), or during follow-up angiography. Fifty (61.0%) patients had images acquired during 
proximal balloon occlusion (Helios, Goodman Inc, Nagoya, Japan) with a dedicated indeflator 
used to inflate the balloon between 0.5-0.7atm and coronary blood flow replaced by continuous 
infusion of Ringer’s lactate at a rate of 0.5-1.2ml/sec using a power injector (Mark-V ProVis, 
Medrad, Inc. Indianola, PA, US). Images were acquired with a pullback speed of 1.0mm/sec. 
Thirty-two (39.0%) patients underwent OCT imaging with an upgraded OCT system (M3, 
LightLab Imaging Inc., Westford, MA, USA), using the non-occlusive technique with flushing of 
viscous iso-osmolar contrast (Iodixanol 320, Visipaque™, GE Health Care, Cork, Ireland) 
through the guiding catheter at a pullback speed of 3 mm/sec. As the OCT image wire is fragile 
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and does not have the handling properties of a guidewire, its passage distal to the region of 
interest must be facilitated by the use of a catheter. In our experience, we have found both single 
lumen (e.g. Transit, Cordis, Johnson & Johnson, Miami, FL, US) or double lumen (e.g.0.023” 
TwinPass, Vascular Solutions Inc, Minneapolis, Minnesota, US) catheters useful in this respect. 
 
ADVANTAGES DISADVANTAGES 
 Expensive dedicated occlusive balloon not 
required 
 Minimal vessel instrumentation (over-the-
wire catheter for wire exchange) 
 Ostial and proximal segments can be 
imaged 
 Examination of long segments is simplified 
 Better and more consistent image quality 
 Patient discomfort and ECG changes are 
minimized 
 Potentially nephrotoxic and expensive 
contrast is used 
 Requires a well positioned guiding catheter 
at the ostium of the left or right coronary 
artery to facilitate adequate flush and blood 
clearance 
Table 1: Advantages and disadvantages of the non-occlusive technique 
 
Results 
Clinical and procedural characteristics are shown in Table 2. The non-occlusive technique 
allowed visualization of larger numbers of ostial and proximal coronary segments, including the 
left main, many of which could not be examined using the occlusive technique (which requires 
the use a balloon proximal to the region of interest). Moreover, using the non-occlusive 
technique, we were able to perform multi-vessel imaging in a significantly higher number of 
patients. The additional procedure time for OCT imaging was significantly shorter with the non-
occlusive compared to occlusive technique (8.5±5.2 vs. 19.9±8.5 min, p<0.001).  
Of note, the non-occlusive technique allowed for a shorter pullback time thanks to the faster 
acquisition speed, despite achieving a longer pullback distance (37.8±9.0mm vs. 28.2±6.2mm, 
p<0.001) and thus a greater length of vessel visualized. The non-occlusive technique was also 
better tolerated by patients, with a significantly reduced incidence of procedure-related chest pain 
(68% vs. 15.6%, p<0.001).  
Contrast volume for OCT imaging was higher for the non-occlusive compared with occlusive 
technique (30.3±11.0ml vs. 3.4±3.0ml, p<0.001). Although the occlusive technique uses Ringer’s 
lactate, a small amount of contrast is required to guide positioning of the balloon and image wire. 
However, there were no cases of contrast nephropathy or significant post-procedural rises in 
creatinine concentration in either group.  
 
Discussion 
This is the first report comparing the two different approaches to intra-coronary OCT image 
acquisition in clinical practice. The “off-label” non-occlusive technique resulted in a shorter 
OCT procedure time and was able to provide a larger amount of information with a longer 
pullback distance achieved. This technique was also applicable to more ostial and proximal 
coronary segments and resulted in significantly less patient discomfort, overcoming the 
limitations inherent with the use of balloon occlusion. This was, however, at the expense of a 
larger contrast load. 
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 Entire 
group 
(n=82) 
Occlusive 
technique 
(n=50) 
Non-
occlusive 
technique 
(n=32) 
p value
Age (years) 64.7 ± 9.1 63.1 ± 9.6 67.0 ± 7.7 0.061
Male gender 62 (76) 39 (78) 23 (72) 0.528
Diabetes mellitus 19 (23) 10 (20) 9 (28) 0.423
Hypertension  57 (69) 31 (62) 26 (81) 0.064
Current/Ex Smoker 48 (58) 31 (62) 17 (53)  0.559
Dyslipidemia  73 (89) 41 (82) 32 (100) 0.011
Prior CABG  9 (11) 1 (2) 8 (25) 0.001
Baseline serum creatinine (Ƭmol/l) 95 ± 22 93 ± 25 94 ± 23 0.872
Indication for OCT imaging     
Lesion/plaque characterization  8 (10) 6 (12) 2 (6) 0.392
PCI guidance (post-stenting)  47 (57) 32 (64) 15 (47) 0.126
Stent tissue coverage assessment  27 (33) 12 (24) 15 (47) 0.031
Target vessel imaged     
     N 105 58 47  
Left main stem  1 (1) 0 (0) 1 (2) 0.447
Left anterior descending  46 (44) 28 (48) 18 (38) 0.301
Left circumflex  26 (25) 12 (21) 14 (30) 0.283
Right 28 (26) 18 (31) 10 (21) 0.261
Graft 4 (4) 0 (0) 4 (9) 0.037
Vessel segment imaged     
Ostial 12 (11) 2 (3) 10 (21)  0.005
Proximal  38 (36) 14 (24) 24 (51) 0.004
Mid  36 (34) 23 (40) 13 (28) 0.198
Distal 14 (13) 7 (12) 7 (15) 0.672
Multi-vessel imaging 18 (22) 7 (14) 11 (34) 0.030
Mean OCT procedural time (min) 14.4±9.1 19.9±8.5 8.5±5.2 <0.001
Mean contrast volume for OCT imaging (ml) 15.6±15.5 3.4±3.0 30.3±11.0 <0.001
Mean OCT pullback length (mm) 32.7 ± 9.1 28.2 ± 6.2 37.8±9.0 <0.001
OCT tolerability/safety     
Patient chest pain 39 (47.5) 34 (68) 5 (15.6) <0.001
Major arrhythmia (AV block, AF, VT, 0 0 0  - 
Contrast induced nephropathy 0 0 0  - 
Vessel dissection/perforation 0 0 0  - 
CABG-coronary artery bypass surgery; PCI-percutaneous coronary intervention; OCT-optical coherence tomography; AV-atrio-
ventricular; AF-atrial fibrillation; VT-ventricular tachycardia; VF-ventricular fibrillation; 
Table 2: Clinical and procedural characteristics 
 
The highly detailed images obtained by OCT have given a new dimension to the understanding 
of atherosclerotic plaque and coronary stenting.(2-10) Despite its widespread use, the technique 
is highly specialized and requires adequate proctorship. Such a demanding image acquisition 
process has led to reservation amongst many interventionalists as to the true advantage of OCT 
compared to traditional intravascular ultrasound (IVUS), which, although at a lower resolution, is 
generally well tolerated by patients and simpler to use. The use of an occlusive balloon remains 
quite cumbersome and, in the vast majority of cases, results in patient discomfort with associated 
electrocardiographic changes, even though such events are usually transient and resolve 
completely when the balloon is deflated. Hence, a non-occlusive technique is attractive on a 
number of fronts, and could result in wider diffusion amongst the interventional community. 
The improved patient tolerance, quicker procedural time and simpler procedural requirements, 
meant that OCT could be applied to multi-vessel imaging, thereby allowing a more 
comprehensive assessment of the coronary tree. Pathological and OCT studies have confirmed 
the predilection of thin cap fibroatheroma, notoriously associated with the risk of sudden cardiac 
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death and acute coronary syndromes, in proximal parts of the coronary arteries. (2,11,12) 
Therefore, the ability to image such segments with OCT, which can quantify cap thickness, is 
crucial for characterizing plaques in-vivo. 
The contrast load required to achieve blood clearance during non-occlusive OCT imaging is an 
important consideration. Contrast is more viscous that other flush solutions (e.g. saline, ringer’s 
lactate) and it is this property that ensures excellent blood clearance during imaging. An average 
30ml additional contrast needs to be balanced against the clinically relevant information provided 
by OCT compared to traditional imaging techniques such as IVUS. Moreover, we found no rise 
in post-procedural creatinine levels, despite most patients (57%) undergoing PCI in the same 
session.  
 
 
Conclusions 
Both modalities of OCT imaging can be safely performed in clinical practice. The non-occlusive 
technique is simpler and better tolerated by patients and allows for a more comprehensive 
assessment of the coronary tree. New developments with even faster acquisition speeds and the 
use of alternative, non-contrast based flushing solutions will mean quicker OCT assessments 
with even less contrast load.  
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Reproducibility of quantitative OCT data
  
Aims: To assess the inter and intra observer reproducibility for strut count, strut apposition and strut tissue 
coverage measurements with optical coherence tomography (OCT). 
Methods and results: Ten drug-eluting stents (244 frames, 1712 struts) imaged with OCT 9 months after 
implantation were analyzed by 2 independent analysts. One of the analysts repeated the analysis of 5 stents (120 
frames, 795 struts) one week later. Offline analysis was performed with the proprietary LightLab Imaging 
software. The number of struts was counted and lumen and stent area contours were traced. Tissue coverage 
thickness was measured at 360 degrees of vessel circumference and in front of every individual strut. The number of 
malapposed struts was determined. There was good agreement for strut number count (Kendall’s Tau-b 0.90 for 
inter and 0.94 for intraobserver variability). The relative difference for lumen area, stent area and tissue coverage 
measurements were around 1%. There was complete inter and intraobserver agreement for malapposed struts 
classification (4 out of 1708 struts, Kappa=1). 
Conclusions: In a corelab setting, the inter and intra observer reproducibility for strut count, strut apposition 
and strut tissue coverage measurements with OCT is excellent. This emphasizes the value of OCT as a tool for 
the clinical long-term assessment of stents. 
 
 
Optical coherence tomography (OCT) is a light-based imaging modality that can provide in vivo 
high-resolution images of the coronary artery(1). This technique offers the possibility to identify 
coronary stents and individual stent struts(2).  Further, it is able to provide detailed information 
about struts apposition and tissue coverage. This is of special interest in drug-eluting stents 
(DES) in which the neointimal proliferation is inhibited to such extent that might not be 
visualized with conventional intracoronary IVUS(3). Animal studies demonstrated good 
correlation between intracoronary OCT and pathology for neointimal thickness measurements 
(4,5). However, no criteria have been established for the quantitative analysis of stents on a per 
strut level with OCT. The objective of the present study was to assess the inter and intra 
observer reproducibility for strut count, strut apposition and strut tissue coverage measurements 
with OCT. 
 
Methods 
Study population 
Ten stents (244 frames, 1712 struts) were analyzed in 8 asymptomatic patients undergoing an 
intracoronary OCT study 9 months after sirolimus (Cypher Select, Cordis, Johnson & Johnson, 
Miami, FL; 40%) or biolimus-eluting (Biomatrix III, Biosensors, Morges, Switzerland; 60%) stent 
implantation.  The target vessel was the LAD in 50%, the LCX in 20% and the RCA in the 30% 
of the cases.  
 
OCT acquisition 
The OCT acquisition was performed using a commercially available system for intracoronary 
imaging (LightLab Imaging Inc, Westford, Massachusetts, US). The ImageWire (LightLab 
Imaging Inc, Westford, Massachusetts, US) consists of an optical fiber core (125 μm) covered by 
a protective sheath with a maximum outer diameter of 0.019”. It was positioned distal to the 
region of interest using a double lumen catheter (Twin Pass catheter, Vascular Solutions Inc) that 
had been previously placed in the artery over a conventional guide wire. The automated pullback 
was performed at 3 mm/s while the blood was removed by the continuous injection of iso-
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osmolar contrast (Iodixanol 370, Visipaque™, GE Health Care, Ireland) at 37° Celsius through 
the guiding catheter. The data was stored on CD for offline analysis. 
 
OCT quantitative analysis 
The analysis was performed with the proprietary LightLab software for off-line analysis 
(LightLab Imaging, Westford, Massachusetts, US).  The data was imported in the workstation 
using the LightLab database format.  
 
Z-Offset correction 
The Z-Offset was adjusted in the catheterization laboratory before image acquisition while 
holding the ImageWire between two fingers. The Z-Offset is set properly when the ImageWire 
sheath is aligned with the yellow fiducials in the OCT image. During image acquisition, the 
optical fibres can stretch, especially at the beginning of the pullback. This may produce changes 
in the size of the Z-Offset along the pullback that can affect the accuracy of the measurements. 
Therefore, the Z-Offset was checked and modified if necessary in all the pullbacks before 
performing any measurement. To correct the Z-offset in saved pullbacks a frame in which the 
ImageWire sheath was in direct contact with the vessel wall was selected. In this frame the Z-
Offset was corrected aligning the ImageWire sheath and the vessel wall with the yellow fiducials. 
This value of the Z-Offset was applied at the beginning of the pullback. If needed, the Z-Offset 
was recalibrated again along the pullback. The corrected Z-Offset was the same for both 
analysists.  
 
Definition of the region of interest and frame selection 
The region of interest (ROI) comprised the stented region and the reference segments. The ROI 
was systematically analysed in longitudinal intervals throughout the pullback. The stented region 
was defined as the region comprised between the first and the last frame with circumferentially 
visible struts. The reference segments were defined as the 5 mm proximal and distal to the stent. 
Frames were excluded when they presented severe artefacts such as incomplete blood clearance 
or non-uniform rotation distortion. When a frame was not analyzable an alternative frame 
located within the 2 proximal or distal frames was selected for analysis. No overlapping stent 
segments were included in the analysis. 
 
Lumen analysis 
The lumen contour was obtained with an automated detection algorithm available in the 
LightLab proprietary software and additional manual corrections were performed if necessary.   
 
Stent analysis 
Strut definitions:  stent struts can show different appearances in OCT. In the present study 
structures were considered struts according to the following definitions. 
a) Highly reflective surfaces (metal) with cast dorsal, radial shadows. 
b) Highly reflective surfaces without dorsal shadowing. 
c) Sector shaped shadows with sharp defined borders radial to the lumen.  
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Stent area 
The stent contour was traced using a multiple point detection function. A support point for the 
contour was set in the middle of the endoluminal border of each stent strut.  A semi-automated 
contour was then applied linking the points. 
 
Struts coverage definitions and measurements 
The tissue coverage area was calculated as stent area minus lumen area. Assessment of tissue 
coverage thickness was performed using a new function of the software which provides 360 
degrees measurements, at 1 degree incremental, around the circumference of a given cross 
sectional image, developed in collaboration by Cardialysis-Cleveland, Cardialysis-Rotterdam and 
Lightlab (Figure 1). This also permits the measurement of the tissue located in front of every 
strut that was defined as strut coverage. The mean, maximum and minimum tissue coverage per 
strut were calculated. 
 
 
Figure 1: Tissue coverage measurement. A. Sirolimus eluting stent 9 months after stent implantation. B. The 
figure shows the lumen contour (white) and the stent contour (green). The tissue coverage area was calculated as 
stent area minus lumen area. The tissue coverage thickness was measured in 360 points (represented by the white 
chords). C. Magnification of 2 struts showing all the measurements (white chords) of the tissue coverage in front of 
every strut. For every strut the minimum, maximum and mean strut coverage was calculated.   
 see colour section
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 Malapposition definitions and measurements 
Malapposition was defined as separation of at least one stent strut from the vessel wall. To 
evaluate apposition by OCT, especially with DES, some considerations must be taken into 
account. Most DES are constituted by a metal body covered by a polymer. Since OCT can show 
only the endoluminal surface of the strut due to limited penetration through the metal, strut and 
polymer thickness must be considered in assessing apposition for each type of stent design.  For 
the present study a strut was considered malapposed if the distance from its endo-luminal 
surface to the vessel wall was higher than the sum of the metal and polymer thickness (Figure 2).  
 
 
Figure 2: Malapposition. A. Example of a malapposed strut in a sirolimus eluting stent at 9 months follow up. B. 
Magnification of the malapposed strut. The yellow line represents the lumen contour and the white line corresponds 
to the stent contour. The distance from the endoluminal surface of the strut to the vessel wall (red arrow) was 440 
μm (higher than the sum of the metal and polymer thickness for this type of stent).  
 
Reproducibility design 
The reproducibility for the struts count and the malapposition and tissue coverage thickness 
measurements were tested independently.  
 
Strut count reproducibility 
In order to assess the interobserver variability for the struts count, two experienced observers 
analyzed independently 100 cross sections and counted the number of struts in each one. To test 
the intraobserver variability one of the two observers repeated the analysis of 50 randomly 
selected cross sections one week later. 
 
Strut apposition and tissue coverage reproducibility 
Two experienced observers analyzed independently 10 stents in order assess the interobserver 
variability for the struts apposition and tissue coverage measurements. One of the observers 
repeated the analysis in 5 of the cases one week later to evaluate the intraobserver variability. 
see colour section
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Statistical analysis 
The agreement of the number of struts counted in the same frame was estimated by calculating 
the Kendall’s Tau-b rank correlation coefficient with its 95% confidence interval.  
The inter and intraobserver reproducibility for lumen, stent and tissue coverage measurements 
were tested at 3 levels: per stent, per frame and per strut. 
On a per stent level the mean and minimum lumen and stent area and the mean lumen and stent 
diameters were compared. The mean tissue coverage area and the mean, minimum and 
maximum tissue coverage thickness and strut coverage were also compared.  The lumen, stent 
and tissue coverage volume were calculated by Trapezoidal rule. In the proximal and distal 
reference, the mean luminal area, diameter and volume were compared.  
On a per frame level the luminal and stent areas and diameters were compared as well as the 
tissue coverage area and the mean, minimum and maximum tissue coverage thickness and strut 
coverage. In the frames corresponding to the proximal and distal edge, the mean luminal area 
and diameter were compared.  
On a per strut level the mean, minimum and maximum tissue coverage in front of every strut 
were compared.  
The reproducibility was calculated by estimating the residual standard deviation in an ANOVA 
model. The true value is expected to be within 1.96 times the calculated reproducibility of the 
single measurement for 95% of the observations.  In addition the agreement between both 
observations has been expressed in Bland-Altman plots. The Bland-Altman plot depicts the 
differences of each pair of observations versus their mean values with reference lines for the 
mean difference of all paired observations and its 95% confidence limits, the so-called limits of 
agreement.  
The Kappa coefficient for the agreement between observers for struts classification as 
incompletely apposed was tested for being not equal to zero. 
 
Results 
A total of 244 frames and 1712 struts were evaluated for the interobserver reproducibility and 
120 frames, 795 struts were evaluated for the intraobserver variability.  
 
Strut count reproducibility 
Interobserver variability 
There was complete agreement in the number of struts between the two observers in 55% of the 
cross sections, difference of 1 strut in 31%, difference of 2 struts in 9% and difference of more 
than 2 struts in only 5% of the cross sections. The correlation between both observers was high, 
i.e. Kendall’s Tau-b was 0.90 (95% confidence interval 0.85 – 0.94). 
 
Intraobserver variability 
There was complete agreement in the number of struts in 72% of the cross sections, difference 
of one strut in 24% and difference of 2 struts in 4% of the cross sections. The correlation 
between both observations was very high, i.e. Kendall’s Tau-b was 0.94 (95% confidence interval 
0.91 – 0.97). 
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Lumen, stent and tissue coverage measurements reproducibility 
 
Stent level 
The results for the inter and intraobserver reproducibility at the stent level are summarized in 
Tables 1 and 2 respectively.   
 
Table 1 Difference  Limits of Agreementªªª
    
Observation
 1 
Observation
 2 Absolute
Relative 
(Obs1/Obs2)
Reproducib
ilityªª Lower Upper 
Stent Mean Stent Area 
(mm²) 
5.44 ± 1.6 5.47 ± 1.5 -0.02 ± 0.2 1.0 0.1043 -0.32 0.28 
 Mean Luminal 
Area (mm²) 
4.71 ± 1.5 4.70 ± 1.5 0.00 ± 0.0 1.0 0.0173 -0.05 0.05 
 Mean Tissue 
Coverage  Area 
(mm²) 
0.60 ± 0.5 0.63 ± 0.5 -0.03 ± 0.1 0.9 0.0780 -0.25 0.20 
 Min Stent Area 
(mm²) 
3.89 ± 1.2 3.84 ± 1.1 0.05 ± 0.2 1.0 0.1549 -0.39 0.49 
 Min Luminal 
Area (mm²) 
3.24 ± 1.1 3.26 ± 1.1 -0.01 ± 0.0 1.0 0.0158 -0.05 0.02 
 Mean Tissue 
Coverage  
Thickness (mm) 
0.08 ± 0.1 0.08 ± 0.1 0.00 ± 0.0 0.9 0.0100 -0.03 0.02 
 Min Tissue 
Coverage  
Thickness (mm) 
0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0  0.0000 0.00 0.00 
 Max Tissue 
Coverage  
Thickness (mm) 
0.33 ± 0.1 0.33 ± 0.1 0.01 ± 0.0 1.1 0.0179 -0.04 0.06 
 Mean Strut 
Coverage (mm) 
0.08 ± 0.1 0.09 ± 0.1 -0.01 ± 0.0 0.9 0.0066 -0.02 0.01 
 Min Strut 
Coverage (mm) 
0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0 0.0 0.0067 -0.02 0.02 
 Max Strut 
Coverage (mm) 
0.31 ± 0.1 0.32 ± 0.1 0.00 ± 0.0 1.0 0.0158 -0.05 0.04 
 Mean Stent 
Diameter (mm) 
2.60 ± 0.4 2.61 ± 0.4 -0.01 ± 0.0 1.0 0.0253 -0.08 0.07 
 Mean Luminal 
Diameter (mm) 
2.41 ± 0.4 2.41 ± 0.4 0.00 ± 0.0 1.0 0.0038 -0.01 0.01 
 Stent Volume 
(mm³) 
101.58 ± 
48.2 
102.15 ± 
48.3 
-0.58 ± 2.7 1.0 1.8894 -5.97 4.81 
 Luminal Volume 
(mm³) 
91.76 ± 48.0 91.67 ± 47.9 0.09 ± 0.5 1.0 0.3347 -0.87 1.05 
 Tissue Coverage  
Volume (mm³) 
13.49 ± 11.6 14.13 ± 10.3 -0.65 ± 2.5 0.9 1.7454 -5.57 4.27 
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Table 1 Difference  Limits of Agreementªªª
    
Observation
 1 
Observation
 2 Absolute
Relative 
(Obs1/Obs2)
Reproducib
ilityªª Lower Upper 
 In-stent 
Obstruction 
Volume (%) 
13.73 ± 10.3 14.46 ± 9.0 -0.73 ± 2.2 0.9 1.5341 -4.95 3.49 
Distal 
reference 
Mean Luminal 
Area (mm²) 
4.13 ± 1.5 4.14 ± 1.4 0.00 ± 0.0 1.0 0.0085 -0.03 0.02 
 Mean Luminal 
Diameter (mm) 
2.20 ± 0.3 2.20 ± 0.3 0.00 ± 0.0 1.0 0.0067 -0.02 0.02 
 Luminal Volume 
(mm³) 
18.39 ± 11.1 18.40 ± 11.1 -0.02 ± 0.1 1.0 0.0492 -0.16 0.12 
Proximal 
reference 
Mean Luminal 
Area (mm²) 
5.33 ± 2.4 5.27 ± 2.3 0.06 ± 0.1 1.0 0.1051 -0.23 0.35 
 Mean Luminal 
Diameter (mm) 
2.55 ± 0.6 2.54 ± 0.6 0.01 ± 0.0 1.0 0.0198 -0.04 0.07 
 Luminal Volume 
(mm³) 
23.05 ± 8.6 22.87 ± 8.5 0.17 ± 0.4 1.0 0.3030 -0.67 1.01 
Table 1. Interobserver reproducibility at stent level. N=10 stents. Min: minimum. Max: maximum. Obs1: 
observer 1 Obs2: observer 2. ªª Reproducibility defined as residual standard deviation. ªªª Bland-Altman limits of 
agreement defined as mean ± 1.96 SD of absolute difference. 
 
 
Frame level 
The results for the inter and intraobserver reproducibility at the frame level are summarized in 
Tables 3 and 4 respectively.  Figures 3 and 4 show the results for the lumen, stent and tissue 
coverage area and mean neointimal thickness for inter and intraobserver reproducibility 
respectively. 
Figure 3: Interobserver 
reproducibility. Bland-Altman 
plots for the interobserver 
variability for mean lumen (A), 
stent (B) and tissue coverage 
area (C) and mean tissue 
coverage thickness (D). 
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 Table 2   Difference  Limits of Agreementªªª
    Observation 1 Observation 2 Absolute
Relative 
(Obs1/Obs2) Reproducibilityªª Lower Upper 
Stent Mean Stent 
Area (mm²) 
5.95 ± 1.7 5.90 ± 1.6 0.05 ± 0.1 1.0 0.0621 -0.11 0.21 
 Mean Luminal 
Area (mm²) 
4.97 ± 1.6 4.98 ± 1.6 -0.01 ± 
0.0 
1.0 0.0186 -0.06 0.05 
 Mean Tissue 
Coverage Area 
(mm²) 
0.80 ± 0.7 0.76 ± 0.8 0.04 ± 0.1 1.1 0.0518 -0.09 0.17 
 Min Stent Area 
(mm²) 
4.01 ± 1.0 3.88 ± 0.9 0.13 ± 0.2 1.0 0.1487 -0.24 0.49 
 Min Luminal 
Area (mm²) 
3.14 ± 0.6 3.14 ± 0.6 0.00 ± 0.0 1.0 0.0077 -0.02 0.02 
 Mean Tissue 
Coverage 
Thickness 
(mm) 
0.10 ± 0.1 0.09 ± 0.1 0.00 ± 0.0 1.1 0.0060 -0.01 0.02 
 Min Tissue 
Coverage 
Thickness 
(mm) 
0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0  0.0000 0.00 0.00 
 Max Tissue 
Coverage 
Thickness 
(mm) 
0.37 ± 0.1 0.35 ± 0.2 0.02 ± 0.0 1.1 0.0161 -0.02 0.05 
 Mean Strut 
Coverage (mm) 
0.11 ± 0.1 0.11 ± 0.1 0.00 ± 0.0 1.1 0.0029 -0.01 0.01 
 Min Strut 
Coverage (mm) 
0.00 ± 0.0 0.00 ± 0.0 0.00 ± 0.0  0.0000 0.00 0.00 
 Max Strut 
Coverage (mm) 
0.35 ± 0.2 0.34 ± 0.2 0.01 ± 0.0 1.1 0.0122 -0.01 0.04 
 Mean Stent 
Diameter (mm) 
2.72 ± 0.4 2.71 ± 0.4 0.01 ± 0.0 1.0 0.0138 -0.02 0.05 
 Mean Luminal 
Diameter (mm) 
2.48 ± 0.4 2.48 ± 0.4 0.00 ± 0.0 1.0 0.0043 -0.01 0.01 
 Stent Volume 
(mm³) 
112.26 ± 58.0 111.37 ± 57.3 0.89 ± 1.5 1.0 1.1265 -2.00 3.78 
 Luminal 
Volume (mm³) 
98.63 ± 58.2 98.74 ± 58.3 -0.11 ± 
0.5 
1.0 0.3502 -1.17 0.94 
 Tissue 
Coverage 
Volume (mm³) 
18.05 ± 15.2 17.03 ± 16.0 1.02 ± 1.6 1.1 1.2617 -2.18 4.23 
 In-stent 
Obstruction 
Volume (%) 
16.81 ± 13.8 16.07 ± 13.9 0.74 ± 1.1 1.1 0.8790 -1.44 2.93 
Peter BW 13-5.indd   118 13-05-09   16:18
119
Reproducibility of quantitative OCT data
  
 Table 2   Difference  Limits of Agreementªªª
    Observation 1 Observation 2 Absolute
Relative 
(Obs1/Obs2) Reproducibilityªª Lower Upper 
Distal 
reference 
Mean Luminal 
Area (mm²) 
3.93 ± 1.4 3.93 ± 1.4 0.00 ± 0.0 1.0 0.0039 -0.01 0.01 
 Mean Luminal 
Diameter (mm) 
2.19 ± 0.3 2.19 ± 0.3 0.00 ± 0.0 1.0 0.0023 -0.01 0.01 
 Luminal 
Volume (mm³) 
17.14 ± 8.6 17.14 ± 8.6 -0.01 ± 
0.0 
1.0 0.0239 -0.08 0.07 
 Luminal 
Volumeª (mm³) 
17.68 ± 9.2 17.69 ± 9.2 -0.01 ± 
0.0 
1.0 0.0196 -0.07 0.04 
Proximal 
reference  
Mean Luminal 
Area (mm²) 
5.86 ± 4.9 5.79 ± 4.8 0.07 ± 0.1 1.0 0.0628 -0.07 0.21 
 Mean Luminal 
Diameter (mm) 
2.60 ± 1.2 2.58 ± 1.2 0.02 ± 0.0 1.0 0.0121 -0.01 0.04 
 Luminal 
Volume (mm³) 
18.61 ± 14.4 18.38 ± 14.2 0.23 ± 0.3 1.0 0.2035 -0.27 0.72 
 Luminal 
Volumeª (mm³) 
18.46 ± 15.3 18.23 ± 15.1 0.23 ± 0.2 1.0 0.1977 -0.21 0.67 
Table 2. Intraobserver reproducibility at stent level. N=5 stents. Min: minimum. Max: maximum. Obs1: 
observation 1. Obs2: observation 2. ªª Reproducibility defined as residual standard deviation. ªªª Bland-Altman limits 
of agreement defined as mean ± 1.96 SD of absolute difference. 
 
 
 
Figure 4: Intraobserver reproducibility. Bland-Altman plots for intraobserver variability for mean lumen (A), 
stent (B) and tissue coverage area (C) and mean tissue coverage thickness (D). 
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Figure 5: Strut coverage measurement reproducibility. Bland-Altman plots for the inter (A) and intraobserver 
(B) reproducibility for mean strut coverage measurements. 
 
 
Strut level 
Tables 5 and 6 show the inter (A) and intraobserver (B) reproducibility for the measurements at 
the strut level.  Figure 5 shows the variability for the mean strut coverage.  
 
Malapposition classification reproducibility 
The observers had complete agreement for the classification of malapposed struts (4 out of 1712 
struts malapposed, Kappa coefficient 1). The intraobserver analysis show the same result (4 out 
of 795 struts malapposed, Kappa coefficient 1) 
 
Discussion 
Due to its high resolution OCT can be a very valuable tool for the evaluation of the acute and 
long-term impact of stent implantation. OCT offers the possibility to assess stent apposition in 
great detail and allows the visualization and measurement of the tissue covering the struts even if 
this consists on tiny layers as it is frequently observed in DES(3). As the use of OCT is 
increasing rapidly, standardization of the methodology to measure and report stent apposition 
and tissue coverage is needed as well as data about the reproducibility of these measurements. 
Our results show that the methodology described in the present study allows analysis of stents 
by experienced analysts in a highly reproducible way. 
Stent struts can have different appearances by OCT. The reproducibility of struts count has not 
been previously reported. Our data suggests that the inter and intraobserver variability for strut 
count is low when applying strict strut definitions. For the intraobserver variability, only in 4% of 
the cases the difference between the 2 observations was more than one single strut while for the 
interobserver in only 5% of the cases the difference was higher than 2 struts.  
High accuracy and precision for diameters measurement in vitro using proprietary software from 
LightLab has been reported(6) . Tanimoto et al reported a low interobserver variability for lumen 
and stent area measurements with OCT using dedicated computer-assisted contour analysis(7).  
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Table 3 Difference  Limits of Agreementªª
    Observer 1 Observer 2 Absolute
Relative 
(Obs1/Obs2) Reproducibilityª Lower Upper 
Stent Stent Area (mm²) 5.67 ± 1.7 5.71 ± 1.7 -0.03 ± 0.2 1.0 0.1694 -0.50 0.44 
 Luminal Area 
(mm²) 
4.95 ± 1.7 4.95 ± 1.7 0.00 ± 0.1 1.0 0.0380 -0.10 0.11 
 Tissue Coverage 
Area (mm²) 
0.56 ± 0.7 0.59 ± 0.6 -0.03 ± 0.2 0.9 0.1400 -0.41 0.36 
 Mean Tissue 
Coverage 
Thickness (mm) 
0.07 ± 0.1 0.07 ± 0.1 0.00 ± 0.0 0.9 0.0177 -0.05 0.05 
 Min Tissue 
Coverage 
Thickness (mm) 
0.02 ± 0.0 0.02 ± 0.0 0.00 ± 0.0 0.4 0.0132 -0.04 0.03 
 Max Tissue 
Coverage 
Thickness (mm) 
0.15 ± 0.1 0.15 ± 0.1 0.00 ± 0.0 1.0 0.0207 -0.06 0.06 
 Mean Strut 
Coverage (mm) 
0.08 ± 0.1 0.08 ± 0.1 -0.01 ± 0.0 0.9 0.0099 -0.03 0.02 
 Min Strut 
Coverage (mm) 
0.03 ± 0.1 0.04 ± 0.1 -0.01 ± 0.0 0.6 0.0125 -0.04 0.03 
 Max Strut 
Coverage (mm) 
0.14 ± 0.1 0.14 ± 0.1 0.00 ± 0.0 1.0 0.0141 -0.04 0.04 
 Stent Diameter 
(mm) 
2.66 ± 0.4 2.66 ± 0.4 -0.01 ± 0.1 1.0 0.0409 -0.12 0.10 
 Luminal 
Diameter (mm) 
2.47 ± 0.4 2.47 ± 0.4 0.00 ± 0.0 1.0 0.0090 -0.02 0.03 
Distal 
reference 
Luminal Area 
(mm²) 
4.34 ± 1.6 4.35 ± 1.6 -0.01 ± 0.0 1.0 0.0148 -0.05 0.03 
 Luminal 
Diameter (mm) 
2.28 ± 0.4 2.28 ± 0.4 0.00 ± 0.0 1.0 0.0077 -0.02 0.02 
Proximal 
reference 
Luminal Area 
(mm²) 
5.25 ± 2.1 5.20 ± 2.0 0.05 ± 0.1 1.0 0.0944 -0.21 0.30 
 Luminal 
Diameter (mm) 
2.54 ± 0.5 2.53 ± 0.5 0.01 ± 0.0 1.0 0.0180 -0.04 0.06 
 
Table 3. Interobserver reproducibility at frame level. N=244 frames. Min: minimum. Max: maximum. Obs1: observer 1 
Obs2: observer 2. ª Reproducibility defined as residual standard deviation. ªª Bland-Altman limits of agreement defined as 
mean ± 1.96 SD of absolute difference. 
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Table 4 Difference  Limits of Agreementªª
    Observer 1 Observer 2 Absolute 
Relative 
(Obs1/Obs2) Reproducibilityª Lower Upper 
Stent Stent Area (mm²) 6.28 ± 1.7 6.23 ± 1.7 0.05 ± 0.2 1.0 0.1224 -0.27 0.38 
 Luminal Area 
(mm²) 
5.33 ± 1.8 5.34 ± 1.8 -0.01 ± 0.1 1.0 0.0596 -0.17 0.16 
 Tissue Coverage 
Area (mm²) 
0.75 ± 0.9 0.70 ± 0.9 0.05 ± 0.1 1.6 0.1021 -0.22 0.32 
 Mean Tissue 
Coverage Thickness 
(mm) 
0.09 ± 0.1 0.08 ± 0.1 0.00 ± 0.0 1.2 0.0117 -0.03 0.04 
 Min Tissue 
Coverage Thickness 
(mm) 
0.03 ± 0.1 0.03 ± 0.1 0.00 ± 0.0 1.1 0.0197 -0.06 0.05 
 Max Tissue 
Coverage Thickness 
(mm) 
0.17 ± 0.2 0.17 ± 0.2 0.00 ± 0.0 1.1 0.0168 -0.04 0.05 
 Mean Strut 
Coverage (mm) 
0.10 ± 0.1 0.10 ± 0.1 0.00 ± 0.0 1.1 0.0083 -0.02 0.02 
 Min Strut Coverage 
(mm) 
0.05 ± 0.1 0.05 ± 0.1 0.00 ± 0.0 1.1 0.0181 -0.05 0.05 
 Max Strut Coverage 
(mm) 
0.17 ± 0.2 0.16 ± 0.2 0.00 ± 0.0 1.1 0.0125 -0.03 0.04 
 Stent Diameter 
(mm) 
2.80 ± 0.4 2.79 ± 0.4 0.01 ± 0.0 1.0 0.0272 -0.06 0.08 
 Luminal Diameter 
(mm) 
2.57 ± 0.4 2.57 ± 0.4 0.00 ± 0.0 1.0 0.0131 -0.04 0.04 
Distal 
reference 
Luminal Area 
(mm²) 
3.98 ± 1.6 3.98 ± 1.6 0.00 ± 0.0 1.0 0.0109 -0.03 0.03 
 Luminal Diameter 
(mm) 
2.20 ± 0.4 2.20 ± 0.4 0.00 ± 0.0 1.0 0.0041 -0.01 0.01 
Proximal 
reference 
Luminal Area 
(mm²) 
5.86 ± 3.8 5.79 ± 3.7 0.07 ± 0.1 1.0 0.0826 -0.12 0.27 
 Luminal Diameter 
(mm) 
2.60 ± 0.9 2.58 ± 0.9 0.02 ± 0.0 1.0 0.0164 -0.02 0.05 
 
Table 4. Intraobserver reproducibility at frame level. N=120 frames. Min: minimum. Max: maximum. Obs1: 
observation 1. Obs2: observation 2. ª Reproducibility defined as residual standard deviation. ªª Bland-Altman limits of 
agreement defined as mean ± 1.96 SD of absolute difference. 
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Table 5 Difference  
Limits of Agreemen
tªª 
  
Observer 
1 
Observer 
2 Absolute
Relative 
(Obs1/Obs
2) 
Reproducibilit
yª Lower Upper 
Min Coverage Strut 
(mm) 
0.09 ± 0.1 0.10 ± 0.1 -0.01 ± 
0.0 
0.9 0.0179 -0.05 0.04 
Mean Coverage 
Strut (mm) 
0.10 ± 0.1 0.11 ± 0.1 -0.01 ± 
0.0 
0.9 0.0174 -0.05 0.04 
Max Coverage Strut 
(mm) 
0.11 ± 0.1 0.11 ± 0.1 -0.01 ± 
0.0 
0.9 0.0175 -0.05 0.04 
 
Table 5. Interobserver reproducibility at strut level. N=1712 struts. Min: minimum. Max: maximum. ª 
Reproducibility defined as residual standard deviation.  
ªª Bland-Altman limits of agreement defined as mean ± 1.96 SD of absolute difference. 
 
 
Table 6 Difference  Limits of Agreementªª
  Observer 1 Observer 2 Absolute
Relative 
(Obs1/Obs2) Reproducibilityª Lower Upper 
Min Coverage 
Strut 
(mm) 
0.13 ± 0.1 0.13 ± 0.1 0.00 ± 
0.0 
1.1 0.0161 -0.04 0.05 
Mean 
Coverage 
Strut 
(mm) 
0.14 ± 0.1 0.13 ± 0.1 0.00 ± 
0.0 
1.1 0.0153 -0.04 0.04 
Max 
Coverage 
Strut  
(mm) 
0.14 ± 0.1 0.14 ± 0.1 0.00 ± 
0.0 
1.0 0.0154 -0.04 0.04 
 
Table 6. Intraobserver reproducibility at strut level.  N=795 struts. Min: minimum. Max: maximum. ª 
Reproducibility defined as residual standard deviation.  
ªª Bland-Altman limits of agreement defined as mean ± 1.96 SD of absolute difference. 
 
However, no specific study to assess the reproducibility of strut apposition and strut tissue 
coverage measurements by OCT has been reported. 
Recently several OCT studies evaluating the struts apposition and tissue coverage in DES in 
humans at different time intervals using proprietary off-line software provided by LightLab 
Imaging have been published (8-11). 
In most of these studies, the operator manually traced the stent and lumen area, to derive the 
tissue coverage area. Stent struts apposition and tissue coverage are usually individually measured 
at 1-mm intervals. However the way of reporting the tissue coverage varies between studies. 
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Some authors report just tissue coverage thickness without detailed methodology (8,12). Other 
studies report the minimum, maximum or average tissue coverage but the selection method, the 
number of measurements and calculations method was not specified (9,10). The methodology 
used in the present study provides 360 data points for tissue coverage thickness for each cross 
section. Further the mean, the minimum and the maximum tissue coverage is reported for each 
individual strut. The mean tissue coverage per strut is derived from all the measurements at 
equidistant intervals along the strut.  
Prati et al reported high inter and intraobserver reproducibility for neointima thickness 
measurements with OCT in carotid rabbit model (r² 0.88 and 0.90 respectively)(4). Another 
study in humans comparing tissue coverage between SES and BMS reported 6 ± 8 μm and 8±8 
μm intra and interobserver variability for the measurement of tissue coverage(8). However the 
authors did not specify if the measurements correspond to mean, minimum or maximum tissue 
coverage, how many measurements were performed per strut or in which part of the strut 
measurements were taken.  
In the present study we observed absolute differences around 10 μm for the maximum and 
minimum strut coverage in repeated measurements. Those differences are in the limit of 
resolution of the technique. The absolute differences for tissue coverage area were 0.06±0.02 
mm² and 0.04±0.02 mm² for the intra and interobserver variability respectively. Similar results 
were found when comparing stent and lumen area. A very good reproducibility for lumen 
measurement was expected as the automatic contour detection was used and not modified by the 
analyst in the majority of cases. The differences found in the present study are smaller than the 
ones reported previously by Xie et al for area measurements with OCT (0.3 ±0.5 mm² and 
0.2±0.4 mm² for the intra and interobserver variability respectively). There are no reports on the 
reproducibility of lumen, stent and tissue coverage volumes derived from OCT. We found 
absolute differences around 1 mm³ for the intra and 0.65 mm³ for the interobserver variability 
for tissue coverage volume. Similar values (0.99 and 0.55 mm³ for the intra and interobserver 
respectively) were obtained for the stent volume. As expected, the lumen volume variability was 
even lower (around 0.10 mm³) as it was derived from automatic contour detection.  
The higher resolution of OCT makes this technique superior to IVUS for the detection and 
measurement of tissue covering the stent struts. An IVUS study reported 62% of inter-observer 
agreement for the presence of neointimal tissue with discrepancy between observers in very thin 
neointimal layers and when the neointimal area was <2 mm2(13). In the present study evaluating 
DES, a very good agreement was found between observers for the measurement of tissue 
coverage even when the mean tissue coverage area was less than 1 mm2. An increased variability 
in the classification of individual struts was observed when the tissue coverage was below 50 μm. 
This may be related to the image resolution but also to software limitations. Automatic 
algorithms for detecting stent coverage from OCT datasets are under development(14). This 
could help eliminating the remaining small observer-related variability found in our study.  
Kubo et al reported a good intra and interobserver agreement (Kappa=0.90 and 0.75 
respectively) for malapposed struts classification in sirolimus eluting stents(15). Those results are 
in line with our study in which the agreement between observers for malapposed struts was 
excellent (kappa=1) even when applying customized cut-off points for each stent. However our 
results are limited by the small number of malapposed struts found in our population. 
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Clinical implications 
The evaluation of strut apposition is essential in the evaluation of new stents designs as IVUS 
data have suggested a possible relation between apposition and the risk of stent thrombosis in 
DES(16,17). However interpretation of malapposition as assessed by OCT requires caution. Due 
to the high image resolution, malapposition of stent struts is a relatively common finding by 
OCT(8) but its clinical implications remain poorly understood. Incomplete endothelial struts 
coverage has been identified in pathology as the most powerful histological predictor of stent 
thrombosis(18,19).  Pathological data in human suggests that neointimal coverage of stent struts 
could be used as a surrogate marker of endothelialization due to the good correlation between 
strut coverage and endothelialization. Animal data suggest good correlation between mean 
neointimal thickness measured by histology and OCT (4). The present study confirms that the 
tissue covering the strut can be measured with high reproducibility. However, the clinical 
relevance of uncovered struts as detected by OCT is not clear as some studies have reported 
presence of uncovered struts at follow-up not associated to clinical events(15). Further 
investigation and studies with longer follow up are needed in this field. 
Although OCT has proved to be a highly informative imaging technique in assessing stents, 
standardization of the analysis of such images is not yet in place. In addition, OCT is a rapidly 
evolving imaging technology, and there is lack of large stent trials with long-term clinical follow-
up linking OCT findings and clinical events. Thereby this methodology of analysis is prone to 
changes in the future in order to adjust to the new clinical needs.  
 
 
Conclusions 
In a corelab setting, the inter and intra observer reproducibility for strut count, strut apposition 
and strut tissue coverage measurements with OCT is excellent. This finding emphasizes the value 
of OCT as a tool for the clinical long-term assessment of stents. 
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OCT and the evaluation of stents
Optical coherence tomography (OCT) is a light-based imaging modality long been applied to the 
field of ophthalmology, now also showing tremendous potential in the coronary circulation.  
Compared to traditional intravascular ultrasound (IVUS), OCT has a ten-fold higher resolution 
given the use of light rather than sound. This advantage has seen OCT successfully applied to 
the assessment of atherosclerotic plaque (including thin cap fibroatheroma and macrophage 
distribution within a culprit lesion), stent apposition and tissue coverage, introducing a new era 
in intravascular coronary imaging. (1-13) The issue of stent tissue coverage is particularly 
pertinent given that autopsy series have identified a link between incomplete stent 
endothelialisation and long-term stent thrombosis. (14) Therefore, the detailed imaging afforded 
by OCT may give further crucial insights into this condition, which, although uncommon, is 
catastrophic.  
This chapter will address the application of OCT to the coronary arteries, with particular 
reference to the assessment of coronary stents. This field has emerged as one of the more 
promising for interventional cardiology with OCT able to traverse some of the limitations of 
IVUS by giving unique insights into tissue coverage, an ‘intensely’ debated topic in the current 
discussion surrounding drug-eluting stents (DES) and their long-term safety.  
 
OCT principles  
OCT utilises a near infrared light source (1310nm wavelength) in combination with advanced 
fibre-optics to create a dataset of the coronary artery. Both the bandwidth of the infrared light 
used and the wave velocity are orders of magnitude higher than in medical ultrasound (Table 1).  
 
 
 IVUS OCT
Dynamic range 40-60dB 90-110dB
Resolution 
axial 100-150μm 10-15μm
lateral 150-300 μm 25-40μm
Penetration (tissue) 4-8mm 1.5mm
Frame rate 30/sec 15-20/sec
Pull-Back Speed 0.5-1.0mm/sec 1.0-3.0mm/sec
Wire artefact ++ +
Complexity + +++
Table 1: Comparison between optical coherence tomography (OCT) and intravascular ultrasound (IVUS) 
The resulting resolution depends primarily on the ratio of these parameters, and is one order of 
magnitude larger than that of IVUS: the axial resolution of OCT is about 15 μm. The lateral 
resolution is mainly determined by the imaging optics in the catheter and is approximately 25 
μm. The imaging depth of approximately 1.0-1.5mm within the coronary artery wall is limited by 
the attenuation of light in the tissue. Analogous to ultrasound imaging, the echo time delay of the 
emitted light is used to generate spatial image information, the intensity of the received (reflected 
or scattered) light is translated into a (false) colour scale. As the speed of light is much faster than 
that of sound, an interferometer is required to measure the backscattered light. (15,16) 
The interferometer splits the light source into two “arms” – a reference arm and a sample arm, 
which is directed into the tissue. The light from both arms is recombined at a detector, which 
registers the so-called interferogram, the sum of reference and sample arm fields. Because of the 
large source bandwidth, the interferogram is non-zero only if the sample and reference arms are 
of equal length, within a small window equal to the coherence length of the light source. (17) In 
the most straightforward embodiment of OCT (called time-domain OCT; TD-OCT), the length 
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of the reference arm is scanned over a distance of typically a few millimetres, by moving a 
mirror. The point from which intensity is collected from the sample arm is moved through the 
tissue accordingly, and the amplitude of the recorded interferogram in a scan corresponds to the 
reflectivity of the tissue along the direction of the sample beam. By scanning the beam along the 
tissue, in a rotary fashion for intravascular imaging, an image is built up out of neighbouring 
lines.  
The imaging catheter 
A catheter for intracoronary OCT imaging is part of the sample arm of the interferometer 
described above. The optical signal is transmitted by a single-mode fibre, which is fitted with an 
integrated lens micro-prism assembly to focus the beam and direct it towards the tissue. The 
focus is approximately 1mm outside the catheter. 
The first commercial system used a design in which the fibre itself is rotating inside a stationary 
sheath, but other realisations are possible. Designs involving a high-torque speedometer cable 
transmitting the rotation has been demonstrated, (18) where the fibre is inside the hollow cable. 
In order to scan the vessel lengthwise, the catheter-imaging tip is pulled back while rotating, 
usually inside a transparent sheath, allowing to collect a three dimensional dataset of the 
coronary artery. Both rotary and pullback motion are driven proximally by a motor outside the 
patient. The current commercially available imaging probe (ImageWire™ LightLab Imaging Inc., 
Westford, MA, USA) has a maximum outer diameter of 0.019″ (with a standard 0.014" 
radiolucent coiled tip) and contains a single-mode fibre optic core within a translucent sheath. 
The image wire is connected at its proximal end to the imaging console that permitted real-time 
data processing and two-dimensional representation of the backscattered light in a cross-
sectional plane. 
Technical considerations 
As infra-red light is unable to penetrate through red blood cells, OCT imaging must be 
performed in a blood-free environment. This has traditionally been performed with the use of a 
proximal balloon positioned in the coronary artery which is transiently inflated to occlude the 
vessel. A 30 second time limit is set into the console and imaging should be terminated 
prematurely at any stage should there be patient intolerance, arrhythmia or hemodynamic 
instability. As a result of the proximal balloon occlusion, such coronary segments are therefore 
unable to be optimally imaged with first generation OCT. Large vessels, such as the left main are 
also prohibitive with the balloon occlusion method, although increasingly, a non-occlusive 
technique is being adopted.  
Balloon occlusion method  
An OCT catheter is initially advanced distal to the area of interest over a conventional coronary 
guide wire, which is then replaced with the OCT imaging wire. The OCT catheter is then 
withdrawn proximal to the stented segment that is visualised using an automated pullback 
system. During image acquisition, coronary blood flow is replaced by continuous flushing of 
Ringer’s lactate at 0.5-1.0ml/sec using a power injector (e.g. Mark V ProVis, Medrad, Inc. 
Indianola, PA, US). The highly compliant occlusion balloon remains inflated proximal to the 
lesion at 0.8atm for a maximum of 30sec.  
Non-occlusive technique 
With refinements in the OCT system, higher acquisition speeds permit imaging without the need 
for proximal vessel balloon occlusion. (19) Here, the optical wire is advanced distal to the area of 
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interest, with the position confirmed by fluoroscopy. To facilitate passage of the wire distal to 
the area of interest, a single lumen (e.g. Transit, Cordis, Johnson & Johnson, US) or dual lumen 
catheter (0.023” TwinPass, Vascular Solutions Inc, Minneapolis, Minnesota, US) is required over 
a conventional guide wire. An automated pullback is commenced during simultaneous contrast 
infusion of a viscous iso-osmolar contrast (e.g. Iodixanol 320, Visipaque™, GE Health Care, 
Cork, Ireland) at 37 degree Celsius connected to the standard Y-piece of the guiding catheter. 
Flushing can either be performed manually or using an infusion pump at a rate of between 2-
4ml/sec. The pullback is stopped after visualisation of the complete stented segment or in case 
of significant signs of ischaemia, arrhythmia or patient intolerance.  
The non-occlusive technique avoids the cumbersome balloon occlusion requirements and 
involves flushing of contrast via the guiding catheter during simultaneous imaging, usually at a 
pullback of 3 mm/sec (see below). In our experience, the non-occlusive technique is less time 
consuming, results in less patient chest pain and permits visualisation of ostial and proximal 
coronary segments. 
OCT Safety 
Several groups have reported their clinical experience with OCT over the last few 
years.(7,10,11,13,20-26) Nevertheless, only limited information about acute complications of this 
procedure is available. Recently, Yamaguchi et al (27) examined the feasibility of OCT and IVUS 
imaging in 76 patients. Although transient chest pain and electrocardiographic changes caused by 
imaging were not considered as part of their study, there were no adverse events reported 
following both IVUS and OCT, with the latter being performed exclusively using the occlusive 
method. 
A number of risks need to be considered. Thrombus has been reported (28) during OCT 
instrumentation and highlights the need for careful systemic anticoagulation, usually with weight 
adjusted heparin. Transient chest pain and ST segment depression on the electrocardiogram are 
not uncommon and usually resolve immediately following OCT pullback. Arrhythmias are 
uncommon yet must be immediately recognised and treated. Several studies have shown the 
incidence of ventricular fibrillation (VF) during coronary angioplasty is about 1.5%,(29,30) with 
the rate dropping down to around 0.6% for diagnostic procedures.(31,32) In addition to 
ischaemia, other mechanisms have also been identified including reperfusion, electrolyte 
imbalances, coronary instrumentation, osmolarity and electrolyte composition of contrast agents 
and intra-coronary thrombus. (33-39).To reduce the incidence of VF during OCT imaging, iso-
osmolar contrast such as Iodixanol (Visipaque™, GE Health Care, Cork, Ireland) is 
recommended with the non-occlusive technique. The advantage lies in its higher viscosity 
relative to other agents, which permits optimal blood clearance for OCT imaging at the given 
flush volumes through the guiding catheter. This agent has also been shown to have a lower 
propensity to cause VF given its lower osmolality, higher viscosity and higher concentration of 
sodium and calcium chloride molecules compared to other non-ionic media. (40-43) 
The role of OCT in stent imaging 
Coronary artery lesions and results following percutaneous coronary intervention (PCI) are 
usually assessed angiographically. This luminogram technique provides a unique overview of the 
coronary tree, information regarding anatomy and topography and can confirm the presence of 
atherosclerosis with high specificity. The prognostic relevance for subsequent cardiac events, 
such as myocardial infarction, however, is limited. Furthermore, stent implantation and 
optimisation undertaken using angiographic guidance alone has been shown to result in more 
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frequent incomplete stent expansion and an increased future risk of target vessel 
revascularisation when compared to guidance with IVUS. (44-47) 
Unlike conventional stents, which develop circumferential coverage with an average thickness of 
500μm or more, well visualised with IVUS and angiography, DES delay and prevent the 
hyperplastic response so that the average late lumen loss for DES can be lower than 100μm, (48) 
which means this amount of intimal thickening will not be detectable by IVUS.  
Coronary angioscopy is able to visualise strut tissue coverage, but this highly specialised 
technique lacks the ability for quantification. Hence, OCT is an attractive alternative, able to 
circumvent many of these limitations, and, with its high-resolution, can precisely assess the in-
vivo tissue responses following stent implantation. OCT is also becoming an integral tool to 
assess emerging stent technologies that are increasingly becoming more sophisticated such as 
bioabsorbable polymers and biodegradable magnesium alloy stents, (49) and thus demanding 
highly detailed assessments both in the initial animal testing phases but also in the clinical trial 
setting. 
OCT for the assessment of acute stent apposition 
Traditionally, IVUS has been the imaging modality to assess stent apposition, both acutely and, 
at follow-up. Inherent with its use however is the limited resolution. Two studies (50,51) using 
conventional IVUS suggested that stent malapposition did not increase the risk of major adverse 
cardiac events. Nevertheless, both studies detected a surprisingly small number of malapposed 
stents using the IVUS derived criterion of at least 1 malapposed strut (51/708 cases, 7.2% and 
16/229 cases, 7.0% respectively).  
Studies using OCT in the acute setting following stent implantation have demonstrated a high 
proportion of malapposed struts, even after optimal high pressure post-dilatation, with this 
phenomenon being particularly evident in regions of stent overlap.(11) In an evaluation of OCT 
findings following stent implantation to complex coronary lesions, Tanigawa et al (20,52) 
examined a total of 6,402 struts from 23 patients (25 lesions) and found 9.1±7.4% of all struts in 
each lesion treated were malapposed. Univariate predictors of malapposition on multilevel 
logistic regression analysis where: implantation of a sirolimus-eluting stent (SES), presence of 
overlapping stents, longer stent length and type C lesions. Likely mechanical explanations for 
malapposition of stent struts include increased strut thickness, closed cell design or acute stent 
recoil. The latter has been demonstrated in SES to be in the range of 15%, despite the use of 
high pressure balloon dilatation. (53) The long-term sequeale of malapposed struts found 
immediately following implantation using OCT however is currently unknown. 
 
OCT for the assessment of stent tissue coverage 
Several small studies have recently been published highlighting the application of OCT in the 
detection of stent tissue coverage at follow-up. Importantly, OCT permits the quantification of 
tissue coverage with high reliability. (54) Matsumoto et al (6) studied 34 patients following SES 
implantation. The mean neointima thickness was 52.5 microns, and the prevalence of struts 
covered by thin neointima undetectable by IVUS was 64%. The average rate of neointima-
covered struts in an individual SES was 89%. Nine SES (16%) showed full coverage by 
neointima, whereas the remaining stents had partially uncovered struts. (6)  
Similarly, Takano et al (10) studied 21 patients (4,516 struts) 3 months following SES 
implantation. Rates of exposed struts and exposed struts with malapposition were 15% and 6%, 
respectively. These were more frequent in patients with ACS than in those with non-ACS (18% 
vs 13%, p <0.001; 8% vs 5%, p <0.005, respectively). The same group have recently reported 2 
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year follow-up OCT findings with the thickness of neointimal tissue at 2-years being greater than 
that at 3-months (71 ±93 μm vs. 29 ± 41 μm, respectively; p<0.001). Frequency of uncovered 
struts was found to be lower in the 2-year group compared to the 3-month group (5% vs. 15%, 
respectively; p<0.001) and, in contrast, prevalence of patients with uncovered struts did not 
differ between the 3-month and the 2-year group (95% vs. 81%, respectively) highlighting that 
exposed struts continued to persist at long-term follow-up. (21) 
Chen et al (55) recently used OCT to image SES and BMS at different time points following 
implantation. Of the 10 SES and 13 BMS imaged, the authors identified a significantly higher 
number of incompletely apposed and uncovered stent struts in patients receiving SES compared 
to BMS. The results of these small observational studies are compatible with evidence from 
animal and human post-mortem series showing that DES cause significant impairment in arterial 
healing resulting in incomplete re-endothelialisation with persistence of fibrin. (14,56) The 
importance of this is heightened by autopsy data implicating incomplete endothelialisation as a 
possible substrate for late stent thrombosis. (57)  
With the reduction of in-stent hyperplasia induced by DES, other mechanisms of restenosis due 
to mechanical stent failure have become apparent. The causes behind DES failures remain 
complex and multi-factorial. Of the two established first generation DES, the SES (Cordis, J&J, 
Miami, Florida, US) has been particularly linked to cases of stent fracture, likely as a result of its 
closed cell design compared with other DES employing an open cell system. (58) The higher 
imaging resolution of OCT compared to IVUS permits a detailed assessment in such cases, as 
demonstrated recently by Shite et al. (6)  and Barlis et al. (59) 
  
In addition to quantifying the amount of neointima present, OCT can also characterise this 
tissue in a qualitative manner. Neointimal tissue can show a variety of morphologies ranging 
from homogenous, bright, uniform tissue to inhomogeneous or eccentric. OCT findings can 
possibly reflect fibrin deposition and incomplete healing (60) as well as rapid lesion progression 
(61) and neovascularisation. (62) OCT may also be used to provide complimentary information 
on stent apposition and other conditions not infrequently observed following stenting, including 
dissection, tissue prolapse, restenosis, fracture and thrombosis. (1,59,63).  van Beusekkom et al 
(1) have also reported on the OCT features of the coronary artery following treatment with 
vascular brachytherapy. Here, the treated area shows several changes in vascular architecture, 
namely the appearance of a three layered artery with the intima becoming more pronounced and 
the media and adventitial layers becoming more reflective, indicating collagen deposition, the 
appearance of eccentric neointimal tissue and the disappearance of a clear demarcation between 
media and adventitia, indicating disappearance or fibrosis of the media with inward remodelling. 
(1) Figures 1 and 2 demonstrate the application of OCT post-stenting and show the diverse 
pathology able to be visualised in-vivo by this unique technique. 
 
Typical Stent imaging artefacts 
Although OCT has enabled a clear visualisation of stents and their relation to the vessel wall, a 
number of imaging artefacts need to be recognised. 
Shadowing behind stent struts 
The light source used for OCT is unable to penetrate metal resulting in dorsal shadowing behind 
the stent strut (Figure 3A). When interpreting OCT images, the thickness of the whole stent strut 
(including metal and polymer) must be taken into consideration rather than only the visible 
endo-luminal strut surface. Shadowing also limits the interpretation of structures behind the 
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stent strut and this remains a limitation of OCT, particularly also given its poor tissue 
penetration (< 1.5mm). Furthermore, the OCT imaging plane rarely intersects the stent struts 
perpendicularly thereby resulting in shadows much larger than the actual width of the stent strut. 
 
 
 
Figure 1 The application of optical coherence tomography (OCT) post-stenting. A: shows a stent immediately 
following implantation across a bifurcation. The struts at the carina are clearly seen to be malapposed (arrow) B: 
OCT cross section with magnification (insert, top left) showing a dissection flap immediately following implantation of 
a stent C: Demonstrates significant intimal hyperplasia occurring 8 months following stent implantation. The intimal tissue is 
seen to have a layered pattern with the endo-luminal aspect showing a bright, reflective and homogenous 
appearance in contrast to the layer abutting the stent struts which is seen to be poorly reflective. The thickness 
measured at the 2 points indicated was A-0.82mm and B-0.40mm 
 
Figure 2 – Shows the contrasting amount of tissue covering struts in a bare metal (BMS) and drug-eluting stent 
(DES). The tissue thickness overlying the BMS measured between 0.14 and 0.42mm. In contrast, the DES was 
covered by a thin, concentric layer of tissue measuring 0.09mm. 
 
Bright reflections saturating an entire line (spikes) 
If the imaging beam hits a strut perpendicularly, it reflects a very large fraction of the beam back 
towards the catheter. This strong signal may saturate the detector registering the interferogram, 
producing a readily recognisable artefact of bright radial streaks centred on struts. (Figure 3B) 
A B C
see colour section
see colour section
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Multiple reflections (stent – catheter – stent) 
In a similar geometry, near-specular reflection, light may bounce back between catheter and strut 
more than once. The optical catheter itself reflects part of the received light back into the tissue. 
Strong reflectors, such as struts, may produce an appreciable signal in the second reflection. The 
optical path length of light in the secondary reflection is double that of the primary feature. 
Hence, a double reflection will show up as an apparent second strut appearing behind the first at 
twice the distance from the catheter. (Figure 3C) 
 
 
Figure 5 – A: Circumferential stent struts are shown covered by a thin layer of tissue. Dorsal shadowing is evident 
behind the stent struts (S) with only the luminal surface of the strut visible with OCT. B: demonstrates 
circumferential stent struts with shadowing and bright reflections caused by saturation of the detector registering the 
inferogram (arrow) C: Arrow indicates a double reflection between stent and catheter. This can occur if a stent strut 
is imaged face-on, and reflects the OCT beam specularly. Shadows of other stent struts are marked by s; stent struts 
that do not show up as the typical bright dot, but do cast a shadow, are imaged under an oblique angle. * is a guide 
wire artefact. White bar is 1 mm. 
 
Summary: OCT for stent imaging 
To date, OCT has shown a broad application in interventional cardiology both for the immediate 
and late follow-up of coronary stents. The ability to give highly detailed images in-vivo has shed 
greater light on the tissue responses following stenting and will provide essential feedback 
regarding emerging stent technologies. Nevertheless, current OCT requires an intricate imaging 
procedure and is not suited to tortuous or large calibre coronary arteries. OCT is unable to 
provide functional details about the neointima with a prior histological study confirming 
neointimal tissue can still be present over stent struts but can show limited functionality, best 
demonstrated by the Evans blue dye-exclusion test. (64) Furthermore, a number of interesting 
appearances have also been described including ‘hypodense’ regions beneath stent struts. (61,65) 
Such appearances remain an intense area of ongoing research with thoughts that they may 
represent areas of fibrinoid necrosis.(66) An example is demonstrated in figure 4 from a patient 
who had a DES implanted 9 months prior.   
see colour section
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Figure 4 – Hypodense areas (arrows) imaged at 9 month following drug-eluting stent implantation. Such areas may 
represent fibrinoid necrosis although intense research is ongoing to delineate such regions further. 
 
OCT – emerging developments 
The real benefit of OCT lies in its ability to provide high-resolution imaging in-vivo. New stents 
including bioabsorbable magnesium stents or those made with poly-lactic acid offer an exciting 
era into the management of coronary artery disease with the potential to eliminate some of the 
problems related to permanent metallic stents. The development of such technologies however 
remains time consuming and expensive, often necessitating the sacrifice of animals to retrieve 
the stents. (67) The high-resolution imaging capabilities of OCT gives the potential for rapid in-
vivo assessment of tissue response to various stent designs, thereby also limiting the dependency 
on large numbers of animals. (67) The use of OCT serially is also an attractive concept giving 
unique insights into the time course of stent endothelialisation following implantation.  
OCT remains a specialised intra-coronary imaging technique with dedicated procedural 
requirements and thus should only be performed by trained operators. As has been seen above, 
to accomplish adequate images, blood must be temporarily cleared and this task adds a new 
element to the procedure, particularly for operators trained in IVUS where a relatively simple, 
rapid-exchange imaging catheter is advanced over a standard guide wire. The need for balloon 
occlusion and intra-coronary flush are at the forefront of emerging developments to simplify the 
OCT image acquisition process. Faster pullback speeds offer the potential to scan an entire stent 
within a matter of 5-6 seconds. Such speeds are currently under development in OCT systems 
using optical frequency domain imaging (OFDI).  
Optical frequency domain imaging (OFDI) 
The development of faster image acquisition speeds, with greater penetration depth, without loss 
of vital detail and resolution is a great advancement on current OCT systems. Rather than using 
a broadband light source as in conventional OCT systems, OFDI incorporates a novel 
wavelength-swept laser source, the reason for its alternative moniker “swept-source OCT” (SS-
OCT) (68-70). From the signal received in one wavelength sweep, the depth profile can be 
see colour section
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constructed by the Fourier transform operation that is performed electronically in the data 
processing unit. All other components of an OFDI system (the interferometer, the catheter, 
including the imaging optics, display) are comparable in principle to those in a conventional 
OCT system. The scan speed, or line rate, in a TD-OCT system are limited by the achievable 
mechanical scan speed of the reference arm mirror, and by the sensitivity of the signal 
detection.(71) The source wavelength in OFDI can be swept at a much higher rate than the 
position scan of the reference arm mirror in a TD-OCT system. In addition, SS-OCT has a 
higher sensitivity than TD-OCT at large line rates and scan depths (72-74). These features can be 
put to good use in larger scan speeds, of the order of 105 lines per second. In an OFDI system, 
the wavelength range of the sweep determines the resolution of the image, while the imaging 
depth is inversely related to the instantaneous spectral width of the source. 
The increased sensitivity of SS-OCT/OFDI also allows for larger imaging depths. The 
attenuation of light by the tissue is the same for TD-OCT and OFDI, but the lower noise of the 
latter makes it possible to discern weaker signals that would be indistinguishable from the 
background in TD-OCT (73). The depth range from which useful anatomical information can be 
extracted is extended by a factor of about 3. (75) Clinically, this advantage enables the assessment 
of coronary micro-structures well beyond the arterial-lumen border. 
In the five years since the inception of SS-OCT, a continuous increase in scan speed was 
achieved. The first demonstrated system (68) exhibited a fourfold increase in scan speed at 
15,600 lines per second, while fastest, fully functioning SS-OCT systems to date reach a line rate 
of 370,000 lines per second. (76) An experimental system with 5 MHz line rate has been 
demonstrated. (77) This development begs the question where the OCT speed limit lies, and to 
what use this tremendous gain in speed can be put. 
OFDI and other swept-source systems produce images much faster than standard video-rate, so 
recorded data has to be replayed for inspection by the operator. Currently, OCT systems scan 
200-500 angles per revolution (frame), and 5-10 images per mm in a pullback. If these 
parameters are maintained with high-speed systems, 2 cm/s (or higher) pullback speeds are 
possible at the same sampling density as conventional OCT data. This high pullback speed and 
the need for a fast-revolving imaging tip pose high demands on the mechanics of the disposable 
catheter. 
 
At present, SS-OCT data acquisition is limited by the data transfer rate from the acquisition 
system to the processing system. With state of the art electronics, the data acquisition rate of the 
newest SS-OCT systems is higher than the transfer rate, so all data has to be stored on the 
acquisition board, (76) limiting acquisition time. 
The high scan speeds have been employed for real-time volumetric imaging of dynamic 
phenomena including fast pullbacks for intra-coronary imaging with minimal ischaemia, (75) and 
retinal scans with minimal motion artefacts. (78) Imaging of dynamic phenomena in time, or 
rather removing motion artefacts, are the prime applications of high-speed OCT. 3-Dimensional 
rendering of volumes becomes possible if motion during the scan is limited. 
A 3-D representation of a stent in porcine coronaries has been demonstrated, (75) although its 
construction was still off-line. Advances in data processing could lead to real-time construction 
of volume-rendered 3D datasets, providing further insight into stent positioning. The high data 
rate of novel OCT technologies could also be used to increase sampling density, either in the 
longitudinal (pullback) or angular direction. A smaller spacing between frames in a pullback 
would lead to a better sampling of small scale features in the arterial or stent geometry that 
would be missed at 100 Ƭm inter-frame distance. Denser sampling in the angular direction would 
facilitate speckle filtering in OCT images. Speckle is a major obstacle for the development of 
parametric and quantitative imaging techniques. These possibilities are still largely unexplored. 
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Clinical applications of OFDI 
Clinically, OFDI has been introduced to select catheterization laboratories and has been 
successfully used to assess coronary stents and atherosclerotic plaque.(79) Our first experience 
with the OFDI system at the Thoraxcenter (Erasmus MC, Rotterdam, The Netherlands) has 
been promising. The OCT catheter is easily advanced into the coronary artery, similar to 
conventional IVUS. Large coronary arteries can be visualized over the complete vessel 
circumference, ostial lesions and left main lesions can be imaged. Automated pullback speeds up 
to 20mm/sec allow for a very fast imaging procedure, thereby minimising ischemia. As a result, 
long pullbacks can be performed with a significant reduction in the amount of flush required.  
Summary and Conclusions 
OCT has caused intense interest in interventional cardiology. Its application to the assessment of 
coronary stents has been greeted with strong enthusiasm and is now also being incorporated into 
large multi-centre randomised stent trials aimed at complementing angiographic and clinical 
endpoints. Such applications are currently unique to OCT and, despite the recent progress of 
non-invasive techniques such as 64 multi-slice computed tomography (MSCT), conventional 
stents still represent a challenge to distinguish lumen and intimal hyperplasia within the stent. 
Reports showing that reconstruction of MSCT images using specific kernels offer good 
correlation with angiography are encouraging but unlikely to make this technique a reliable 
alternative at the present time.  
The ability to provide high-resolution imaging in-vivo is the most significant concept 
circumventing the limitations of other imaging modalities such as IVUS or the need for multiple 
animal experiments. Refinements in acquisition speeds with OFDI will also make the technique 
less procedurally demanding and thus able to be applied to many more centres, thereby 
remaining a key tool in the armamentarium of researchers and interventional cardiologists alike. 
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LEADERS Trial OCT sub-analysis
Objectives: This study sought to evaluate tissue coverage of stents using optical coherence tomography (OCT) in 
a group of patients from the randomized LEADERS trial. 
Background: Delayed and incomplete stent strut endothelialization is the most likely explanation of late stent 
thrombosis, a rare but devastating phenomenon, more frequent after drug-eluting stent (DES) implantation. OCT 
has 10 times greater resolution than intravascular ultrasound and thus appears to be a valuable modality for the 
assessment of stent strut coverage. The LEADERS trial was a multicenter, randomized comparison of a 
biolimus-eluting stent (BES) with biodegradable polymer with a sirolimus-eluting stent (SES) using a durable 
polymer.  
Methods: Fifty-six consecutive patients received OCT during angiographic follow-up at 9 months. OCT images 
were acquired using a non-occlusive technique at a pullback speed of 3mm/sec.  Data were analyzed using a 
Bayesian hierarchical random-effects model, which accounted for the correlation of lesion characteristics within 
patients and implicitly assigned analytical weights to each lesion depending on the number of struts observed per 
lesion. 
Results: Twenty patients were included in the analysis in the BES group (29 lesions with 4592 struts) and 26 
patients in the SES group (35 lesions with 6476 struts). A total of 83 struts were uncovered in the BES group 
and 407 out of 6476 struts were uncovered in the SES group (weighted difference -1.4%, 95% CI -3.7 to 0.0%, 
p=0.04). Results were similar after adjustment for pre-procedure lesion length, reference vessel diameter, number of 
implanted study stents and presence of stent overlap. There were 3 lesions in the BES and 15 lesions in the SES 
group that had 5% of all struts uncovered (difference -33.1% 95% CI -61.7 to -10.3%, p<0.01).  
Conclusions: Strut coverage at an average follow-up of 9 months appears to be more complete in patients 
allocated to BES as compared with SES. The impact of this difference on clinical outcome and, in particular, on 
the risk of late stent thrombosis, is yet to be determined.  
 
Until recently, trials comparing drug-eluting stents (DES) and bare metal stent (BMS) used 
intravascular ultrasound (IVUS) to confirm that DES reduce restenosis and intimal proliferation. 
(1-5) However, the thin layer of neointima observed after implantation of DES is often below the 
100 μm axial resolution of IVUS. Incomplete stent strut endothelialization has recently received 
attention with studies suggesting an association with the long-term risk of stent thrombosis, (6) 
but it cannot be detected by IVUS. Optical coherence tomography (OCT) has 10 times greater 
resolution than IVUS and thus appears to be the ideal imaging modality for the assessment of 
tissue coverage of DES. Observational data using OCT in first generation sirolimus-eluting stents 
suggest that stent struts may still remain uncovered 2 years after implantation. (7) Evidence of a 
small but clear increase of late stent thrombosis has led to the increase in the duration of dual 
anti-platelet therapy beyond the customary 3-6 month period of the initial DES trials, (8,9) with 1 
year now recommended by the AHA/ACC/SCAI guidelines, (10) mainly based on theoretical 
reasoning, without robust studies supporting this recommendation. 
The LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) study, was a 
multi-center, randomized non-inferiority trial comparing a biolimus-eluting stent (BES) using a 
biodegradable polymer with a widely used sirolimus-eluting stent (SES) with durable polymer. At 
9 months, BES were non-inferior to SES for the primary composite endpoint of cardiac death, 
myocardial infarction (MI), or clinically-indicated target vessel revascularization (TVR). (11) 
Frequency of cardiac death, MI and clinically-indicated TVR were similar for both stent types 
(composite endpoint of 9.1% for BES, 9.9% for SES, p=0.59). In the angiographic sub-study, 
BES were non-inferior to SES in in-stent percentage diameter stenosis at 9 month follow-up with 
an in-stent restenosis rate of 5.5% versus 8.7% (p=0.20), respectively. (11) 
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Durable polymer surface coatings may be one of the causes for incomplete endothelialization of 
first-generation DES. The BES uses biodegradable polylactic acid, which is co-released with 
biolimus during 6–9 months and degrades into carbon dioxide and water. Since the stainless steel 
surface of BES is free of additional primer polymer coatings, only the metal stent backbone 
remains in situ once the polymer has degraded. A second feature distinguishing BES and SES is 
that the coating is only abluminal, possibly favoring endothelialization of the stent.  In a sub-
study of the LEADERS trial we therefore set out to compare tissue coverage between BES and 
SES using OCT. 
Methods 
The design of the LEADERS study has been published elsewhere. (11) The study applied an ‘all-
comers’ approach including patients aged 18 years or older with chronic stable coronary artery 
disease or acute coronary syndromes, including non-ST-elevation and ST-elevation MI. There 
was no limit for the number of treated lesions, vessels, or lesion length and no patients were 
excluded on the basis of co-morbid disorders or age, apart from the following pre-specified 
criteria: known allergy to acetylsalicylic acid, clopidogrel, heparin, stainless steel, sirolimus, 
biolimus, or contrast material; planned surgery within 6 months of percutaneous coronary 
intervention (PCI) unless the dual anti-platelet therapy could be maintained throughout the peri-
surgical period; pregnancy; participation in another trial before reaching the primary endpoint; 
and inability to provide informed consent. All patients were discharged on acetylsalicylic acid of 
at least 75 mg daily indefinitely and clopidogrel 75 mg daily for at least 12 months.The study 
complied with the declaration of Helsinki and was approved by all institutional ethics 
committees. The trial is registered with ClinicalTrials.gov, number NCT00389220. All patients 
provided written, informed consent for participation in this trial.  
Randomization was done centrally after diagnostic coronary angiography and before PCI by use 
of a telephone allocation service. Patients were randomly allocated on a 1:1 basis to treatment 
with BES (BioMatrix Flex, Biosensors Inc, Newport Beach, CA, USA) or SES (Cypher SELECT, 
Cordis, Miami Lakes, FL, USA), and to active angiographic follow-up at 9 months or clinical 
follow-up only on a 1:3 basis using a factorial design. The OCT sub-study was performed at 2 of 
the 10 LEADERS sites (Royal Brompton Hospital, London, UK and Thoraxcenter, Erasmus 
Medical Center, Rotterdam, The Netherlands). Randomized patients were eligible if they 
underwent follow-up angiography. Exclusion criteria specific to follow-up with OCT imaging 
were renal impairment (serum creatinine  200 mmol/L) and left ventricular ejection fraction 
(LVEF) < 30%. The OCT sub-study was approved by the trial Steering Committee and local 
Institutional Review Boards. 
Optical coherence tomography 
For the purpose of the sub-study, OCT was performed at follow-up only using the M3 system 
(LightLab Imaging, Westford, MS, USA) at 20 frames per second allowing retrieval of the 
imaging core at 3mm/sec for 30 seconds (90mm) with a non-occlusive imaging technique (12), 
following administration of intravenous heparin and intra-coronary nitrates. A standard guide 
wire was advanced distally in the target vessel. A single lumen (e.g. Transit, Cordis, Johnson & 
Johnson, Miami, FL, USA or ProGreat, Terumo Co, Tokyo, Japan) or a double lumen catheter 
(0.023” TwinPass, Vascular Solutions Inc, Minneapolis, MN, USA) was then advanced distal to 
the previously stented region. Following withdrawal of the guide wire, the optical ImageWire 
(LightLab Imaging, Westford, MS, USA) was passed through the catheter and OCT imaging 
commenced at a pullback of 3.0mm/sec, during flush of 2-4 ml/sec of iso-osmolar contrast 
(Iodixanol 320, Visipaque™, GE Health Care, Cork, Ireland) through the guiding catheter to 
replace blood flow and permit visualization of the stented segment and intima-lumen interface. 
Scanning was prematurely terminated if there was any hemodynamic instability, arrhythmia or 
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patient intolerance. If the stented segment was too long to be safely imaged in a single pull-back, 
image acquisition was stopped and recommenced from the same position during a second 
contrast injection. Anatomic landmarks such as side branches, calcifications or stent overlap 
segments were used for longitudinal view orientation. 
Offline OCT data analysis was undertaken by an independent core laboratory (Cardialysis BV, 
Rotterdam, The Netherlands) blinded to stent type allocation, clinical and procedural 
characteristics of the patients. Analysis of contiguous cross-sections at 1mm longitudinal intervals 
within the stented segment was performed using proprietary software (LightLab Imaging, 
Westford, Massachusetts, US).  Intra and inter observer reliability were evaluated in previous 
studies and found to be >0.95, (13-15) as could be expected in view of the clear visualization of 
intimal tissue and struts allowed by OCT. Recently, Barlis et al (16) demonstrated a low intra and 
inter-observer variability when assessing OCT strut tissue coverage at follow-up (reproducibility 
coefficients 26.7Ƭm and 24.1Ƭm, intraclass correlation coefficient 99.4% and 99.6%, 
respectively). 
Metallic stent struts typically appear as bright, signal intense structures with dorsal shadowing. 
The number of stent struts was determined in each cross section. Stent coverage was classified as 
not visible/incomplete when there were points of the stent struts with no visible tissue coverage 
or as complete when tissue was seen overlying the strut. Thickness (μm) of the tissue coverage on 
the luminal side of each strut was measured at the middle of the long axis of the strut. A linear 
measurement line was drawn from the endoluminal leading edge perpendicular to the long axis of 
the strut towards the luminal leading edge of the strut Struts were classified as apposed (when the 
strut was in contact with the vessel wall) or malapposed if protruding into the lumen at a distance 
greater than the strut thickness (154μm for the SES and 112μm for the BES).  
For malapposed struts, the presence of tissue was qualitatively assessed also on the abluminal 
surface to confirm circumferential coverage.  
 
Sample Size Calculation and Statistical Analysis 
The OCT sub-study was a superiority study. To estimate differences between BES and SES, we 
used a Bayesian hierarchical random-effects model based on Markov chain Monte Carlo 
simulation methods with vague priors. (17) The model included random-effects at the level of 
lesions and patients, fully accounting for the correlation of lesion characteristics within patients 
and implicitly assigning analytical weights to each lesion depending on the number of struts 
observed per lesion. The pre-specified primary endpoint of the sub-study was the difference in 
percentage of uncovered struts between BES and SES. Assuming average numbers of 1.5 lesions 
per patients and 160 struts per lesion and a design factor of 1.5 (defined as standard error derived 
from the Bayesian hierarchical random-effects model assuming clustering of lesions within 
patients divided by the crude standard error derived from conventional analysis assuming 
independency of lesions), we estimated that the inclusion of 22 patients per group would yield 
greater than 90% power to detect a difference in uncovered struts of 4% between BES and SES 
at a two-sided type I error of 0.05. Secondary endpoints were the differences in percentage of 
malapposed struts and in percentage of malapposed and uncovered struts. After logarithmic 
transformation of the data, we also estimated the difference between groups in neointimal 
thickness. Finally, we determined differences in the percentage of lesions with any struts with 
unfavourable outcome, with at least 5%, and with at least 10% of struts with unfavourable 
outcome, with unfavourable outcomes defined in accordance with definitions used for primary 
and secondary endpoints.  
Differences between groups were estimated from the median of the posterior distribution of the 
50,001 to 100,000 iteration, with the initial 50,000 iterations discarded as ‘burn-in’. We derived 
95% credibility intervals (95% CI) from the 2.5th and 97.5th percentiles of the posterior 
Peter BW 13-5.indd   149 13-05-09   16:18
Chapter 11
150
distribution, also calculating two-sided p-values from the posterior distribution. 95% credibility 
intervals and p-values from posterior distributions can be interpreted similarly to conventional 
95% confidence intervals and p values. Sensitivity analyses were adjusted for pre-procedure lesion 
length, reference vessel diameter, number of implanted study stents and presence of stent 
overlap. Finally, we restricted the analysis of the primary endpoint to patients with analyzable 
OCT data who had been randomly allocated to angiographic follow-up. Baseline characteristics 
of lesions, procedural results and angiographic follow-up data were analyzed as previously 
described, (8) using mixed maximum-likelihood logistic and linear regression models that allowed 
for correlation of more than one lesion within patients. Statistical analyses were performed using 
WinBUGS version 1.4.3 (Imperial College and MRC, United Kingdom) and Stata, version 10.0 
(StataCorp, College Station, TX).  
 
Results 
Figure 1 shows the profile of the OCT sub-study. Twenty eight patients allocated to BES and 32 
patients allocated to SES were eligible for the sub-study, and 26 and 30 patients respectively 
received OCT, all undertaken using the non-occlusive technique. Figure 2 presents some 
examples of the spectrum of OCT findings observed. Six patients in the BES and 4 patients in 
the SES group were excluded from the analysis because of low quality of OCT images. Twenty 
patients were included in the analysis in the BES group (29 lesions with 4592 struts) and 26 
patients in the SES group (35 lesions with 6476 struts).  
Baseline clinical and angiographic characteristics of the 46 patients are presented in Tables 1 and 
2. Characteristics were similar in both groups, except for differences in the percentage of patients 
with small-vessel disease and in reference vessel and minimal lumen diameter at lesion level. In 
addition, more patients had a history of hypercholesterolemia in the SES group, even though 
overall cholesterol levels were comparable between groups (4.31 mmol/l in the BES versus 4.17 
mmol/l in the SES group, difference -0.13, 95% confidence interval -0.90 to 0.63, p=0.73). The 
left anterior descending artery (LAD) and the right coronary artery (RCA) were the most 
frequently imaged vessels (Table 2). Procedural results were similar between groups, with a trend 
towards smaller minimal lumen diameters in-stent in patients allocated to SES (Table 3). Control 
angiography was performed at a median of 9.1 months (interquartile range 9.0 to 9.3 months). 
Table 4 presents results of angiographic follow-up, which were similar between groups and 
compatible with results of the main trial. (8) 
OCT analysis 
Figure 3 shows a graphical representation of stent strut coverage in lesions.  Table 5 (top) 
presents results of the principal analysis of the primary endpoint. A total of 83 out of 4592 struts 
in 29 lesions were uncovered in the BES group (weighted estimate 0.6%, 95% CI 0.2 to 1.6%) 
and 407 out of 6476 struts in 35 lesions were uncovered in the SES group (2.1%, 95% CI 0.9 to 
4.4), with a weighted difference between groups of -1.4% (95% CI -3.7 to 0.0%, p=0.04). Results 
were similar after adjustment for pre-procedure lesion length, reference vessel diameter, number 
of implanted study stents and presence of stent overlap (difference -2.0%, 95% CI -5.7 to -0.1, 
Table 6). There were 2 and 8 lesions that had 10% uncovered struts in BES and SES groups, 
respectively (difference -10.2%, 95% CI -30.9 to 1.3%, p 0.08), 3 and 15 lesions had 5% 
uncovered struts (difference -33.1% 95% CI -61.7 to -10.3% p <0.01) and 17 and 24 lesions had 
any uncovered struts (difference -11.1%, 95% CI -44.8 to 19.7% p 0.48). A total of 28 and 86 
struts were malapposed in BES and SES groups, respectively (difference -0.2%, 95% CI -0.8 to 
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0.2%, p=0.19). Results were similar in adjusted analyses (difference -0.3%, 95% CI -0.6 to 0.0% p 
0.08, Table 6). A total of 0 and 1 lesions had 10% malapposed struts in BES and SES groups, 
respectively (difference -0.4%, 95% CI –7.6 to 0.0% p 0.05), 1 and 6 lesions had 5% 
malapposed struts (difference -8.4% 95% CI -25.5 to -0.1% p 0.05) and 11 and 17 lesions had any 
malapposed struts (difference -13.7%, 95% CI -47.8 to 20.9% p 0.42). A total of 11 and 41 struts 
were both malapposed and uncovered in the BES and SES groups, respectively (difference -
0.1%, 95% CI -0.4 to 0.0%, p=0.13). Results were similar in adjusted analyses (difference -0.2%, 
95% CI -0.6 to 0.0% p 0.08, Table 6). None of the lesions had 10% struts, which were both 
malapposed and uncovered, 0 and 2 lesions had 5% (difference -5.1% 95% CI -20.1 to 1.5% p 
0.12) and 6 and 14  lesions had any malapposed and uncovered struts (difference -21.0%, 95% CI 
-48.7 to 5.9% p 0.12).  
Figure 4 presents the distribution of neointimal thickness across all struts. For 67% of all struts, 
tissue thickness was below 100 micron, the resolution of IVUS. The average tissue thickness was 
67.6 μm (95% CI 56.0 to 81.7μm) in the BES and 57.1μm (95% CI 48.4 to 67.6μm) in the SES 
group, respectively (p=0.19). 
 
Safety of OCT 
Mean contrast volume used for coronary flushing was 37.4 ml (SD 12.3). There were no cases of 
contrast-induced nephropathy. In 1 patient, contrast flushing during OCT imaging induced 
ventricular fibrillation. Sinus rhythm was promptly restored following external cardioversion. 
Deep guide catheter intubation during contrast injection was thought to have caused the 
arrhythmia. The patient made an uneventful recovery and was discharged as planned the 
following day.  
 
Discussion 
The LEADERS trial is the first, large, multi-center randomized study to incorporate an OCT 
sub-study to help address the issue of tissue coverage following DES implantation. Quantitative 
coronary angiography (QCA) and IVUS lack the spatial resolution to accurately quantify tissue 
coverage. Hence, OCT, with a resolution of approximately 15 μm, is ideal for the purpose of 
comparing presence and extent of tissue coverage in the 2 stents studied.  
The SES was the first DES to be introduced and is covered by two layers of durable polymer 
with a top coating for slow drug release. The availability of up to 8 years clinical follow-up after 
SES implantation and evidence of greater efficacy in reducing restenosis and late lumen loss in 
direct or indirect comparison with other DESs (9,18-20) has made SES the current gold standard 
of treatment. Pathological follow-up examinations at autopsy following implantation of a SES 
have shown that neointimal healing is still incomplete after 16 months, (21) a specific problem 
which may prolong the period of thrombotic risk. Struts directly exposed to the blood flow may 
be surrogates for thrombotic risk given that pathological studies have identified a lack of tissue 
healing in cases of stent thrombosis. (6,22) Furthermore, exposed struts, particularly if 
malapposed, are also likely to result in flow disturbance which can be pro-thrombotic. (23,24)  
The polymer coating as a system for drug delivery has been implicated as being pro-inflammatory 
and retard healing and coverage. (22)  A number of OCT results after implantation of DES have 
been reported (13,14,25-27) Takano et al,10 undertook OCT examination at 3 months and 2 years 
following SES implantation in 21 patients. The thickness of tissue at 2-years was greater than that 
at 3-months (71±93μm versus 29±41μm, respectively; p<0.001). Frequency of struts with no 
visible coverage was lower in the 2-year group compared to the 3-month group (5% versus 15%, 
respectively; p< 0.001), with a prevalence of patients with uncovered struts between 3 months 
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and 2 years falling from 95% to 81%, respectively. Matsumoto et al11 examined 57 SES in 34 
patients at 6 months after implantation and found the median tissue thickness to be 52.5μm with 
89% of struts covered and 11% exposed. These studies are limited by the small sample size and 
by the fact the population consisted almost exclusively of single short SES because of the 
limitations of the balloon occlusive technique used for OCT image acquisition.  
Recently, results from a randomized trial of OCT in long lesions requiring overlap stenting were 
presented. (26) In 22 patients receiving SES, 6% of all struts had no visible coverage at 6 month 
follow-up. In our study, 407 out of 6476 struts were uncovered among patients allocated to SES, 
which corresponds to approximately 6% in a naive analysis ignoring the clustered nature of the 
data. Accounting for the nature of the data in a Bayesian hierarchical random-effects model yields 
a lower estimate of 2.1% is observed in this study, which suggests that the type of analysis has 
dramatic effects not only on the precision of estimates, but also on their estimated magnitude.  
The duration of dual anti-platelet therapy after SES already extends far beyond the 2–3 months 
of treatment required in the initial SES studies. (8) The empirical solution of one year is 
recommended by the ACC/AHA/SCAI guidelines but this recommendation partially contradicts 
the ESC Guidelines of PCI (6-12 months) and  is often not adhered to by individual 
cardiologists. The duration of dual anti-platelet treatment is often prolonged to 2 or more years 
or lifelong because physicians fear that the extension of percutaneous treatment to complex 
lesions facilitated by the low restenosis rate of SES has increased the risk of late stent thrombosis, 
(28-32), particularly with the use of multiple stents and kissing stents for bifurcation lesions.   
We exclusively used a non-occlusive method to acquire OCT images performed during contrast 
flush via the guiding catheter with no requirement for the cumbersome occlusion balloon 
method used in all the other published studies. This ensured that the broad ‘all-comer’ inclusion 
criteria for the LEADERS trial were reproduced in the OCT sub-study in which ostial, proximal 
and multi-vessel stenting were all imaged by OCT. 
The OCT results of our study in all comers with great lesion complexity confirms previous 
studies by showing that only a small percentage of SES struts are not covered with tissue 9 
months after SES implantation. Still, only a minority of lesions after SES implantation had full 
lesion coverage at 9 months and half the lesions treated had less than 95% tissue coverage. The 
absence of longitudinal studies correlating intimal coverage of DES and late stent thrombosis is 
the main limitation of this and other OCT studies at this stage. Although OCT has a high 
resolution permitting clear visualization of the tissue surrounding stent struts, we can only 
hypothesize as to its exact composition, particularly around unapposed struts. With its 
homogenous, highly reflective appearance, it is likely in keeping with neointimal proliferation 
(especially at 9 month follow-up) rather than fibrin or unendothelialized tissue which typically has 
a heterogeneous appearance.  
Contemporary DES technologies are now geared toward eliminating the potential causes of poor 
tissue coverage and hence, to develop a stent that has similar anti-proliferative properties to the 
first generation SES but with the added advantage of no or a lower risk of late stent thrombosis. 
The low incidence of stent thrombosis with first generation DES also means that comparison 
studies need thousands of patients and several years of follow-up to show differences in clinical 
outcome and this makes any surrogate end-point highly valuable. 
The BES did not differ from SES in the quantity of tissue overlying the stent struts (67.6 m 
compared with 57.1m for the SES, p=0.19), suggesting similar efficacy in preventing 
restenosis to SES, as confirmed by the results of the main study. (8) The BES contained fewer 
exposed stent struts, which translated into more than 95% of the stents showing near complete 
coverage versus less than 2/3 in the SES group. These results suggest that better intimal coverage 
may be achieved with the BES compared with the SES. This difference may have a bearing on 
long-term thrombotic risk and may help address the vexing issue of the optimum duration of 
dual anti-platelet therapy while implicating the polymer as a potential source of failure to 
endothelialize stent struts long-term.  
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The presence of the abluminal coating and the  biodegradable polymer  is not the only reason 
which possibly explained this difference. The better apposition observed at 9 month follow-up 
can be explained by fewer instances of late acquired malapposition due to the absence of 
hypersensitivity reaction against the biodegradable polymer. It may also reflect a better initial 
apposition immediately after stent implantation, allowed by the thinner more pliable struts and 
different stent design. A previous study using OCT immediately following SES or paclitaxel-
eluting stent (PES, Taxus, Boston Scientific, Natick, US) implantation found a significantly higher 
proportion of SES struts to be malapposed compared with the PES. (33) This is likely, in part, to 
be due to the closed cell design and the thicker strut profile of the SES. (33) 
 
Study limitations 
Stent strut coverage is not a clinical outcome, but only a surrogate for long-term stent thrombosis 
and safety. The presence or absence of neointimal coverage is limited by the resolution of OCT 
and struts reported as bare could have a very thin covering of tissue (<10μm), though the 
biological protection offered by such a thin coverage is debatable. (34) Furthermore, the number 
of patients included was small, enrolled only in two centers and differences in patient and lesion 
characteristics may have clouded our conclusions despite the randomized nature of the trial and 
the robustness of results to adjusting for lesion characteristics.    
The choice of a 9 month OCT examination was empiric and in line with the follow-up arm of the 
main LEADERS trial. An earlier OCT assessment may have helped to assess the rapidity of 
tissue coverage while a later examination may have offered more relevant information for the 
process of very late (>1 year) stent thrombosis. A recent OCT follow-up study with SES 
confirmed the presence of ongoing uncovered stent struts even at 2 years follow-up indicating 
that failure of early tissue coverage might become a permanent observation. (7) OCT was not 
carried out immediately following stent implantation so that the mechanism of malapposition of 
struts cannot be accurately determined so that we are unable to distinguish persisting or late 
acquired malapposition. 
Multilevel analysis was used in this study as standard statistical approaches are inappropriate in 
data with significant clustering. In fact, even though more than 10,000 strut-related data points 
were available, these were not independent observations (struts within the same lesion and 
lesions within the same patient are likely to be similar), thus violating a fundamental assumption 
of classic statistical tests. Formal sample size calculations are difficult in this situation and no 
power calculation algorithm exists, which is based on generally accepted assumptions regarding 
intra-cluster correlation and design factors. 
Conclusions 
Strut coverage appears to be more complete in patients allocated to BES as compared with SES. 
The impact of this difference on clinical outcome and, in particular, on the risk of late stent 
thrombosis, is yet to be determined. 
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Figure 2:  Examples of OCT findings 
A. This 73 year old male received a biolimus-eluting stent (BES) 9 months prior to the right coronary artery. 
The stent is seen covered by a thin, uniform layer of tissue overlying all stent struts that are well apposed to 
the vessel wall. 
B. Offline OCT analysis. A total of 14 stent struts are visible in this cross section with the observer having 
measured the thickness of tissue overlying each of the struts, expressed in the colored panel (top left) in 
mm. The mean neointimal thickness in this frame was 0.27mm (270μm).  
C. Sirolimus-eluting stent (SES) struts are observed circumferentially. Struts between 7 and 11 o’clock are 
apposed but uncovered by tissue. Struts from 1 – 5 o’clock are observed covered with a very thin layer of 
tissue (mean thickness 0.03mm or 30μm). The stent was implanted in a patient who received 2 SES to the 
mid left anterior descending artery (LAD) 9 months prior following a presentation with a non-ST elevation 
myocardial infarction. He was asymptomatic at 9 month follow-up. 
D. Nine month follow-up of a BES implanted in the LAD across the diagonal bifurcation. A solitary strut is 
observed (arrow) malapposed at the level of the carina. The strut was seen covered by a thick, uniform and 
homogenous tissue. 
E. This OCT pullback frame from a 78 year-old male with prior stenting to the LAD/diagonal bifurcation 
with a SES. Struts are observed (1-3 o’clock) to be malapposed to the vessel wall with a heterogeneous 
tissue with different signal attenuations that may represent thrombotic material. The patient was 
asymptomatic at 9 month follow-up and on dual anti-platelet therapy. 
F. Left main coronary artery OCT. This patient had a proximal LAD stent implanted 9 months prior. We 
extended the pullback beyond the stent into the left main coronary artery which demonstrates a well 
demarcated, non-flow limiting, low attenuation plaque (12 o’clock) consistent with calcium. Our sub-study 
exclusively used a non-occlusive technique for OCT imaging which requires pullback of the image wire 
during simultaneous flush of contrast via the guiding catheter. This is a significant advance over the 
traditional method of OCT imaging in which a proximally positioned balloon is inflated during image 
acquisition. Hence, ostial and proximal segments of coronary arteries were all able to be imaged thereby 
supporting the ‘all comer’ design of the LEADERS trial without any OCT anatomical exclusions. 
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     Biolimus-eluting stent                  Sirolimus-eluting stent 
Figure 3: Graphical representation of stent coverage in lesions. 
Grey horizontal bars represent lesions. Each uncovered strut is represented by a red line. 
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Figure 4: Distribution of neointimal thickness.  
Note that dimensions <100μm are below the resolution of intravascular ultrasound (IVUS). 
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Table 1: Baseline characteristics of patients 
 Biolimus-eluting 
stent 
(N = 20) 
Sirolimus-eluting 
stent 
(N = 26) 
 
p value 
Age (years) 64.9 (10.2) 63.0 (11.4) 0.56 
Males 14 (70.0%) 18 (69.2%) 0.96 
Diabetes mellitus 4 (20.0%) 5 (19.2%) 0.95 
 Diabetes requiring insulin 2 (10.0%) 1 (3.9%) 0.40 
Hypertension 10 (50.0%) 17 (65.4%) 0.29 
Hypercholesterolemia 9 (45.0%) 20 (76.9%) 0.03 
Current smoker 5 (25.0%) 10 (38.5%) 0.33 
Family history of CAD 11 (55.0%) 17 (65.4%) 0.47 
History of MI 5 (25.0%) 9 (34.6%) 0.96 
History of PCI 3 (15.0%) 6 (32.1%) 0.49 
 With drug-eluting stent  2 (10.0%) 1 (3.9%) 0.40 
Previous CABG 1 (5.0%) 4 (15.4%) 0.26 
Stable angina pectoris 12 (60.0%) 16 (61.5%) 0.92 
Acute coronary syndrome 8 (40.0%) 10 (38.5%) 0.43 
 Unstable angina 1 (5.0%) 4 (15.4%)  
 Non-ST-elevation MI  2 (10.0%) 2 (7.7%)  
 ST-elevation MI 5 (25.0%) 4 (15.4%)  
Multi-vessel disease 5 (25.0%) 3 (11.5%) 0.23 
Small-vessel disease (RVD < 2.75 mm) 8 (40.0%) 21 (80.8%)        < 0.001 
Study lesions per patient   0.37 
 One 12 (60.0%) 17 (65.4%)  
 Two 7 (35.0%) 7 (26.9%)  
 Three 0 (0.0%) 2 (7.7%)  
 Four or more 1 (5.0%) 0 (0.0%)  
De-novo lesions only 18 (90.0%) 25 (96.2%) 0.40 
Long lesions (> 20 mm) 7 (35.0%) 13 (50.0%) 0.31 
Number of lesions per patient 1.5 (0.8) 1.4 (0.6) 0.71 
Off-label use 14 (70.0%) 23 (88.5%) 0.12 
Data are mean (SD) or number (%). CAD = coronary artery disease. PCI = percutaneous coronary intervention. CABG = 
coronary artery bypass grafting. MI = myocardial infarction. RVD = reference vessel diameter. p values are from t-test for 
continuous and chi2-test for categorical data. 
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Table 2: Baseline characteristics of lesions 
 Biolimus-eluting stent Sirolimus-eluting stent p value 
Target lesion coronary artery   0.15 
 Left main 0/29 (0.0%) 0/35 (0.0%)  
 Left anterior descending 15/29 (51.7%) 12/35 (34.3%)  
 Left circumflex 3/29 (10.3%) 10/35 (28.6%)  
 Right 11/29 (37.9%) 13/35 (37.1%)  
 Bypass graft 0/29 (0.0%) 0/35 (0.0%)  
De novo lesions 27/29 (93.1%) 34/35 (97.1%) 0.45 
Lesion length (mm)    
 Assessed* 14.3 (14.5) 13.3 (9.1) 0.80 
 Assessed or estimated† 17.3 (14.7) 20.9 (19.0) 0.41 
Reference vessel diameter (mm)† 2.7 (0.6) 2.4 (0.5) 0.02 
Minimal lumen diameter (mm)§ 0.93 (0.60) 0.63 (0.53) 0.04 
Stenosis (% lumen diameter) § 66.9 (20.3) 73.4 (21.0) 0.20 
Total occlusion 5/28 (17.9%) 9/34 (26.5%) 0.42 
Severe Calcification 3/29 (10.3%) 3/33 (9.1%) 0.87 
Pre-procedure TIMI flow   0.30 
 Grade 3 5/28 (17.9%) 9/34 (26.5%)  
 Grade 2 1/28 (3.6%) 3/34 (8.8%)  
 Grade 3 1/28 (3.6%) 4/34 (11.8%)  
 Grade 4 21/28 (75.0%) 18/34 (52.9%)  
Data are mean (SD) or number of lesions/number assessed (%). Assessments were not possible in all 64 lesions with 
angiographic assessments; therefore the number of lesions differs according to outcome. TIMI = thrombolysis in myocardial 
infarction. * 21 lesions assessed in the biolimus-eluting stent group and 22 in the sirolimus-eluting stent group. † 29 lesions 
assessed in the biolimus-eluting stent group and 35 in the sirolimus-eluting stent group. § 27 lesions assessed in the biolimus-
eluting stent group and 34 in the sirolimus-eluting stent group 
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Chapter 12
A Randomised Optical Coherence Tomography Study of 
Coronary Stent Strut Coverage and Luminal Protrusion with 
Rapamycin-Eluting Stents 
Phil Moore, Peter Barlis, Jonathan Spiro, Michael Roughton, Charles Isley, 
Carlo Di Mario, Rajesh Kharbanda, Miles Dalby 
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Objective: We used optical coherence tomography (OCT) which has a resolution of <20Ƭm to analyse thin 
layers of neointima in rapamycin-eluting coronary stents. 
Background: Lack of neointimal coverage has been implicated in the pathogenesis of drug-eluting coronary stent 
(DES) thrombosis. Angiography and intracoronary ultrasound lack the resolution to examine this. 
Methods: We conducted a randomised trial in patients receiving polymer-coated rapamycin-eluting stents 
(Cypher®, Cordis, Johnson & Johnson, Miami Fl, USA) and non-polymer rapamycin eluting stents (Yukon®, 
Translumina, Hechingen, Germany) to examine neointimal thickness, stent strut coverage and protrusion at 90 
days. Twenty-four patients (n=12 for each group) underwent stent deployment and invasive follow-up at 90 days 
with OCT. 
Main outcome measure: The primary end point was binary stent strut coverage. Co-primary end points 
were neointimal thickness and stent strut luminal protrusion. 
Results: No patient had angiographic restenosis. For polymer-coated rapamycin-eluting and non-polymer 
rapamycin-eluting stents respectively, (mean (sd)), neointimal thickness was 77.2Ƭm (25.6) versus 191.2Ƭm 
(86.7) p<0.001. Binary stent strut coverage was 88.3% (11.8) versus 97.2% (6.1) p=0.030. Binary stent 
strut protrusion was 26.5% (17.5) versus 4.8% 
(8.6) p=0.001. 
Conclusions: Mean neointimal thickness for the polymer-coated rapamycin-eluting stent was significantly less 
than the non-polymer rapamycin-eluting stent but as a result coverage was not homogenous with >10% of struts 
being uncovered. High-resolution imaging allowed development of the concept of the protrusion index and >25% of 
struts protruded into the vessel lumen with the polymer-coated rapamycin-eluting stent compared with <5% with 
the non-polymer rapamycin-eluting stent. These findings may have important implications for the risk of stent 
thrombosis and therefore future stent design. 
 
Polymer-coated drug-eluting coronary stents reduce restenosis and repeat revascularisation.(1,2) 
Lack of endothelial coverage, however, has been reported as the most powerful predictor of 
stent thrombosis in post mortem series (3) which in turn carries a high mortality. (4,5,6) 
Coronary angiography and intravascular ultrasound lack the resolution to assess thin layers of 
coverage. In contrast, optical coherence tomography (OCT) is safe, feasible, has a resolution of 
<20Ƭm, and has been correlated well with histological analysis of neointima making it suitable 
for this application. (7,8,9) 
 
Methods 
We undertook a randomised study comparing a polymer-coated rapamycin-eluting stent 
(Cypher®, Cordis, Johnson & Johnson, Miami, FL, USA) with a non-polymer rapamycin-eluting 
stent (Yukon®, Translumina, Hechingen, Germany) to examine whether one device was 
superior to the other with regard to the primary and co-primary end points of binary stent strut 
coverage, neointimal thickness, and luminal strut protrusion. Approximately 200 patients were 
screened for trial participation between October 2006 and July 2007, and 51 were randomised 
and underwent stent deployment as part of the study. Twenty-four patients completed the trial 
with 90-day angiography and OCT. Relatively slow recruitment and significant drop out were 
due in large part to patient concerns about the risks and inconvenience associated with follow up 
catheterisation and in particular the fact that OCT was a relatively new technology. Blocked 
randomisation was carried out by the use of sealed envelopes, with patients per block allocated in 
a 1:1 ratio between the polymer coated and non-polymer rapamycin-eluting stents. Follow-up 
used 90-day angiography with quantitative coronary angiography and OCT. Inclusion criteria 
were; age 18-75 years, stable angina pectoris or acute coronary syndrome pain-free for 24 hours. 
Exclusion criteria were: ST-elevation myocardial infarction, cardiogenic shock, chronic total 
occlusion, bifurcation procedure, left ventricular ejection fraction <30% and renal impairment 
(serum creatinine >200umol-1). Stent deployment was performed using angiography but without 
intracoronary imaging. Patients received loading doses of aspirin (300mg) and clopidogrel 
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(600mg) at least 2 hours before the index procedure if they were not on maintenance therapy, 
followed by planned lifelong aspirin 75mg daily and clopidogrel 75mg daily for a minimum of 
one year. 
Ninety days was used as the study end point for two reasons. Firstly, early reports of OCT in a 
non-randomised series had presented data from 2 month follow up demonstrating a large and 
significant difference between stent strut coverage with bare metal and sirolimus eluting polymer 
coated stents on which the power calculation was based, (10) and secondly there was a clinical 
desire to gain mechanistic insight into the potential safety of the withdrawal of clopidogrel at this 
relatively early time in non-polymer rapamycin eluting stents, as compared with the usually 
recommended one year for polymer coated rapamycin eluting stents. 
 
Optical coherence tomography image acquisition 
OCT was performed with the M2 system (LightLab Imaging Inc., Westford, MA, USA) as 
previously described. (11) Briefly, an over-the-wire proximal occlusion balloon catheter 
(Helios™, Goodman Inc, Nagoya, Japan) was deployed and the imaging catheter advanced 
(ImageWire™, LightLab Inc., Westford, MA, USA) with the light source distal to the stent. The 
occlusion balloon was inflated to a maximum of 0.7 atmospheres for a maximum of 30 seconds 
with continual electrocardiographic monitoring whilst the coronary artery was infused with 
Ringer’s lactate at 0.5-1.0ml/sec using a power injector (Mark V ProVis, Medrad, Inc. Indianola, 
PA, US). A motorised pullback at 1mm/sec was performed acquiring cross sectional images at 
15.6 frames/sec. Frames analysed were those occurring at every 1mm (15 frames). In addition, 
the 2 adjacent frames both proximal and distal to the frame were also assessed to confirm tissue 
coverage or absence of tissue and apposition. If the stent could not be visualized with a single 
pullback (due to a long stent or patient intolerance), scanning was prematurely terminated and 
the pull-back stopped with a second pull-back started from the site where it was interrupted. 
Anatomic landmarks such as side branches, calcifications or stent overlap segments were used 
for longitudinal orientation. 
 
 
Optical Coherence Tomography Analysis 
OCT data analysis was performed offline using proprietary software (LightLab Imaging, 
Westford, Massachusetts, US). Analysis of angiographic images, QCA (Medis, Leiden, NL) and 
OCT was performed by experienced investigators (PB, PM). Regarding blinding, the very 
different presentation of the two stent types (including in particular the hub of the devices, and 
the angiographic appearances of the markers) made it impractical to blind the operators, 
however for the angiographic and OCT analysis investigators were blinded to the randomisation 
arm. The analyst was blinded to all clinical and procedural variables and thus, did not have any 
knowledge of stent sizes or stent type. When a strut was felt to be ‘malapposed’, the distance 
from the strut to lumen surface was recorded. Only after completion of the analysis was the stent 
type used to then confirm presence or absence of malapposition by incorporating the actual strut 
thickness for the 2 stents used. This is required as OCT is unable to penetrate through metal and 
thus can only visualise the luminal aspect of the stent strut. A blooming effect can result from 
hyperdense signals arising from metal struts. It is an optical property of the inferometer and 
hence an inevitable part of OCT. We did observe this and on the few occasions it was apparent, 
a frame immediately proximal or distal was selected without this effect. Although we are aware 
of such an effect, this was not an issue observed in the few stent struts malapposed. (12) 
Neointimal thickness (Ƭm) on the luminal side of each strut section was measured. 
Neointimal area (mm2) was calculated by manually tracing and subtracting the stent and luminal 
areas. Percentage neointimal area was calculated as ([Stent area – lumen area]/Stent area) x 100. 
Binary strut coverage (%) was calculated as (number of strut sections covered /total number of strut 
sections examined) x100. Apposition: Strut sections in contact with the vessel wall were defined as 
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apposed. Strut sections were malapposed if protruding into the lumen at a distance greater to the 
strut thickness (154Ƭm for the polymer-coated rapamycin-eluting stent and 90Ƭm for the non-
polymer rapamycin-eluting stent). Protrusion was defined as projection of the luminal surface of 
the strut section (whether covered or not) into the lumen, relative to the intima between the 
adjacent strut sections. The protrusion ratio (%) was calculated as (number of protruding strut 
sections/total number of strut sections) x 100. In the text, all parameters quoted are for the 
group level analysis of total number of strut sections studied in each stent type cohort. The terms 
apposition, protrusion and coverage are demonstrated in figure 1. 
 
 
 
Figure 1: Schematic diagram of stent strut malapposition, coverage, protrusion and restenosis 
 
Three-dimensional reconstruction 
Representative OCT sections appearing to show protruding stent struts were subjected to 3-
dimensional reconstruction for comparison with the known stent geometry to support validation 
of OCT for quantifying this characteristic. Intensity iso-contours delineating the lumen-wall 
interface were extracted from the OCT data. 
Points on the extracted iso-contours were then used to reconstruct a triangulation of the lumen-
wall interface. (13) Image coloration gives a qualitative indication of the local curvature of the 
surface and highlights particular features of the lumen wall interface. 
 
Ethics and Trial Registration 
The study was approved by the Brompton, Harefield and NHLI Ethics Committee, UK 
(06/Q0404/61). All patients enrolled gave written informed consent. International Randomised 
Controlled Trial Registration No ISRCTN42475919. 
 
End points and Statistical methods 
The primary end point was binary stent strut coverage (%). Co-primary end points were 
neointimal thickness (Ƭm) and luminal strut protrusion (%).Secondary end points were 
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malapposition and stent, lumen and neointimal areas. The power calculation was based upon 
limited presented non randomised data available at the time suggesting a significant difference in 
stent strut coverage between bare metal (n=5) and polymer coated rapamycin eluting stents 
(n=12) with 2 month OCT follow up.10 In this study there was a large (>2 fold) difference in 
strut coverage between the two stent types, and we estimated that 12 patients in each group 
would be adequate to demonstrate a difference in coverage between the two stent types in our 
study based on the premise that the non-polymer rapamycin eluting stent would probably yield a 
coverage intermediate between that of a bare metal stent and the polymer coated rapamycin-
eluting stent. 
To account for the repeated measurements within each patient, the values for each endpoint 
were derived for each individual frame (n=623), and then the average of all that patient’s frames 
was calculated to give a final summary value for each patient. Comparisons between the polymer 
coated and polymer free rapamycin eluting stent groups were made using t-tests. For the main 
outcomes the results are presented as mean (sd) along with the mean difference and the 
associated 95% confidence interval. A two-sided p-value of p<0.05 was considered to be 
statistically significant. In order for this trial to be considered as having a positive outcome, the 
primary end point had to achieve a p value of <0.05. Other p-values are exploratory in nature. 
Analysis was carried out using STATA 9.2 (StataCorp, Tx). 
 
 
Results 
 
Patient characteristics and procedural details are summarised in Table 1. 
 
There were no significant complications of stent implantation. At follow up angiography and 
OCT analysis, chest pain or ST segment elevation on continuous ECG recording mandated 
balloon deflation, and in all cases this resulted in prompt resolution of pain and return of the 
ECG to baseline. There were no incidences of ventricular fibrillation or visible thrombus during 
the OCT. All study stents were patent at follow up with no cases of angiographic restenosis 
(defined as >50% diameter angiographic stenosis relative to the proximal reference segment). 
 
A total of 5330 strut sections were analysed (polymer-coated rapamycin-eluting stent - 2465 and 
non-polymer rapamycin-eluting stent - 2865). The OCT outcome data is shown in Table 2, and 
summarised in figures 2-4 at both group and patient levels. The primary end point of binary stent 
strut coverage indicated significantly greater binary coverage with the non-polymer rapamycin-
eluting stent than the polymer coated rapamycin-eluting stent. 
A representative 3-dimensional reconstruction of a polymer-coated rapamycin-eluting stent with 
evidence of protruding struts matched closely with the known strut geometry of the bare in vitro 
stent and is compared with a non-protruding, non-polymer rapamycin-eluting stent (Figure 5).   
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Variable polymer rapamycin 
stent 
non-polymer 
rapamycin stent 
Number 12 12
Age (years) 61.6 (55.0, 66.2) 62.3 (53.7, 63.8)
Male 11 (92) 10 (83)
Follow-up (mean days) 91 (85, 92) 91 (86, 96)
Hypertension 8 (67) 8 (67)
Diabetes 4 (42) 3 (25)
Hypecholesterolemia 10 (83) 11 (92)
Current or Ex-smoker 6 (50) 7 (58)
Vessel Treated 
LAD 9 (75) 6 (50)
Cx 2 (17) 4 (33)
RCA 1 (8) 2 (17)
Clinical syndrome 
Acute coronary syndrome 4 (33) 3 (25)
Chronic stable angina 6 (67) 9 (75)
Total number stents 19 18
Stent diameter (mm) 3.0 (2.8, 3.0) 3.0 (2.5, 3.0)
Stent length (mm) 18 (18, 18) 21 (18, 23)
Deployment pressure 17.5 (14.5, 20) 16 (14, 18)
 
Table 1: Baseline clinical and procedural characteristics 
 
 
 
 
Variable  Polymer 
Coated 
rapamycin 
stent 
Mean 
(SD)  
Non-Polymer 
Rapamycin 
stent Mean 
(SD)  
Difference (95% 
CI)  
p value 
Neointimal thickness (um) 72.7 (25.6) 191.2 (86.7) 118.6 (64.4, 172.7)  <0.001 
Strut Coverage (%)  88.3 (11.8) 97.2 (6.1) 8.9 (0.9, 16.8)  0.030  
Protruding struts (%)  26.5 (17.5) 4.8 (8.6) -21.7 (-33.34, -10.0)  0.001  
Struts counted per frame (n)  8.2 (1.3) 8.4 (1.3) 0.2 (-0.9, 1.3)  0.700  
Apposed and uncovered struts (%)  8.9 (12.4) 2.4 (6.0) -6.6 (-16.0, 3.0)  0.170  
Malapposed struts (%)  2.2 (2.1) 1.2 (1.1) -0.9 (-3.2, 1.3)  0.380  
Uncovered and malapposed struts (%)  1.7 (1.6) 0.4 (0.8) -1.3 (-2.5, -0.1)  0.049  
Covered and malapposed struts (%)  0.4 (0.8) 0.2 (0.4) -0.2 (-0.8, 0.3)  0.410  
Stent area (mm2)  8.8 (2.0) 8.0 (1.9) -0.8 (-2.5, 0.8)  0.310  
Lumen area (mm2)  8.0 (2.0) 6.1 (1.7) -1.9 (-3.5, -0.4)  0.020  
Neointimal area (mm2)  0.3 (0.2) 1.2 (0.8) 0.9 (0.3, 1.4)  0.002  
 
Table 2: OCT analysis results 
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Figure 2: Combined results of neointimal thickness by the randomised stent groups [bar chart n= 5330 strut 
sections presented as mean (sd)] and by patient [histogram n=24 patients presented as median (IQR)]. 
 
 
 
 
Figure 3 Combined results of binary strut coverage by the randomised stent groups [bar chart 
n= 5330 strut sections presented as mean (sd)] and by patient [histogram n=24 patients presented as median (IQR)]. 
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Figure 4 Combined results of binary luminal strut protrusion by the randomised stent groups [bar chart n= 5330 
strut sections presented as mean (sd)] and by patient [histogram n=24 patients presented as median (IQR)] 
 
 
Discussion 
 
These data demonstrate that although the polymer-coated rapamycin-eluting stent shows 
reduced neointimal thickness compared with the non-polymer rapamycin-eluting stent, this is 
associated with a significantly higher number of uncovered and luminally protruding struts. 
Experimental data suggests these may be adverse features. Importantly, angiographic late loss is a 
parameter based focally upon the point of maximum neointimal hyperplasia, and therefore 
relevant when considering flow limitation. In contrast this methodology provides a more global 
picture of stent strut neointimal growth, coverage and protrusion, which are often non-uniform 
and is likely therefore to be more representative when considering potential predictors of 
thrombotic risk. Regarding the polymer coat as a system for drug delivery, evidence suggests that 
this may be pro-inflammatory in its own right and may retard healing and therefore coverage. 
(14) The etched porous surface of the non-polymer rapamycin-eluting stent as a drug delivery 
system in contrast has no potentially pro-inflammatory coating.  
A number of OCT series have been reported; (15,16,17) however investigators are still working 
toward consensus with regard to which parameters are the most pathophysiologically relevant, 
what precise methodology should be used to analyse the images, and, as yet, have reported no 
randomised trial data. Observational studies using OCT have examined neointimal thickness in 
the polymer-coated rapamycin-eluting stent. Takano et al, (10) undertook OCT examination at 3 
months and 2 years following polymer-coated rapamycin-eluting stent implantation in 21 
patients. The neointimal thickness at 2-years was greater than that at 3-months (71±93Ƭm versus 
29±41Ƭm, respectively; p<0.001). Frequency of uncovered struts was lower in the 2-year group 
compared to the 3-month group (5% versus 15%, respectively; p< 0.001). However, the 
prevalence of patients with uncovered struts did not differ between the 3-month and the 2-year 
group (95% versus 81%, respectively). 
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Figure 5: Representative 2-dimensional optical coherence tomography image of stent strut sections of an uncovered 
polymer rapamycin-eluting stent and a covered non-polymer rapamycin-eluting stent with paired 3-dimensional 
reconstructions and reference photograph of a polymer-coated rapamycin-eluting stent. 
 
 
Matsumoto et al (11) examined 57 polymer-coated rapamycin-eluting stents in 34 patients at 6 
months after implantation and found the median neointimal thickness to be 52.5Ƭm with 89% of 
struts covered and 11% exposed. This compares with our findings at 3 months post 
implantation, with a mean neointimal thickness of 77Ƭm and 89% of struts covered. 
 
 
Neointimal thickness 
In the present study, the neointimal thickness seen with the non-polymer rapamycin-eluting stent 
was significantly greater than with the polymer-coated rapamycin-eluting stent. Dose ranging 
studies when compared with a bare metal stent, have indicated significant angiographic anti-
restenotic efficacy for the non-polymer rapamycin-eluting stent (18) although it has not been 
formally compared with the polymer-coated rapamycin-eluting stent in a clinical trial. In the 
randomised ISARTest study, the non-polymer rapamycin-eluting stent however was seen to be 
noninferior to a polymer-coated paclitaxel-eluting stent (Taxus®, Boston Scientific Inc, Natick, 
US) (mean difference in angiographic late loss between the groups was 0.002mm p=0.02), with 
see colour section
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no significant differences between angiographic restenosis rates or target vessel revascularisation 
(19). Furthermore, a recently published registry series of patients treated with more than 200 
non-polymer rapamycin stents and the paclitaxel stent indicated no difference in major adverse 
cardiac event rates at 6 months. (20) 
 
 
Strut protrusion 
Although the concept of stent strut protrusion and flow disturbance as a potential contributor to 
stent thrombosis is not widely recognized, the protrusion of a foreign body into the coronary 
lumen will disturb flow at the blood-intima interface, potentially inducing complex flow patterns 
which may be thrombogenic in their own right. We suggest that the stent strut protrusion ratio 
may potentially be an important parameter when considering the safety of intracoronary stents. 
Regarding the 3d reconstruction, this was an exploratory technique which was applied to some 
representative OCT 2d images and is being further developed, but was not used quantitatively in 
this study. 
 
 
Study limitations 
Stent strut coverage is not a clinical outcome, but an important potential surrogate for 
thrombosis and therefore stent safety. The presence or absence of neointimal coverage is clearly 
as defined by the resolution of OCT and struts reported as bare could have had a thin covering 
of tissue (<10Ƭm), though at this level the biological protection of the coverage has been 
debated. (21) The trial was small in terms of patient numbers; however, more than 5000 strut 
sections were analysed with on average more that 150 per patient driving the statistical power. 
From a statistical standpoint, there were some unequal variances, however, the t-test remains 
robust when variances are not equal and, furthermore, re-analysing all outcomes in table 3 using 
the Mann-Whitney test, which makes no distributional assumptions, gave extremely similar 
results in all cases. OCT was performed at a single, relatively early time point. This was 
considered appropriate in the light of the drive to develop drug-eluting stents in which dual anti-
platelet therapy can potentially be stopped relatively early to reduce bleeding risk, allow non-
cardiac surgery and reduce cost. Neointimal heterogeneity of optical signal in different stent 
types has been described; however, neointimal compositional analysis was beyond the scope of 
this study which focussed upon anatomical coverage. Finally, OCT was not performed 
immediately after stent deployment. Although this may have provided some useful comparative 
information, it was judged that at this point in the evolution of the technique two OCT 
procedures was excessive from an ethical standpoint. 
 
 
Conclusions 
This trial demonstrated that the polymer-coated rapamycin-eluting stent exhibited low 
neointimal thickness, however, this was at the expense of >10% of the struts being uncovered 
and > 25% protruding into the lumen at 90-days by OCT criteria. The non-polymer rapamycin-
eluting stent in contrast exhibited greater neointimal thickness (with no angiographic or clinical 
restenosis) with <3% of struts uncovered and <5% protruding. These findings have to be 
interpreted in the context of reduced neointimal thickness being the very mechanism by which 
the efficacy of polymer coated rapamycin-eluting stents is achieved, with a proven reduction in 
subsequent target vessel revascularisation. Nevertheless, uncovered and protruding struts may be 
surrogates for thrombotic risk with the former indicating delayed healing, exposing the stent 
strut to the blood and the latter resulting in flow disturbance. These findings challenge the 
paradigm that less in-stent restenosis is better within a coronary stent and we hypothesize that at 
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least enough neointima to cover the stent struts and prevent protrusion may be important for 
safety. In addition it raises the possibility of earlier clopidogrel withdrawal in patients treated with 
non-polymer rapamycin-eluting stents than with polymer coated rapamycin-eluting stents. 
Proving these concepts will need clinical outcome trials, however, stent coverage and protrusion 
are logical parameters which can be employed in small scale trials to investigate the potential 
safety of new and existing coronary stent technologies. 
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Chapter 13
Optical coherence tomography to assess malapposition in 
overlapping drug-eluting stents 
Jun Tanigawa, Peter Barlis, Konstantinos Dimopoulos, Carlo Di Mario 
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Aim: Overlapping drug-eluting stents (DES) are frequently implanted to cover long segments of diseased and injured 
vessel, or as a bailout technique for edge dissection or incomplete lesion coverage. DES overlap is, nevertheless, 
associated with strut malapposition and poor intimal coverage, which may increase the risk of stent thrombosis. The 
aim of this study is to evaluate stent strut apposition in overlapping DES.  
Methods and results: We assessed strut apposition in 10 overlapped segments (20 DES, 10 patients, 661 
struts) immediately after implantation, using optical coherence tomography (OCT). Struts were defined as malapposed 
when no contact with the intima was detected by OCT. Despite aggressive stent optimisation using balloons with a final 
balloon/artery ratio of 1.26±0.18 at a maximum inflation pressure of 18.0±1.9atm, 41.8±21.5% of struts were 
malapposed in the overlapping segment, compared to 20.1±17.6% in the proximal and 9.7±10.6% in the distal 
segment (p <0.05 for both).  
Conclusion: OCT revealed that 40% of struts within an overlapped DES segment were malapposed, and this may 
explain the reported delay in endothelialisation in such segments. 
 
 
Coverage of the entire injured and diseased vessel segment is an established principle in the 
deployment of drug-eluting stents (DES) and a key factor in optimising DES efficacy to limit 
restenosis. This strategy requires stent coverage from healthy to healthy segments, thus demanding 
the implantation of multiple stents when lesions are long. Implantation of multiple overlapping 
stents is also required following initial DES implantation when extensive dissection or residual 
stenosis is present. The use of overlapping stents may lead to local arterial toxicity with exposure to 
inappropriately high levels of anti-proliferative drug or polymer. This phenomenon remains a 
concern and may predispose to delayed endothelialisation. Moreover, overlapping layers of stent 
struts and sub-optimal stent expansion and apposition to the intima can also lead to stent 
thrombosis.(1) Optical coherence tomography (OCT) is a new intravascular imaging modality, which 
uses infrared light and offers ten-fold higher resolution (10-15Ƭm) and fewer artefacts compared to 
intravascular ultrasound, thereby enabling precise assessment of stent optimisation.(2,3) The present 
study aimed to assess the frequency of DES strut malapposition within overlapped segments 
immediately following implantation and angiographic optimisation. 
 
 
Methods 
 
Study population 
Between February and October 2006, 10 patients who received overlapping DES were assessed using 
OCT (20 stents, 10 lesions). The OCT examination took place following angiographic optimisation. 
Overlapping DES was used as a primary strategy for very long lesions or bailout for residual stenosis 
or dissection following the implantation of the first stent. Pre-dilatation or direct stenting and 
selection of stent type were left to the discretion of the operator, but the same type of DES was used 
for each lesion and stent implantation was always followed by high-pressure post-dilatation at the 
overlapping segment. Stent optimisation was accomplished with conventional angiographic guidance 
aiming at a residual diameter stenosis < 20% by visual estimate.  
 
 
OCT procedure 
The OCT system used in this study (LightLab Imaging Inc., Westford, MA, US) has been described 
previously.(3,4) In brief, lesions were imaged during proximal occlusion and continuous infusion of 
Ringer’s lactate at 0.5-1.5ml/sec. An OCT catheter (Helios™ proximal occlusion catheter) and an 
OCT imaging wire (ImageWire™) were used. The lesion was visualised with an automated pullback 
system at 1.0mm/sec acquiring cross sectional images at 15.4 frames/sec. Off-line analysis of 
contiguous cross-sections in overlapped stents was performed at 1mm intervals. The overlapped 
struts were assessed as well as the 2 adjacent cross-sections immediately proximal and distal (Figure 
1).  
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Figure 1: Schema of two overlapped stents demonstrating the areas assessed using optical coherence tomography  
 
 
Strut malapposition was defined as no contact between the strut and intima. As OCT can show only 
the surface of stent struts due to its limited penetration through the metal, the measured distance 
between the strut surface and the luminal surface (Figure 2) was adjusted based on each stent 
thickness. Each cut-off was determined as the total of the metal and polymer thickness plus 10Ƭm 
(OCT longitudinal resolution) (Table 1). Struts protruding into the ostium of a side branch were 
excluded from the analysis. 
 
 
 
 
Figure 2: Measurement of distance between the endoluminal surface of the strut and intima Note that OCT can only 
show the endoluminal surface of the strut due to its limited penetration through metal. 
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㻌  Metal 
thickness 
Polymer 
thickness 
Total 
thickness 
Malapposed*
Cypher Select 140 7 154  170
Taxus Liberte 97 15 127  140
Co Star 89 No 89  100
Values are presented as μm
*Distances from endoluminal surface to the intima
 
Table 1. Strut thickness and classification of apposition of the drug-eluting stents used in this study 
 
 
Statistical analysis 
 
Statistical analysis was performed using R version 2.4.1 and StatView 5.0 (SAS Institute Inc., Cary, 
NC, US). Comparison between groups was performed using the two-sample Wilcoxon test for 
continuous variables. A two-tailed p-value of <0.05 was used as the criterion for statistical 
significance for all analyses. 
 
 
Results 
 
Clinical and lesion characteristics 
 
Table 2 lists the clinical and lesion characteristics for the 10 patients. All lesions studied were 
complex (ACC/AHA classification type B or C), including 3 severely calcified lesions. Cypher Select 
(Cordis, Johnson and Johnson Co., Miami Lake, FL, US), CoStar (Conor Medsystems, Inc., 
Hamilton Court Menlo Park, CA, US) and Taxus Liberte (Boston Scientific, Natick, MA, US) stents 
were used in this study. There were no OCT-related complications such as haemodynamic instability 
or arrhythmias during image acquisition and no subsequent deterioration of flow or coronary 
dissection. 
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1 F 74 Yes No Yes No Yes Stable angina LCx type C No 
2 M 71 No No No Yes No Stable angina LAD type B No 
3 M 64 No No Yes No Yes Stable angina RCA type C Yes 
4 M 65 Yes No No No Yes Stable angina RCA Type C Yes 
5 F 54 No Yes Yes Yes Yes ACS LAD Type B No 
6 M 66 Yes No No Yes Yes Stable angina LCx Type C Yes 
7 M 54 Yes No No Yes Yes Stable angina LAD Type C No 
8 M 79 No No No Yes Yes Stable angina RCA Type C No 
9 M 65 No Yes Yes No Yes Stable angina LAD Type C No 
10 M 66 Yes No Yes Yes No ACS RCA Type B No 
MI – myocardial infarction; LCx – left circumflex artery; RCA – right coronary artery, LAD – left anterior descending artery 
 
Table 2: Clinical and lesion characteristics 
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Angiographic and procedural characteristics 
 
Table 3 lists the angiographic and procedural characteristics. The mean number of stents used per 
lesion was 2.2±0.4. In only one case was direct stenting performed. Mean total stent length was 
47.9±7.3mm. Post-dilatation was used in all cases with non-compliant balloons at a mean pressure of 
18.0±1.9atm. The balloon to artery ratio was 1.26±0.18. In 8 of 10 patients (80%), the distal stent 
was implanted first followed by the proximal stent in an overlap fashion.  
 
 
 
  Stent type, Cypher Select, n (%)  6 (60)
  Stent type, Taxus Liberte, n (%)  1 (10)
  Stent type, CoStar, n (%) 3 (30)
  Number of stents  2.2±0.4
  Average stent diameter (mm) 2.86 ± 0.31 
  Total stent length (mm) 47.9 ± 7.3
  Pre-dilatation, n (%) 9 (90)
  Post-dilatation, n (%) 10 (100)
  Maximum balloon diameter (mm) 3.08 ± 0.24 
  Maximum balloon artery ratio 1.26 ± 0.18 
  Maximum balloon pressure (atm) 18.0 ± 1.9
Quantitative coronary angiographic results
 Pre-procedural 
  Reference vessel diameter (mm) 2.49 ± 0.40 
  Minimal lumen diameter (mm) 1.00 ± 0.38 
  Diameter stenosis (%) 58.5 ± 18.1 
  Lesions length (mm) 28.9 ± 9.3
 Post-procedural 
  Reference vessel diameter  (mm) 3.01 ± 0.38 
  Minimal lumen diameter (mm) 2.49 ± 0.35 
  Diameter stenosis (%) 17.4 ± 6.5
LAD: Left anterior descending artery, RCA: Right coronary artery, LCx: Left circumflex artery 
 
Table 3. Angiographic and procedural characteristics 
 
OCT analysis 
 
A total of 661 struts in 53 cross sections were analyzed (239 struts in the overlapping segment, 228 
struts in the proximal segment and 194 struts in the distal segment). The proportion of malapposed 
struts differed significantly between the overlapped (41.8±21.5%) and both the proximal 
(20.1±17.6%) and distal (9.7±10.6%) non-overlapped segments (Figure 3).  
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Figure 3: Percentage of malapposed struts 
 
Discussion 
 
Using high resolution intravascular imaging with OCT, our study has shown that a high proportion 
of the stent struts located within an overlapped segment remain malapposed, despite high pressure 
balloon dilatation with appropriately sized balloons. Furthermore, the region immediately proximal 
to the overlap segment has a greater number of malapposed struts.  
OCT is a new intravascular imaging modality, which uses infrared light and offers 10 time’s higher 
resolution (10-15Ƭm) and fewer artefacts compared to IVUS. The clinical application of 
intracoronary OCT has already been demonstrated both in stable patients and in those with acute 
coronary syndromes (5) and was used without complication in our patients.  
The high malapposition rate in the overlap segment immediately following DES implantation and 
aggressive optimisation is an important finding and one that has not previously been reported using 
OCT. Prior studies have raised concerns regarding the safety of overlapping DES, with particular 
reference to the phenomenon of ‘double dose’ of metal, polymer and drug in this stented segment.(6) 
One third of patients enrolled in SIRIUS, E-SIRIUS and TAXUS-VI study received multiple 
overlapping stents.(7-9)  In a recent pooled analysis of five clinical trials of the sirolimus-eluting stent 
(SES, Cypher, Johnson & Johnson, Miami, USA), 575 patients with stent overlap (337 SES, 238 
BMS) were compared to 1162 patients with single stents (697 SES, 465 BMS).(6) Stent overlap was 
associated with a greater late lumen loss in stent and more frequent angiographic restenosis, 
regardless of stent type.(6) 
Concerns that stent overlap may increase the likelihood of stent strut malapposition and thus the 
propensity for restenosis and thrombosis therefore remain unanswered. An animal study, showed 
persistent inflammation, fibrin deposition, and delayed endothelialisation following DES 
implantation compared with bare metal stents, particularly at overlapping segments. (10) This may be 
related to excess inhibition of neointimal hyperplasia as a result of the double dose of sirolimus. 
Using OCT 6 months after SES implantation, Matsumoto et al (11) found that overlapping SES 
struts showed malapposition more frequently than did non-overlapping struts. The clinical 
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significance of this however remains unclear, particularly as this study did not assess stent strut 
apposition at implantation.  
In our study, we found a significant difference in the rate of strut malapposition between the 
proximal and distal stented segments (20.1% vs. 9.7%, p=0.012). This difference could be due to 
vessel tapering or the deployment order of the overlapping stents. Since coronary dilatation balloons 
and stents have a longitudinally uniform size, it is less likely that struts in the proximal part of the 
stent become optimally apposed to the intima. Furthermore, when the intended strategy is that of 
overlapping stents, the distal stent is usually implanted first followed by the proximal stent. This may 
results in a funnelling effect with the proximal stent expansion being restricted by the already 
deployed distal stent. Deployment of the proximal stent first may limit this phenomenon, but may 
prove technically challenging. 
 
 
 Limitations 
 
This was an observational study with a small sample size. For this reason, this report was limited to 
individual patient data and few overall summary statistics and comparisons. The sample size also 
precludes any formal assessment of predictors of strut malapposition in overlap segments with larger 
studies needed to address this and other concerns related to the long-term issues of DES safety and 
any differences that may exist between different stent platforms. 
 
 
Conclusions 
This preliminary study has shown that overlapping DES are associated with a considerable risk of 
immediate malapposition. Moreover, the segment proximal to the overlap appears more prone to 
malapposition compared to the distal stented segment, despite aggressive stent optimisation using 
adequately sized balloons with high pressures. This phenomenon, never before documented, may 
contribute to delayed endothelialisation and result in an increased risk of stent thrombosis although 
larger studies are needed to confirm these findings and determine their relation to late DES 
complications. 
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Chapter 14
Heavily calcified coronary lesions preclude strut apposition despite high 
pressure balloon dilatation and rotational atherectomy: In-vivo 
demonstration with optical coherence tomography 
Jun Tanigawa, Peter Barlis, Carlo Di Mario 
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Heavily calcified lesions (HCL) continue to represent challenges not always solved by low profile, non-compliant 
high-pressure balloons, or bladed balloons. Uncrossable or unexpandable lesions need lesion modification using 
ablating devices such as rotational atherectomy. We assessed 3 HCL treated with drug-eluting stents using a new 
intravascular imaging device, Optical Coherence Tomography with tenfold superior resolution and fewer artifacts 
compared to conventional intravascualr ultrasound. Insights from this highly sensitive imaging technique outline the 
high prevalence of persistent stent strut malapposition in this group despite high-pressure dilatation or rotational 
atherectomy. 
 
 
Crossing the lesion, initial dilatation by balloons and final stent expansion may present a 
challenge to the operator’s skill and experience in heavily calcified lesions (HCL) due to a highly 
angulated lumen and resistance to optimal expansion (1,2). If balloons do not cross or expand 
and the poorly steerable thin uncoated Rotablator® (Boston Scientific, Natick, MA, US) wire can 
be advanced, rotational atherectomy provide favorable lesion modification, which can facilitate 
lesion dilatation and stent expansion (3,4). Other methods of lesion preparation (cutting balloon, 
high pressure pre- and post-dilatation) have been advocated to obtain optimal stent expansion 
and apposition. Based on the examination of 3 representative cases with optical coherence 
tomography (OCT), we explain why optimal strut apposition remains an elusive target in the 
presence of heavy eccentric calcified plaques. 
 
Case report 
 
CASE 1 
A 66-year-old male admitted with typical angina pectoris on a background of hypertension, 
hyperlipidemia and previous myocardial infarction underwent coronary angiography. This 
demonstrated long segments of heavily calcified severe stenoses in the mid left circumflex artery 
(Figure 1). The lesions were sequentially dilated with both 1.5 and 2.0mm non-compliant 
balloons up to 16atm. Three sirolimus-eluting stent (SES, Cypher SelectTM, Cordis, Johnson and 
Johnson Co., Miami Lake, FL, US), 2.5x18, 3.0x13 and 3.0x23mm were implanted in an 
overlapping fashion and post-dilated with a non-compliant 3.0mm balloon to 22atm. Although 
his angiogram showed optimal lesion dilatation with only minimal lumen haziness (Figure 1C), 
OCT (LightLab Imaging Inc., Westford, MA, US) revealed sub-optimal stent expansion and poor 
stent strut apposition (5). Despite multiple high-pressure lesion dilatations, optimally 
circumferential expansion could not be achieved. Figure 2A shows elliptical stent expansion 
limited by heavily calcified superficial eccentric plaque (*). Irregular contours of the stent struts 
maintained a circular geometry and were unable to fully conform to the slit like lumen induced by 
the severe calcification. Although circumferential expansion shows greater minimal lumen 
diameter compared to elliptic expansion (3.17x2.86mm vs. 3.33x1.97mm), some struts still 
remain malapposed to the intima at the intimal tear between the superficial eccentric calcification 
and non-calcified intima (Figure 2). Although stent expansion was acceptable, matching the distal 
reference lumen area, the irregularity of the lumen contours due to protruding eccentric 
calcification precluded complete strut apposition. We administered IIb/IIIa inhibitors and 
recommended long-term dual anti-platelet treatment. Clinical follow-up at 4 months is uneventful. 
 
CASE 2 
A 71-year-old male admitted with angina pectoris on a background of hypertension, 
hyperlipidemia and previous myocardial infarction underwent coronary angiography. This 
demonstrated HCL in the mid right coronary artery. As no balloon could cross the stenosis, a 
rotablator wire was inserted and a 1.5mm burr used, followed by multiple sequential dilatations 
using a 2.0, 3.0 and 3.5mm non-compliant balloon up to 20Atm. A 3.5x28mm Cypher Select 
stent (Cordis, Johnson & Johnson, Miami, FL, USA) was implanted and post-dilated with a short 
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3.5mm non-compliant balloon up to 24atm (Figure 3). OCT (Figure 4) showed that rotational 
atherectomy created a small circular divot in the eccentric calcified plaque extending for half of 
the vessel circumference, which resulted in complex lumen geometry. This crater (E, F arrow 
heads) measured 1.60mm in diameter, almost equivalent to the rotablator burr size of 1.5mm, 
contributed to the incomplete expansion of the lesion despite high-pressure dilatation and 
preventing full stent strut apposition (E, double arrow).  
 
CASE 3 
A 57-year-old male with stable angina was electively transferred following unsuccessful balloon 
angioplasty of the mid left circumflex bifurcation lesion, resistant to expansion using 
conventional balloons due to heavy calcification. After engagement of 7Fr guiding catheter, 
rotational atherectomy using 1.75mm burr was successfully performed and followed by pre-
dilatation using 3.0 and 3.5mm non-compliant balloon up to 20atm. Paclitaxel-eluting stent 
(Taxus LiberteTM, Boston Scientific, Natick, MA, US) was implanted (4.0x16mm, 16atm) in the 
main vessel crossing the side branch and post-dilated using kissing inflation technique (3.5mm 
for the main vessel and 2.5mm for the side branch, up to 14atm, Figure 5). Although his 
angiogram showed an optimal result at the main vessel, OCT imaging demonstrated similar 
findings (Figure 6) as identified in case 2, a crater formation (arrow heads) with diameters of 
1.69mm (A) and 1.83mm (B) beside the remaining fibro-calcified plaque (*), preventing complete 
lesion expansion and full stent strut apposition (arrows). 
 
 
 
Discussion 
Even in the HCL, the majority can be treated with balloon dilatation and stent implantation alone 
(3). Many, however, may not be optimally expanded and stent struts may not be fully apposed to 
the intima as shown in case 1. The importance of this is underscored with findings from the e-
Cypher registry correlating HCL with future occurrence of stent thrombosis (6). At times, stent 
expansion and apposition are often confused. Stent expansion is defined in relation to the lumen 
diameter of the proximal or distal vessel (reference diameter), while stent apposition is a 
description of the strut’s attachment to the intima (plaque or vessel wall), regardless of whether it 
is properly expanded or not. OCT remains inferior to IVUS in guiding stent expansion since the 
external elastic membrane diameter is not always detectable due to its limited penetration of 
around 1.5mm and scan range of approximately 5mm. Although it is still controversial, stent 
under expansion and sub-optimal strut apposition following drug-eluting stent (DES) 
implantation are suggested as possible causes of stent thrombosis (7). Both stent under expansion 
and strut malapposition were clearly identified in the 3 cases, even when rotational atherectomy 
was performed. Although there have not been any reports in the literature comparing expansion 
in HCL versus non-calcific lesions, in our experience malapposition and poor expansion are 
more frequent in the treatment of HCL and this may account for sub-optimal long-term result 
associated with HCL.  
Rotational atherectomy for the HCL is quite useful to improve procedural success thanks to 
lesion modification (removal of dense calcification) leading better stent expansion (4). However, 
in cases 2 and 3, the superficial calcification was not completely cleared, preventing optimal stent 
expansion and apposition. Stent expansion and apposition are completely different concepts; 
stent expansion is defined in relation to the lumen diameter of the proximal or distal vessel, while 
stent apposition is a description of the strut’s attachment to the intima (plaque or vessel wall), 
regardless of whether it is properly expanded or not. Both are desirable to optimize DES safety 
and efficacy. Even with maximum dilatation using adequately sized balloons at high-pressure 
and/or rotational atherectomy using small burrs acquiring angiographically optimal stent 
deployment, full stent expansion and apposition cannot be optimally achieved in HCL. Sizing-up 
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the burr might enable better lesion modification resulting in better stent expansion and strut 
apposition. It is, however, unknown whether routine usage of aggressive rotational atherectomy 
is superior to conventional balloon dilatation as a means of lesion modification followed by DES 
implantation due to a lack of systemic long-term results of such a strategy. Clinical consequences 
of such gross malapposition also remain unknown (e.g. long-term double anti-platelet therapy 
needed to prevent late stent thrombosis), but may impinge on the elution properties of DES, 
activate fibrin and platelet more and may result in accelerated intimal hyperplasia or stent 
thrombosis. In this case series, OCT clearly showed how HCL behave when dilated using 
conventional balloons and modified using rotational atherectomy. It is often a challenge to 
achieve optimal stent expansion and strut apposition in such lesions; however this remains one of 
the major benefits of DES.  
 
 
Figure 1: Case 1 - Coronary Angiography 
A) Pre-procedural caudal left anterior oblique view showing tortuous diffuse stenosis in the mid left circumflex 
artery, B) Pre-procedural caudal right anterior oblique view, C) Post-procedural caudal right anterior 
oblique view. Optical Coherence Tomography assessment was performed using automatic pull-back system 
and arrows (a, b) correspond to OCT cross-sectional images as shown in Figure 2-a, b. 
 
 
Figure 2: Optical Coherence Tomography findings following conventional balloon dilatation and stent implantation 
A) Elliptical stent expansion limited by superficial calcification (*) and intimal flaps  (double arrows) outside the stent 
at the border between superficial calcification and non-calcified intima (white arrow head), B) Circular stent 
expansion with an intimal tear between the superficial calcification (*) and non-calcified intima (arrow head), where 
stent struts are malapposed. Intimal tear was distinguished from branches using adjacent cross-sectional OCT images 
and corresponding angiogram.  
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A) Figure 3: Coronary angiography of the right coronary artery in Case 2 Left anterior oblique view indicating 
severe calcification in the mid segment, B) Rotational atherectomy using 1.5mm burr, C) Cypher Select 
Stent 3.5x28mm, D) Post-dilatation using 3.5mm balloon up to24atm 
 
 
 
 
Figure 4: Final result of Case 2 and Optical Coherence Tomography findings 
A) Angiographic result following stent implantation E, F) A crater formation (arrowhead) beside the remaining 
superficial eccentric calcification (*) located on the same side of the two branches (C,D +) where the Rotablator has 
shifted (wire bias) during ablation.  The diameter of the crater was 1.60mm almost equivalent to the Rotablator burr 
size of 1.5mm. Note struts (arrows) are malapposed at the crater. This crater corresponded with the protuberance on 
the outer contour of the right coronary artery on angiography, just above the level of the side branch (5A, dotted 
line). 
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Figure 5: Pre- and post-procedural angiography and procedures (Case 3) Severe calcification in the mid left 
circumflex artery (A,B) was ablated using 1.75mm Rotablator burr (C) and followed by Taxus Liberte stent 
(4.0x16mm, 16atm) implantation (D) and final kissing inflation (E). Final result was optimal (E). 
 
 
 
Figure 6: Optical Coherence Tomography findings of Case 3 
As in Case 2, a crater formed by the rotational atherectomy burr beside the fibro-calcified plaque (A,B), where stent 
struts are malapposed (B). A crater formation (arrowhead) can be seen beside the remaining superficial eccentric 
calcification (*) 
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Background: Stent strut malapposition correlates with poor intimal coverage and this may increase the risk of 
late stent thrombosis. At present, there is limited data on whether stent strut thickness and stent design impact on 
acute apposition. We aimed to investigate the influence of stent strut thickness and design on acute stent strut 
apposition (SSA) immediately following drug-eluting stent (DES) implantation using optical coherence tomography 
(OCT), a technique with higher resolution and fewer artefacts than intravascular ultrasound.  
Methods: Thirty-six DES in 23 patients (25 lesions) were studied by OCT. SSA was defined as embedded 
when a strut was buried in the intima for more than half its thickness, protruding when apposed to the intima but 
not embedded and malapposed when there was no intimal contact.  
Results: Cypher Select stents were implanted in 52%, Taxus Liberte in 32%, Costar in 12% and Endeavour 
in 4%. A total of 6,402 struts were evaluated. Despite stent optimisation using balloons with a final 
balloon/artery ratio of 1.26±0.19 at a maximum inflation pressure of 17.5±3.0atm, only 57.1±20.7% of 
struts were embedded, whereas 33.8±18.4% were protruding and 9.1±7.4% were malapposed. Stent type was a 
strong predictor of malapposition on logistic multilevel analysis (OR 3.95, 95%CI: 1.27-12.23, p=0.017). At 
12 months follow-up, there were no adverse clinical events. 
Conclusion: Despite angiographic optimisation with high pressures and adequately sized balloons, malapposed 
stent struts are frequently found in complex coronary lesions and more often following the implantation of Cypher 
Select stents which have a thicker stent strut and closed cell design. With no adverse clinical events at 12 months 
follow-up, this likely represents a benign phenomenon at least as long as combined anti-platelet therapy is 
maintained.  
 
 
Although drug-eluting stents (DES) have dramatically reduced restenosis compared to bare metal 
stents (BMS), restenosis and stent thrombosis continue to present a challenge, especially in 
complex coronary lesions (1-5). The issue of late and very late stent thrombosis has cast a cloud 
on the use of DES (6-9), resulting in an empirical increase in the duration of dual anti-platelet 
therapy beyond the customary 6-12 months. Although the magnitude of this phenomenon 
remains unclear, recent studies have found a link between sub-optimal stent strut apposition 
(SSA) and delayed endothelialisation which may predispose to stent thrombosis.(6,10,11) 
Previous studies have demonstrated a link between stent strut thickness and long-term restenosis 
and target lesion revascularisation (TLR),(4,12) there is currently no data specifically assessing the 
influence of stent strut thickness on apposition in the DES era. 
Optical coherence tomography (OCT) is a relatively new intravascular imaging modality, which 
uses infrared light and offers 10 times higher resolution (10-15Ƭm) and fewer artefacts compared 
to intravascular ultrasound (IVUS), thereby enabling precise assessment of stent optimisation. 
(13) The present study used OCT to identify predictors of sub-optimal apposition and, in 
particular, the influence of stent strut thickness and design and examine 12-month clinical 
outcomes. 
 
Methods 
 
Patient Enrolment and Pharmacological Treatment 
From January 2005, OCT became the mainstay intravascular imaging modality used at our 
institution to assess results of stent implantation. For this particular study, we only enrolled 
patients undergoing percutaneous coronary intervention for complex coronary lesions defined as 
long (>20mm), heavily calcified or at a bifurcation. Clinical exclusion criteria were: poor renal 
function (serum creatinine >1.5mg/dL), left ventricular ejection fraction <30% and 
haemodynamic instability. Angiographic exclusion criteria were: residual thrombus or dissection; 
lumen diameter proximal to the stented lesion smaller than 2.5mm or greater than 4.0mm by 
visual estimate; ostial or very proximal lesion (<15mm from ostium); recanalised chronic total 
occlusion; severe tortuosity; final post-procedural Thrombolysis In Myocardial Infarction (TIMI) 
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grade flow <3. All patients provided written informed consent prior to the procedure approved 
by the local institutional ethics committee.  
All patients were pre-treated with aspirin and clopidogrel (300-600mg loading dose) and both 
were continued for 1 year. Heparin was used to maintain an activated clotting time (ACT) 250 
seconds. Upstream use of glycoprotein IIb/IIIa inhibitor therapy was left to the operator’s 
discretion. 
 
Definitions and Clinical Follow-up 
Technical success was defined as restoration of TIMI flow grade 3 with stent implantation and 
residual stenosis <20% by visual estimate. Procedural success was defined as technical success in 
the absence of death, Q-wave or non-Q wave MI (> 3 fold increase of creatine kinase MB), 
stroke, pericardial effusion requiring pericardiocentesis, emergency coronary artery bypass 
grafting (CABG), defined as bypass surgery within 24 hours of the procedure. Confirmed stent 
thrombosis was defined as angiographically or pathologically documented stent occlusion with 
TIMI grade 0 or 1 flow or residual thrombus at the stent site occurring within 24 hours of the 
index procedure (acute), between 24 hours and 1 month after the procedure (sub-acute) or more 
than 1 month after the procedure (late thrombosis). Suspected stent thrombosis was defined as 
sudden death or MI with electrocardiographic changes in the territory of the treated artery 
without demonstration at angiography or on post-mortem examination.  
Clinical follow-up was performed by outpatient visit and telephone enquiries. Patients were 
evaluated for survival-free of major adverse cardiac events (MACE), such as death, non-fatal MI 
or repeat target vessel revascularisation (TVR).  
 
Coronary Interventions 
Coronary interventions were performed electively according to standard practice with DES 
implantation through a 6 Fr guiding catheter with an inner diameter of 0.071”. Stent optimization 
was accomplished with conventional angiographic guidance aiming at a residual diameter stenosis 
<10% by visual estimate. Implantation of multiple stents (2) with overlap was always followed 
by high pressure post-dilatation using non-compliant balloons. Four different DES were used in 
this study (Cypher SelectTM, Cordis, Johnson and Johnson Co., Miami Lake, FL, US, Taxus 
LiberteTM Boston Scientific, Natick, MA, US, EndeavorTM , Medtronic, Santa Rosa, CA, US and 
CoStarTM (Conor Medsystems, Inc., Hamilton Court Menlo Park, CA, US). 
 
 OCT Imaging 
The OCT system used in this study (LightLab Imaging Inc., Westford, MA, US) has been 
described previously.(1) Briefly, an over-the-wire OCT catheter (Helios™ proximal occlusion 
catheter) is advanced distal to the stented lesion over a conventional coronary guide wire, which 
is then replaced with the OCT imaging wire (ImageWire™). The OCT catheter is then 
withdrawn proximal to the stented segment and the lesion visualised using an automated pullback 
system at 1.0mm/sec. During image acquisition, coronary blood flow is replaced by continuous 
infusion of Ringer’s lactate at 0.5-1.5ml/sec using a power injector (Mark V ProVis, Medrad, Inc. 
Indianola, PA, US). The highly compliant occlusion balloon remains inflated proximal to the 
lesion at 0.5 or 0.7atm for a maximum of 30sec. Meticulous attention must be paid to 
haemodynamic monitoring of the patient during the proximal occlusion and intra-coronary flush.   
Cross sectional images are acquired at 15.4 frames/sec. In case the lesion is not fully imaged in 
the first pullback, the imaging sensor is left in position and a second or occasionally third 
pullback is required to achieve complete lesion assessment. In such circumstances, the pullback is 
stopped as soon as a decision is taken to deflate the balloon and stop the infusion, and the new 
pullback is started after patient recovery from exactly the same position whilst the blood is being 
cleared by a new infusion. 
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Off-line OCT Analysis 
Analysis of contiguous cross-sections within the stented segment was performed at 1 mm 
intervals. In each selected cross section, the distance between endoluminal edge of the strut and 
intima was measured. Measurements were classified into 3 grades of apposition: ‘embedded’, 
‘protruding’ or ‘malapposed’.(1) Since only the endoluminal surface of struts can be identified with 
OCT, distances were adjusted based on the thickness of the strut including the polymer layer 
(Table 1). Struts buried in the intima for more than half of their thickness were defined as 
‘embedded’, those apposed to the intima but not embedded were defined as ‘protruding’ and those 
with no contact to the intima were defined as ‘malapposed’ (Figure 1). Struts protruding into a side 
branch ostium were excluded from the analysis.  
 
 
Figure 1: Classification of stent strut apposition  
The distance between the endoluminal surface of the strut and the intima was measured by OCT and adjusted for 
strut thickness to calculate the gap between the strut and the intima. Based on this value, struts were classified into 3 
grades: embedded, protruding and malapposed.  
 
 
Strut thickness
  Metal Strut Polymer Total Thickness Embedded Protruding Malapposed
Cypher Select 140 7 154 <80 80-160 160 
Taxus Liberte 97 15 127 <65 65-130 130 
Endeavor 91 8* 107 <55 55-110 110 
Co Star 89 No 89 <45 45-90 90 
Values are (μm), *Average thickness of uneven endo- and abluminal polymers
Table 1. Strut thickness and classification of apposition of the DES used in this study 
 
Statistical Analysis 
Statistical analysis was performed using R version 2.4.1 (The R Foundation for Statistical 
Computing, Vienna, Austria) and MLwiN version 2.02 (Centre for multilevel modelling, 
University of Bristol, UK) with residual iterated generalised least squares and pseudoquasi-
likelihood model specifications. Data are expressed as mean ± standard deviation for continuous 
variables and as percentages for categorical variables. Comparison between groups was 
performed using the two-sample Wilcoxon test for continuous variables and Fisher’s exact test 
for count data. Distribution of strut-to-intima distance was graphically represented by means of 
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histograms of probability densities (with a total histogram area of 1). The Shapiro-Wilk test was 
used to assess normality of continuous variables.  
 
Since the observation of struts in the same stent are not independent of each other, it would be 
wrong to use standard regression analysis to identify predictors of strut malapposition, as this 
assumes independence of observations. Given the hierarchical nature of the data (stent struts 
nested within lesions nested within patients), multilevel logistic regression with malapposition as 
the outcome variable was applied to address random and fixed effects at the strut, lesion and 
patient levels. At the lesion level, presence of calcification, type C lesions, stent type (Cypher 
versus non-Cypher), stent length, stent diameter, maximal balloon size and maximum inflation 
pressure were considered. At the patient level, age, sex and diabetes mellitus were considered. A 
two-tailed p-value of <0.05 was used as the criterion for statistical significance for all analyses.  
 
Results 
Baseline Clinical Characteristics 
Between February 2006 and August 2006, 36 stents implanted in 25 complex lesions from 23 
patients were assessed using OCT. Baseline clinical characteristics are shown in Table 2. Mean 
age of patients was 64.5±10.3 years with 91.3% male. Diabetes mellitus was a risk factor in 17.4% 
of patients with nearly half of the patients presenting with an acute coronary syndrome.  
 
 
n=23 patients 
Age (years) 64.5±10.3
Male gender, n (%) 21 (91.3)
Hypertension, n (%) 14 (60.8)
Hyperlipidemia, n (%) 20 (86.9)
Diabetes Mellitus, n (%) 4 (17.4)
Smoker (current/former), n (%) 17 (73.9)
Familial history of IHD, n (%) 14 (60.1)
Stable angina, n (%) 14 (60.1) 
ACS presentation, n (%) 11 (47.8)
Previous MI, n (%) 7 (30.4)
Previous CABG, n (%) 3 (13.0)
Table 2. Baseline Clinical Characteristics 
 
Angiographic and Procedural Characteristics 
Angiographic and procedural characteristics are shown in Table 3. All lesions were complex 
(ACC/AHA classification type B or C), including long and severely calcified lesions as well as 
bifurcations. The LAD was the target vessel in almost half of all cases.  
Cypher SelectTM (Cordis, Johnson and Johnson Co., Miami Lake, FL, US) and Taxus LiberteTM 
(Boston Scientific, Natick, MA, US) stents were predominantly used while EndeavorTM 
(Medtronic, Santa Rosa, CA, US) and CoStarTM (Conor Medsystems, Inc., Hamilton Court Menlo 
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Park, CA, US) stents were used in 4 cases. Overlap stenting was performed in 40% of cases due 
to long lesion length. During OCT acquisition, intra-coronary infusion with Ringer’s lactate was 
performed at a rate of 0.92±0.25 (Range: 0.5-1.5) ml/sec. There was no haemodynamic instability 
or arrhythmias during acquisition and no subsequent coronary dissection. Only one patient had 
transient slow flow because of air embolisation after withdrawal of the occlusion catheter. 
Treatment with air aspiration and intra-coronary nitroprusside led to prompt restoration of 
TIMI-grade-3 flow. The patient had presented with an acute coronary syndrome and the peak 
post-procedural troponin I and creatine kinase were 1.23Ƭg/L and 387U/L respectively. 
 
OCT assessment of strut apposition 
A total of 6,402 struts were evaluated (256±108 struts/lesion). An average of 57.1±20.7% struts 
were embedded, 33.8±18.4% protruding and 9.1±7.4% malapposed per lesion. The mean 
difference in SSA classification between the 2 observations made by the same operator was 1.8% 
(95% limits of agreement [LA]: -11 to 7.1%) for embedded, 0.043% (95% LA: -7.9 to 7.8%) for 
protruding and 1.8% (95% LA: -2.1 to 5.6%) for malapposed struts. Interclass correlation 
coefficient for the three categories was 0.98 (95% CI: 0.94-0.99) for embedded, 0.98 (95% CI: 
0.95-0.99) for protruding and 0.95 (95% CI: 0.86-0.98) for malapposed.  
The rate of malapposed struts per lesion ranged between 0 and 21.7% of the total struts assessed, 
with 88% of lesions having at least 1 malapposed strut. 
 
Predictors of strut malapposition 
Univariate predictors of malapposition on multilevel logistic regression analysis are shown in 
table 4 and figure 2. Implantation of a Cypher stent was a strong predictor of malapposition, 
together with the presence of a overlapping stents, a longer stent length, a type C lesion, 
performance of post-dilatation, a higher maximal inflation pressure and diabetes mellitus. 
 
 
 
Figure 2: Predictors of 
malapposition on multilevel 
logistic regression analysis in the 
overall population and the subset 
of patients treated with either 
Cypher or Taxus stents (significant 
predictors only shown for the 
latter).  
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n=25 lesions
Angiographic Characteristics 
ACC/AHA classification n, (%) 
Type B 
Type C 
16 (64) 
  9 (36) 
Target vessels, n (%) 
LAD 
RCA 
LCx 
12 (48) 
  7 (28) 
  6 (24) 
Location, n (%) 
Proximal 
Mid 
Distal 
  5 (20) 
15 (60) 
  5 (20) 
  Bifurcation, n (%) 12 (48)
  Severe calcification, n (%)  6 (24)
Stent type 
Cypher Select, n (%)  13 (52)
Taxus Liberte, n (%)   8 (32)
Endeavor, n (%)   1 (4)
CoStar, n (%)   3 (12)
Average stent number per lesion 1.4 ± 0.6
Average stent diameter (mm) 2.97 ± 0.35
Total stent length (mm) 32.5 ± 14.4
Pre-dilatation (%) 19 (76)
Post-dilatation (%) 20 (80)
Maximum balloon diameter (mm) 3.09 ± 0.30
Maximum balloon artery ratio 1.26 ± 0.19
Maximum balloon pressure (atm) 17.5 ± 3.0
Multiple stenting (%overlapping/ %culotte) 10 (40)/ 4 (16)
QCA Pre-procedural 
  Reference vessel diameter (mm) 2.51 ± 0.43
  Minimal lumen diameter (mm) 1.07 ± 0.34
  Diameter stenosis (%) 57.0 ± 14.0
  Lesions length (mm) 18.9 ± 11.1
 QCA Post-procedural 
  Reference vessel diameter  (mm) 2.98 ± 0.43
  Minimal lumen diameter (mm) 2.59 ± 0.43
  Diameter stenosis (%) 13.3 ± 6.1
Table 3. Angiographic and Procedural Characteristics 
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Difference of Stent Type: Cypher and Taxus 
To further investigate the role of stent type on SSA, separate analysis was performed using only 
data from lesions in which the 2 most commonly used types of DES (Cypher Select, n=13 and 
Taxus Liberte, n=8) were implanted. Data on a total of 21 lesions were analysed. There were 
more overlapping stents in the Cypher group (6 (46.2%) versus 1 in the Taxus group (12.5%), 
p=0.173) and pre-MLD was lower in the Taxus group (0.95±0.28mm versus 1.22±0.27mm in the 
Cypher group, p=0.053).  
A significant difference was found in % embedded (40.2±8.6% vs. 73.3±13.6%. p<0.0001), % 
protruding (48.1±10.1% vs. 23.0±10.5%, p<0.0001) and % malapposed (11.6±6.6% vs. 
3.7±5.2%, p=0.007) struts between the Cypher and Taxus group (Figure 3). In fact, a wider 
distribution of the distance between the endoluminal surface of the strut and the intima was 
observed in the Cypher group, with more struts at less than 50Ƭm from the intima in the Taxus 
group (Figure 4). Stent type was a strong predictor of malapposition on multilevel logistic 
regression analysis, together with overlap stenting, post-dilatation, type C lesions, diabetes 
mellitus and maximal balloon inflation pressure (Figure 2).  
 
 
 
 Figure 3: Differences in stent strut apposition: Cypher Select vs. Taxus Liberte 
Cypher Select stent struts were less likely to be embedded and more likely to be protruding and malapposed 
compared with Taxus Liberte stents. 
 
 
Clinical Outcomes 
Twelve month follow-up was available for all patients. Five months after the index procedure, 1 
patient had repeat angiography to evaluate chest pain and an equivocal exercise stress test. He 
had a heavily calcified long lesion of the LCx treated with 3 Cypher stents in an overlap fashion. 
Angiography showed an excellent result of the previously stented segment with no other 
coronary stenosis. There were no adverse events encountered and no episodes of stent 
thrombosis.  
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Figure 4: Histograms of probability densities of the distance between the endoluminal surface of the strut 
and the intima for the Cypher and Taxus Groups 
A wider distribution of distances is seen for Cypher Select stents, with more struts lying at a greater distance from 
the intima compared to Taxus Liberte stents. 
 
 
Discussion 
 
This is the first study using OCT to assess stent strut apposition systematically following 
implantation. Our study has shown that in complex coronary lesions, stent strut malapposition 
persists despite angiographic optimisation. Further, the thinner struts of the Taxus Liberte stent 
with its open cell design were more likely to be embedded to the vessel wall compared to the 
thicker Cypher stent struts employing a closed-cell system. Nevertheless, using high pressure 
stent expansion with properly sized balloons, the absence of clinical events at 12 follow-up 
suggests that the frequent persistence of malapposed struts remains a benign phenomenon.   
 
Comparison with previous studies 
Information on what is currently known linking strut malapposition and stent thrombosis is 
primarily derived from pathological series. Ante-mortem correlations are scarce but 2 studies 
(14,15)  using conventional intravascular ultrasound (IVUS) suggested that stent malapposition 
did not increase the risk of major adverse cardiac events. Nevertheless, both studies detected a 
surprisingly small number of malapposed stents using the IVUS derived criterion of at least 1 
malapposed strut (51/708 cases, 7.2% and 16/229 cases, 7.0%).  Our study found a greater 
proportion of malapposed struts, mainly because of the more detailed assessment afforded by 
OCT. Nevertheless, like the previous IVUS studies which found no adverse clinical outcomes as 
a result of malapposed struts, our study confirms this with mid-term follow-up.  
 
Classification of apposition 
In the present study, we propose novel OCT derived cut-off values to stratify SSA as embedded, 
protruding or malapposed. This classification takes into consideration the thickness of the 
different DES in current use. Our data suggest that just over half of all DES struts implanted in 
complex coronary lesions were optimally embedded in the vessel intima despite aggressive 
optimisation of stent deployment. It remains, however, unknown whether these minor degrees of 
strut protrusion or malapposition now detected with OCT are of clinical and prognostic 
significance beyond mid-term follow-up. 
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Causes of incomplete apposition 
In our study, stent type was a strong predictor of strut malapposition. Cypher Select stents 
showed almost 50% less embedded struts compared to the Taxus Liberte stents (figure 3). The 
Cypher Select stent has thicker metal struts (140Ƭm) compared to other stents (89-97Ƭm) and this 
may affect the stent’s conformability to the uneven intimal surface. Since the stents also have 
different design, it is difficult to know how much of the difference in apposition is due to strut 
thickness and how much is due to the close cell design of Cypher Select stent, which ensures 
more uniform coverage and radial support (16) but may be inferior to other designs in terms of 
conformability.  
Higher pre-MLD and higher maximum dilatation pressure were associated with a lower number 
of embedded struts in our study. This sounds paradoxical, as one would expect optimal stent 
deployment in less severe lesions and with higher inflation pressures. Stent struts deployed in 
tighter lesions are more likely to be pressed against the intima and become embedded during 
balloon inflation compared to struts in milder lesions. Higher pressures were used by the 
operators when there was angiographic evidence of poor balloon or lumen expansion and reflect 
the presence of resistant fibrotic or calcific wall changes. As indicated in figure 5, there is no 
potential for full apposition in the non-circular geometry of eccentric focal heavy calcification 
and, higher pressures increase lumen expansion but may paradoxically increase malapposition 
under these circumstances. 
 
 
 
Figure 5: Optical coherence tomography of a severely calcified lesion 
A. Right caudal view showing an eccentric and long calcific stenosis in the mid portion of the left circumflex.  
B. Final angiographic result following Cypher stent implantation and high pressure post-dilatation. The black 
arrow indicates the region imaged by OCT. 
C. OCT imaging showing transformation of stent geometry caused by the eccentric focal heavy calcification 
(*). Struts are completely malapposed to the intima at the segment between fibrous intima and area of 
superficial calcification (white arrows).  
 
Clinical implications of malapposition 
Considerable interest exists linking the use of DES with late and very late stent thrombosis. The 
aetiology for this relation however remains ill-defined. Malapposition has been found to correlate 
with poor intimal coverage and subsequent stent thrombosis in autopsy series.(7,10,11) 
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Conceptually, it is obvious that a strut fully embedded has a lower potential to trigger fibrin and 
platelet deposition than a strut floating in the lumen. Matsumoto et al (17) reported malapposed 
struts were more frequently incompletely covered with intima. Recently, Takano et al (18) also 
confirmed this finding investigating sirolimus-eluting stents with OCT 3 months after 
implantation. Bare struts were also more frequently observed in patients presenting with acute 
coronary syndrome (ACS) and, such struts were also more often malapposed (18).  
 
Univariate predictors of % embedded 
  Estimate 95% CI p-value 
Stent Type: Taxus Liberte vs. Cypher Select 33.11 23.66-45.26 <0.001 
                   Endeavor vs. Cypher Select 53.89 32.06-75.72 <0.001 
                   CoStar vs. Cypher Select 34.20 20.73-47.67 <0.001 
Pre-procedural Minimal Lumen Diameter -27.08 -50.89- -3.26 0.028 
Smoking -18.50 -35.44- -1.56 0.034 
Maximum Dilatation Pressure -2.74 -5.45- -0.03 0.048 
Multivariate predictors of % embedded
Stent Type: Taxus Liberte vs. Cypher Select 33.11 23.66-45.26 <0.001 
                   Endeavor vs. Cypher Select 53.89 32.06-75.72 <0.001 
                   CoStar vs. Cypher Select 34.20 20.73-47.67 <0.001 
Univariate predictors of % malapposed
Stent Type: Taxus Liberte vs. Cypher Select -7.93 -13.60- -2.26 0.009 
                   Endeavor vs. Cypher Select -11.63 -24.73- 1.47 0.080 
                   CoStar vs. Cypher Select 3.84 -4.24 -11.92 0.337 
Post Dilatation 9.59 3.00 -16.18 0.006 
Multiple Stenting 7.21 1.82-12.61 0.011 
Total Stent Number per Lesion 6.33 1.62-11.05 0.011 
Maximum Dilatation Pressure 1.17 0.24-2.09 0.016 
Total Stent Length 0.21 0.01-0.41 0.045 
Post-procedural Diameter Stenosis 0.49 0.01-0.96 0.045 
Multivariate predictors of % malapposed
Stent Type: Taxus Liberte vs. Cypher Select -5.84 -11.13- -0.54 0.03 
                   Endeavor vs. Cypher Select -9.03 -20.82- 2.76 0.13 
                   CoStar vs. Cypher Select 6.44 -1.02 -13.90 0.09 
Maximum Dilatation Pressure 1.03 0.21-1.84 0.02 
Table 4. Univariate and Multivariate Predictors of % Embedded and Malapposed Struts 
 
 
The lack however of adverse events at 1 year, even in patients with a high number of malapposed 
struts in our study and in previous IVUS studies suggests that other factors must be at play. All 
our patients were prescribed dual anti-platelet therapy for 12 months which, in itself, may act to 
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protect against thrombus formation on malapposed struts. After reviewing autopsy studies, Joner 
et al (7) identified that stent thrombosis was multi-faceted with predictors in addition to 
malapposition being a polymer induced hypersensitivity reaction, ostial and/or bifurcation 
stenting, restenosis and strut penetration into a necrotic core. Therefore, it appears malapposition 
is but one piece of the yet to be completed puzzle. 
 
Limitations 
As this was a small non-randomised study, it cannot be excluded that the difference observed 
between the Cypher and Taxus stents could be due to differences in baseline and treatment 
characteristics. Although multilevel logistic regression was used accounting for the hierarchical 
nature of the data, this was limited to univariate analyses and produced estimates with relatively 
large confidence intervals due to the small number of lesions and patients included in this study. 
Further, larger studies with longer follow-up and serial OCT examinations are essential to truly 
understand the importance of malapposition on strut coverage and its possible relation to late 
stent thrombosis. 
 
Conclusions 
Despite angiographic optimisation with high pressures and adequately sized balloons, 
malapposed stent struts are frequently found in complex coronary lesions and more often 
following the implantation of Cypher Select stents which have a thicker stent strut and closed cell 
design compared to other DES. With no adverse clinical events at 12 months follow-up, this 
likely represents a benign phenomenon at least as long as combined anti-platelet therapy is 
maintained.  
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OCT assessment of stent fracture
Drug-eluting stents (DES) have made a tremendous impact on the practice of percutaneous coronary intervention. 
Recently however, long-term DES failures have become a focal point, particularly with restenosis and thrombosis. 
An uncommon, yet important cause of DES failure is stent fracture. Of the two established first generation DES, 
the sirolimus-eluting stent (SES) has been particularly linked to cases of stent fracture, likely as a result of its 
closed cell design compared with other DES employing an open cell system. We present 2 cases of SES fracture 
confirmed using high-resolution intravascular optical coherence tomography giving unique insights into the in-vivo 
appearance of this complication. 
 
Drug-eluting stents (DES) have significantly reduced restenosis compared to bare metal stents 
(BMS) and have helped establish percutaneous coronary intervention (PCI) as the mainstay 
invasive therapy for patients with coronary artery disease. More recently however, attention has 
been drawn to the problems of late DES failures, particularly stent thrombosis. The causes 
behind DES failures remain complex and multi-factorial. When in-stent restenosis occurs, this is 
usually focal in nature while mechanical factors such as stent fracture have also been implicated 
[1]. Of the two established first generation DES, the sirolimus-eluting stent (SES, Cordis, J&J, 
Miami, Florida, US) has been particularly linked to cases of stent fracture, likely as a result of its 
closed cell design compared with other DES employing an open cell system [2]. We present 2 
cases of SES fracture confirmed using high-resolution intravascular optical coherence 
tomography (OCT) giving unique insights into the in-vivo appearance of this complication. 
 
Case 1 
A 66-year-old diabetic male underwent coronary artery bypass grafting (CABG) in 2002 because 
of symptomatic angina. The right internal mammary artery (RIMA) was grafted to the left 
anterior descending (LAD) while the left internal mammary artery (LIMA) was grafted to the 
dominant left circumflex artery obtuse marginal branch. In 2004 he was admitted because of 
escalating angina. Angiography revealed a patent RIMA graft however the LIMA graft contained 
a critical stenosis in the highly angulated mid-segment (Figure 1A). Following pre-dilatation, two 
3.5 mm bare metal Driver (Medtronic Inc., Minneapolis, US) stents were deployed giving a very 
good angiographic result (Figure 1B). 
In 2005, he presented with a non-ST-elevation myocardial infarction and was found to have 
severe in-stent restenosis of the LIMA graft (Figure 1C). Following pre-dilatation, a 3.5 × 33 mm 
SES was implanted and post-dilated with a non-compliant balloon (Figure 1D).  
In 2007, because of angina, a nuclear perfusion scan was arranged. This revealed extensive 
reversible perfusion defects in the infero-lateral wall. Repeat coronary angiography revealed that 
the LIMA graft had a significant stenosis at the hinge point within the previously stented 
segment (Figure 2). Using optical coherence tomography, we confirmed the presence of a 
fracture of the SES implanted in 2005 with gross hyperplasia and almost complete obliteration of 
the lumen (minimal lumen area 0.71 mm2). Further, the SES lacked circumferential struts with 
extensive disarray, consistent with fracture (Figure 2B–C). 
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Figure 1 A: Illustrates the left internal mammary artery (LIMA) graft with a critical stenosis in the highly angulated 
mid-segment. B: Immediate angiographic appearance following pre-dilatation and implantation of two 3.5 mm bare 
metal Driver (Medtronic Inc., Minneapolis, US) stents. C: Angiography 12 months following initial stent 
implantation demonstrating critical in-stent-restenosis. D: Final angiographic result following treatment with a 
3.5 × 33 mm sirolimus-eluting stent (SES). 
 
Figure 2 Two years following stenting, angiography confirmed a significant stenosis at the hinge point within the 
previously stented segment (black arrow). A: Optical coherence tomography (LightLab Imaging Inc., Westford, MA, 
USA) was acquired during simultaneous contrast flush through the guiding catheter at a pullback speed of 1 mm/s. 
This proximal cross-section shows 2 layers of stent struts coinciding with the previously deployed bare metal stent 
(black arrow) and the SES (white arrow). B–C: Imaging at the level of the stenosis reveals gross hyperplasia and 
almost complete obliteration of the lumen (minimal lumen area 0.71 mm2) with absence of circumferential struts. D. 
OCT distal to the stenosis showed the struts of the SES were widely patent with thin coverage of neointimal tissue 
(10–30 Ƭm). 
see colour section
see colour section
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As a result of the previous failures, we were reluctant to implant a further stent and elected to 
attempt recanalisation of the occluded native proximal LCx. With bilateral femoral access, a 
guide wire was passed retrogradely through the LIMA graft through the anastomosis of the 
obtuse marginal in the direction of the native LCx. Using the retrograde wire as a guide (Figure 
3A), we were able to pass a hydrophilic wire antegradely, pre-dilate the occlusion and, finally 
implant two Taxus Liberte stents (Boston Scientific, Natick, US), both expanded to 3.0 mm at 
high pressure (Figure 3B). The patient remains symptom-free 12 months following the recent 
procedure. 
 
Figure 3. Recanalisation of the native occluded left circumflex artery was undertaken with the left coronary artery 
and the left internal mammary artery graft retrogradely. Using the retrograde wire as a guide, a hydrophilic wire was 
advanced antegradely. The occlusion was pre-dilated with final implantation of two Taxus Liberte stents (Boston 
Scientific, Natick, US). 
 
Case 2 
A 62-year-old man with strong family history of coronary artery disease developed new onset 
chest pain. He was found to have a high calcium score (> 2000) on computed tomography and 
subsequently underwent coronary angiography. This demonstrated a significant lesion in the 
proximal and mid-LAD that was sub-totally occluded together with diffuse disease in the 
diagonal branch (Figure 4A). Percutaneous coronary intervention was discussed and this was 
performed with the implantation of 2 SES in an overlapping fashion (2.25 × 23 mm followed by 
2.5 × 18 mm proximally) post-dilated to 18 18 atm with a 2.5 mm balloon (Figure 4B). Nine 
months following the procedure, the patient presented with recurrent chest pain. Coronary 
angiography revealed 2 discrete areas of restenosis occurring within the previously implanted 
SES at 2 hinge points of the LAD (Figure 4C, white arrows). There was also disease progression 
in the proximal LAD. OCT was undertaken to assess the lesions in greater detail. Coinciding 
with the 2 regions of restenosis, OCT showed focal stent fracture with significant intimal 
hyperplasia, lack of circumferential stent struts and altered stent and vessel geometry (Figure 5). 
The lesions were treated with high-pressure balloon dilatation and with new stent implantation 
to the diseased proximal LAD segment (Figure 4D). The patient remains symptom-free at 9-
month follow-up and with aggressive risk factor modification. 
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Figure 4. Antero-posterior cranial view showing the left anterior descending artery with significant stenosis in the 
mid-segment and diagonal branch. Immediately following implantation of 2 sirolimus-eluting stents. Nine-month 
follow-up angiography showed 2 sites of restenosis but no obvious fracture. Following high-pressure balloon 
dilatation and further stent implantation. 
 
 
Figure 5. OCT demonstrating a widely patent stent with a thin layer of neointimal tissue. B–D: Shows the more 
distal lesion with significant luminal narrowing as a result of intimal hyperplasia. The cross-sections demonstrate the 
lack of circumferential stent struts and altered stent and vessel lumen geometry. E: Shows the OCT appearance at 
the level of the side branch. 3 stent struts are shown at the carina with no visible tissue coverage (black arrow) while 
the surround stent struts show an exaggerated intimal tissue response (white arrow). F: Demonstrates 
circumferential stent struts covered by a thin tissue layer. Also evident is a fibro-calcific plaque (black arrows) with 
its low reflective appearance and sharp margins. G–H: Shows the lack of circumferential stent struts resulting in 
considerable disruption of vessel and lumen geometry. 
see colour section
see colour section
Peter BW 13-5.indd   218 13-05-09   16:18
219
OCT assessment of stent fracture
Discussion 
Although uncommon, stent fracture is increasingly being reported in the literature and, in the 
DES era, is more often associated with SES [3], [4], [5], [6] and [7]. In a recent study of 530 
patients who received DES with follow-up angiography, Lee et al. [2] identified stent fracture in 
10 (1.9%) patients, all restricted to those with SES. Similarly, Aoki et al. [6] studied 280 patients 
following SES implantation and identified stent fracture in 2.6% of cases. In this study, 
significant multivariate predictors of stent fracture were saphenous vein graft location (OR 35.88; 
95% CI 2.73–471.6, p = 0.006), implanted stent length (OR 1.04; 95% CI 1.01–1.07, p = 0.02), 
and right coronary artery location (OR 10.00; 95% CI 1.11–89.67, p = 0.04). In another study, 
Lee et al. [8] followed up 588 patients and found 26 patients with SES in-stent restenosis (ISR) 
and 30 BMS ISR lesions. Of 26 cases of ISR lesions associated with SES, stent fracture was 
identified in 10. There were no cases of stent fracture in the BMS group. In 7 patients that 
received a single SES, the fracture occurred at the mid-segment of the stent. As a result of the 
lack of stent fracture within BMS, the authors concluded that the lack of stent protection by 
neointima at an early stage of stent implantation might contribute to stent fracture. 
Stent fracture has been identified in cases of under or over-expanded stents, long stented 
segments, repetitive kinking caused by vessel movement during the cardiac cycle and in tortuous 
vessels. Furthermore, the closed cell design of the SES and thicker metal struts (metal and 
polymer thickness of 154 Ƭm) may be critical in making this stent more rigid and inflexible 
compared with other stent types. This should be considered in situations where lesions occur at 
hinge points and the operator may then consider an alternative stent to implant. 
The diagnosis of stent fracture has traditionally been limited to findings on coronary 
angiography. Recently however, Yamada et al. [7] demonstrated the limitations of angiography by 
studying 102 consecutive patients receiving SES. Angiography failed to detect any cases of stent 
fracture at 6 months whereas intravascular ultrasound (IVUS) identified 3 cases. Although IVUS 
remains the current gold standard for the detailed assessment of the results following stent 
implantation, this too has several limitations. The resolution of IVUS is in the realms of 150 mm 
and the sound echoes frequently cause artifacts. In our 2 cases, we used a relatively new imaging 
technology using near infra-red light with 10 times the resolution of IVUS and fewer artifacts. 
The use of OCT to confirm stent fracture in our report highlights the unique detail afforded by 
this technique. In the first case, stent fracture was identified within an arterial conduit and was 
clearly related to the repeated hinge motion during the cardiac cycle. In the second case, no overt 
signs of fracture were evident on angiography however this was clearly demonstrated with OCT 
at 2 sites within the previously implanted stents. The excess intimal hyperplasia, altered stent 
geometry and complete fracture of the stents with lack of circumferential struts are dramatic on 
OCT. Furthermore, the power of the SES to inhibit neointimal tissue is shown in the relatively 
normal distal stented segments. Still, the advantage of DES over BMS remains their inherent 
ability to restrict this intimal tissue and therefore limit restenosis and, when this does occur, 
mechanical failure must be considered. 
The treatment of stent fracture requires the operator to consider the underlying cause and then 
the likelihood of recurrence. As a result of this, in the first case, we elected not to introduce a 
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further stent but targeted the native vasculature as a means to improve perfusion. In the second 
case, post-dilatation at the sites of fracture and of the entire stented segment gave a very 
acceptable result and also addressed the issue of possible stent under-expansion following the 
initial implantation. When repeat stenting is considered, this may be accomplished using a 
different DES, while, more recently, Koh and Mathur described the successful implantation of a 
polytetrafluoroethylene-coated Jomed stent (Jomed International AB, Helsingborg, Sweden) 
within a saphenous vein graft stent fracture lesion [9]. This novel approach, using a stent with 2 
layers, provides greater support and resistance to areas of high mechanical stress. 
Although stent fracture remains uncommon, it is an increasingly reported cause of DES ISR, 
particularly with SES. A number of factors have been implicated, both vessel and stent specific 
that need to be considered when optimizing stent deployment to achieve a long lasting outcome. 
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Incomplete stent apposition and delayed healing following STEMI
 
Objective: To compare the frequency of incomplete stent apposition (ISA) and struts not covered by tissue at 
long term follow-up (as assessed by optical coherence tomography, OCT) in drug-eluting stents (DES) implanted 
during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) vs 
DES implanted for unstable and stable angina.  
Background: ISA and the absence of strut endothelialization may be linked to stent thrombosis. DES 
implanted for STEMI may have higher risk of thrombosis.  
Methods: Consecutive patients in whom OCT was performed at least 6 month following DES implantation 
were included in the study. Stent struts were classified based on the presence of absence of ISA and tissue coverage.  
Results: Forty-seven lesions in 43 patients (1356 frames, 10140 struts) were analyzed (48.9% stable angina, 
17% unstable angina, 34% STEMI). Median follow up time was 9 (range 7-72) months. DES implanted 
during primary PCI presented ISA more often than DES implanted in stable/unstable angina patients (75% vs 
25.8% p=0.001). The frequency of uncovered struts was also higher in the STEMI group (93.8% vs 67.7% 
p=0.048). On multivariate analysis, DES implantation in STEMI was the only independent predictor of ISA 
(OR 9.8, 95%CI 2.4-40.4 p=0.002) and presence of uncovered struts at follow-up (OR 9.5 95%CI 1.0-90.3 
p=0.049). 
Conclusions: DES implanted for STEMI had higher frequency of incompletely apposed struts and uncovered 
struts as assessed by OCT at follow up. DES implantation during primary PCI in STEMI was an independent 
predictor of ISA and presence of uncovered struts at follow-up. 
 
 
Primary percutaneous coronary intervention (PCI) is the recommended treatment for ST 
elevation myocardial infarction (STEMI) (1). Stent implantation during primary PCI presents 
some challenges namely the presence of abundant thrombotic material that can potentially 
contribute to suboptimal stent deployment. The use of drug eluting stents (DES) in this setting is 
under debate due to the concerns about a potentially higher risk of stent thrombosis in this 
population (2). Recent IVUS studies suggest that the presence of incomplete stent apposition 
(ISA) is potentially linked to late stent thrombosis(3). Gradual absorption of the thrombus that 
was present during primary PCI has been postulated to contribute to late acquired stent 
malapposition (4). Endothelial struts coverage has been identified in pathological series as the 
most powerful histological predictor of stent thrombosis(5). DES inhibit neointimal proliferation 
to such extent that it might not be visualized with conventional intracoronary imaging techniques 
such as IVUS. Optical Coherence Tomography (OCT) is a high-resolution light-based imaging 
modality that can provide a very detailed assessment of stent apposition and tissue strut 
coverage. 
The objective of the present study was to compare the frequency of ISA and uncovered struts 
(as assessed by OCT) at long term follow up in DES implanted during primary PCI for STEMI 
vs DES implanted  for stable or unstable (IB/IIB/IIIB Braunwald classification) angina.  
 
 
Methods 
Patient sample 
All consecutive patients between January 2007 and May 2008 in whom OCT was performed for 
follow-up of a DES implanted at least 6 months prior were included in the study. Exclusion 
criteria were repeated revascularization in the target vessel, depressed left ventricular function, 
coronary chronic total occlusions and impaired renal function. All patients gave written informed 
consent. 
 
OCT acquisition 
The OCT acquisition was performed using a commercially available system for intracoronary 
imaging (LightLab Imaging, Westford, Massachusetts, US). The ImageWire (LightLab Imaging, 
Westford, Massachusetts) was positioned distal to the region of interest using a double lumen 
Peter BW 13-5.indd   223 13-05-09   16:18
Chapter 17
224
 
catheter (Twin Pass catheter, Vascular Solutions Inc) that had been placed in the artery over a 
conventional guide wire. The automated pullback was performed at 3 mm/s while the blood was 
removed by the continuous injection of iso-osmolar contrast (Iodixanol 320, Visipaque™, GE 
Health Care, Ireland) at 37° Celsius through the guiding catheter. The data was digitally stored 
for offline analysis. 
 
OCT analysis 
Offline analysis was performed with the proprietary LightLab software (LightLab Imaging, 
Westford, Massachusetts, US). The analysts (Cardialysis BV, Rotterdam, The Netherlands) were 
blinded to clinical and procedural characteristics. The stented region was defined as the region 
comprised between the first and the last frame with circumferentially visible struts. For this 
region one frame was selected every mm and the lumen and stent area contours were drawn. 
Stent longitudinal symmetry ratio was defined as minimum stent area /maximum stent area.  
  
Incomplete stent apposition definitions and measurements 
Incomplete stent apposition (ISA) was defined as separation of at least one stent strut from the 
vessel wall not related with a side branch (Figure 1). A strut was considered incompletely 
apposed if the distance from the endo-luminal surface of the strut to the vessel wall was higher 
than the sum of the metal and polymer thickness. The cut-off points used for each stent type 
were: paclitaxel eluting stent (Taxus, Boston Scientific Corp, Natick, MA) 130μm, sirolimus 
eluting stent  (Cypher Select, Cordis, Johnson & Johnson, Miami, FL) 160μm, everolimus eluting 
stent (Xience V, Abbot Vascular, Santa Clara, CA) 90μm and biolimus eluting stent (Biomatrix 
III, Biosensors, Morges, Switzerland) 120μm. The number of malapposed struts, the maximal 
incomplete stent apposition length (maximum distance from the endo-luminal surface of the 
strut to the vessel wall) and the incomplete stent apposition area were measured. Calcification 
could not be accurately evaluated due to the shadow caused by stent struts in OCT. 
 
 
 
 
Struts coverage definitions and measurements 
The struts were classified as uncovered when a tissue layer on the endoluminal surface could not 
been clearly distinguished. In the covered struts, the tissue coverage thickness was measured per 
strut as the distance from the central aspect of the endoluminal surface of the strut to the lumen. 
The total tissue coverage area was calculated as stent area – lumen area. The % of tissue coverage 
area was calculated as the tissue coverage area /stent area x 100. The tissue coverage volume was 
Figure 1: Incomplete stent apposition and 
uncovered struts.  
Optical coherence tomography cross section 
corresponding to a patient treated with DES 
implantation during primary PCI in the right coronary 
artery due to an inferior ST elevation myocardial 
infarction 9 months before. The red arrows indicate 
incomplete stent apposition while the white arrows 
show some struts not covered by tissue. From 12 to 5 
it can be observed behind the struts an irregular 
material suggestive of organized thrombus. * 
Guidewire artefact.  
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calculated as the tissue coverage area x stent length. The % tissue coverage volume area was 
calculated as the tissue coverage volume/stent volume x 100. The tissue coverage symmetry per 
frame was analyzed using the following ratio: (Maximum tissue coverage thickness per frame – 
minimum tissue coverage thickness per frame)/Maximum tissue coverage thickness per frame. 
This ratio can have values between 0 and 1. The closer the ratio is to 1 the higher is the 
asymmetry of the tissue coverage (Figure 2). To evaluate the distribution of the uncovered struts 
along the stent we calculated the % of frames with at least one uncovered strut in the lesions that 
showed uncovered struts.  
 
 
Figure 2: Tissue coverage symmetry patterns. 1A and 1B: Asymmetric tissue coverage with uncovered struts: 
while some struts are covered by a thick layer of tissue, other struts (from 2 to 5) are covered by a very thin layer and 
there is even one uncovered strut (indicated by the white arrow). 2B and 2B: Asymmetric tissue coverage without 
uncovered struts: all the struts are covered by tissue that shows very different thickness along the vessel 
circumference.  3A and 3C: Symmetric tissue coverage: all the struts are covered by tissue that shows similar 
thickness along the vessel circumference. 
 
Statistical analysis 
Statistical analysis was performed using SPSS 12.0.1 for Windows (SPSS Inc., Chicago, IL). 
Categorical variables are expressed as percentages and continuous variables are expressed as 
mean ± standard deviation, median and (range) or median and (interquartile range). ISA and strut 
coverage comparisons were performed per lesion. Ʒ² was used for the comparisons of categorical 
variables between groups. For the comparisons of continuous variables Student t test or non 
parametric (Mann-Whitney) test were used according to their distribution. Multiple logistic 
regression analysis was performed to assess independent predictors of ISA and uncovered struts. 
Variables considered clinically relevant and with p<0.15 in the univariate analysis were included 
in the models. 
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Results 
 
Clinical and procedural characteristics 
Fifty patients followed up with OCT after DES implantation were initially enrolled in the study. 
Seven patients were excluded for image quality not appropriate for analysis. Finally 43 patients 
(47 vessels, 47 lesions) were included (16 STEMI, 27 stable/unstable angina).  
The mean age was 64.5±11.7 years and 63.8% were males. Regarding cardiac risk factors, 47.8%, 
21.3% and 70.2% had hypertension, diabetes mellitus, and hyperlipidemia, respectively and 
19.1% were smokers. The studied vessel was the left anterior descending in 57%, the circumflex 
in 19% and the right coronary artery in 24% of the lesions. The indication for stent implantation 
was stable angina in 47% (20/43), unstable angina in 16% (7/43) and STEMI in 37% (16/43). 
The stent implanted was Taxus™ in 10.6%, Cypher Select™ in 55.3%, Xience V™ in 2.1%, and 
Biomatrix III™ in 32%. The median time to follow-up angiography and OCT examination was 9 
(7-72) months. The mean stent diameter, stent number and stent imaged length were 2.9±0.3 
mm, 1.8±0.8 and 28±15 mm respectively.  
 
OCT quantitative analysis 
A total of 10140 struts from1356 frames were analyzed. The mean lumen area, mean stent area 
and mean neointimal area were 6.42±2.11mm², 7.11± 2.06 mm² and 0.67±0.47 mm² respectively. 
The stent symmetry ratio was 0.63±0.16.  
  
ISA frequency by OCT  
The frequency of incompletely apposed struts was 68/10140 (0.6%). Forty-five out of the 68 
incompletely apposed struts (66.1%) were not covered by tissue. Forty out of 1356 frames 
(2.9%) had at least one incompletely apposed strut.  In 20 out of 47 lesions (42.6%) incomplete 
stent apposition of at least one strut was found. In the lesions with ISA the mean percentage of 
frames with ISA was 9.3±7.1%. 
 
Struts coverage by OCT  
The frequency of uncovered struts in the total sample was 6.1% (624/10140).  Twenty-one 
percent (285/1356) of all the analyzed frames presented at least 1 strut uncovered. In 36 out of 
47 lesions (76.6%) at least one uncovered strut was visualized. The mean neointima symmetry 
ratio was 0.73±0.13. Twenty-six struts out of the 10140 (0.2%) were covered by an irregular 
material suggestive of organized thrombus (Figure 3) 
 
 
Figure 3: Struts covered by organized thrombus. Optical coherence tomography cross-sections corresponding 
to a DES implanted in the LAD more than 4 years ago due to an anterior ST elevation myocardial infarction. In A 
and B the blue arrows indicate the presence of an irregular highly reflective material (suggestive of organized 
thrombus) covering some struts. C represents a cross section more proximal where some uncovered struts can be 
observed (white arrows).    
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STEMI patients 
Sixteen out the 47 lesions studied were treated with DES implantation during primary PCI due 
to STEMI. Table 1 shows the baseline characteristics of the STEMI patients in comparison with 
the rest of the sample. The time to follow up was 11.5 months (range 7-59) for the STEMI 
group and 9 months (range 9-72) for the rest of the patients. There were no significant 
differences in lumen area (6.5±2.0 Vs 6.4±2. for STEMI and stable/unstable angina respectively 
p=0.86), stent area (7.2±2.0 vs 7.0±2.0 for STEMI and stable/unstable angina respectively 
p=0.78) or stent symmetry ratio (0.58±0.17 vs 0.65±0.15 for STEMI and stable/unstable angina 
respectively p=0.13).   
 
 
 STEMI Stable/unstable 
angina  
p-value 
Age (years) 64±12 64±11 0.85 
Male (%) 50.0 71.0 0.13 
HTA (%) 50.0 46.7 0.53 
DM (%) 31.3 16.1 0.2 
Dyslipidemia (%) 75.0 67.7 0.43 
Smoker (%) 31.3 12.9 0.13 
Family history (%) 62.5 67.7 0.48 
Vessel (%) 0.46 
    LAD 68.8 51.6  
    LCX 18.7 19.4  
    RCA 12.5 29.0  
Stent type (%) 0.48 
    Taxus™ 13.3 9.7  
    Cypher™ 53.3 54.8  
    Xience™ 6.7 0.0  
    Biomatrix™ 26.7 35.5  
Number stents  1.53±0.52 2.03±0.94 0.08 
Stent imaged length (mm) 24.9±10.5 29.9±17.6 0.3 
Table 1. Baseline characteristics in ST elevation myocardial infarction (STEMI) and stable/unstable angina patients.  
Age, gender and cardiovascular risk factors are compared per patient (STEMI=16 stable/unstable angina=27). The 
rest of the variables are compared per lesion (STEMI=16 stable/unstable angina=31). 
 
 
 
STEMI 
(n=16) 
Stable/unstable 
angina (n=31) 
p-value 
Number of incompletely apposed struts 2 (0-13) 0 (0-5) 0.001 
Number of incompletely apposed uncovered 
struts 
1 (0-13) 0 (0-4) <0.001 
Number of incompletely apposed covered 
struts 
0.5 (0-3) 0 (0-5) 0.02 
ISA area (mm2) 0.28 (0.17-0.67) 0.35 (0.23-0.44) 0.5 
Maximum ISA length (μm) 235 (162-297) 250 (230-600) 0.4 
Table 2. Differences in incomplete stent apposition (ISA) between lesions treated with drug-eluting stent 
implantation for ST elevation myocardial infarction (STEMI) and lesions treated for stable/unstable angina. 
Number of struts is expressed as median and range. ISA area and maximum ISA length are expressed as median and 
IQ range. 
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ISA in STEMI patients   
Figure 4 represents the frequency of ISA in lesions treated with DES implantation for STEMI 
and the rest of the lesions. Table 2 shows the differences in the number of incompletely apposed 
struts (covered and not covered), maximum ISA length and ISA area in lesions treated for 
STEMI and lesions treated for stable/unstable angina. 
 
 
 
Figure 4: Difference in ISA frequency between ST elevation myocardial infarction (STEMI) patients and 
stable/unstable angina patients. ISA frequency is shown per lesion (number of lesions with at least one 
incompletely apposed strut/total number of lesions), per frame (number of frames with at least one incompletely 
apposed strut/total number of frames) and per strut (number of incompletely apposed struts/total number of 
struts). 
 
 
Uncovered struts in STEMI patients 
Figure 5 shows the difference in frequency of uncovered struts between lesions treated for 
STEMI and lesions treated for stable/unstable angina. The number of uncovered struts, the 
mean tissue coverage thickness, area and volume and the tissue coverage symmetry ratio in both 
groups are indicated in Table 3.  
 
Predictors of incomplete stent apposition (ISA) 
Multiple logistic regression analysis was performed to determine the independent predictors of 
ISA. The following variables were included in the model: age, time follow-up, stent length, stent 
symmetry ratio, stent implantation during primary PCI. The only independent predictor of ISA 
was DES implantation during primary PCI for STEMI (OR 9.8, 95%CI 2.4-40.4 p=0.002).  
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 STEMI (n=16) Stable/unstable angina  (n=31) p-value
Number of uncovered struts  26.8±20.8 6.2±7.5 0.001
Uncovered strut distribution (%) 40.7±25.2 16.4±19.8 0.001
Mean tissue coverage area (mm²) 0.72±0.63 0.65±0.37 0.68
% tissue coverage area 12.4±9.9 11.0±6.9 0.58
Tissue coverage volume (mm³) 17.7±21.6 21.9±22.04 0.54
% tissue coverage volume  10.0±9.4 10.3±6.7 0.91
Tissue coverage thickness* (μm) 110±48 90±53 0.22
Tissue coverage symmetry ratio 0.79±0.23 0.70±0.13 0.02
Table 3. Differences in struts coverage between lesions treated with drug-eluting stent implantation for ST elevation 
myocardial infarction (STEMI) and lesions treated for stable/unstable angina. 
 
 
 
 
 
Figure 5: Difference in uncovered struts frequency between ST elevation myocardial infarction (STEMI) 
patients and stable/unstable angina patients.  Data is shown per lesion (lesions with at least one uncovered 
strut/total number of lesions), per frame (frames with at least one uncovered strut/total number of frames) and per 
strut (number of uncovered struts/total number of struts). 
 
 
Predictors of uncovered struts 
In the multivariate model for uncovered struts predictors the following variables were included: 
age, time follow up, stent length, stent area and stent implantation during primary PCI. DES 
implantation during primary PCI for STEMI was the only independent predictor of uncovered 
struts at follow up (OR 9.5 95%CI 1.0-90.3 p=0.049).  
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Discussion 
To our knowledge this is the first such study to use the high-resolution capabilities of intra-
coronary OCT to examine stent strut apposition and tissue coverage at follow-up in patients 
with STEMI treated with primary PCI. The main findings are: 1. DES implanted for STEMI had 
a higher frequency of incompletely apposed and uncovered struts as assessed by OCT at follow 
up. 2. DES implantation during primary PCI in STEMI is an independent predictor of both ISA 
and presence of uncovered struts at follow up.  
DES have consistently demonstrated a reduction in restenosis rates when compared to bare 
metal stents (BMS) in different clinical settings including primary PCI for the treatment of 
STEMI(6). However, concerns have been raised about a potentially higher risk of stent 
thrombosis following DES implantation during primary PCI (7). Further ISA and lack of 
complete stent endothelialization have been identified as factors related to stent thrombosis(4,5).  
    
Incomplete stent apposition (ISA) 
Overall the frequency of incompletely apposed struts was very low (0.6%). In our study patients 
with STEMI treated with DES implantation during primary PCI had a higher frequency of ISA. 
Our results are in concordance with IVUS studies that have identified a higher incidence of late 
ISA in STEMI patients specially when treated with DES. Hong et al reported an incidence of 
late ISA after primary PCI in STEMI of 11.5% after BMS implantation and 31.8% after DES 
implantation (8). In our sample 75% of the lesions treated with DES during primary PCI showed 
evidence of ISA. The higher frequency of ISA observed in the present study can be explained by 
the higher resolution of OCT in comparison with IVUS(9). The results of the present study are 
also in line with a recent OCT study that identified a higher incidence of ISA in sirolimus-eluting 
stents implanted in unstable vs stable angina patients (33% vs 4%)(10).  
The dissolution of thrombus jailed after stent implantation during primary PCI has been 
postulated as one of the possible causes of the higher incidence of late ISA in STEMI 
patients(4). Plaque rupture (characterized by a necrotic core with an overlying thin-ruptured cap 
infiltrated by macrophages and with paucity of smooth muscle cells) is the most frequent 
underlying substrate in STEMI. Stent implantation over a ruptured plaque with strut penetration 
into necrotic core have also been related to ISA in acute coronary syndromes (11). The clinical 
implications of ISA are controversial. Several studies have reported that the presence of ISA 
after DES implantation is not associated with adverse events at long term follow up (8,12,13). 
However, recently published IVUS observations suggest a possible relation between incomplete 
DES apposition and subsequent stent thrombosis (3,4). The clinical significance of ISA as 
detected by OCT is poorly understood. In fact, incomplete apposition of stent struts is a 
relatively common finding by OCT, while the vast majority of the patients do not experience 
clinical events in the long-term(14) . In addition, not all patients that experience DES thrombosis 
show strut malapposition(15,16). In the present study none of the patients with ISA as assessed 
by OCT presented with adverse clinical events.  
 
 
Strut coverage  
DES inhibits neointimal proliferation to such extent that it may not be detectable by IVUS(17). 
The high resolution of OCT allows the visualization and measurement of tiny layers of tissue 
covering the stent struts(18). In the present study, the global frequency of uncovered individual 
struts was 6.1% and a high proportion of lesions (36/47) presented uncovered struts. This is in 
agreement with different OCT studies recently published reporting strut coverage in DES at 
follow up (14,19). A long-term follow up with OCT in a group of patients treated with SES 
revealed that 81% of the patients presented uncovered struts at 2 years follow-up(20). In the 
present study 8 out of the 9 lesions with more than 2 years follow-up demonstrated uncovered 
struts by OCT and interestingly in 6 out of those 8 lesions the DES were implanted during 
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primary PCI. The frequency of struts with no visible coverage was significantly higher in STEMI 
patients treated during primary PCI (15 out of 16 lesions). Likewise, the distribution of 
uncovered struts within the stent was more spread in STEMI patients (reflected in a higher 
proportion of frames with uncovered struts). The mean neointimal thickness did not differ 
between STEMI and stable/unstable angina patients but the neointima showed a more 
asymmetric distribution in STEMI patients. Our findings are in agreement with pathological 
studies showing delayed endothelialization at the culprit site in acute myocardial infarction 
patients treated with DES compared with the culprit site in patients receiving DES for stable 
angina(21).   
 
A recent study reporting a lower incidence of full tissue coverage in unstable than in stable 
angina is also in line with our observations(10). Pathological data suggests a relation between 
arterial healing and underlying plaque morphology. In an autopsy study, Nakazawa et al found a 
higher percentage of uncovered struts in patients with stents implanted in plaques with high risk 
features (such as plaque rupture and TCFA) as compared with those with stable plaque 
morphology (21). Despite a lack of OCT assessment during the primary PCI procedure in our 
study, it is accepted that plaque rupture is the most frequent underlying event leading to 
STEMI(22). The stent contact with an avascular tissue such as necrotic core and the different 
drug distribution due to the presence of thrombus are some of the factors that could explain the 
delayed coverage of struts in unstable patients(21,23). The more asymmetric distribution in the 
cross section of the tissue covering the struts found in STEMI patients might also be related 
with the eccentricity and composition of the plaque underlying the stent implantation(24).  
 
Endothelial struts coverage has been identified in pathological series  as the most powerful 
histological predictor of stent thrombosis(5). Pathological data in human suggests that neointimal 
coverage of stent struts may be a surrogate marker of endothelialization (25). However, Kubo et 
al reported that the presence of a higher incidence of uncovered struts by OCT in unstable 
patients was not associated with adverse outcomes at 9 months(10). In the present study no 
adverse events occurred at follow up even when the frequency of uncovered struts was high. The 
clinical significance of the presence of uncovered struts as assessed by OCT remains unknown 
and would require specific long-term follow up studies. Despite the high resolution of the 
technique, coverage of the strut with an individual cell layer can not be excluded. Currently, OCT 
cannot well distinguish the tissue type covering the struts, e.g. a neointimal layer from fibrin. 
Furthermore, different types of neointimal tissue with different optical properties can be 
observed and may have different functionality(26). The development of quantitative tissue 
characterization by OCT might be helpful to better understand the clinical implications of strut 
tissue coverage.  
 
Limitations 
The present study is observational and non-randomized. No formal sample size calculation was 
performed. Another limitation is the lack of serial OCT assessments with OCT only performed 
at long-term follow-up. Therefore it was not possible to distinguish between persistent and late 
acquired ISA. The presence of positive remodelling as cause of late ISA (as demonstrated 
previously in IVUS) can not be excluded. Likewise, no information was available about the 
underlying plaque in which the stent was implanted. Only DES were included in the study. 
Therefore we can not exclude that BMS would not have behaved similarly when implanted in the 
setting of STEMI.  
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Conclusions 
 
DES implanted for STEMI had higher frequency of incompletely apposed struts and uncovered 
struts as assessed by OCT at follow up. DES implantation during primary PCI in STEMI was an 
independent predictor of ISA and presence of uncovered struts at follow up. Whether these 
findings have a causal link to the heightened rate of stent thrombosis in STEMI patients remains 
to be confirmed by larger studies. 
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Chapter 18
A Critical Appraisal of the Safety Concerns Tempering the Success of Drug-
Eluting Stents: Novelties in Cardiac Imaging – Optical Coherence 
Tomography 
Peter Barlis, Carlo Di Mario, Heleen van Beusekom, Evelyn Regar 
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A Critical appraisal of the safety of DES
In order to improve our understanding of late stent thrombosis and to assess the individual risk 
of a patient or lesion, there is clinical need to assess vascular healing after stenting in vivo. We 
will discuss the potential and limitations of optical coherence tomography (OCT) for imaging of 
drug eluting stents (DES).  
OCT, a light based imaging modality (1), has recently become available for intracoronary 
application (2-4). Because of the shorter wavelength of infrared light compared to ultrasound, 
OCT has a ten-fold higher image resolution than conventional intravascular ultrasound (IVUS), 
150 micron for IVUS as compared to 15 micron for OCT. This advantage renders OCT 
particularly useful for the assessment of coronary stents. 
OCT observations in drug-eluting stents immediately after implantation 
For the past two decades, IVUS has been used to assess the acute result following stenting, 
giving valuable information on stent expansion, strut apposition and signs of vessel trauma 
including dissections and tissue prolapse (5,6). IVUS studies (7,8) suggested that stent strut 
malapposition is a relatively uncommon finding, observed in approx 7% of cases, and that strut 
malapposition does not increase the risk of subsequent major adverse cardiac events. In contrast, 
OCT can visualise the complex coronary arterial wall structure after stenting in much greater 
detail (9). As a result, OCT studies in the acute post stent setting (10) have demonstrated a 
relatively high proportion of stent struts, not completely apposed to the vessel wall, even after 
high pressure post-dilatation. Furthermore, this phenomenon is particularly evident at regions of 
stent overlap (11). Tanigawa et al (12) examined a total of 6,402 struts from 23 patients (25 
lesions) and found 9.1±7.4% of all struts in each lesion treated were malapposed. Univariate 
predictors of malapposition where: implantation of a sirolimus-eluting stent (SES), presence of 
overlapping stents, longer stent length and type C lesions. Likely mechanical explanations for 
malapposition of stent struts include increased strut thickness, closed cell design or acute stent 
recoil. The latter has been demonstrated in SES to be in the range of 15%, despite the use of 
high pressure balloon dilatation (13). While these findings are impressive and helpful for the 
improvement of future stent designs, today the clinical relevance and potentially long-term 
sequeale of malapposed struts as detected by OCT are currently unknown. 
OCT observations in drug eluting stents at long-term follow-up 
Unlike conventional stents, which develop circumferential coverage with an average thickness of 
500 micron or more, well visualised with IVUS and angiography, drug-eluting stents delay and 
prevent the hyperplastic response so that the average late lumen loss for drug-eluting stents can 
be lower than 100 micron (4) which means this thin layer of intimal thickening can be below the 
resolution of IVUS. Coronary angioscopy is able to visualise strut tissue coverage to a certain 
extent, but this highly specialised technique lacks the ability for quantification and the ability to 
assess thin amounts of neotinima. Hence, OCT is an attractive alternative, able to circumvent 
many of these limitations and, with its high-resolution, can precisely assess the in vivo tissue 
responses following stent implantation (14). Specific applications of OCT relevant for late stent 
thrombosis are discussed below. 
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a) Visualisation and quantification of stent strut tissue coverage 
OCT can reliably detect early and very thin layers of tissue coverage on stent struts (Figure 1-4). 
Several small studies have recently been published highlighting the application of OCT in the 
detection of stent tissue coverage at follow-up. Importantly, OCT permits the quantification of 
tissue coverage with high reliability (15).  
 
Figure 1. In vivo OCT (LightLab Imaging Boston, MA, USA) in a porcine coronary artery. A) Baseline OCT 
immediately after stent implantation shows adequate stent expansion and apposition of the struts against the normal 
coronary wall. B) Magnification demonstrating the stent strut vessel wall interface. C) Follow-up investigation at five 
days. The stent struts are clearly visible and show thin, bright reflective tissue coverage in the magnification D) 
Histology E) confirms the presence of a thin neointimal layer. 
 
Matsumoto et al (16) studied 34 patients following sirolimus eluting stent (SES) implantation. 
The mean neointima thickness was 52.5 microns, and the prevalence of struts covered by thin 
neointima undetectable by IVUS was 64%. The average rate of neointima-covered struts in an 
individual SES was 89%. Nine SES (16%) showed full coverage by neointima, whereas the 
remaining stents had partially uncovered struts. Similarly, Takano et al (17) studied 21 patients 
(4,516 struts), three months following SES implantation. Rates of exposed struts and exposed 
struts with malapposition were 15% and 6%, respectively. These were more frequent in patients 
with acute coronary syndrome (ACS) than in those with non-ACS (18% vs 13%, p <0.001; 8% 
vs 5%, p <0.005, respectively). The same group recently reported two year follow-up OCT 
findings (18) with the thickness of neointimal tissue at 2-years being greater than that at 3-
months (71±93micron vs. 29±41 micron, respectively; p<0.001). Frequency of uncovered struts 
was found to be lower in the 2-year group compared to the 3- month group (5% vs. 15%, 
respectively; p<0.001). Conversely, prevalence of patients with uncovered struts did not differ 
between the 3- month and the 2-year follow-up study (95% vs. 81%, respectively) highlighting 
that uncovered struts continued to persist at long-term follow-up. Chen et al (19) recently used 
see colour section
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OCT to image SES and bare metal stents (BMS) at different time points following implantation. 
Of the 10 SES and 13 BMS imaged, the authors identified a significantly higher number of 
incompletely apposed and uncovered stent struts in patients receiving SES compared to BMS. 
The results of these small observational studies are compatible with evidence from animal and 
human post-mortem series showing that DES cause impairment in arterial healing, some with 
suggested incomplete re-endothelialisation and persistence of fibrin(oid) (20,21) possible 
triggering late stent thrombosis (22). 
 
 
Figure 2. In vivo OCT (LightLabImaging™, Boston, MA, USA) in the LAD in a patient presenting with in-stent 
restenosis. A) The coronary angiogram shows a lumen narrowing within the stent that is covering the second 
diagonal branch. OCT visualises the complex coronary anatomy in great detail. The stent is covered by a thick 
neointima that shows a layered appearance with a bright, highly reflective luminal layer, an intermediate layer and a 
dark, signal poor layer surrounding the struts (B). The diagonal take off can be clearly seen (C) as well as a stent strut 
that is “floating” in the carina (D). 
 
However, OCT observations need to be interpreted with caution. OCT is limited by its 
resolution of 15 micron which is greater than the thickness of an individual layer of endothelial 
cells. Therefore, coverage that is not visible by OCT does not exclude the presence of an 
endothelial layer. Second, the presence of tissue coverage does not necessarily imply the presence 
of a functionally intact endothelium. Early experimental stent data showed that endothelial 
function can vary considerably and show evidence of damage when subjected to the Evan’s blue 
dye exclusion test (23), even in the presence of a well structured neotintimal layer. In 
consequence, morphology should not be confused with function. 
see colour section
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Figure 3. Demonstrates the information that can be gathered from IVUS (20Mhz, lower panels) and from OCT 
imaging (mid and upper panels, LightLabImaging™, Boston, MA, USA) in patients at follow-up after stent 
implantation. These are corresponding cross sections within a stent, imaged by both, OCT in the upper panels and 
by IVUS in the lower panels. The images represent the same spots within a coronary artery (A, B, C), and illustrates 
the different quality of information that can be obtained by OCT as compared to conventional grey scale IVUS. A) 
Three layers of stents can be seen. OCT is able to clearly visualise the individual stent struts, the neointimal layers 
separating the different stents and the very thin coverage of the most inner, luminal stent struts. B) a bright, 
eccentric and relatively thick neointimal layer can be seen C) an eccentric thick neointimal layer is visible, however, 
the structure of this neointima differs considerably from the example B) with a low-reflective and speckled 
appearance. 
 
b) Assessment of structural details of tissue coverage 
OCT also permits the characterisation of neointimal tissue in a qualitative way. This is a great 
advantage as such information has not been available in vivo until now. The limited resolution, 
together with artefacts induced by metallic stent struts does not allow the characterisation of 
such details by IVUS. With OCT, neointimal tissue can show a variety of morphologies ranging 
from homogeneous, bright, uniform tissue to optically heterogeneous tissue or eccentric tissue of 
various thickness. Furthermore, structural details within the tissue can be observed such as 
intimal neovascularisation (24) or a layered appearance, typically observed in restenotic regions 
(25). Variations in the appearance of strut coverage can be seen within an individual patient, 
within an individual stent or within stents of different design. OCT findings, such as dark, signal-
see colour section
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poor halos around stent struts may reflect fibrin deposition and incomplete healing, as described 
in pathologic and animal experimental series (20,21). However, there is paucity of data 
demonstrating directly the OCT appearance of different components in neointimal tissue as 
defined by histology. Post-mortem imaging of DES in human coronaries is difficult and might 
be limited by the fact that the optical tissue properties show variations with temperature and 
fixation (26). Long-term animal OCT observations in DES are scarce. 
 
Figure 4. OCT (LightLab Imaging Boston, MA, USA) findings in two patients presenting with late drug-eluting 
stent (DES) thrombosis. OCT was performed in both cases immediately after thrombus aspiration and reveals 
completely different morphologic findings, possible suggesting two different mechanisms for late stent thrombosis, 
focal restenosis and incomplete strut coverage. I) Patient with late stent thrombosis three months after DES 
implantation in the left circumflex artery. OCT reveals an adequately expanded stent, all struts are well apposed 
against the vessel wall. All struts show tissue coverage, which is more pronounced in the proximal portion of the 
stent (D) as compared to the distal stent portion (A). There is focal in-stent restenosis (B, C) with severe lumen 
narrowing (MLA 1.63 mm2). The neointima shows a layered appearance with a luminal bright, highly reflective 
layer, an intermediate layer and a dark, signal poor layer surrounding the struts. Remnants of the thrombus are 
focally seen focally as irregular mural structures, protruding into the lumen (A, C). II) Patient with very late stent 
thrombosis four years after DES implantation in the left anterior descending artery. OCT reveals an adequately 
expanded stent, however, there is incomplete stent strut apposition at the proximal stent edge with incomplete tissue 
coverage in 21% of struts. (E) The distal stent portion, shows a well expanded and apposed stent with thin tissue 
coverage by OCT. F) irregular lumen borders with intraluminal remnants of the thrombus. G) proximal stent 
portion showing a strut without visible tissue coverage in 12 o’clock position and thrombus fragments in the lumen. 
H) proximal stent edge with incomplete apposition of five stent struts (arrows) against the vessel wall. The distance 
to the vessel wall is 200 micron. OCT shows tissue around the stent struts (DD thrombus, neointima). GWA: 
guidewire artefact. 
 
see colour section
Peter BW 13-5.indd   241 13-05-09   16:18
Chapter 18
242
c) Assessment of stent strut vessel wall interaction and strut apposition 
The interest in the long-term stent strut vessel wall interaction is manifold and includes the 
assessment of the stability of the acute result, the visualisation of complex anatomy that is not 
accessible by angiography or IVUS and the clearer understanding of reasons for stent failures, 
when they do occur. The unique optical properties of OCT can also be applied to the study and 
evaluation of new stent designs including bioabsorbable stents. Morphologic changes of the 
absorbable, polylactic acid stent struts and the vessel wall during follow-up have been recently 
described and show the unique capabilities of this in vivo imaging modality (27). Stent strut 
malapposition remains an important consideration. Postulated causes for stent strut 
malapposition are various and include incomplete stent expansion, stent recoil or fracture, late 
outward vessel remodelling or the dissolution of thrombus that was compressed during PCI 
between the stent strut and the vessel wall. Regardless of the pathophysiologic mechanism, the 
major concern in stent malapposition remains in the assumption that areas of strut 
malapposition cause non-laminar and turbulent blood flow characteristics, which in turn can 
trigger platelet activation and thrombosis. Here, prospective, serial OCT observations 
immediately and at longer term follow-up after stenting may improve our understanding of these 
complex mechanisms and shed light on the likely clinical significance of this phenomenon. 
Reasons for DES failure are poorly understood. With the reduction of in-stent hyperplasia, other 
mechanisms of restenosis due to mechanical stent failure have become apparent. Of the two 
established first generation DES, the sirolimus-eluting stent (Cordis, Johnson & Johnson, Miami, 
FL, USA) has been particularly linked to cases of stent fracture, likely as a result of its closed cell 
design compared with other DES employing an open cell system (28). The higher imaging 
resolution of OCT compared to IVUS permits a detailed assessment in such cases, as 
demonstrated recently by Shite et al (29) and Barlis et al (30). 
 
Conclusion & future developments 
OCT is a light-based diagnostic tool that allows in vivo imaging of the coronary artery wall in 
unparalleled detail (31). OCT can reliably visualise very thin stent strut tissue coverage as early as 
five days after implantation, and permits for its qualitative and precise quantitative assessment. 
These unique capabilities favour OCT as the new golden standard for the evaluation of coronary 
stents. Recent improvements in OCT technology, with frequency-domain OCT, will allow for a 
simple imaging procedure and offer the potential for large scale, prospective studies, 
indispensable to address vexing clinical questions such as the relationship of drug-eluting stent 
deployment, vascular healing, the true time course of endothelial stent coverage and late stent 
thrombosis. This may also better guide the optimal duration of dual anti-platelet therapy that 
currently remains unclear and rather empiric. 
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OCT and the assessment of bioabsorbable stents
A 65-year-old man underwent elective percutaneous coronary intervention for a stenosis in the 
proximal left anterior descending artery (LAD). As part of the PROGRESS study (designed as a 
first-in-man coronary study in 65 patients in 7 European centres), a 3.5x15mm magnesium based 
bioabsorbable stent (Lekton Magic Stent, Biotronik, Bulach, Switzerland) was implanted 
achieving an excellent angiographic result. Fifteen months following the initial intervention, an 
exercise treadmill test to evaluate exertional dyspnoea was positive. Angiography revealed a new 
and separate lesion in the mid-LAD/diagonal artery that was treated successfully with 2 
sirolimus-eluting stents (Cypher Select, Cordis, J&J) in a culotte fashion. In the previously treated 
proximal segment, the vessel lumen was patent with no signs of narrowing or edge effect (Panel 
A). Imaging using intravascular ultrasound (IVUS, Panel B) and optical coherence tomography 
(OCT, Panel C) showed absence of circumferential stent struts with shadowing. Small, scattered 
and circumscribed zones of high intensity (arrows) indicated the previous stent strut position 
(Panel B-C). All struts were covered by a thin neointimal layer with a thickness between 80 and 
140 microns (Panel C). 
 
The bioabsorbable stent is constructed from a magnesium alloy containing also Zirconium 
(<5%), Yttrium (<5%), and rare earth elements (<5%). The struts disappear over time but their 
position can still be identified due to the fact that the strut material is absorbed and the space 
filled in by calcium apatite complex, accompanied by a phosphorous compound. These stents are 
compatible with cardiac magnetic resonance imaging and multi-slice computed tomography and 
can be used as vehicles for possible drug and gene delivery. Such a novel technology may prove 
useful in negating some of the untoward complications of current permanent metallic stents, 
namely stent thrombosis and the need for prolonged dual anti-platelet therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
Panel A Coronary angiography 
in the right caudal view showing 
the proximal left anterior 
descending artery (LAD) 15 
months after implantation of a 
magnesium bioabsorbable stent. 
The stented area is indicated by 
the dashed line. The arrow 
indicates the region imaged by 
IVUS and OCT.  
 Panel B and C B: IVUS and 
C: OCT imaging of the 
previously stented segment at 
15 months follow-up. The 
vessel wall is without stent 
struts after absorption but small, 
well defined zones of high 
intensity (arrowheads) are 
scattered indicating the previous 
stent strut position. There is a 
thin, concentric layer of 
neointima with thickness 
between 80μm and 140μm 
(panel C).  
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Optical Coherence Tomography Findings in Very Late (4 Years) Paclitaxel-
Eluting Stent Thrombosis 
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OCT in very late stent thrombosis
The mechanisms of late coronary stent thrombosis, a complication with high morbidity and 
mortality (1), are poorly understood. Late thrombosis in drug-eluting coronary stents has been 
associated with delayed endothelialization of the stent struts or systemic and intra-stent 
hypersensitivity reaction (2). We present in-vivo findings in a patient with very late stent 
thrombosis. In 2003, a 60-year-old man with a history of stable angina and smoking underwent 
elective placement of two overlapping paclitaxel-eluting stents (3.0x16 mm and 2.75x28mm, 
Boston Scientific, Natick, MA) and post-dilation with a noncompliant balloon, for a significant 
stenosis of the left anterior descending artery (LAD). The discharge medication consisted of 
aspirin, Clopidogrel (12 months), beta-blockers and statins. Four years after stenting, the patient 
presented with acute anterior myocardial infarction caused by late stent thrombosis while under 
chronic aspirin therapy (Figure 1). After thrombus aspiration intravascular ultrasound (IVUS) 
and intravascular optical coherence tomography (OCT) were performed, showing incomplete 
coverage of 21% of the stent struts, which may reflect delayed vascular healing (Figure 2 and 3). 
Pathology of the thrombotic material showed a recent multilayered thrombus (Figure 4). Post-
procedure, the patient was treated with abciximab (Centocor, Leiden, Netherlands) and was 
discharged with sustained aspirin and Clopidogrel therapy. 
 
 
 
Figure 1: Coronary angiogram: Left: thrombotic occlusion of the LAD, dotted line indicates stented segment. Right: 
result after thrombus aspiration (Export catheter, Medtronic, Minneapolis, MI), with TIMI III antegrade flow and 
moderate residual stenosis in the mid-portion of the stented segment. A-D indicate locations of intracoronary 
imaging. 
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Figure 2: Intracoronary imaging after thrombus aspiration. Upper panels: IVUS (Atlantis, Boston Scientific, 
Natick, MA), lower panels: OCT (LightLab Imaging™, Boston, MA; cross sectional and longitudinal view) A) distal 
reference showing eccentric plaque in 11-4 o’clock position. B) distal stent portion, showing a well expanded and 
apposed stent with thin tissue coverage by OCT that is missed by IVUS. C) irregular lumen borders with 
intraluminal remnants of the thrombus D) proximal stent edge with incomplete apposition of 5 stent struts (arrows) 
against the vessel wall. The distance to the vessel wall is 200Ƭm. OCT shows tissue around the stent struts (DD 
thrombus, neointima). Incomplete stent apposition may be caused initial malapposition or acquired malapposition 
caused by a vascular response to the stent. GWA= guide wire artefact; C= catheter artefact. 
 
 
 
Figure 3: Spectrum of tissue 
coverage as seen by OCT in 
this stented segment. Tissue 
coverage was not visible in 
21% (n=110) of the struts, 
while 79% (n=411 of 521) of 
the struts showed tissue 
coverage of various thickness. 
A) no visible coverage B) very 
thin coverage (40ʅm) C) 
maximal coverage (140 ʅm). 
 
see colour section
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Figure 4: Histology of the aspirated thrombus: recent multilayered thrombus showing Zahn lines and containing 
abundant leukocytes consisting of eosinophils (E), neutrophils (N) and lymphocytes (L). 
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Tissue coverage in DES
The nineties have seen a parallel growth of intravascular ultrasound (IVUS) and stent 
implantation, heralded and explained by the seminal observations that stents implanted at low 
pressure under angiographic guidance alone are frequently under-deployed and have higher risk 
of thrombosis.(1) With a high price to pay in terms of late hyperplasia in the first months after 
implantation, meticulous attention was paid to overexpansion as a potential remedy to reduce 
restenosis. Despite conflicting results of studies of IVUS guided stenting, (2,3)  IVUS was largely 
applied to guide stenting in complex coronary lesions. (4) The introduction of drug-eluting stents 
(DES) has reset the boundary of optimal stent expansion to prevent thrombosis and restenosis, 
with risk thresholds as low as 4.5 mm2, achievable in most cases without ultrasound guidance. (5) 
The new challenge for interventional cardiology became late stent thrombosis and IVUS seemed 
inadequate to prevent this new evil, with late malapposition (6) but not post-procedural 
malapposition (7) correlated with late thrombosis.  
 
Unlike conventional stents which develop circumferential coverage with an average thickness of 
500μm or more, well visualized with IVUS and angiography (1mm late loss),(8) DES delay and 
prevent the hyperplastic response so that the average late lumen loss for sirolimus- or paclitaxel- 
eluting stents can be lower than 100μm, (9) which means the amount of intimal thickening will 
not be detectable with IVUS because of its limited axial resolution and the presence of artifacts 
around struts.  
 
Suzuki et al (10) suggest that another intravascular imaging technique may replace IVUS for the 
more refined assessment required by DES. In the 11 stents with a small hyperplastic response 
measured with histology, IVUS overestimated lumen area and underestimated in-stent 
hyperplasia. In this swine model of stent overexpansion, the optical coherence tomography 
(OCT) measurements were much closer to the histological measurements. The receiver operator 
curve of sensitivity-specificity showed a greater diagnostic accuracy, approaching the unity as 
opposed to a disappointing 0.78 with IVUS (see Suzuki et al, Figure 5). This was expected since 
OCT has a far greater resolution than IVUS and was initially introduced to study superficial 
plaque components, (11) with studies claiming the technique is also able to detect macrophages 
in unstable plaques. (12,13)  
 
Several small studies have recently been published highlighting the application of OCT for the 
in-vivo detection of stent tissue coverage at follow-up.(14-16) The study by Matsumoto et al (17) 
used both IVUS and OCT in 34 patients following sirolimus-eluting stent (SES) implantation. 
The mean neointima thickness was 52.5 microns, and the prevalence of struts covered by thin 
neointima, undetectable by IVUS, was 64%. The average rate of neointima-covered struts in an 
individual SES was 89%. Nine SES (16%) showed full coverage by neointima, whereas the 
remaining stents had partially uncovered struts. This small series confirms the superiority of 
OCT over IVUS for the detection of thin layers of neointimal tissue following stent 
implantation. 
 
 The crisp OCT images obtained in swines by Suzuki et al (10) in their experimental model are 
perfectly reproducible in patients in daily clinical practice. A cumbersome technique of proximal 
balloon occlusion and sub-selective intra-coronary flushing with crystalloid solutions was used in 
this study. This strategy can be replaced by continuous injection of a viscous contrast medium 
via the guiding catheter.(18) The OCT image wire is not steerable but can be inserted via an over 
the wire (OTW) lumen larger than 0.019” using either a single lumen (e.g.Transit, Cordis, 
Johnson & Johnson, Miami FL, USA) or a double lumen Monorail-OTW catheter such as the 
TwinPass 0.023” (Vascular Solutions Inc, Minneapolis, Minnesota, US).  
The use of the non-occlusive (flush-only) technique is compatible with OCT systems capable of 
acquisition speeds between 2 and 3mm/sec, thereby fast enough to generate interpretable images 
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in a safe and rapid manner, perfectly tolerated with no chest pain or major ECG changes or 
arrhythmias if an iso-osmolar contrast agent such as Iodixanol 370 (Visipaque™, GE Health 
Care, Ireland) is used. (8,19) The OCT procedure is also set to become greatly simplified with 
the introduction into clinical practice (within 1-2 years) of Fourier or optical frequency domain 
imaging (OFDI) technologies, (20) with acquisition speeds of 20mm/sec enabling complete 
pullbacks in only a matter of 3-5 seconds and eliminating the need for proximal vessel balloon 
occlusion. 
 
The scary picture of DES associated with increased mortality and myocardial infarction (21,22) 
has lost credit (23-25). Still, the sirolimus-eluting stent Cypher (J&J, Cordis, Miami, FL,USA) and 
the paclitaxel-eluting stent TAXUS (BSC, Boston, MS, USA), the only 2 DES with sufficient 
number of observations at late follow-up, show a small but worrisome increase in late 
thrombosis. (23,26)  
 
Trialists are faced with the challenge of studying a phenomenon so rare and so far in time from 
the initial treatment to require prolonged studies of tens of thousands of patients to provide 
meaningful answers. Studies of the magnitude of the largest secondary prevention or 
thrombolytic mega-trials are very difficult to be carried out because of cost and availability of 
patients and suitable centers. The duration of these trials is an equally important problem since 
their results risk being invalidated by the availability of new anti-platelet treatments and new 
DES, the latter with the potential to offer more safety because of thinner struts and more 
conformable designs and biologically tissue friendly coatings and drugs. OCT has the potential to 
offer surrogate end-points to test the ability of new DES to promote consistent tissue coverage 
of all struts. Studies of new DES should include OCT sub-studies of adequate size and with 
serial examinations at well selected time intervals after implantation. Such studies could identify 
the most promising DES and provide evidence to guide duration of anti-platelet treatment after 
different DES types.  
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Assessment of Culprit and Remote Coronary Narrowings Using Optical 
Coherence Tomography with Long-Term Outcomes 
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Assessment of culprit and remote lesions using OCT
Much of what is currently known about vulnerable plaque (VP) stems from post-mortem studies that have 
identified several characteristics of plaques making them prone to rupture, including the presence of a thin fibrous 
cap and a large lipid core. This study used optical coherence tomography (OCT) to assess culprit and remote 
coronary narrowings and to investigate whether intra-coronary OCT in living patients, was able to visualize 
morphologic features associated with VP in post-mortem studies. Twenty-three patients successfully underwent 
OCT prior to percutaneous coronary intervention. The culprit lesion and mild-moderate coronary narrowings 
remote from the target stenosis were investigated. By OCT, the culprit lesion was found to be fibrous in 39.1%, 
fibro-calcific in 34.4% and lipid-rich in 26.1% of cases. There were 2 patients meeting the criteria for thin-cap 
fibroatheroma (TCFA) (defined as the presence of a signal-rich fibrous cap covering a signal-poor lipid/necrotic 
core with a cap thickness <0.2mm). The majority of plaques at remote segments were proximal to the culprit 
lesion (73.9%) and predominantly fibrous and lipid-rich. OCT identified 7 TCFA lesions in 6 patients with a 
mean cap thickness of 0.19±0.05mm, extending for 103 ±49° of the total vessel circumference. At 24-months 
clinical follow-up, the only event occurred in a patient with in-stent restenosis who underwent repeat percutaneous 
revascularization. There were no clinically apparent plaque rupture-related events in the 6 patients found to have 
remote TCFA. This study has showed that OCT can be safely applied to image beyond the culprit lesion and that 
it can detect in-vivo morphologic features that have been associated with plaque vulnerability by retrospective 
pathologic examination. In conclusion, the detection of TCFA, particularly in stable patients is desirable and may 
principally allow for early intervention and prevention of adverse events. 
 
 
Acute coronary syndromes (ACS) including myocardial infarction (MI) are leading causes of 
death in industrialized countries, often caused by rupture of vulnerable plaque (VP). The 
detection of VP in the early phase of coronary artery disease therefore remains essential to limit 
morbidity and mortality while helping to target specific therapeutic interventions. Through 
retrospective, post-mortem studies, several characteristics of plaques that are prone to rupture 
have been identified including: the presence of a thin fibrous cap (<65 microns in thickness); a 
large lipid core and activated macrophages near the cap. The limitation of such studies however 
remains their inability to provide crucial detail regarding the natural history and progression of 
VP, and, therefore prognosis. Several imaging modalities have been used to assess and identify 
VP including coronary angioscopy, intravascular ultrasound (IVUS) and magnetic resonance 
imaging.(1-3) Recently, there has been significant interest in the field of VP detection using 
optical coherence tomography (OCT)(1,4-13) as it permits high-resolution (10-20 microns) 
imaging, principally suited to detect and quantify the thickness of a thin cap fibroatheroma 
(TCFA) and to estimate macrophage distribution.(9,14,15) In this study, we investigated whether 
intra-coronary OCT in living patients, was able to visualize morphologic features that have been 
associated with VP in post-mortem studies.  
 
Methods 
 
Between February and August 2004, this single-center, observational pilot study examined 
patients with coronary artery disease. Twenty-three patients scheduled for coronary stent 
implantation underwent OCT before angioplasty. The culprit lesion and mild to moderate 
coronary lesions remote from the target stenosis were investigated. Patients were selected based 
on the presence of stable or unstable angina pectoris with objective evidence of ischemia. 
Clinical exclusion criteria were: poor renal function (serum creatinine >1.5mg/dL), left 
ventricular ejection fraction <30% and hemodynamic instability. Angiographic exclusion criteria 
were: lumen diameter proximal to the lesion <2.5mm or >4.0mm by visual estimate; ostial 
lesion; chronic total occlusion. All patients were pre-treated with aspirin and clopidogrel (600mg 
loading dose) and both were continued for 1 year. Heparin was used to maintain an activated 
clotting time >250 seconds. All patients provided written informed consent prior to the 
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procedure. Clinical follow-up was performed by regular outpatient visit and telephone interview 
up to two years. 
The OCT system used in this study (LightLab Imaging Inc., Westford, MA, US) has been 
described previously.(1,16) Briefly, an OCT balloon catheter (Helios™, Goodman, Nagoya, 
Japan) is advanced distal to the lesion over a conventional coronary guide wire, which is then 
replaced with the OCT imaging wire (ImageWire™). The OCT catheter is then withdrawn 
proximally and the lesion and segments distal and proximal to the lesion visualized using an 
automated pullback system at 1.0mm/sec. During image acquisition, coronary blood flow is 
replaced by continuous infusion of Ringer’s lactate at 0.8 ml/sec using a power injector (Mark V 
ProVis, Medrad, Inc. Indianola, PA, US). The highly compliant occlusion balloon remains 
inflated proximal to the lesion at 0.5 or 0.7atm for a maximum of 30sec. Cross-sectional images 
are acquired at 15.6 frames/sec. 
Analysis of contiguous cross-sections was performed at 1mm intervals. In each selected cross 
section, plaque characterization was according to the following established OCT criteria: 1) 
Fibrous, 2) Fibrocalcific and 3) Lipid-rich.(17) Capped fibroatheroma was defined as the 
presence of a signal-rich fibrous cap covering a signal-poor lipid/necrotic core with a cap 
thickness <0.2mm and extending for more than one quadrant of the vessel circumference. The 
plaque had to be visualized in at least 5 consecutive frames. 
Following OCT examination, coronary interventions were performed according to standard 
practice with stent implantation. Stent optimization was accomplished with conventional 
angiographic guidance aiming at a residual diameter stenosis <20% by online quantitative 
coronary angiography. Statistical analyses were performed using SPSS 12.0.1 for Windows (SPSS 
Inc., Chicago, IL). Data are expressed as mean ± standard deviation for continuous variables or 
as median (interquartile range) if appropriate and as percentages for categorical variables. In 
order to evaluate the interobserver agreement for plaque characterization, a subset of plaques 
was classified by a second observer and the kappa statistic was calculated. To assess the 
reproducibility of cap thickness a set of fibrous caps were also measured by a second 
independent observer; the absolute mean difference between two observers’ measurements and 
its standard deviation was calculated.  
 
Results 
 
Baseline clinical and lesion characteristics are shown in Table 1. There was 1 case of transient 
atrio-ventricular block during OCT pullback in a 72 year-old man with single vessel disease. His 
further clinical course was uneventful and was discharged as planned the following day.  
OCT analysis of the coronary artery wall was possible in all patients. Mean OCT pullback length 
was 28.8±12.2mm. Quantitative measurements at the culprit site showed a mean minimal lumen 
area (MLA) and mean minimal lumen diameter (MLD) of 2.38±0.93mm2 and 1.45±0.33mm 
respectively. A wide spectrum of plaque morphologies was seen both at the culprit lesion and in 
remote segments. 
 
The culprit lesion OCT characteristics are also shown in Table 1. The agreement between 
observers for determining plaque type was good (kappa value of 0.85). There were 2 patients 
meeting the criteria for TCFA. A 58-year-old female with type 1 diabetes mellitus and 
hypertension presented with non-ST elevation MI. Coronary angiography revealed single vessel 
disease in the LAD. OCT demonstrated a tight lesion with a MLA of 0.68mm2 irregular lumen 
contours, signs of plaque fissure/rupture and mural thrombus. The other patient was a 62-year-
old male with a history of prior MI, presenting with angina (CCS III). Angiographically, three-
vessel disease was present with a culprit lesion in the LAD. OCT visualized a non-ruptured 
TCFA with a cap thickness of 180 μm and a circumferential extent of 100º with a MLA of 
3.42mm2. Both patients underwent uneventful coronary stent implantation. 
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Variable n=23
Age (years) 61 ± 11
Men  18 (78)
Diabetes mellitus  2 (9)
Hypertension  13 (57)
Dyslipidemia* 11 (48)
Current smoker  5 (22)
Prior myocardial infarction 6 (26)
Number of coronary arteries narrowed >50%
     1 14 (61)
     2 5 (22)
     3 4 (17)
Clinical presentation 
Silent myocardial ischemia 1 (4)
Stable angina pectoris 18 (78)
Unstable angina pectoris 4 (17)
Target vessel 
Left anterior descending 14 (61)
Left circumflex 3 (13)
Right 6 (26)
Culprit lesion morphology assessed by optical 
coherence tomography 
23 lesions
  Fibrous 9 (39)
  Fibrocalcific 8 (35)
  Lipid-rich 6 (26)
* Total cholesterol 5.0 mmol/L or treatment with a lipid-lowering drug 
Table 1: Baseline clinical and lesion characteristics 
 
Most plaques (73.9%) at remote segments were found to be proximal to the culprit lesion. 
Fibrous and lipid-rich plaques were more common while there was one patient with a 
fibrocalcific plaque distal to the culprit lesion in the RCA (Figure 1).  
 
OCT identified 7 TCFA lesions in 6 patients. One patient presented with stable angina, 3 with 
unstable angina, and 2 patients had a recent history of ACS. These latter patients underwent 
primary PCI for acute MI caused by thrombotic occlusion in another vessel 2 weeks prior and 
were re-scheduled for elective PCI to a residual lesion in a non-infarct related artery. The mean 
cap thickness was 0.19±0.05mm, extending for 103 ±49° of the total vessel circumference. 
Three of these TFCA lesions showed an irregular inner lumen contour with evidence of mural 
thrombi in two lesions (Figure 2). The reproducibility of fibrous cap measurements revealed an 
absolute mean difference between two observers of 0.010 +/- 0.016 mm, with the limits of 
agreement (i.e., 1.96SD of mean difference) of 0.043,-0.023. 
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Figure 1: Angiography demonstrating a calcific mid-vessel lesion. A further calcific plaque with sharp and well-
delineated margins was also observed by OCT remote and distal to the culprit lesion with attached mural thrombus 
 
 
Two year clinical follow-up was available in all patients. There were no deaths or MI. There was 
1 case of target lesion revascularization due to in-stent restenosis in a 65-year-old male 8 months 
following the index procedure. The patient was successfully treated with repeat PCI. There were 
no adverse events in the patients with TCFA at remote segments during 24 months follow-up 
with most patients classified as CCS 1 angina pectoris. All patients were on treatment with statin 
therapy. 
 
 
Figure 2: Thin-cap fibroatheroma (TCFA) assessed by OCT overlying a large lipid-rich plaque (2-5 o’clock 
position). The bright, highly reflective fibrous cap measured between 30-80 microns 
 
 
 
 
see colour section
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Discussion 
The main findings of this study are: 1) OCT can be safely used in-vivo to demonstrate the 
heterogeneity of coronary plaques at culprit and remote sites 2) Intravascular OCT can detect in-
vivo morphologic features that have been associated with plaque vulnerability by retrospective 
pathologic examination 3) the lack of long-term clinical events in our patients with TCFA gives a 
unique, ante-mortem insight into such lesions, even though the sample size is small. 
The recent introduction of OCT has proven to be an innovative contribution to the in-vivo 
detection of VP and TCFA. Its unique image resolution, in the range of 10-15μm, is in the 
magnitude of 10 times higher than that of IVUS and permits superior visualization of plaque 
morphology.(18) Although OCT suffers from the inherent lack of tissue penetration (<2mm), it 
is ideally served to examine the arterial lumen and the lumen–vessel interface. Yabushita et al 
(17) performed an in-vitro study of more than 300 human atherosclerotic artery segments. When 
compared to histological examination, OCT had a sensitivity and specificity of 71-79% and 97-
98% for fibrous plaques, 95-96% and 97% for fibrocalcific plaques, and 90-94.5% and 90-92% 
for lipid-rich plaques, respectively. Further, the inter-observer and intra-observer variability of 
OCT measurements were high (κ values of 0.88 and 0.91 respectively).  
The use of OCT to assess culprit lesions in-vivo has shown favorable results. In 57 patients, Jang 
et al (8) found that lipid-rich plaques were found in 90%, 75% and 59% of patients presenting 
with recent acute MI, ACS and stable angina, respectively. The frequency of TCFA (defined as 
lipid-rich plaque with cap thickness <65μm) was 72%, 50%, and 20% in the AMI, ACS and 
stable patients, respectively (p=0.012). Our study, demonstrating TCFA predominantly in 
patients with a recent history of ACS seems to be in-line with this observation. 
Of note, the study by Jang et al (8) did not use a motorized pullback for OCT image acquisition. 
The authors positioned the OCT wire at the level of the tightest stenosis, judged 
angiographically. This has several limitations, particularly the inability to detect continuous cross-
sections of the coronary artery. Our study utilized an automated pullback at 1.0mm/sec with a 
relatively long pullback of the coronary artery permitting the visualization of additional plaques, 
both proximal and distal to the culprit lesion. We judged the severity of the culprit lesion using 
OCT rather than angiography which is associated with its inherent limitations, namely its low 
resolution and inability to accurately discriminate between plaques. 
Recently, Kubo et al (4) used OCT, with IVUS and angioscopy to assess culprit plaque 
characteristics in 30 patients presenting with AMI. The imaging devices were consecutively used 
following initial mechanical thrombectomy. The incidence of plaque rupture by OCT was 73%, 
significantly higher than that detected by both angioscopy (47%, p= 0.035) and IVUS (40%, p 
=0.009). The incidence of TCFA was 83% in this patient population and only OCT was able to 
estimate the fibrous cap thickness (mean 49±21μm). Further, intracoronary thrombus was 
observed in all cases by OCT and angioscopy but was identified only in 33% of patients by IVUS 
(p< 0.001). The different patient populations evaluated likely explains the lower frequency of 
thrombi in our study as compared to that of Kubo et al. We did not recruit patients with AMI 
due to the relatively prolonged OCT imaging required to visualize both culprit and remote 
segments. Moreover, compared to the study by Kubo et al, our study extended OCT imaging 
beyond the culprit lesion, thereby giving a more representative indication about the presence of 
TCFA in non-culprit segments.  
The presence of TCFA in regions remote to the culprit lesion in 26% of patients in our study is 
an interesting observation and one that has not been shown previously using OCT. One possible 
explanation relates to the widely accepted understanding that atherosclerosis is a systemic disease 
with focal manifestations. In a study using multi-slice computed tomography (MSCT), Kunimasa 
et al (19) assessed 21 patients with ACS and 53 patients with non-ACS. The presence of CT-low-
density plaques (defined as a CT density of < 68 Hounsfield units), were more frequent in the 
ACS group than in the non-ACS group (81 vs 43%, p=0.03). In addition, the CT density of the 
non-culprit lesion was significantly lower in patients with ACS than in those with non-ACS. 
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While the presence of >1 unstable plaque is a relatively common occurrence in patients with 
ACS and AMI,(19,20) this does not provide a comprehensive explanation of our findings, 
particularly given patients with AMI were excluded, and, the majority of patients had presented 
with stable angina pectoris.  
The localization of TCFA in the proximal coronary segments has not been previously reported 
using in-vivo OCT. Such a finding has been confirmed in post-mortem studies with a low 
incidence of TCFA in patients dying of sudden cardiac death (1.3±1.4 TCFA per heart) of which 
most were clustered in the proximal segment of the artery, particularly the LAD.(21,22). It is 
thought that focal areas of low shear stress in proximal segments contribute to this phenomenon 
resulting in the migration of lipids and monocytes into the vessel wall and accelerating the 
atherosclerotic process.(23-25)   
The incidence of TCFA is dependent on the OCT criteria applied to make the diagnosis. We 
used rather conservative criteria requiring a relatively extensive lipid/necrotic core occupying 
more than one quadrant of the vessel circumference. This approach was chosen to exclude the 
chance for confusion with calcification, a potential limitation that has been described in a 
pathology series.(26) We applied a relatively high cut-off value of <200microns for cap thickness, 
possibly overestimating the incidence of true TCFA. However, it is difficult to translate a cut-off 
value defined by pathology into the clinical setting. Although the most accepted threshold to 
define a cap as "thin" has been set as <65 microns, this was based on post-mortem studies.(27) 
Extrapolation to in vivo studies requires caution. It is well established that anisotropic tissue 
shrinkage occurs during tissue fixation.(28) Shrinkage (particularly of collagen tissue, the main 
component of fibrous cap) of up to 60%, 15% and 80% can occur during critical-point-drying, 
free-drying and air-drying respectively.(29) Furthermore, post-mortem contraction of arteries is 
an additional confounding factor.(30) It is likely therefore that the threshold used to define a thin 
cap in vivo should be higher than 65 microns. Finally a number of important ex-vivo studies 
have used a higher (>200 microns) threshold.(31-33) Indeed, one of these studies identified a 
mean cap thickness of 260 μm and 360 μm for vulnerable and non-vulnerable plaques 
respectively.(33)  
The present study is not randomized and includes a relatively small sample size. In addition, 
OCT was restricted to a relatively short coronary artery segment, therefore, and unlike 
pathological studies, does not allow us to draw conclusions on the incidence of TCFA within the 
complete coronary tree. Further, the study did not involve routine angiographic and OCT 
follow-up. Still, its prospective design and use of a sensitive imaging device has given the first 
insight into the potential time course of such lesions. Obviously, larger studies, possible using 
multimodal imaging which allows the assessment of macrophage accumulation and collagen 
composition will help make clearer the pathogenesis and natural history of such VP with a 
tremendous potential to reduce the burden of cardiovascular disease. 
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Background: The risk of rupture and subsequent thrombosis of the atherosclerotic coronary plaques is related 
to the presence of necrotic core with high lipid content. We conducted an exploratory pilot trial to compare the 
capability for lipid tissue detection using four intra-coronary diagnostic techniques: IVUS Greyscale (IVUS GS), 
IVUS Radiofrequency Data (IVUS RFD) Analysis, Optical Coherence Tomography (OCT) and 
Intravascular Magnetic Resonance Spectroscopy (IVMR). 
Methods: Twenty-four matched target plaques were analyzed with the 4 techniques in non-culprit lesions in 
patients with stable angina. Following IVUS pullback, OCT and IVMR was performed. Plaque composition 
was assessed using established criteria of each technology.  
Results: Atherosclerotic plaques classified as soft by IVUS GS were mainly composed by fibro-fatty (80%) or 
necrotic core (20%) by IVUS RFD. These soft plaques were classified as “lipid rich” by OCT in the majority of 
cases (80%). IVMR confirmed the presence of lipid with a lipid fraction index ranging between 36 and 79 in 
these soft plaques. Besides this good agreement for soft plaques, IVUS GS, IVUS RFD and OCT had 100% 
agreement in the identification of calcified plaques. 
Conclusion: The present study explored multi-modality imaging of atherosclerotic plaque in-vivo. Assessing 
specifically lipid-rich plaques, there was generally good agreement for lesion components identified as soft by 
traditional IVUS GS with RFD and OCT whereas IVMR showed a varying amount of lipid in these regions. 
Nevertheless there continues to remain inherent variation, namely as a result of the different imaging resolutions 
and the lack of common nomenclature and classification.  
 
 
 
Acute coronary syndromes (ACS) are common initial manifestations of coronary atherosclerosis. 
The propensity of atherosclerotic lesions to destabilize is highly dependent on their composition, 
with autopsy studies of sudden cardiac death victims showing that the most frequent cause of 
the coronary occlusion is rupture of a thin-cap fibroatheroma (TCFA) plaque (1). Such lesions 
are characterized by a large necrotic core (tissue with lipid-rich necrotic areas containing 
remnants of foam cells, lymphocytes, cholesterol clefts and microcalcification) with a thin, 
fibrous cap, usually < 65 microns in thickness (2). Since the necrotic core is a tissue with high 
lipid content, discrimination of lipid-rich tissue may have an important impact on the detection 
of lesions prone to rupture. 
Intravascular ultrasound (IVUS) greyscale (GS) is the most often employed diagnostic technique 
for the evaluation of extent and distribution of coronary atherosclerotic plaque (3), however, its 
specificity and sensitivity for tissue identification is limited (4,5). Spectral analysis of IVUS 
radiofrequency data (RFD) is a tool developed in the last few years for more reliable analysis of 
plaque composition (6,7). Optical coherence tomography (OCT) is a high-resolution imaging 
modality that uses reflected near-infrared light to visualize vascular microstructures and it has 
been successfully applied for the characterization of coronary atherosclerotic plaques in-vivo (8). 
Intravascular magnetic resonance spectroscopy  (IVMR) is a new technique developed to identify 
specifically the lipid component of plaques based on the self-diffusion of water molecules that is 
translated into a lipid fraction index (LFI) (9).   
These four imaging modalities have in common, the ability to give a detailed assessment of the 
composition of atherosclerotic plaques but do differ in the means of achieving this. Currently, it 
is unclear to what extent these techniques, with different physical properties and varying 
resolution, are able to give comparable results. We conducted this exploratory pilot trial to 
compare the capability for lipid tissue detection using these four intra-coronary diagnostic 
modalities (IVUS GS, IVUS RFD Analysis, OCT and IVMR) while comparing these findings to 
each other and to IVUS GS, the most widely used and standardized method for plaque 
characterization.  
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Methods 
 
Study population 
Patients with stable angina undergoing percutaneous coronary intervention (PCI) were included 
in this pilot study. Following treatment of the culprit vessel, an IVUS pullback was performed in 
a non-culprit vessel containing a non-flow limiting stenosis (defined as less than 50% diameter 
stenosis by online quantitative coronary angiography, QCA). Following the IVUS pullback, OCT 
and IVMR acquisitions were performed. Heavily calcified and tortuous vessels and those with a 
minimal lumen diameter <2mm were excluded. Patients with depressed left ventricular function, 
coronary chronic total occlusions and impaired renal function were also excluded. All patients 
gave written informed consent. 
 
Coronary angiography 
All angiograms were evaluated after intra-coronary administration of nitrates using commercially 
available software for QCA [Cardiovascular Angiography Analysis System II (CAAS II), Pie 
Medical, Maastricht, the Netherlands].  
 
IVUS and RFD acquisition and analysis  
IVUS was performed using the Eagle Eye 20-MHz catheter (Volcano Corporation, Rancho 
Cordova, USA) with an automatic continuous pullback at a rate of 0.5 mm/sec. The GS and the 
RFD were acquired during the same pullback (6). IVUS GS plaque analysis was performed by 
visual assessment and consensus of two experienced observers. Plaque type was classified 
according to the Consensus Document of the American College of Cardiology (10) as: normal 
vessel wall, soft plaque (echogenicity lower than the adventitia), fibrous plaque (intermediate 
echogenicity), and calcified plaque (echogenicity higher than the adventitia with acoustic 
shadowing). 
The RFD analysis was performed offline with pcVH software (Volcano Corporation Rancho 
Cordova, USA) that permits semi-automated contour detection and provides the compositional 
structure of the vessel. The IVUS RFD analysis remains observer independent, using spectral 
analysis to classify the four different components of the atherosclerotic plaque and gives a 
colour-coded map distinguishing between fibrous tissue (green), fibro-lipid tissue (light green), 
necrotic core (red) and dense calcium (white).  
 
OCT acquisition and analysis 
The OCT acquisition was performed using a commercially available system for intracoronary 
imaging (LightLab Imaging, Westford, Massachusetts, US). It operates at a wavelength of 1310 
nm and has an axial resolution of 10 μm and a lateral resolution of 20 μm. We used a 0.019” 
ImageWire (LightLab Imaging, Westford, Massachusetts) in combination with a proximal, low 
pressure (0.4 atm) occlusion balloon (Helios, Goodman Inc, Japan) with simultaneous distal 
flush delivery (lactated ringers at 37°Celsius; flow rate 0.5ml/sec). Images were acquired during a 
pullback rate of 1.0 mm/sec. 
Plaque components were assessed by two experienced observers and classified according to 
previously published data as: normal vessel wall, fibrous plaque (homogeneous, signal-rich 
regions), lipid rich plaque (signal-poor regions with diffuse borders) and fibro-calcific plaque 
(well-delineated, signal-poor regions with sharp borders) (8). 
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IVMR acquisition and analysis 
The IVMR system consisted of a self-contained 5.2 F over-the-wire IVMR catheter, without 
external magnets or coils, a patient interface unit and a console. A pullback through the region of 
interest was performed using a dedicated device allowing controlling stepwise rotation (120 
degrees) and withdrawal (1.6mm) of the catheter. To eliminate motion artefacts, and to improve 
image resolution, the IVMR catheter was stabilized against the arterial wall by inflation of a 
partially occlusive, low-pressure balloon (1 atm). The time required for each acquisition was 51 
seconds. The magnetic fields generated by the probe located at the tip of the catheter, created a 
sector shaped (60 degrees), field of view (FOV) looking sideways into the artery wall. Acquired 
data was displayed as colour-code sectors of the LFI for the FOV. Blue indicated no lipid; grey 
corresponded to intermediate lipid content and yellow indicated high lipid content.  
 
Matching of the different diagnostic pullbacks to the target plaque 
Documentation of all catheter positions was made using angiographic landmarks. The 
localization of the IVUS, OCT and IVMR probes in the vessel were filmed using bi-plane 
angiography both pre and post acquisition. Biplane angiography served to determine the target 
segment and for orientation of the catheter position in a longitudinal (IVUS, OCT, IVMR) and 
cross sectional (IVMR) plane. The longitudinal orientation of the probes was determined by 
angiographically visible side branches (Figure 1). The cross-sectional orientation of the probe 
was determined by the presence of side branches visible in the longitudinal and cross-sectional 
views of IVUS (11)  and OCT and the  specifically designed, radiopaque  rotation markers for 
IVMR.  Acquisitions, in which rotation of the probe could not be clearly confirmed by the 
marker, were excluded from the analysis. 
Matched samples from all 4 diagnostic modalities were analysed in 1.6 mm longitudinal intervals, 
the target plaques were defined as 60 degrees sectors of the vessel wall in accordance to the 
acquired IVMR datasets (Figure 2A and 2B). 
 
Statistical analysis 
Data are expressed as mean ± standard deviation for continuous variables and as percentages for 
categorical variables. 
 
 
 
Results 
Patient and procedural characteristics  
Twenty-four matched target plaques were collected from five patients. The intracoronary 
diagnostic devices were successfully advanced to the area of interest in all the patients. There 
were no cases of coronary spasm, dissection, acute closure or perforation. During OCT and 
IVMR pullbacks transient signs of ischemia with ST segment changes were documented. 
Following the procedure, all patients remained symptom-free with no detected elevation in the 
creatinine kinase -MB or Troponin-T enzymes.  
IVUS GS, IVUS VH and OCT imaging were successfully performed in all target lesions. IVMR 
pullbacks contained 6 acquisition cycles in 3 patients and 4 in the remaining 2 patients due to 
chest pain or transient ECG changes that completely resolved immediately after balloon 
deflation. Two IVMR acquisitions were excluded, as complete, 120-degree rotation could not be 
judged definitively.  
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Figure 1. Matching of the OCT and IVUS pullbacks. The position of the IVUS, Optical Coherence 
Tomography (OCT) and Intravascular Magnetic Resonance Spectroscopy (IVMR) probe along the vessel was filmed 
before and after each acquisition (A). The “matching” of the region of interest in the IVUS (B) and OCT (C) 
pullback was based on the presence of anatomical landmarks (e.g. side branches visible in the longitudinal and cross-
sectional views). To determine the longitudinal position of the IVMR probe in the vessel, a side branch was used as 
a marker. From the landmark to the proximal part of the vessel one frame every 1.6 mm was selected. D1: first 
diagonal, D2: second diagonal, SB: septal branch, LAD: left anterior descendent coronary artery.  CS: cross section. 
 
 
see colour section
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Figure 2. Analysis of the targeted matched plaques. 2A) Matching of the cross sections in a) IVUS greyscale b) 
IVUS Radiofrequency Data Analysis and c) Optical Coherence Tomography pullbacks. 2B) Analysis screen.  After 
matching corresponding cross sections based on their longitudinal orientation, the region of interest is defined 
according to the orientation of the Intravascular Magnetic Resonance probe towards the vessel wall.  The figure 
illustrates the results of the six target matched plaques (60 degrees sector) analyzed in one patient. Prox: proximal 
Dist: distal. 
 
 
 
see colour section
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Target plaque characteristics  
The interrogated artery was the proximal LAD in 75% of the cases, and the proximal RCA in 
25%. The reference vessel diameter, minimal lumen diameter and percent diameter stenosis were 
3.2 ± 0.2 mm, 2.2 ± 0.4 mm and 34 ± 11%, respectively. By IVUS, the vessel area was 14.3 ± 4.9 
mm2, the mean luminal area was 8.3 ± 3.2 mm2 and the mean plaque burden was 41± 22% in the 
imaged vessel. 
 
Characteristics of the target plaques by the different techniques 
We analyzed 24 matched target plaques using the four techniques.  
 
Plaque morphology by IVUS Grey-scale 
IVUS GS identified normal vessel wall, soft plaque, fibrous plaque and calcific plaque in 62.5%, 
20.8%, 8.3% and 8.3% of cases respectively. 
 
Plaque composition by IVUS RF analysis 
Using IVUS RF, the analyzed target plaque was defined as normal vessel wall in 62.5% of the 
cases. The remainder were necrotic core (4.2%), fibro-fatty (16.7%) and fibrous (8.3%), Dense 
calcium was the main component in 8.3% of the cases. 
 
Plaque morphology by OCT 
The evaluated target plaque was considered normal by OCT in 54.2% of the cases, lipid rich 
plaque in 20.8%, fibrous plaque in 16.7% of the cases, and fibrocalcific plaque in 8.3% of the 
cases. 
 
Plaque composition by IVMR 
The result of the IVMR was yellow (high LFI) in 16.7%, grey (intermediate LFI) in 25% and blue 
(indicating low LFI) in 45.8% of the analyzed target plaques. In 12.5% the result was black, 
which indicates artefact. The minimum LFI was 0 and the maximum was 80, with a mean of 30 
± 48. The mean LFI was 73 ± 3.9 in the yellow regions, 42 ± 1.5 in the grey regions and 17.2 ± 
2.8 in the blue regions. 
 
Comparison of IVUS GS findings with other techniques (Table 1) 
 
Comparison IVUS GS and IVUS RFD analysis 
When the vessel was defined as normal by IVUS GS, it was normal by IVUS RF analysis in 
100% (15/15) of the segments. When the plaque was defined as soft by IVUS GS, it was 
predominantly composed of fibro-fatty tissue by RF analysis in 80% (4/5) of the cases and 
necrotic core in 20% (1/5) of cases. The fibrous plaques by IVUS GS where also (2/2) fibrous in 
the RFD analysis. When the plaque was calcified by IVUS GS, it was composed predominantly 
of dense calcium in all the RFD analysis (2/2) matched plaques. 
 
Comparison IVUS GS and OCT findings 
When the vessel was normal by IVUS GS, it was normal by OCT in 80% (12/15) of the cases, 
but in 20% (3/15) of the matched sectors considered normal by IVUS GS examination, it was 
possible to identify fibrous plaques with OCT.  When the plaque was defined as soft by IVUS 
GS it was mainly “lipid rich” by OCT (80% of the cases 4/5). The fibrous plaques by GS were 
fibrous by OCT in 50% of the cases (1/2) and normal vessel wall in another 50% (1/2). As with 
RFD analysis, all the calcified plaques by IVUS GS were also fibro-calcific plaques by OCT 
(2/2). 
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 Normal Soft Fibrous Calcified Total 
Normal 15 0 0 0 15 
NC 0 1 0 0 1 
Fibrofatty 0 4 0 0 4 
Fibrous 0 0 2 0 2 
DC 0 0 0 2 2 
Total 15 5 2 2 24 
 Normal Soft Fibrous Calcified Total 
Normal 12 1 0 0 13 
Lipid rich 0 4 1 0 5 
Fibrous 3 0 1 0 4 
Calcified 0 0 0 2 2 
Total 15 5 2 2 24 
 Normal Soft Fibrous Calcified Total 
Blue 10 0 1 0 11 
Grey 3 3 0 0 6 
Yellow 1 2 1 0 4 
Black 1 0 0 2 3 
Total 15 5 2 2 24 
 
Table 1. Results of the interrogated 24 matched target plaques with the four techniques. IVUS: Intravascular 
Ultrasound RFD: Radiofrequency Data OCT: Optical Coherence Tomography IVMR: Intravascular Magnetic 
Resonance Spectroscopy. 
 
Comparison IVUS GS and IVMR findings  
When the analyzed segment was normal by IVUS GS, it was blue by IVMR in 66% of cases 
(10/15). The normal vessel wall was identified as grey by IVMR in 20% (3/15) and as yellow in 
6% (1/15). In 6% (1/15) of the normal vessel wall sectors the result of the IVMR was black. 
When the target plaque was described as soft by IVUS GS assessment, it was grey by IVMR in 
60% (3/5) of the cases and yellow in 40% (2/5) of the cases. Of the two target plaques identified 
as fibrous by IVUS GS, one was classified as blue by the IVMR and the other as yellow. The 
calcified target plaques by IVUS GS were classified in 100% (2/2) of the cases as black (artefact) 
in the IVMR. The mean LFI was 52 ± 17 in the soft plaques, 46 ± 36 in the fibrous and 25 ± 21 
in the normal vessel wall.  
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Discussion 
A body of various clinical, post mortem and experimental observations suggest that the 
composition of atherosclerotic plaque is an important determinant for subsequent clinical 
outcome. This knowledge triggered the development of a variety of new technological 
approaches for the analysis of plaque structure and chemical composition. It is however 
challenging to estimate the accuracy of a given diagnostic method in vivo due to the fact that no 
‘gold standard’ method is available. A pragmatic way to get an indication for the plausibility of 
the information acquired in the clinical setting can be the cross correlation of different 
techniques. In the present study, the ability of four different intra-coronary diagnostic modalities 
to detect the lipid components of atherosclerotic plaque was tested. The atherosclerotic plaques 
classified as soft by IVUS GS were mainly composed by fibro-fatty or necrotic core in the RFD 
analysis. These soft plaques were classified as “lipid rich” by OCT in most of the cases while 
IVMR always classified as intermediate or high lipid content the plaques identified as soft by 
IVUS GS. The 3 techniques of IVUS GS, IVUS RFD and OCT had a 100% agreement in the 
identification of calcified plaques. All these plaques were displayed as artefact by IVMR.  
The detection of plaque components by IVUS is based on visual assessment of GS images and is 
highly influenced by the observer’s experience and interpretation. It has been reported that soft 
(hypo-echoic) plaques usually have a high lipid content (12,13), but histological correlations have 
shown that IVUS GS, has low sensitivity (46%) for lipid detection (5,14). In the present study, 
when compared with the findings of the IVUS RFD, all plaques classified as soft by IVUS GS 
were composed of fibro-fatty or necrotic tissue. The spectral analysis of IVUS RFD has been 
validated with histopathology ex-vivo (15) and in vivo (16), demonstrating high predictive accuracy. 
This technique has the advantage of being observer independent and importantly, permits the 
identification of necrotic core. However, histological comparisons have shown some 
misclassification due to overlap between tissues in the RFD spectrum ((15)).   
The use of OCT and IVUS GS showed good correlation for the detection of soft and lipid-rich 
plaques respectively. For lipid-rich plaques a sensitivity ranging from 90 to 94% and specificity 
ranging from 90% to 92% have been reported for OCT(8). Despite its high resolution, one 
drawback of current OCT systems is the limited penetration depth (1.5-2.0mm) that does not 
allow the detection of lipid pools or calcium behind thick fibrous caps. Further, the tissue 
characterization by OCT is observer dependent. An incorrect classification between calcium and 
lipid deposits by OCT has been described in comparisons with histology (17) and this may 
explain this phenomenon in a study by Jang et al where there was no difference in lipid-rich 
plaques defined by OCT criteria in ACS and stable angina patients (18).  In the present study, we 
found concordance between the techniques for calcified and “lipid-rich” plaques with all plaques 
identified as fibro-calcific by OCT also found to be calcified by IVUS GS and RFD analysis and 
were displayed as black (“artefact”) by the IVMR system. 
IVMR is a technique specifically developed to identify the lipid composition of plaque. It has 
demonstrated a strong correlation with histology in lipid-rich tissue detection in both the aorta 
and coronary arteries of patients suspected of dying of cardiovascular causes (19).  In the present 
study, plaques classified as soft by IVUS GS were identified as regions with intermediate to high 
LFI by IVMR. However there were 4 plaques that had intermediate or high lipid content by 
IVMR but were classified as normal vessel wall by IVUS GS and one fibrous plaque by IVUS 
showed high LFI in the IVMR analysis. This may reflect higher sensitivity of IVMR for lipid 
detection compared to IVUS. One of the main advantages of IVMR is that it is observer 
independent and that it allows the quantification of the lipid component. A previous ex vivo study 
suggested that IVMR could identify TCFA (19,20). However this application is not possible at 
present in the in vivo scenario where the scan area is restricted to 60 degrees sectors of the vessel 
wall. The small sample volume, the lack of structural information and the complex definition of 
the location of the probe in the arterial wall are the main limitations of the IVMR system at this 
point in time.   
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Presently, a number of imaging modalities are vying to accomplish plaque characterization and 
detection. Our study demonstrates the feasibility of assessing different physical aspects of 
atherosclerotic plaques in-vivo by multi-modality imaging. However, such an approach is 
complicated by a rather cumbersome matching process originating from varying sample 
volumes, resolutions and accuracies and, secondly, different terminologies, thresholds and cut-
off values for the different technologies. Obviously, the “gold standard” for lipid detection is 
histopathology, but the reported classifications are qualitative and difficult to apply 
homogenously to the findings of all these in-vivo techniques. This may be aided by defining 
histological plaque composition based on quantitative and uniformly applied criteria (21). 
Currently, findings gained from different diagnostic modalities cannot be considered equivalent. 
This should be considered when interpreting and designing clinical trials involving plaque 
detection and characterization. 
 
Limitations 
The main limitations of the present study are:  1) the small sample size 2) lack of histological 
correlation 3) the localization of the sector scanned by IVMR was difficult to precisely assess due 
to the simplified spatial representation associated with the technique; however specifically 
designed rotation markers, meticulous inspection and exclusion of doubtful rotations were used 
to optimize data analysis. 
 
Conclusions 
The present study explored multi-modality imaging of atherosclerotic plaque in-vivo. Assessing 
specifically lipid-rich plaques, there was generally good agreement for lesion components 
identified as soft by traditional IVUS GS with RFD and OCT whereas IVMR showed a varying 
amount of lipid in these regions. Nevertheless there continues to remain inherent variation, 
namely as a result of the different imaging resolutions and the lack of common nomenclature 
and classification.  
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Vulnerable plaque rupture
Atherosclerosis as a disease entity remains an intensely researched field, given the tendency for 
considerable morbidity and mortality. This attention has given rise to exciting opportunities in 
developing tools aimed at early detection and possible targeting of specific therapeutic 
interventions. One such modality is optical coherence tomography (OCT) that permits high-
resolution visualization of backscattered light. This has given unique insights into disease 
processes and with greater detail than traditional grey scale intravascular ultrasound (IVUS). We 
present a 69-year-old man with 1 week of crescendo angina 9 months following stent 
implantation to the left anterior descending artery (LAD). Angiography demonstrated a new 
lesion in the mid LAD and diagonal branches. Assessment of the region with OCT revealed a 
high lipid content plaque with a thin fibrous cap (maximal thickness 20 microns). In association, 
rupture of the thin cap was apparent, occurring at both shoulders of the plaque with associated 
mural thrombus. The patient was treated with further stent implantation and remains symptom-
free at 3 months follow-up. 
The predilection for plaque to rupture at the shoulder region is interesting. Pathological studies 
have shown that this region demonstrates intense inflammatory cell infiltrate, particularly with 
macrophage cells and lymphocytes. When activated, macrophages release matrix 
metalloproteinases in the vessel wall, which in-turn can induce ‘weak spots’ that become 
susceptible to rupture. Other factors also implicated in this increased vulnerability at the plaque 
shoulder include neovascularization with expression of adhesion molecules, and increased 
biomechanical stresses occurring around cellular microcalcification within the thin cap.  
Several imaging modalities have been used to assess and identify vulnerable plaque (VP) 
including coronary angioscopy, IVUS and magnetic resonance imaging. Recently, there has been 
significant interest in the field of VP detection using OCT. This modality permits high-resolution 
(10-20 microns) imaging, in the vicinity of 10 times greater than IVUS and has become a key tool 
to detect and quantify thin cap fibroatheroma and macrophage distribution. This individual 
clinical observation supports the evidence gained from post mortem observations pointing to the 
plaque ‘shoulder’ as a site of vulnerability for rupture.  
 
Panel Legend A. Angiography in the right cranial view demonstrated stenosis in the mid left anterior descending 
artery (LAD) involving both small diagonal branches. The previously implanted LAD stent proximally was widely 
patent. The region corresponding to the optical coherence tomography (OCT) images is shown with the black 
arrow. B-C. Intravascular 
OCT (LightLab Imaging, 
Westford, Massachusetts, US) 
was acquired using a non-
occlusive technique with a 
3.0mm/sec pullback. OCT 
clearly demonstrated the 
presence of a lipid-rich plaque 
in the 6 to 9 o/clock position 
characterized by low 
reflectivity, speckled 
appearance with diffuse 
margins. This was covered 
with a bright rim of fibrous 
tissue corresponding to thin-
cap fibroatheroma (TCFA). 
Mural thrombus was evident 
in all OCT cross-sections. The 
TCFA measured 20 microns 
thick and was found to be 
ruptured at each of the two 
shoulders of the plaque 
(arrows). 
 
see colour section
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Objectives: Atherosclerotic plaque rich in necrotic core is prone to develop at bifurcations. This study aimed to 
evaluate the in-vivo frequency and distribution of high-risk plaques (i.e necrotic core rich) at bifurcations using a 
combined plaque assessment with IVUS virtual histology (IVUS-VH) and optical coherence tomography (OCT).  
Methods: From 30 patients imaged with IVUS-VH and OCT, 103 bifurcations were selected. The main 
branch was analyzed at the proximal rim of the ostium of the side-branch, at the in-bifurcation segment and at the 
distal rim of the ostium of the side-branch. Plaques with more than 10% confluent necrotic core by IVUS-VH 
were selected and classified as fibroatheroma (FA) or thin-cap fibroatheroma (TCFA) depending on the thickness 
of the fibrous cap by OCT (> or 65μm for FA and TCFA respectively). 
Results: 27 FA (26.2%) and 18 TCFA (17.4%) were found. Overall the % of necrotic core decreases from 
proximal to distal rim (16.8% vs 13.5% respectively p=0.01) while the cap thickness showed an inverse tendency 
(130±105 vs 151±68Ƭm for proximal and distal rim respectively p=0.05). The thin caps were more often 
located in the proximal rim (15/34, 44.1%), followed by the in-bifurcation segment (14/34, 41.2%) and were 
less frequent in the distal rim (5/34 14.7%). 
 Conclusions: The proximal rim of the ostium of the side-branch has been identified as a region more likely to 
contain thin fibrous cap and a greater proportion of necrotic core.  
 
 
 
High-risk atherosclerotic plaques (i.e. rich with necrotic core) are prone to develop at bifurcations 
due to the specific shear stress conditions present in these regions(1,2). Stented bifurcations 
lesions represent a complex lesion subset at high-risk of restenosis and thrombosis (3,4). These 
phenomena may reflect certain procedural aspects such as incomplete stent apposition, under-
expansion or gap regions (5,6) but may also be associated with specific compositional and 
morphological plaque features in these regions. Thin-cap fibroatheroma (TCFA) has been 
described as the plaque with an increased risk of rupture (7). Such lesions are characterized by a 
large necrotic core with a thin fibrous cap, usually < 65 microns in thickness (8). Recently, it has 
been reported that TCFA detection could be improved by the combined use of intravascular 
ultrasound virtual histology (IVUS-VH) and optical coherence tomography (OCT)(9).  
IVUS-VH uses spectral analysis of IVUS radiofrequency data to identify four tissue types in the 
atherosclerotic plaque, among them necrotic core (10). Optical coherence tomography (OCT) is a 
high-resolution imaging modality that uses reflected near-infrared light allowing a very precise 
visualization and measurement of vascular microstructures such as the fibrous cap (11). To our 
knowledge, in vivo characterization of necrotic core rich plaques at bifurcation regions has not 
been explored. The objective of the present study was therefore to evaluate in-vivo the frequency 
and distribution of high-risk plaques at bifurcation lesions using a combined plaque assessment 
with IVUS-VH and OCT. 
 
Methods 
Study population 
All the patients admitted in our hospital between January 2005 and March 2008 in whom IVUS-
VH and OCT were performed in the same vessel were investigated for bifurcations adequately 
visualized by both imaging techniques. The indication for the IVUS-VH and OCT was the 
assessment of intermediate, non-flow limiting lesions by angiography or post stent implantation 
assessment. Only regions located more than 5 mm beyond the stent were included. All patients 
gave written informed consent.  
 
 
IVUS-VH acquisition  
IVUS was performed using the Eagle Eye 20 MHz catheter (Volcano Corporation, Rancho 
Cordova, CA, USA) with an automatic continuous pullback at a rate of 0.5 mm/sec. Greyscale 
images and radiofrequency data required for VH analysis were acquired during the same pullback. 
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The VH processing was performed offline with pcVH 2.1 software (Volcano Corporation 
Rancho Cordova, USA) that permits semi-automated contour detection and provides the 
compositional structure of the vessel. The IVUS-VH uses spectral analysis to classify the four 
different components of the atherosclerotic plaque and gives a colour-coded map distinguishing 
between fibrous tissue (green), fibro-fatty tissue (light green), necrotic core (red) and dense 
calcium (white). 
 
OCT acquisition  
The OCT acquisition was performed using a commercially available system for intracoronary 
imaging and a 0.019” ImageWire (LightLab Imaging, Westford, Massachusetts, US). Red blood 
cells represent a non-transparent tissue causing multiple light scattering and substantial signal 
attenuation. Therefore, for adequate OCT image acquisition blood must be temporarily removed 
from the vessel. In seventy-seven percent of the cases this was achieved with the occlusion 
technique in which a proximal, low-pressure (0.4 atm) occlusion balloon (Helios, Goodman Inc, 
Nagoya, Japan) is inflated with simultaneous distal flush delivery (lactated ringer; flow rate 
0.8ml/sec) to remove blood from the vessel lumen. Images were acquired during a pullback rate 
of 1.0 mm/sec. The possibility to increase the pullback speed up to 3 mm/s in the new OCT 
system permitted 23% of the cases to be acquired exclusively using a non-occlusive technique in 
which the blood was removed by the continuous injection of contrast (Iodixanol 370, 
Visipaque™, GE Health Care, Cork, Ireland) through the guiding-catheter. The non-occlusive 
technique reduces the procedural time and the incidence of chest pain and ECG changes during 
image acquisition without affecting the image quality(12).  
 
 
Bifurcation selection and analysis 
Simultaneous visual assessment of IVUS-VH and OCT pullbacks, in two contiguous screens, 
allowed the selection of all bifurcations that could be identified with both techniques (13). To 
ensure proper matching between two imaging modalities that have different lateral resolutions 
(20 μm for OCT and 300 μm for IVUS) and depth penetration, a strict selection of the frames 
was followed. Only the main branch was analyzed. The lesion analysis included: i. proximal rim 
of the ostium of the side-branch cross section (first frame proximal to the take-off of the side-
branch); ii. in-bifurcation cross section (frame with the larger ostial diameter of the side-branch) 
and iii. distal rim of the ostium of the side-branch cross section (first frame distal to the take off 
of the side-branch) (Figure 1). In each bifurcation the plaque location in relation to the flow 
divider was analyzed (Figure 2). 
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Figure 1: Bifurcation selection and analysis 
Bifurcations that could be identified in both IVUS-VH and OCT pullbacks were included. A strict selection of the 
analyzed cross sections was followed to ensure correct matching between the two techniques. Plaques were analyzed 
only in the main branch. The lesion analysis included: i. proximal rim of the ostium of the side-branch cross section 
(first frame proximal to the take-off of the side-branch); ii. in-bifurcation cross section (frame with the larger ostial 
diameter of the side-branch) and iii. distal rim of the ostium of the side-branch cross section (first frame distal to the 
take off of the side-branch) SB: side-branch CS: cross section. 
 
 
 
Figure 2: Location of the plaque in relation to the flow divider. To describe the plaque location in relation to 
the flow divider, the vessel cross section was divided in 4 quadrants according to the position of the side-branch. 
Quadrants 1 and 4 correspond to the ostium of the side-branch while quadrants 2 and 3 correspond to the part of 
the vessel wall located in front of the ostium of the side-branch. A: greyscale IVUS, B: virtual histology, C: optical 
coherence tomography. 
 see colour section
see colour section
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Plaque type classification  
Two experienced observers jointly analyzed the IVUS-VH data and the OCT measurements in 
the selected frames to characterize the plaque type according to the following hierarchical 
classification:(7,14,15) (Figure 3, 4 and 5):  
 
1. Adaptive intimal thickening (AIT): intimal thickening of less than 600 μm for less 
than 20% of the circumference. 
2. Pathological intimal thickening (PIT): intimal thickening 600 Ƭm for more than 
20% of the circumference with more than 15% of fibro-fatty tissue, and no confluent 
necrotic core or dense-calcium  
3. Fibrotic plaque: plaque constituted predominantly by fibrous tissue without confluent 
NC or dense-calcium. 
4. Fibrocalcific plaque: more than 10% of confluent dense-calcium without confluent NC. 
5. Fibroatheroma (FA): plaque characterized by the presence of more than 10% confluent 
NC covered by a fibrous cap thicker than 65 μm. 
6. Calcified fibroatheroma (CaFA): fibroatheroma that contains more than 10% of 
confluent dense-calcium 
7. IVUS/OCT-derived Thin-Capped Fibroatheroma (TCFA): defined as the presence 
of more than 10% confluent NC at the lumen covered by a thin fibrous cap (<65 μm).  
8. IVUS/OCT-derived Calcified Thin-Capped Fibroatheroma (CaTCFA): TCFA that 
contains more than 10% of confluent dense-calcium. 
 
 
 
Figure 3: Plaque classification algorithm. OCT: optical coherence tomography, VH: virtual histology, CNC: 
confluent necrotic core, FF: fibrofatty, DC: dense calcium, AIT: adaptive intimal thickening, PIT: pathological 
intimal thickening, FC: fibrocalcic, FT: fibrotic, FA: fibroatheroma, CaFA: calcified fibroatheroma, TCFA: thin-cap 
fibroatheroma, CaTCFA: calcified thin-cap fibroatheroma. 
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Figure 4: Low-risk plaques. Matched images of greyscale IVUS (A), virtual histology (B) and optical coherence 
tomography (C) for the 4 types of plaques considered of low-risk. 1: adaptive intimal thickening, 2: pathological 
intimal thickening, 3: fibrocalcific plaque 4: fibrotic plaque.  
 
 
Figure 5: High-risk plaques. Matched images of greyscale IVUS (A), virtual histology (B) and optical coherence 
tomography (C) for the 4 types of plaques considered at high-risk of rupture. 1: fibroatheroma, 2: calcified 
fibroatheroma 3: thin-cap fibroatheroma 4: calcified thin-cap fibroatheroma. 
see colour section
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Fibroatheroma and TCFA are considered high-risk plaques in AHA and Virmani’s 
classifications(7,16). The necrotic core was considered confluent when it was forming a major 
pool. This definition was used to avoid misclassification as high-risk plaques of lesions with 
isolated islets or individual pixels of necrotic core which can be artefacts. The presence of 
confluent NC >10% at the lumen was measured using dedicated in house developed software 
(MATLAB MathWorks, Natick, MA)(9). A validation with pathology of a similar algorithm was 
reported in the CAPITAL study(14). The diagnostic accuracy of IVUS-VH compared to 
histology in different carotid plaque types was 99.4% for TCFA, 96.1% for CaTCFA, 85.9% in 
FA, 85.5% for fibrocalcific, 83.4% in PIT, and 72.4% for CaFA. To overcome the limitations of 
IVUS-VH in the fibrous cap evaluation the classification used in our study combines the 
information about plaque composition provided by IVUS-VH and the measurements of fibrous 
cap as assessed by OCT(9). The thinnest part of the fibrous cap was measured by OCT in all the 
plaques that contain more than 10% of confluent NC to distinguish between FA and TCFA. The 
fibrous cap measurement by OCT was guided by the IVUS-VH to avoid misclassification 
between lipid pools and calcium. The cap was measured in the area where the NC was closer to 
the lumen. The reproducibility of fibrous cap measurements has previously been reported (12).  
If different morphologies were present along the lesion, the highest degree plaque was 
established as the definite plaque type. 
 
 
Statistical analysis 
Statistical analyses were performed using SPSS 12.0.1 for Windows (SPSS Inc., Chicago, IL). 
Continuous variables are expressed as mean ± standard deviation. Categorical variables are 
expressed as percentages.  The bifurcation (lesion) was the unit of analysis without corrections 
for correlated observations in the same subjects. To compare continuous variables between 
lesions, t test or ANOVA were used. To compare continuous variables between different 
segments of the bifurcation paired samples T test or Wilcoxon signed Ranks Test for 2 
dependent samples were used. Comparison among groups for categorical variables was made 
with χ2 method. 
 
 
Results 
Clinical and procedural characteristics 
One hundred and three bifurcations were selected in 32 pullbacks performed in 30 patients.  The 
mean age was 60±7 years and 73% were males. Regarding cardiac risk factors, 48.3% 6.9% and 
72.4% had hypertension, diabetes mellitus, and hyperlipidemia, respectively and 27.6% were 
smokers. Seven percent had prior myocardial infarction and 43.3% had undergone a prior 
percutaneous coronary intervention. The clinical presentation was stable angina in 86.7%, 
unstable angina in 10% and acute myocardial infarction in 3.3%. The investigated vessel was 
LAD in 34%, LCX in 33% and RCA in 33% of the cases. The type of bifurcations studied were 
LAD/diagonal, LAD/septal branch, LCX/marginal and RCA/right ventricular branch in 21.4%, 
12.6%, 33% and 33% of the cases respectively. The indication for IVUS-VH and OCT was 
assessment of intermediate, non-flow limiting lesions by angiography in 40% of the cases and 
post stent implantation assessment in the remaining 60% of cases. All studied lesions were 
considered non- significant by angiographic criteria and had a lumen area >4mm2 by IVUS. 
Overall the mean vessel and lumen area and plaque burden (PB) were 13.9 ± 3.7 mm2, 7.7 ± 2.2 
and 43.2 ± 13% respectively.  Table 1 shows the number of quadrants containing plaque and the 
location of the thickest part of the plaque in relation to the side-branch. 
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Number of quadrants containing plaque
1 25/103  (24.3%) 
2 33/103 (32.0%) 
3 29/103 (28.2%) 
4 16/103 (15.5%) 
Location of the thickest part of the plaque
Quadrant 1 28/103  (27.2%) 
Quadrant 2 18/103 (17.5%) 
Quadrant 3 26/103 (25.2%) 
Quadrant 4 31/103 (30.1%) 
Table 1. Number of quadrants containing plaque and location of the thickest part of the plaque in relation to the 
flow divider.  
 
Frequency of plaque type 
The plaque type was analyzed in 103 lesions and 293 cross sections.  Eight distal and 8 proximal 
rims could not be analyzed due to artefacts. Overall, the frequency of each plaque type per lesion 
was: AIT 20 (19.4%), PIT 16 (15.5%), fibrocalcific 15 (14.6%), fibrotic 7 (6.8%), FA 8 (7.8%), 
CaFA 19 (18.4%), TCFA 10 (9.7%) and CaTCFA 8 (7.8%). In the analyzed cross sections the 
distribution was as follows: AIT 76 (25.9%), PIT 53 (18.1%), fibrocalcific 42 (14.3%), fibrotic 28 
(9.6%), FA 18 (6.1%), CaFA 42 (14.3%), TCFA 21 (7.2%) and CaTCFA 13 (4.4%). 
 
 
Necrotic core and cap thickness distribution  
The NC and cap thickness distribution in the proximal rim, in-bifurcation and distal rim cross 
sections are shown in Figure 6. Overall, the mean NC area and mean percentage of NC decreased 
from proximal to distal while the mean cap thickness showed an inverse tendency. 
 
 
Figure 6:  Necrotic core (NC) area (6A), necrotic core percentage (6B) and cap thickness (6C) distribution in the 
proximal rim of the ostium of the side-branch, in-bifurcation and distal rim cross sections.  
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High-risk plaques distribution, compositional and geometrical analysis 
The distribution of the different plaque types in relation to the location is shown in Table 2.  
Figure 7 shows the number of cross sections with high-risk plaque morphology in the proximal 
rim, in-bifurcation and distal rim.  
 
 
 
Table 2. Distribution of the different plaque types in the proximal rim of the ostium of the side branch, in 
bifurcation and distal rim cross sections. N=293 cross sections. AIT: Adaptative intimal thickening, PIT: 
pathological intimal thickening, FC: fibrocalcic, FT: fibrotic, FA: fibroatheroma, CaFA: calcified fibroatheroma, 
TCFA: thin cap fibroatheroma, CaTCFA: calcified thin cap fibroatheroma. 
 
 
 
Figure 7: Distribution of the high-risk plaques in the proximal rim of the ostium of the side-branch, in-
bifurcation and distal rim cross sections. Number of cross sections with high-risk plaque morphology in the 
proximal rim, in-bifurcation and distal rim FA: fibroatheroma, CaFA: calcified fibroatheroma TCFA: thin-cap 
fibroatheroma CaTCFA: calcified thin-cap fibroatheroma. 
 
 AIT PIT FC FT FA CaFA TCFA CaTCFA Total
Proximal 
rim 
21 
(22.1%) 
19 
(20%) 
13
(13.7%) 
5
(5.3%) 
8
(8.4%) 
14
(14.7%) 
10 
(10.5%) 
5 
(5.3%) 
95
In-
bifurcation 
24 
(23.3%) 
18 
(17.5%) 
15
(14.6%) 
12
(11.7%) 
5
(4.9%) 
15
(14.6%) 
8 
(7.8%) 
6 
(5.8%) 
103
Distal rim 31 
(32.6%) 
16 
(16.8%) 
14
(14.7%) 
11
(11.6%) 
5
(5.3%) 
13
(13.7%) 
3 
(3.2%) 
2 
(2.1%) 
95
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The thin caps were more often located in the proximal rim (15/34, 44.1%), followed by the in-
bifurcation (14/34, 41.2%) and were less frequent in the distal rim (5/34, 14.7%).  The location 
of the thin cap in the 18 lesions classified as TCFAs was as follows: In 4 cases the thinning of the 
cap extended from the proximal rim into the distal rim, in 7 cases the thin cap was located in the 
proximal rim and in the in-bifurcation; in 3 TCFAS the thinning of the cap was located only in 
the in-bifurcation and in 3 only in the proximal rim; there was one TCFA that presented the thin 
cap at both rims while the cap at the in-bifurcation frame was thicker. There were no cases in 
which the thin cap was located only in the distal rim. The mean cap thickness in proximal rim, in-
bifurcation and distal rim in TCFAs is shown in Figure 8.  
 
 
 
Figure 8: Mean cap thickness in the proximal rim of the ostium of the side-branch, in-bifurcation and distal rim 
cross sections in thin-cap fibroatheromas. 
 
 
The vessel area and the plaque burden was significantly greater in the subgroup of lesions 
considered high-risk (FA, CaFA, TCFA and CaTCFA) than in the rest of lesions (16.5 ± 3 mm2 
vs 14.1 ± 3 mm2 p=0.002 and 55 ± 9% vs 42 ± 12% p<0.001 for vessel area and plaque burden 
respectively) while the lumen area was not significantly different (6.8 ± 2 mm2 vs 7.1 ± 2 mm2 
p=0.39). Table 3 shows the PB, NC percentage and cap thickness in FA, CaFA, TCFA and 
CaTCFA.  
 
Plaque type in relation to the clinical presentation 
As exploratory analysis, patients with acute coronary syndromes (ACS) had a significant higher 
proportion of lesions with high-risk morphology plaques than stable patients [17/23 (73.9%) vs 
28/80 (35%) p=0.002]. Specifically the number of lesions with TCFA morphology was 6/23 
(26.1%) vs 12/80 (15%) p=0.2, for ACS and stable patients respectively and the number of 
lesions with FA morphology was 11/23 (47.8%) vs 16/80 (20%) p=0.01 for ACS and stable 
patients respectively. 
Peter BW 13-5.indd   299 13-05-09   16:19
Chapter 25
300
 
 
 FA 
 (n=8) 
CaFA (n=19) TCFA (n=10) CaTCFA 
(n=8) 
p-value
PB (%) 51.7 ± 11 53.7 ± 10 54.2 ± 6 61.8 ± 5 0.13
NC (%) 20.1 ± 5.3 27.1 ± 6 33.0 ± 8 31.7 ± 8 0.002
Cap thickness (μm) 165 ± 59 174 ± 88 49 ± 15 51 ± 13 <0.001
 
Table 3. Plaque burden (PB), necrotic core (NC)  % and cap thickness in fibroatheromas (FA), Calcified 
fibroatheromas (CaFA), thin cap fibroatheromas (TCFA) and calcified thin cap fibroatheromas (CaTCFA).  
 
 
Discussion 
To our knowledge this is the first in-vivo study evaluating the frequency and distribution of high-
risk plaques at bifurcations in coronary arteries using a combined plaque assessment with IVUS-
VH and OCT. The main finding is that the thinning of the fibrous cap occurs more often in the 
proximal rim of the ostium of the side-branch. The NC shows also a differential distribution 
along the bifurcation being higher at the proximal rim.  
 
Multi-modality plaque assessment 
The detection of plaques at potentially high-risk of rupture could prevent future occurrence of 
acute coronary syndromes. At present, multiple techniques are available that evaluate different 
aspects of the atherosclerotic plaque such as its structure, composition or mechanical properties 
(17). The combined information provided by the different methods is essential for better 
identification of high-risk coronary lesions. In this study, a combined approach with IVUS-VH 
and OCT was used. IVUS-VH allows the detection and quantification of NC, one of the main 
components of high-risk plaques. However, the limited axial resolution of IVUS (around 200 μm) 
does not permit an accurate evaluation of the fibrous cap. On the contrary, OCT has a very high 
resolution (10-20 μm) allowing a very precise measurement of the fibrous cap. Sawada et al, 
recently reported the combined use of IVUS-VH and OCT improved the accuracy for TCFA 
detection(9). They studied 126 plaques in 56 patients with angina. Of the sixty-one plaques 
diagnosed as TCFA by IVUS-VH criteria, only 28 had a thin fibrous cap, as measured by OCT. 
In addition, eight OCT-derived TCFA did not have NC in the VH analysis, mainly due to the 
misinterpretation in the OCT analysis caused by dense calcium. This source of error in plaque 
characterization by OCT has previously been described and indicates the difficulty in identify 
TCFAs using only OCT(18). To avoid this misclassification in our study the measurement of the 
fibrous cap in OCT was guided by IVUS-VH. At the present stage neither modality 
independently is sufficient for detecting the highest risk plaques; the combined approach seems 
to be mandatory for the accurate diagnosis of TCFA in vivo. 
 
High-risk plaque frequency, distribution, composition and geometrical 
analysis 
The in- vivo frequency of TCFAs at bifurcations is not known. In our study, in which a highly 
selected population was included, 18 out of 103 bifurcations presented TCFAs (17%). 
Considering that the number of bifurcations in the complete coronary tree is around 15(19), the 
frequency of TCFAs per heart would be around 2.5.  This is in agreement with reported 
pathological data(7). The bifurcation left main/LAD has been studied with IVUS-VH showing 
that the plaque burden and the amount of necrotic core are higher in the LAD than in the left 
main. However, plaque morphology in the different segments of other bifurcations has not been 
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previously evaluated in vivo. The present study, which extended the assessment of bifurcation 
lesions beyond the left main, showed that the amount of necrotic core is higher at the proximal 
rim of the ostium of the side-branch with a thin fibrous cap more often identified in the proximal 
rim. The fibrous cap thickness is determined by the balance between matrix synthesis by the 
smooth muscle cells and matrix degradation by metalloproteinases (MMP) produced by 
macrophages(20). It has been demonstrated that the distribution of inflammatory cells in 
atherosclerotic plaques relates to the direction of the flow with higher concentration of 
macrophages and MMP activity in the upstream or proximal part(21). One of the mechanisms 
that have been proposed for the differential distribution of the high-risk plaques along the artery 
is the influence of endothelial shear-stress. Bifurcations are geometrically irregular regions where 
disturbed laminar flow occurs generating abnormal endothelial shear-stress patterns that may play 
a role in plaque destabilization. Previous studies showed that atherosclerosis develops 
preferentially at low shear stress locations such as the outer wall of bifurcations (2). However in 
our data the thickest part of the plaque did not show a preferential location for this region. 
Different pathological and IVUS studies have confirmed that plaques rupture occurs usually at 
sites of significant plaque accumulation associated with positive remodelling(2,22). This is in 
agreement with our data showing how the vessel area and the plaque burden were higher in high-
risk plaques compared to stable lesions. In line with pathological series, TCFAs in our study were 
located in areas with non-significant lumen compromise, with a mean luminal area of 6.8 ± 2 
mm2(8). Similarly, NC in TCFAs in this population is concordant with previously published 
pathological findings (8).  
 
High-risk plaques in relation to clinical presentation 
Although the comparison between ACS and stable patients in this study was exploratory, patients 
with unstable clinical presentation showed a high-risk profile of plaque types at bifurcations with 
a higher proportion of TCFAs and FA. This is in agreement with previous data regarding TCFA 
detection with IVUS-VH demonstrating that acute coronary syndrome (ACS) patients present a 
significantly higher prevalence of IVUS derived TCFA than stable patients(10).   
 
 
Limitations 
Currently VH derived necrotic core rich plaques can only be consider as allegedly high-risk 
lesions as it has not been demonstrated if they are associated with a higher incidence of clinical 
events at follow up. In the present study OCT and VH were restricted to one or two vessels, 
therefore, and unlike pathological studies, does not allow us to draw conclusions on the incidence 
of TCFA in bifurcations within the complete coronary tree. No comparison with non-bifurcation 
lesions was performed. Still the detailed plaque assessment combining two imaging modalities has 
given the first insight into the distribution of these allegedly high-risk lesions at bifurcations.  
 
Conclusions 
This study, has given unique, in vivo data on the localization of plaque occurring at bifurcation 
lesions. Further, the proximal rim of the ostium of the side-branch has been identified as a region 
more likely to contain thin fibrous cap and a greater proportion of necrotic core.  
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Optical coherence tomography (OCT) has become a key intra-coronary imaging modality able to traverse some of 
the limitations of angiography and intravascular ultrasound. In-vivo imaging with high resolution (around 15 
micrometres) has given unique insights into not only atherosclerotic plaque, but also to the understanding of tissue 
responses underlying stent implantation. Novel developments with faster OCT pullback speeds will further 
simplify the procedural requirements and eventually eliminate the need for proximal vessel balloon occlusion during 
image acquisition. This report explores the current and future developments in OCT technology that will see this 
unique imaging modality become a key player in both the clinical and research arena for the interventional 
cardiologist. 
The application of optical coherence tomography (OCT) to the coronary arteries has offered 
new insights into atherosclerosis and tissue responses following stent implantation. The clear and 
detailed images have generated an intense interest in adopting this technique for both clinical and 
research purposes. The first OCT system for coronary imaging was approved for clinical use in 
the European Union in 2004 and, up to now, more than 100 systems have been installed in 
catheterisation laboratories world-wide. OCT has been used for the detailed assessment of 
atherosclerotic plaque, in particular the quantification of thin-cap fibroatheroma (TCFA) and the 
distribution of macrophages (foam cells) surrounding vulnerable plaques. (1-6) In addition, OCT 
can precisely assess tissue coverage following stent implantation, (7-12) and in this regard, may 
provide greater insights into the potential link between stent endothelialisation and late 
thrombosis. This chapter details current and future developments in OCT imaging, which 
include exciting technological advancements that will consolidate the position of OCT as a key 
diagnostic tool to complement the armamentarium of the cardiologist well into the future. 
Current OCT technology 
At present, two commercial OCT systems, the M2 and 
M3 OCT Imaging Systems (LightLab Imaging, Inc., 
Westford, MA, USA), are available for clinical use.  Both 
employ a dedicated fibre-optic imaging wire 
(ImageWireTM, LightLab Imaging Inc., Westford, MA, 
USA) connected to a patient interface unit (PIU) which, in 
turn, connects to the system console. The imaging wire 
has a maximum outer diameter of 0.019″ (with a standard 
0.014" radiopaque coiled tip) and contains a single-mode 
fibre-optic core that rotates within a transparent sheath. 
Figure 1 illustrates the M2 system console with the cart 
containing the optical imaging engine and the computer. 
The mouse, keyboard, two monitors, and the PIU are all 
mounted on top of the cart. Although both the M2 and 
M3 systems use the identical console and PC-based 
operating system, the latter permits imaging at a higher 
frame rate (20/sec for the M3 vs. 15.6/sec for the M2) 
with a faster maximum pullback speed (3.0mm/sec vs. 
2.0mm/sec). 
Figure 1.  The LightLab M2 System console 
Peter BW 13-5.indd   307 13-05-09   16:19
Chapter 26
308
OCT physics  
Current OCT systems incorporate advanced near-infrared light sources and optical components 
that operate in a wavelength band centred on 1310 nm. Like intravascular ultrasound (IVUS), 
OCT measures the depth of reflections from tissue according to the round-trip propagation time 
of reflected energy. However, as the speed of light is much faster than that of sound, an 
interferometer is required to measure the backscattered light. The interferometer splits the light 
from the source into two paths – a reference path that directs the light to a reference moving 
mirror and a sample path that directs light through the fibre-optic imaging wire into the tissue 
and collects the backscattered light. The light that returns from both paths is recombined at a 
detector, generating the so-called interferogram from the sum of the reference and sample fields 
(Figure 2a). The maximum imaging depth of current OCT systems is 1.0-2.0 mm, depending on 
tissue type, with axial and lateral resolutions of 15 and 25 μm, respectively. 
 
 
Figure 2.  Main components of (A) time-domain and (B) Fourier-domain OCT systems.  The red and blue lines 
depict the sample and reference beams, respectively, that generate the interference signal at the photodetector. 
A 
B 
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The time-domain OCT imaging method on which the M2 and M3 systems are based relies on a 
moving mirror to scan each depth position in the image pixel by pixel.  This mechanical scanning 
process limits the rate at which images can be acquired.  The latest generation of OCT systems 
employ Fourier-domain OCT acquisition methods, described in a later section of this report, that 
enable much faster image acquisition rates and pullback speeds. 
Procedural requirements for OCT imaging 
As near-infrared light penetrates only a short distance through blood, temporary blood clearance 
is required for OCT imaging. To clear blood according to the instructions for use of the 
LightLab M2 system, a proximal occlusion balloon (Helios, Goodman Co. Ltd., Nagoya, Japan) 
is inflated to between 0.5-0.7 atm, while simultaneously flushing  physiological saline or Ringer’s 
lactate solution through the distal lumen of the balloon catheter at a rate of 0.5 – 1 ml/s. 
Refinements in OCT technology have led to faster acquisition speeds and have encouraged a 
gradual shift from the cumbersome occlusive technique to a simpler, non-occlusive approach 
with flushing of viscous contrast through the guiding catheter. Even though initial reports have 
shown this to be feasible, (13) this technique is still regarded as “off-label” although, intrinsically, 
it has a number of advantages and eliminates the risk of balloon-related vessel injury. 
 
Fourier-domain OCT  
Principles  
The development of a new generation of OCT systems with faster image acquisition speeds and 
greater scan depths, without loss of vital detail and resolution, is a major advancement in 
intravascular OCT imaging. Rather than using a broadband light source as in conventional time-
domain OCT systems, Fourier-domain OCT (FD-OCT) imaging systems employ a novel 
wavelength-swept laser as a light source. (Figure 2b) The laser has a narrow spectral output that 
can be tuned electronically over a wide band of wavelengths (typically 1250 – 1350 nm, the same 
spectral band in which time-domain systems operate). As the wavelength of the laser sweeps, 
reflections from refractive-index discontinuities at different depths are encoded in the 
frequencies of the interference signals that they generate. An entire depth scan is reconstructed 
by Fourier transformation of the interference signals recorded during a single sweep of the laser.  
The bandwidth of the laser and width of its wavelength sweep determine the scan depth and 
axial resolution, respectively.   FD-OCT systems can acquire images at line rates at least 10 times 
faster than time-domain systems without loss of image quality. This speed advantage results from 
the elimination of mechanical scanning of the reference mirror and the signal-to-noise 
advantages of Fourier-domain signal processing. 
Fourier-domain OCT has been used for real-time, volumetric imaging of the eye, (14) 
gastrointestinal tract, (15)  and coronary arteries (16). The principal advantage of Fourier-domain 
OCT in intra-coronary imaging applications is that it permits the acquisition of longitudinal 
sequences of cross-sectional images with significantly faster pullback speeds than conventional 
time-domain OCT. Fast pullback speeds are essential for imaging long segments of arteries with 
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minimal ischaemia, eliminating the need for proximal vessel balloon occlusion during image 
acquisition.   
Technical specifications 
Prototypes of FD-OCT systems are now undergoing evaluation in preparation for regulatory 
clearance for commercial sale. Table 1 compares the key specifications of conventional (time-
domain) OCT systems with those of a representative first-generation Fourier-domain OCT 
system (LightLab Imaging, Inc, Westford, MA). The main performance advantages of the 
Fourier-domain OCT system are its faster frame rate, higher image line density, and faster 
maximum pullback speed. To enable imaging of coronary arteries with large lumens (> 4 mm), 
the FD-OCT system also has a wider scan diameter. The penetration depth and resolution of the 
first generation of Fourier-domain OCT systems do not differ significantly from those of 
commercial time-domain OCT systems. 
 
Parameter M2/M3 OCT Fourier-domain OCT 
(LightLab prototype) 
Source Wavelength  1250-1350 nm 1250-1350 nm
Axial resolution 15 – 20 μm 15 – 20 μm
Lateral resolution 25 – 30 μm 25 – 30 μm
Scan diameter (in saline) 6.8 mm 8.3 mm
Frame rate  M2: 15.6 f/sec
M3: 20  f/sec 
100 f/sec
Number of lines/frame M2: 200 
M3: 240 
450
Maximum pullback speed M2: 2.0 mm/sec
M3: 3.0 mm/sec 
20 mm/sec
 
Table 1: Comparison of the commercial time-domain OCT system and a first-generation Fourier-domain OCT 
system  
 
Designed for rapid-exchange delivery, the first generation of FD-OCT imaging catheters can be 
delivered over a 0.014-inch guidewire through a 6F or larger guide catheter and have 2.5- 2.8 F 
crossing profiles. These catheters consist of a fibre-optic imaging core threaded through a hollow 
torque cable that rotates and pulls back within a transparent plastic sheath.  To maintain high 
longitudinal resolution at fast pullback speeds, the torque cable rotates faster than a conventional 
IVUS catheter (100 rotations/sec versus 30 rotations/sec).   
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Preliminary experience with Fourier-domain OCT 
Studies have been conducted to evaluate the safety and performance of prototype versions of the 
FD-OCT systems in both pre-clinical and clinical settings. The results of initial bench tests verify 
the improvements in image acquisition speed, lateral resolution, scan range, and other basic 
imaging specifications listed in Table 1.  A key objective of early preclinical studies in an acute 
porcine model was to develop a reliable flush method that can be applied safely and effectively in 
the catheterisation laboratory. These experiments demonstrated that effective clearing of blood 
from the imaging field can be achieved by injecting saline, angiographic contrast media, or a 
mixture of contrast and saline, through the guide catheter.  In preliminary studies, injection of 14 
ml volume of contrast at a rate less than 4 ml/s was found to be sufficient to achieve an imaging 
period of 2-3 seconds consistently in all of the major coronary branches.  At a pullback rate of 20 
mm/s, an imaging period of 2 seconds is long enough to scan a 4-cm vessel segment.  As saline 
and saline-contrast mixtures have lower viscosities, larger volumes and higher flow rates are 
required to achieve equivalent clear imaging times, especially in distal segments of highly 
branched arteries. The required flush volume depends on the proximity of side branches and the 
location of the imaging probe relative to the tip of the guide catheter.  Therefore, fast rotation 
and pullback rates, combined with tight synchronisation of the movement of the pullback 
mechanism, are essential for imaging segments of arterial segments longer than a few 
centimetres.   
The most extensive series of clinical studies of Fourier-domain OCT imaging to date began in 
October, 2007, at the Helios Heart Centre, Siegburg, Germany, in collaboration with LightLab 
Imaging.  Over a period of 6 months, Dr. Eberhard Grube, who serves as principal investigator, 
and other senior cardiologists at the Centre (Drs. Buellesfeld, Mueller, and Gerkens) recorded 
pullback OCT images from 25 patients during coronary interventions, with an average of 2 
pullback sequences acquired per patient. Figure 3 shows an example of an FD-OCT image 
extracted from a pullback image sequence recorded from one of the patients.  The 
corresponding longitudinal (L)-mode image in the figure shows a profile of the vessel along its 
length. In this case, a 4.9-cm segment of the artery was imaged in 3.3 sec while contrast was 
injected through the guide catheter.  The high resolution of the image is evident from the ability 
to distinguish the thin intimal, medial, and adventitial layers of the artery, with thicknesses less 
than 0.4, 0.15, and 0.2 mm, respectively.   
The high line density of Fourier-domain OCT images is especially valuable for visualisation of 
stented arteries. Figure 4 shows examples of OCT images of stents that were obtained 
immediately after implantation and at long-term follow-up.  In addition to visual assessment of 
the apposition of individual stents struts (Figure 4a), neointimal growth as thin as 20 μm (Figure 
4b) and as thick as a 1 mm (Figure 4c) can be measured precisely along the length of the stent.   
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Figure 4.  Examples of OCT images of stents acquired with a prototype FD-OCT system (LightLab Imaging, 
Westford, MA, USA). (a) Bare-metal stent imaged immediately after implantation. Stent imaged at long-term follow-
up with (b) thin and (c) thick neointimal coverage. [Images courtesy of Dr. E. Grube, Siegburg Heart Center, 
Siegburg, Germany] 
 
Figure 3. An example of an OCT 
image acquired with a prototype 
OCT system (LightLab Imaging, 
Westford, MA, USA) from the 
coronary artery of a patient 
undergoing percutaneous coronary 
intervention. The lengths listed in 
the upper left corner correspond 
to measurements of the 
thicknesses of the intima, media, 
and adventitia, denoted by the 
letters ‘A’, ‘B’ and ‘C’, respectively. 
The L-mode image (lower quarter 
of figure) shows a longitudinal 
image of the artery acquired during 
a 20 mm/s pullback. [Images 
courtesy of Dr. E. Grube, Siegburg 
Heart Center, Siegburg, Germany]. 
see colour section
see colour section
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Figure 5 shows examples of Fourier-domain images of fibrous, calcified, and lipid-rich lesions 
acquired from target arteries of patients undergoing interventional coronary procedures. Fourier-
domain images of the main classes of atherosclerotic lesions exhibit the same defining 
characteristics as those of time-domain OCT images described in earlier publications (2). The 
reduced spacing between angular samples in the Fourier-domain images improves the sharpness 
of plaque boundaries, which may facilitate the detection of thin-capped lesions and lesions 
containing small clusters of foam cells. 
 
Figure 5.  Fourier-domain OCT images of (a) fibrous, (b) calcified, and (c) lipid-rich lesions acquired with a 
prototype FD-OCT system (LightLab Imaging, Westford, MA, USA) [Images courtesy of Dr. E. Grube, Siegburg 
Heart Center, Siegburg, Germany]. 
 
Future developments 
Continued advances in the technology of Fourier-domain OCT promise to improve the ease of 
use and to broaden the applications of OCT imaging in clinical practice and medical research. 
Quantitative plaque characterisation methods aimed at rapid identification of plaque types are 
under development. Computer-assisted detection of stent malapposition and denudation of 
endothelial coverage with OCT is also being explored. These future diagnostic tools, when 
combined with novel three-dimensional, colour-mapped displays, may enable cardiologists to 
detect therapeutic targets in real-time during percutaneous interventions.  
Furthermore, novel stents including bioabsorbable magnesium stents or those made with poly-
lactic acid offer an exciting era into the management of coronary artery disease with the potential 
to eliminate some of the problems related to permanent metallic stents. The development of 
such technologies, however, remains time consuming and expensive, often necessitating the 
sacrifice of animals to retrieve the stents. (17) The high-resolution imaging capabilities of OCT 
gives the potential for rapid in-vivo assessment of tissue response to various stent designs, 
thereby limiting the dependency on statistical comparisons in large numbers of animals. (17) The 
serial use of OCT is also an attractive concept, giving unique insights into the time course of 
stent endothelialisation following implantation. This application has been greeted with strong 
enthusiasm and OCT is now being incorporated into large multi-centre randomised stent trials 
aimed at complementing angiographic and clinical endpoints. 
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Conclusions 
The ability to provide high-resolution imaging in-vivo is one of the most significant advances 
attributable to OCT. With even faster pullback speeds and simplification of the procedural 
requirements (e.g. by eliminating the need for proximal balloon occlusion), OCT will become 
more accessible to a greater number of centres and operators world-wide. Such advances will 
also see OCT consistently applied as a multi-vessel diagnostic modality, able to provide a truly 
representative assessment of the entire coronary tree.  
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Summary and Conclusions
This thesis provides important data regarding the application of intracoronary OCT to the 
clinical and research fields while addressing the important issues of procedural safety and validity 
of OCT-derived data. The technique, with its sophisticated and elegant optics, are appropriately 
reviewed (chapter 2) with insights given into where OCT is placed amongst existing 
intravascular imaging technologies, namely IVUS (chapter 3). More specifically, the thesis 
embraces two key targets for OCT, namely the detailed assessment of coronary stents (chapters 
9-20) and atherosclerotic plaque (chapters 21-24). 
 
 
Safety of OCT 
With the increased diffusion of OCT, surprisingly little has been documented in terms of its 
safety profile apart from isolated cases and small series. As with all aspects of interventional 
cardiology, a number of risks are inherent and, for the first time, chapter 4 recalls the experience 
of 6 European centres with the implementation and use of the technique. In a total of 468 
consecutive patients who underwent OCT, this chapter reviews the clinical indications of OCT 
imaging and explores in detail the safety profile of the technique. The need for a blood-free 
environment to image, often elicits transient chest pain and ECG changes which almost always 
resolve immediately following imaging. The chapter describes a risk of 1% of ventricular 
fibrillation which is inherent with occlusion balloon, contrast flushing and/or deep guide 
catheter intubation. In all cases, coronary spasm was not found to be problematic and this is in 
contrast to prior studies of IVUS. 
 
Feasibility of OCT 
First generation OCT systems demanded the use of an occlusion balloon situated in the 
proximal segment of the vessel inflated during simultaneous injection of Ringer’s lactate via an 
injector (chapter 5). Refinements in OCT technology, with faster acquisition speeds have seen a 
gradual shift from the cumbersome occlusive technique to a simpler non-occlusive technique 
with flushing of viscous contrast through the guiding catheter. This currently remains “off-label” 
however has definite advantages, namely a shorter OCT procedure time and a larger amount of 
information with a longer pullback distance achieved compared to the use of the occlusion 
balloon (chapter 8). The non-occlusive technique is also applicable to most ostial and proximal 
coronary segments with significantly less patient discomfort (chapter 8).  
 
When first confronted with OCT of a coronary artery, one cannot help be impressed by the 
clarity of the images. The understanding of OCT imaging however lies deep beyond this cursory 
assessment and requires appropriate interpretation of the material acquired. This remains one of 
the most painstaking aspects of offline image interpretation yet is one of the most important and 
rewarding once mastered. Chapters 6 and 7 provide compelling evidence of a low intra and 
inter- observer variability expected when analysing OCT data and gives further validity of OCT 
as both a clinical and research tool. Further, OCT has now become integral to a number of 
multi-centre trials of the next generation drug-eluting stents (DES) looking at potentially using 
tissue coverage as a surrogate for long-term healing and, therefore, stent safety (chapter 10 and 
11).  
Clinical applications – Coronary stents 
Much of what is currently known regarding stent safety has arisen based on studies using 
angiographic follow-up or IVUS in addition to invaluable information gained during the 
unfortunate post-mortem setting. In the latter, lack of endothelial coverage however has been 
shown to be a powerful predictor of stent thrombosis. Coronary angiography and IVUS lack the 
resolution to assess thin layers of coverage.  
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In the LEADERS trial OCT sub-study, 46 patients were randomized to receive either biolimus-
eluting (BES) or sirolimus-eluting stents (SES) in an ‘all-comer’ patient population with very few 
exclusion criteria. Twenty patients were included in the analysis in the BES group (29 lesions 
with 4592 struts) and 26 patients in the SES group (35 lesions with 6476 struts). A total of 83 
struts were uncovered in the BES group and 407 out of 6476 struts were uncovered in the SES 
group (weighted difference -1.4%, 95% CI -3.7 to 0.0%, p=0.04) at 9 months follow-up. There 
were 3 lesions in the BES and 15 lesions in the SES group that had 5% of all struts uncovered 
(difference -33.1% 95% CI -61.7 to -10.3%, p<0.01) indicating more complete tissue coverage in 
patients allocated to BES as compared with SES (chapter 10). The impact of this difference on 
clinical outcome and, in particular, on the risk of late stent thrombosis, is yet to be determined 
however further studies with even longer angiographic and OCT follow-up will help give useful 
insights.  
 
In another DES randomised trial, chapter 11 explores 2 different rapamycin-eluting stents (one 
with and one without a polymer coating). At 3-months post implantation, OCT identified a 
mean neointimal thickness of 77.1μm (95% CI 57.7-83.9) and 193.5μm (95% CI 122.7-206.9) 
p=0.016 for the polymer-coated rapamycin-eluting (Cypher) and non-polymer rapamycin-eluting 
(Yukon) stent respectively with no clinical adverse events in both groups. Binary stent strut 
coverage was 89.0% (CI 87.8-90.3) versus 97.2% (95% CI 96.6-97.8) p=0.023 for the Cypher 
and Yukon stents respectively. Such mechanistic trials using super high-resolution imaging with 
OCT may have important implications for the risk of stent thrombosis and therefore future stent 
design.  
 
OCT can be used to guide optimal stent expansion at time of implantation. Indeed, stent 
expansion, apposition and symmetry were the three criteria of IVUS guided optimal stent 
deployment in the bare metal stent era, with at least the criterion of stent expansion maintaining 
its clinical relevance in the DES era. Since infra-red light is unable to penetrate through metal 
struts, OCT visualises only the endo-luminal surface of the strut. Hence, when assessing 
apposition, the strut and polymer thickness should be considered for each type of DES design. 
Chapter 5 provides a classification of strut apposition into one of three categories: Struts buried 
in the intima for more than half of their thickness are defined as ‘embedded’, those apposed to the 
intima but not embedded are defined as ‘protruding’ and those with no contact to the intima are 
‘malapposed’. Using this classification, chapter 14 compared the immediate OCT findings of 4 
different DES implanted to complex coronary lesions. Further, in a separate study of 20 
overlapping DES (10 patients, 661 struts) immediately after implantation, OCT identified 42% 
of struts were malapposed in the overlapping segment, despite aggressive stent optimisation 
(chapter 12). This may be a central factor in the reported delay in endothelialisation occurring in 
overlapping segments. 
 
In addition to stent tissue coverage and apposition, OCT can be a complimentary imaging 
modality when examining stent fracture (chapter 15), absorption of biodegradable magnesium 
stents (chapter 18) and in cases of very late stent thrombosis (chapter 19), thereby yielding 
unique, ante-mortem findings. 
 
Clinical applications – atherosclerotic plaque assessment 
Acute coronary syndromes including myocardial infarction are leading causes of death, often 
caused by rupture of vulnerable plaque (VP). The detection of VP in the early phase of coronary 
artery disease therefore remains essential to limit morbidity and mortality while helping to target 
specific therapeutic interventions. Through retrospective, post-mortem studies, several 
characteristics of plaques that are prone to rupture have been identified including: the presence 
of a thin fibrous cap (<65 microns in thickness); a large lipid core and activated macrophages 
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near the cap. The limitation of such studies however remains their inability to provide crucial 
detail regarding the natural history and progression of VP, and, therefore prognosis. Several 
imaging modalities have been used to assess and identify VP including coronary angioscopy, 
IVUS and magnetic resonance imaging. Recently, there has been significant interest in the field 
of VP detection using OCT as it permits high-resolution imaging, principally suited to detect and 
quantify the thickness of a thin cap fibroatheroma (TCFA) and to estimate macrophage 
distribution (chapter 2).  
 
In chapter 21, OCT was used to assess culprit and remote coronary lesions and to investigate 
whether intra-coronary OCT in living patients, was able to visualise morphologic features 
associated with VP in post-mortem studies. Twenty-three patients successfully underwent OCT 
prior to percutaneous coronary intervention. The culprit lesion and mild-moderate coronary 
lesions remote from the target stenosis were investigated. The majority of plaques at remote 
segments were proximal to the culprit lesion (73.9%) and predominantly fibrous and lipid-rich. 
At 24-months clinical follow-up, the only event occurred in a patient with in-stent restenosis 
who underwent repeat percutaneous revascularisation. The detection of TCFA, particularly in 
stable patients is desirable and may principally allow for early intervention and prevention of 
adverse events long-term. 
 
In chapter 22, OCT was used in addition to other intra-coronary diagnostic techniques [IVUS 
Greyscale (IVUS-GS), IVUS Radiofrequency Data (IVUS-RFD) Analysis and Intravascular 
Magnetic Resonance Spectroscopy (IVMR)] in a unique pilot study to compare the capability for 
atherosclerotic plaque detection. These four imaging modalities have in common, the ability to 
give a detailed assessment of the composition of atherosclerotic plaques but do differ in the 
means of achieving this. Atherosclerotic plaques classified as soft by IVUS GS were mainly 
composed by fibro-fatty (80%) or necrotic core (20%) by IVUS RFD. These soft plaques were 
classified as “lipid rich” by OCT in the majority of cases (80%). IVMR confirmed the presence 
of lipid with a lipid fraction index ranging between 36 and 79 in these soft plaques. Besides this 
good agreement for soft plaques, IVUS GS, IVUS RFD and OCT had 100% agreement in the 
identification of calcified plaques. 
 
In a study of 103 coronary bifurcations from 30 patients, OCT and IVUS-VH were used and 
found that there was a propensity of TCFA occurring in the proximal segments of the 
bifurcation compared to distal segments (chapter 24). Further, patients with acute coronary 
syndromes had a significant higher proportion of lesions with high-risk morphology plaques than 
stable patients [17/23 (73.9%) vs 28/80 (35%) p=0.002] highlighting the proximal rim of the 
ostium of the side-branch as a region more likely to contain thin fibrous cap and a greater 
proportion of necrotic core.  
 
Future directions 
The development of a new generation of OCT systems with faster image acquisition speeds and 
greater scan depths, without loss of vital detail and resolution, is a major advancement in 
intravascular OCT imaging. Rather than using a broadband light source as in conventional time-
domain OCT systems, Fourier-domain OCT (FD-OCT) imaging systems employ a novel 
wavelength-swept laser as a light source (chapter 25). At a pullback rate of 20 mm/s, an imaging 
period of 2 seconds is long enough to scan a 4-cm vessel segment. Such advances will see OCT 
become more accessible to a greater number of centres and operators world-wide. It will also 
expand the utility of OCT with it applied as a multi-vessel diagnostic modality, able to provide a 
truly representative assessment of the entire coronary tree. 
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Conclusions 
The present thesis has encompassed work undertaken during a very exciting period for 
interventional cardiology as a discipline. The demand for a greater understanding of the 
atherosclerotic process, the treatment of more and more complex lesions, and the steady 
introduction of new stents into clinical practice necessitate ongoing scrutiny and study to ensure 
our patients receive the best possible care. OCT has caused intense interest in interventional 
cardiology. Its application to the assessment of coronary stents has been greeted with strong 
enthusiasm. Such applications are currently unique to OCT and, despite the recent progress of 
non-invasive techniques such as 64 multi-slice computed tomography, conventional stents still 
represent a challenge to distinguish lumen and intimal hyperplasia within the stent. The ability of 
OCT to provide high-resolution imaging in-vivo is the most significant concept circumventing 
the limitations of other imaging modalities such as IVUS or the need for multiple animal 
experiments. Refinements in acquisition speeds with FD-OCT will also make the technique less 
procedurally demanding and thus able to be applied to many more centres, thereby remaining a 
key tool in the armamentarium of researchers and interventional cardiologists alike. 
 
Sa
Co
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Samenvatting en Conclusies
Deze thesis verstrekt belangrijke gegevens betreffende de toepassing van intracoronairen 
optisch coherentie tomografie (OCT) op de klinische en onderzoekgebieden terwijl het 
behandelen van de belangrijke kwesties van procedureveiligheid en geldigheid van OCT. 
Optisch coherentie tomografie is herzien (hoofdstuk 2) met inzicht wordt gegeven dat in 
waar OCT onder bestaande intravasculair technologieën wordt geplaatst, namelijk intravasculair 
ultrasone (IVUS) (hoofdstuk 3). Specifieker, omhelst de thesis twee zeer belangrijke 
doelstellingen voor OCT, namelijk de gedetailleerde beoordeling van coronaire stents 
(hoofdstukken 9-20) en atherosclerose (hoofdstukken 21-24). 

Veiligheid van OCT 

Zoals met alle aspecten van interventie cardiologie, een aantal risico's zijn inherent en, voor het 
eerst, hoofdstuk 4  herinnert aan de ervaring van 6 Europese centra met de implementatie van 
OCT. In een totaal van 468 opeenvolgende patiënten ondergingen OCT, herziet dit hoofdstuk 
de klinische aanwijzingen van OCT en onderzoekt in het veiligheidsprofiel van de techniek.  

Haalbaarheid van OCT 

De eerste generatie OCT eisten het gebruik van een occlusieballon (hoofdstuk 5). De 
verbeteringen in OCT technologie, met snellere aanwinstensnelheden hebben een geleidelijke 
verschuiving aan de hinderlijke occlusieve techniek naar een eenvoudigere nietocclusieve 
techniek met het spoelen van contrast. Dit blijft momenteel ‘van-etiket’ nochtans welomlijnde 
voordelen heeft, namelijk een kortere OCT procedure tijd en een grotere hoeveelheid informatie 
met een langere bereikte pullback afstand in vergelijking met het gebruik van de occlusieballon 
(hoofdstuk 8).  

Hoofdstukken 6 en 7 lever dwingend bewijs van een lage intra en inter verwachte 
waarnemersveranderlijkheid wanneer het analyseren van OCT gegevens en geeft verder 
geldigheid van OCT als zowel klinisch als onderzoekhulpmiddel. Verder, is OCT nu integraal 
aan een aantal berechtingen van volgende generatie drug-uitwassende stents (DES) (hoofdstuk 
10 en 11).  

Klinische toepassingen - Coronaire stents 

Veel van wat momenteel gekend betreffende stent veiligheid is heeft zich gebaseerd op studies 
gebruikend angiografische of IVUS in toevoeging aan informatie die tijdens het postmortale. In 
de laatstgenoemden, is het gebrek aan endothelial dekking nochtans getoond om een krachtige 
voorspeller van stent trombose te zijn.  

In de LEADERS OCT vsub-studie, 46 patiënten willekeurig verdeeld om of biolimus-A9 (BES) 
of sirolimus stents (SES) in een `alle-bezoeker' te ontvangen geduldige bevolking met zeer weinig 
uitsluitings criteria met volledigere weefseldekking in patiënten die aan BES wordt toegewezen 
zoals die met SES wordt vergeleken (hoofdstuk 10). Het effect van dit verschil op klinisch 
resultaat en, in het bijzonder, op het risico van recente stent trombose, moet nog worden 
bepaald nochtans verder zullen de studies met nog langere angiografische en OCT follow-up 
helpen nuttig inzicht geven.  

Hoofdstuk 14 vergeleek de directe OCT bevindingen van 4 verschillende DES bij complexe 
coronaire letsels. Verder, in een afzonderlijke studie van 20 het overlappen DES (10 patiënten, 
661 struts) onmiddellijk na inplanting, geïdentificeerda OCT 42% struts waren malapposed in het 
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overlappende gebied (hoofdstuk 12). In toevoeging OCT een vleiende weergave modaliteit zijn 
wanneer het onderzoeken van stent breuk (hoofdstuk 15), absorptie van biologisch afbreekbaar 
magnesium stents (hoofdstuk 18) en in gevallen van zeer recente stent trombose (hoofdstuk 
19). 

Klinische toepassingen - atherosclerotic plaquebeoordeling 

De scherpe coronaire syndromen met inbegrip van myocardiaal infarct leiden doodsoorzaken, 
die vaak door breuk van ‘vulnerable plaque’ (VP). In hoofdstuk 21, OCT gebruikt om beklaagde 
en verre coronaire letsels te beoordelen en te onderzoeken of intra-coronaire OCT in levende 
patiënten, konden visualiseren eigenschappen verbonden aan VP in postmortale studies. In 
hoofdstuk 22, OCT werden naast andere intra-coronaire kenmerkende technieken in een uniek 
proefonderzoek gebruikt om het vermogen voor atherosclerotic plaqueopsporing te vergelijken. 
In een studie van 103 coronaire vertakkingen van 30 patiënten, OCT en IVUS-VH werden 
gebruikt en werden gevonden dat er een tendens die van TCFA in de proximale segmenten van 
de vertakking in vergelijking met distale segmenten voorkomt (hoofdstuk 24).  

Toekomstige richtingen 

De ontwikkeling van een nieuwe generatie van OCT systemen met de snellere snelheden van de 
beeldaanwinst en grotere aftastendiepten, zonder verlies van essentiële detail en resolutie, is een 
belangrijke vordering in intravasculair OCT. Eerder dan het gebruiken van een breedband 
lichtbron zoals in conventionele tijd-domein OCT systemen, Fourier-Domein OCT (FD-OCT) 
wenden de weergavesystemen een nieuwe golflengte-geveegde laser aan als lichtbron (hoofdstuk 
25).  

Conclusies 

De huidige thesis heeft het werk omvat dat tijdens een zeer opwindende periode voor 
interventionalcardiologie als discipline wordt ondernomen. OCT heeft intense rente in 
interventie cardiologie. Zijn toepassing op de beoordeling van coronaire stents is begroet met 
sterk enthousiasme. De verbeteringen in aanwinstensnelheden met zullen FD-OCT ook de 
techniek minder procedureel eisend als zo bekwaam om op veel meer centra zijn van toepassing 
geweest maken, daardoor blijvend zowel een zeer belangrijk hulpmiddel in onderzoeker en 
interventie cardiologie.

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Figure 1: the mobile OCT cart incorporating the system console, monitor, and patient interface unit 
 
Figure 2: The OCT catheter and dedicated optical imaging wire (LightLab Imaging Inc., Westford, MA, USA) in 
current commercial use. The occlusion balloon is positioned proximal to the region of interest and the imaging wire 
is then inserted with real-time image acquisition performed at a rate up to 3 mm/sec 
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Figure 3 – This OCT cross-section shows a thin layer 
of tissue covering the stent struts. As infrared light is 
unable to penetrate the metal struts, shadowing results 
(arrows) 
 
Figure 4: The OCT appearance of lipid-rich 
plaque and TCFA. This plaque has the typical 
characteristics of being poorly reflective with 
diffuse borders (*). The overlying thin fibrous 
cap is bright and highly reflective. The mean 
cap thickness was 44 microns. 
 
 
 
 
* 
* 
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Figure 1. IVUS-Virtual histology proposed lesion types. AIT, adaptative intimal thickening; PIT, pathological 
intimal thickening; FT, fibrotic plaque; FC, fibrocalcific; FA, fibroatheroma;CaFA, calcified fibroatheroma; TCFA, 
thin-capped fibroatheroma. 
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Figure 2. IVUS-palpography. In the upper left side the palpography strain map is opened up. The local strain is 
calculated from the gated radiofrequency traces using cross-correlation analysis and displayed, color-coded, from 
blue (for 0% strain) to red to yellow (for 2% strain). Plaque strain values are assigned a Rotterdam Classification 
(ROC) score ranging from 1 to 4 (ROC I= 0-<0.6 %; ROC II= 0.6- <0.9 %; ROC III= 0.9-<1.2 %; ROC IV= 
>1.2 %). At the bottom, in the same cross-sectional area a high-strain spot (ROC III) is shown (left); in the virtual 
histology (VH) image (right) a confluent necrotic core area in contact with the lumen is seen, suggesting an IVUS-
derived thin capped fibroatheroma.  The IVUS-VH color-code is fibrous tissue (green), fibro-fatty tissue (light 
green), necrotic core (red) and dense calcium (white).  
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Figure 3: thin cap fibroatheroma visualised with OCT as a highly reflective thin band (arrows) 
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Figure 4. Multi-modality imaging in the coronary arteries. The same coronary segment (represented by one 
frame) has been imaged by 4 different imaging techniques. In the grey-scale IVUS (panel A), IVUS-virtual histology 
(panel B), optical coherence tomography (panel C) and intravascular magnetic resonance spectroscopy (IVMR) the 
results of the same frame across different techniques are shown. Of note, in the upper left quadrant of the plaque a 
calcified area is seen in three imaging modalities, but in IVMR where an artifact is observed. On the right hand side, 
the different plaque and tissues types across the coronary imaging techniques is shown. 
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Figure 6: A: Demonstrates the optical coherence tomography (OCT) imaging of a bare metal stent 4 months 
following implantation. The circumferential tissue struts are visible with shadowing induced by the metal. The 
neointimal tissue measured between 140 and 220 microns in thickness 
B: OCT imaging of a drug-eluting stent (DES) at 4 months follow-up showing the circumferential struts with a very 
thin neointimal layer (10-40 microns thick). The arrow indicates a strut with no visible tissue coverage  
 
 
 
Figure 5. IVUS-virtual histology in stented segments. In the left hand side, a coronary angiogram of the left 
coronary system shows on the distal segment of the left circumflex artery an eccentric lesion. A pre-stenting virtual 
histology (VH) frame showed a fibrotic type of plaque (location of VH frame is indicated by a black line). On the 
right hand side, the post-stenting VH frame is depicted. Of note, at the lumen and surrounding areas an increase in 
the amount of “dense calcium” and “necrotic core” is observed. This is due to the presence of stent struts that are 
misclassified by VH. (percutaneous coronary intervention – PCI).  
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Figure 1 Optical coherence tomography classification of stent apposition into embedded, protruding or 
malapposed. 
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Figure 1: Tissue coverage measurement. A. Sirolimus eluting stent 9 months after stent implantation. B. The 
figure shows the lumen contour (white) and the stent contour (green). The tissue coverage area was calculated as 
stent area minus lumen area. The tissue coverage thickness was measured in 360 points (represented by the white 
chords). C. Magnification of 2 struts showing all the measurements (white chords) of the tissue coverage in front of 
every strut. For every strut the minimum, maximum and mean strut coverage was calculated.   
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Figure 2: Malapposition. A. Example of a malapposed strut in a sirolimus eluting stent at 9 months follow up. B. 
Magnification of the malapposed strut. The yellow line represents the lumen contour and the white line corresponds 
to the stent contour. The distance from the endoluminal surface of the strut to the vessel wall (red arrow) was 440 
μm (higher than the sum of the metal and polymer thickness for this type of stent).  
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Figure 1 The application of optical coherence tomography (OCT) post-stenting. A: shows a stent immediately 
following implantation across a bifurcation. The struts at the carina are clearly seen to be malapposed (arrow) B: 
OCT cross section with magnification (insert, top left) showing a dissection flap immediately following implantation of 
a stent C: Demonstrates significant intimal hyperplasia occurring 8 months following stent implantation. The intimal tissue is 
seen to have a layered pattern with the endo-luminal aspect showing a bright, reflective and homogenous 
appearance in contrast to the layer abutting the stent struts which is seen to be poorly reflective. The thickness 
measured at the 2 points indicated was A-0.82mm and B-0.40mm 
Figure 2 – Shows the contrasting amount of tissue covering struts in a bare metal (BMS) and drug-eluting stent 
(DES). The tissue thickness overlying the BMS measured between 0.14 and 0.42mm. In contrast, the DES was 
covered by a thin, concentric layer of tissue measuring 0.09mm. 
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Figure 5 – A: Circumferential stent struts are shown covered by a thin layer of tissue. Dorsal shadowing is evident 
behind the stent struts (S) with only the luminal surface of the strut visible with OCT. B: demonstrates 
circumferential stent struts with shadowing and bright reflections caused by saturation of the detector registering the 
inferogram (arrow) C: Arrow indicates a double reflection between stent and catheter. This can occur if a stent strut 
is imaged face-on, and reflects the OCT beam specularly. Shadows of other stent struts are marked by s; stent struts 
that do not show up as the typical bright dot, but do cast a shadow, are imaged under an oblique angle. * is a guide 
wire artefact. White bar is 1 mm. 
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Figure 2:  Examples of OCT findings 
A. This 73 year old male received a biolimus-eluting stent (BES) 9 months prior to the right coronary artery. 
The stent is seen covered by a thin, uniform layer of tissue overlying all stent struts that are well apposed to 
the vessel wall. 
B. Offline OCT analysis. A total of 14 stent struts are visible in this cross section with the observer having 
measured the thickness of tissue overlying each of the struts, expressed in the colored panel (top left) in 
mm. The mean neointimal thickness in this frame was 0.27mm (270μm).  
C. Sirolimus-eluting stent (SES) struts are observed circumferentially. Struts between 7 and 11 o’clock are 
apposed but uncovered by tissue. Struts from 1 – 5 o’clock are observed covered with a very thin layer of 
tissue (mean thickness 0.03mm or 30μm). The stent was implanted in a patient who received 2 SES to the 
mid left anterior descending artery (LAD) 9 months prior following a presentation with a non-ST elevation 
myocardial infarction. He was asymptomatic at 9 month follow-up. 
D. Nine month follow-up of a BES implanted in the LAD across the diagonal bifurcation. A solitary strut is 
observed (arrow) malapposed at the level of the carina. The strut was seen covered by a thick, uniform and 
homogenous tissue. 
E. This OCT pullback frame from a 78 year-old male with prior stenting to the LAD/diagonal bifurcation 
with a SES. Struts are observed (1-3 o’clock) to be malapposed to the vessel wall with a heterogeneous 
tissue with different signal attenuations that may represent thrombotic material. The patient was 
asymptomatic at 9 month follow-up and on dual anti-platelet therapy. 
F. Left main coronary artery OCT. This patient had a proximal LAD stent implanted 9 months prior. We 
extended the pullback beyond the stent into the left main coronary artery which demonstrates a well 
demarcated, non-flow limiting, low attenuation plaque (12 o’clock) consistent with calcium. Our sub-study 
exclusively used a non-occlusive technique for OCT imaging which requires pullback of the image wire 
during simultaneous flush of contrast via the guiding catheter. This is a significant advance over the 
traditional method of OCT imaging in which a proximally positioned balloon is inflated during image 
acquisition. Hence, ostial and proximal segments of coronary arteries were all able to be imaged thereby 
supporting the ‘all comer’ design of the LEADERS trial without any OCT anatomical exclusions. 
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     Biolimus-eluting stent                  Sirolimus-eluting stent 
Figure 3: Graphical representation of stent coverage in lesions. 
Grey horizontal bars represent lesions. Each uncovered strut is represented by a red line. 
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Figure 5: Representative 2-dimensional optical coherence tomography image of stent strut sections of an uncovered 
polymer rapamycin-eluting stent and a covered non-polymer rapamycin-eluting stent with paired 3-dimensional 
reconstructions and reference photograph of a polymer-coated rapamycin-eluting stent. 
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Figure 1 A: Illustrates the left internal mammary artery (LIMA) graft with a critical stenosis in the highly angulated 
mid-segment. B: Immediate angiographic appearance following pre-dilatation and implantation of two 3.5 mm bare 
metal Driver (Medtronic Inc., Minneapolis, US) stents. C: Angiography 12 months following initial stent 
implantation demonstrating critical in-stent-restenosis. D: Final angiographic result following treatment with a 
3.5 × 33 mm sirolimus-eluting stent (SES). 
Chapter 16
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Figure 2 Two years following stenting, angiography confirmed a significant stenosis at the hinge point within the 
previously stented segment (black arrow). A: Optical coherence tomography (LightLab Imaging Inc., Westford, MA, 
USA) was acquired during simultaneous contrast flush through the guiding catheter at a pullback speed of 1 mm/s. 
This proximal cross-section shows 2 layers of stent struts coinciding with the previously deployed bare metal stent 
(black arrow) and the SES (white arrow). B–C: Imaging at the level of the stenosis reveals gross hyperplasia and 
almost complete obliteration of the lumen (minimal lumen area 0.71 mm2) with absence of circumferential struts. D. 
OCT distal to the stenosis showed the struts of the SES were widely patent with thin coverage of neointimal tissue 
(10–30 Ƭm). 
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Figure 5. OCT demonstrating a widely patent stent with a thin layer of neointimal tissue. B–D: Shows the more 
distal lesion with significant luminal narrowing as a result of intimal hyperplasia. The cross-sections demonstrate the 
lack of circumferential stent struts and altered stent and vessel lumen geometry. E: Shows the OCT appearance at 
the level of the side branch. 3 stent struts are shown at the carina with no visible tissue coverage (black arrow) while 
the surround stent struts show an exaggerated intimal tissue response (white arrow). F: Demonstrates 
circumferential stent struts covered by a thin tissue layer. Also evident is a fibro-calcific plaque (black arrows) with 
its low reflective appearance and sharp margins. G–H: Shows the lack of circumferential stent struts resulting in 
considerable disruption of vessel and lumen geometry. 
Figure 4. Antero-posterior cranial view showing the left anterior descending artery with significant stenosis in the 
mid-segment and diagonal branch. Immediately following implantation of 2 sirolimus-eluting stents. Nine-month 
follow-up angiography showed 2 sites of restenosis but no obvious fracture. Following high-pressure balloon 
dilatation and further stent implantation. 
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Figure 1. In vivo OCT (LightLab Imaging Boston, MA, USA) in a porcine coronary artery. A) Baseline OCT 
immediately after stent implantation shows adequate stent expansion and apposition of the struts against the normal 
coronary wall. B) Magnification demonstrating the stent strut vessel wall interface. C) Follow-up investigation at five 
days. The stent struts are clearly visible and show thin, bright reflective tissue coverage in the magnification D) 
Histology E) confirms the presence of a thin neointimal layer. 
Figure 2. In vivo OCT (LightLabImaging™, Boston, MA, USA) in the LAD in a patient presenting with in-stent 
restenosis. A) The coronary angiogram shows a lumen narrowing within the stent that is covering the second 
diagonal branch. OCT visualises the complex coronary anatomy in great detail. The stent is covered by a thick 
neointima that shows a layered appearance with a bright, highly reflective luminal layer, an intermediate layer and a 
dark, signal poor layer surrounding the struts (B). The diagonal take off can be clearly seen (C) as well as a stent strut 
that is “floating” in the carina (D). 
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Figure 3. Demonstrates the information that can be gathered from IVUS (20Mhz, lower panels) and from OCT 
imaging (mid and upper panels, LightLabImaging™, Boston, MA, USA) in patients at follow-up after stent 
implantation. These are corresponding cross sections within a stent, imaged by both, OCT in the upper panels and 
by IVUS in the lower panels. The images represent the same spots within a coronary artery (A, B, C), and illustrates 
the different quality of information that can be obtained by OCT as compared to conventional grey scale IVUS. A) 
Three layers of stents can be seen. OCT is able to clearly visualise the individual stent struts, the neointimal layers 
separating the different stents and the very thin coverage of the most inner, luminal stent struts. B) a bright, 
eccentric and relatively thick neointimal layer can be seen C) an eccentric thick neointimal layer is visible, however, 
the structure of this neointima differs considerably from the example B) with a low-reflective and speckled 
appearance. 
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Figure 4. OCT (LightLab Imaging Boston, MA, USA) findings in two patients presenting with late drug-eluting 
stent (DES) thrombosis. OCT was performed in both cases immediately after thrombus aspiration and reveals 
completely different morphologic findings, possible suggesting two different mechanisms for late stent thrombosis, 
focal restenosis and incomplete strut coverage. I) Patient with late stent thrombosis three months after DES 
implantation in the left circumflex artery. OCT reveals an adequately expanded stent, all struts are well apposed 
against the vessel wall. All struts show tissue coverage, which is more pronounced in the proximal portion of the 
stent (D) as compared to the distal stent portion (A). There is focal in-stent restenosis (B, C) with severe lumen 
narrowing (MLA 1.63 mm2). The neointima shows a layered appearance with a luminal bright, highly reflective 
layer, an intermediate layer and a dark, signal poor layer surrounding the struts. Remnants of the thrombus are 
focally seen focally as irregular mural structures, protruding into the lumen (A, C). II) Patient with very late stent 
thrombosis four years after DES implantation in the left anterior descending artery. OCT reveals an adequately 
expanded stent, however, there is incomplete stent strut apposition at the proximal stent edge with incomplete tissue 
coverage in 21% of struts. (E) The distal stent portion, shows a well expanded and apposed stent with thin tissue 
coverage by OCT. F) irregular lumen borders with intraluminal remnants of the thrombus. G) proximal stent 
portion showing a strut without visible tissue coverage in 12 o’clock position and thrombus fragments in the lumen. 
H) proximal stent edge with incomplete apposition of five stent struts (arrows) against the vessel wall. The distance 
to the vessel wall is 200 micron. OCT shows tissue around the stent struts (DD thrombus, neointima). GWA: 
guidewire artefact. 
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Figure 2: Intracoronary imaging after thrombus aspiration. Upper panels: IVUS (Atlantis, Boston Scientific, 
Natick, MA), lower panels: OCT (LightLab Imaging™, Boston, MA; cross sectional and longitudinal view) A) distal 
reference showing eccentric plaque in 11-4 o’clock position. B) distal stent portion, showing a well expanded and 
apposed stent with thin tissue coverage by OCT that is missed by IVUS. C) irregular lumen borders with 
intraluminal remnants of the thrombus D) proximal stent edge with incomplete apposition of 5 stent struts (arrows) 
against the vessel wall. The distance to the vessel wall is 200Ƭm. OCT shows tissue around the stent struts (DD 
thrombus, neointima). Incomplete stent apposition may be caused initial malapposition or acquired malapposition 
caused by a vascular response to the stent. GWA= guide wire artefact; C= catheter artefact. 
Figure 3: Spectrum of tissue 
coverage as seen by OCT in 
this stented segment. Tissue 
coverage was not visible in 
21% (n=110) of the struts, 
while 79% (n=411 of 521) of 
the struts showed tissue 
coverage of various thickness. 
A) no visible coverage B) very 
thin coverage (40ʅm) C) 
maximal coverage (140 ʅm). 
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Figure 4: Histology of the aspirated thrombus: recent multilayered thrombus showing Zahn lines and containing 
abundant leukocytes consisting of eosinophils (E), neutrophils (N) and lymphocytes (L). 
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Figure 2: Thin-cap fibroatheroma (TCFA) assessed by OCT overlying a large lipid-rich plaque (2-5 o’clock 
position). The bright, highly reflective fibrous cap measured between 30-80 microns 
 
 
 
 
Figure 1: Angiography demonstrating a calcific mid-vessel lesion. A further calcific plaque with sharp and well-
delineated margins was also observed by OCT remote and distal to the culprit lesion with attached mural thrombus 
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Figure 1. Matching of the OCT and IVUS pullbacks. The position of the IVUS, Optical Coherence 
Tomography (OCT) and Intravascular Magnetic Resonance Spectroscopy (IVMR) probe along the vessel was filmed 
before and after each acquisition (A). The “matching” of the region of interest in the IVUS (B) and OCT (C) 
pullback was based on the presence of anatomical landmarks (e.g. side branches visible in the longitudinal and cross-
sectional views). To determine the longitudinal position of the IVMR probe in the vessel, a side branch was used as 
a marker. From the landmark to the proximal part of the vessel one frame every 1.6 mm was selected. D1: first 
diagonal, D2: second diagonal, SB: septal branch, LAD: left anterior descendent coronary artery.  CS: cross section. 
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Figure 2. Analysis of the targeted matched plaques. 2A) Matching of the cross sections in a) IVUS greyscale b) 
IVUS Radiofrequency Data Analysis and c) Optical Coherence Tomography pullbacks. 2B) Analysis screen.  After 
matching corresponding cross sections based on their longitudinal orientation, the region of interest is defined 
according to the orientation of the Intravascular Magnetic Resonance probe towards the vessel wall.  The figure 
illustrates the results of the six target matched plaques (60 degrees sector) analyzed in one patient. Prox: proximal 
Dist: distal. 
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Panel Legend A. Angiography in the right cranial view demonstrated stenosis in the mid left anterior descending 
artery (LAD) involving both small diagonal branches. The previously implanted LAD stent proximally was widely 
patent. The region corresponding to the optical coherence tomography (OCT) images is shown with the black 
arrow. B-C. Intravascular 
OCT (LightLab Imaging, 
Westford, Massachusetts, US) 
was acquired using a non-
occlusive technique with a 
3.0mm/sec pullback. OCT 
clearly demonstrated the 
presence of a lipid-rich plaque 
in the 6 to 9 o/clock position 
characterized by low 
reflectivity, speckled 
appearance with diffuse 
margins. This was covered 
with a bright rim of fibrous 
tissue corresponding to thin-
cap fibroatheroma (TCFA). 
Mural thrombus was evident 
in all OCT cross-sections. The 
TCFA measured 20 microns 
thick and was found to be 
ruptured at each of the two 
shoulders of the plaque 
(arrows). 
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Figure 2: Location of the plaque in relation to the flow divider. To describe the plaque location in relation to 
the flow divider, the vessel cross section was divided in 4 quadrants according to the position of the side-branch. 
Quadrants 1 and 4 correspond to the ostium of the side-branch while quadrants 2 and 3 correspond to the part of 
the vessel wall located in front of the ostium of the side-branch. A: greyscale IVUS, B: virtual histology, C: optical 
coherence tomography. 
 
 
Figure 1: Bifurcation selection and analysis 
Bifurcations that could be identified in both IVUS-VH and OCT pullbacks were included. A strict selection of the 
analyzed cross sections was followed to ensure correct matching between the two techniques. Plaques were analyzed 
only in the main branch. The lesion analysis included: i. proximal rim of the ostium of the side-branch cross section 
(first frame proximal to the take-off of the side-branch); ii. in-bifurcation cross section (frame with the larger ostial 
diameter of the side-branch) and iii. distal rim of the ostium of the side-branch cross section (first frame distal to the 
take off of the side-branch) SB: side-branch CS: cross section. 
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Figure 4: Low-risk plaques. Matched images of greyscale IVUS (A), virtual histology (B) and optical coherence 
tomography (C) for the 4 types of plaques considered of low-risk. 1: adaptive intimal thickening, 2: pathological 
intimal thickening, 3: fibrocalcific plaque 4: fibrotic plaque.  
 
 
Figure 5: High-risk plaques. Matched images of greyscale IVUS (A), virtual histology (B) and optical coherence 
tomography (C) for the 4 types of plaques considered at high-risk of rupture. 1: fibroatheroma, 2: calcified 
fibroatheroma 3: thin-cap fibroatheroma 4: calcified thin-cap fibroatheroma. 
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Figure 3. An example of an OCT 
image acquired with a prototype 
OCT system (LightLab Imaging, 
Westford, MA, USA) from the 
coronary artery of a patient 
undergoing percutaneous coronary 
intervention. The lengths listed in 
the upper left corner correspond 
to measurements of the 
thicknesses of the intima, media, 
and adventitia, denoted by the 
letters ‘A’, ‘B’ and ‘C’, respectively. 
The L-mode image (lower quarter 
of figure) shows a longitudinal 
image of the artery acquired during 
a 20 mm/s pullback. [Images 
courtesy of Dr. E. Grube, Siegburg 
Heart Center, Siegburg, Germany]. 
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Figure 4.  Examples of OCT images of stents acquired with a prototype FD-OCT system (LightLab Imaging, 
Westford, MA, USA). (a) Bare-metal stent imaged immediately after implantation. Stent imaged at long-term follow-
up with (b) thin and (c) thick neointimal coverage. [Images courtesy of Dr. E. Grube, Siegburg Heart Center, 
Siegburg, Germany] 
 
 
Figure 5.  Fourier-domain OCT images of (a) fibrous, (b) calcified, and (c) lipid-rich lesions acquired with a 
prototype FD-OCT system (LightLab Imaging, Westford, MA, USA) [Images courtesy of Dr. E. Grube, Siegburg 
Heart Center, Siegburg, Germany]. 
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